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Somatic cell nuclear reprogramming (SCNR) by eggs is a way to forcibly 
transform the nuclei of terminally differentiated somatic cells to an embryonic 
state and gain totipotency (Gurdon et al., 1958). Additionally, induced 
pluripotency is applied to transform identities of somatic cells to induced 
pluripotent stem cells by overexpression of combinatorial Yamanaka factors 
(iPS, Takahashi et al., 2006). Although both approaches aim to derive cells 
with highest plasticity, the mechanisms and differences between these 
procedures are not yet clear. 
 
In my thesis, I used quantitative polymerase chain reaction (QPCR) and RNA-
seq plus 5-bromouridine 5’-triphosphate (BrUTP) pulldown to evaluate the 
transcriptional reprogramming by maternal factors and overexpressed 
transcription factors during SCNR by Xenopus oocytes, which are inactive in 
DNA replication and cell division. 
 
QPCR measures changes in the steady-state levels of transcripts within 2 
days of nuclear transfer to Xenopus oocytes (Oocyte-NT). Three pairs of 
Yamanaka factor homologs were tested by QPCR and Yamanaka factor 
homologues regulated similar sets of pluripotency genes in mouse embryonic 
fibroblasts (MEFs). 
 
Pioneer factor mFoxA1 could not up-regulate most pluripotency genes and 
their binding targets of neurogenic genes in MEFs while pioneer factors are 
proposed to bind to their targets even if they may reside in inaccessible 
	 III	
chromatin. This shows that the existence of other factors is needed at 
specified developmental stages. Hence, gene activation by transcription 
factors in the Oocyte-NT system requires not only corresponding binding on 
regulatory elements of linked genes but transcription cooperators to exert 
effective gene activation. 
 
Additionally, RNA-seq plus BrUTP pulldown measures the extent to which 
oocytes change the transcriptional activity of nuclei transplanted to oocytes. 
Through RNA-seq plus BrUTP pulldown, I compared the reprogrammed 
transcriptomes of embryonic and somatic cells, including mouse embryonic 
stem cells, mouse embryonic fibroblasts and mouse myoblasts, to 
demonstrate the effects of maternal factors and overexpression of 
transcription factors on gene activities during SCNR by oocytes. 
 
Importantly, I find that maternal factors of oocytes and the overexpression of 
transcription factors exert different strategies to reprogram somatic cells. 
Oocyte factors reprogram the donor cell nuclei to an oocyte-steady state 
except for the SCNR resistance genes and xklf2-HA overexpression 
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Abbreviations and explanations 
9.2ng/0ng =(relative expression of xklf2-HA mRNA samples)/(relative expression of no 
mRNA injection samples) 
BrUTP 5-Bromouridine 5′-triphosphate 
cKO conditional knockout 
CPM counts per million mapped reads 
DE differentially expression/differentially expressed 
Egg-NT nuclear transfer to eggs 
EpiSC epiblast-derived stem cell 
ESC embryonic stem cell 
FC fold change 
FPKM  fragments per kilobase of exon per million mapped reads 
GV  germinal vesicle 
HA human influenza hemaggluitinin 
 
(used as a tag for Western blotting) 
hKLF4 human kruppel-like factor 4 
hOCT4 human octamer-binding transcription factor 
 (aka human POU5F1) 
iPSC induced pluripotent stem cell 
-log10(p-value) -(the logarithm to base 10 of probability value) 
MBT      midblastula transition 
MDS multidimentional scaling 
 (a means of visualizing the level of similarity of a individual cases of a dataset) 
MEF      mouse embryonic fibroblast 
MEF-NT  reprogrammed transcriptome of MEF by Xenopus oocyte factors 
mESC mouse embryonic stem cell 
mESC-NT  reprogrammed transcriptome of mESC by Xenopus oocyte factors 
mMyo      mouse myoblast 
mMyo-NT reprogrammed transcriptome of mMyo by Xenopus oocyte factors 
mSox2 mouse SRY-box 2 
Oocyte-NT nuclear transfer to oocytes 
OSKM Oct4, Sox2, Klf4 and Myc 
 (a combination of transcription factors, used to induce pluripotency) 
SLO Streptolysin O 
QPCR Quantitative polymerase chain reaction 
SCNR somatic cell nuclear reprogramming 
SCNT somatic cell nuclear transfer 
TF transcription factor 
xklf2 Xenopus kruppel-like factor 4 
xpou60 Xenopus POU class 5 homeobox 3, gene 3 
 (aka Xenopus pou5f3.3) 
xsox2 Xenopus SRY-box 2 
YF Yamanaka factor 
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Chapter 1 Introduction 
 
Somatic cell nuclear reprogramming (SCNR) is the process by which 
terminally differentiated cells revert to a stem cell state or turn into other cell-
types1. Three approaches can be utilized to achieve SCNR, including somatic 
cell nuclear transfer, cell fusion and overexpression of transcription factors 
(Figure 1.1)1,2. Through these SCNR approaches, researchers can investigate 
the mechanistic details behind SCNR and have a better idea how to apply 
SCNR techniques to regenerative medicine, drug discoveries and other 
applications3,4. 
 
Mechanistic studies have uncovered the roles of reprogramming factors in 
epigenetic and transcriptional changes during SCNR1. The involvement of the 
appropriate reprogramming factors at the different phases and the removal of 
inadequate memories in somatic cell nuclei lead to successful SCNR1. 
However, the efficiency of SCNR is usually low and the mechanisms requires 
clarification2.  
 
In order to further understand the mechanistic details of SCNR, my project 
compares the difference in transcriptional reprogramming between native 
maternal factors and overexpression of transcription factors via somatic cell 
nuclear transfer in non-dividing Xenopus oocytes. From this comparison, I 
would like to ask if transcription factors help to induce totipotency and how 




Figure 1.1 Experimental systems for studying nuclear reprogramming2. 
(A) Somatic cell nuclear transfer 
(B) Cell fusion 




1.1 Reprogramming of somatic cell nuclei by three SCNR 
approaches and the phenotypic assessment 
For SCNR approaches, reprogramming factors are provided to induce and 
support the SCNR process. These reprogramming factors might be 
modulators of chromatin conformation, such as DNA 
methyltransferases/demethylases, canonical histones and histone variants, 
chromatin modifiers/remodelers, and are capable of changing the accessibility 
of chromatin1,5. To reprogram somatic cells to other cell identities, 
transcriptional regulators, namely transcription factors, cofactors and non-
coding RNAs, are also needed and are able to change the characteristics of 
cells1,4. 
 
In these SCNR studies, it is sometimes arguable that the plasticity of donor 
cells are uncertain while cells with higher plasticity, rather than terminally 
differentiated somatic cells, are used for SCNR and these cells are more 
susceptible to reprogramming factors1. To clearly understand SCNR, this 
section introduces studies that utilized three SCNR approaches and includes 
the information about the donor cell types, the reprogrammed cells and the 




1.1.1 SCNR to totipotency  
Totipotency is the capability of a cell to give rise to cells in both embryonic 
and extra-embryonic lineages6. Therefore, the criterion used to assess the 
totipotent state of a cell is to confirm if this cell/zygote can generate an entire 
organism6. In nature, totipotent zygotes can be formed from oocytes/eggs and 
sperm through fertilization. Artificially, cloning an adult from somatic nuclei 
can also be achieved via nuclear transfer to eggs and it has been achieved in 
many species7,8.  
 
While applying nuclear transfer to eggs, components in eggs empower 
somatic nuclei regain totipotency and develop to adult animals9. In the early 
1950s, Briggs and King performed nuclear transfer to enucleated eggs from 
blastula and gastrula cells and the resulting cells yield tadpoles of Rana 
Pipiens successfully10,11. Later, Gurdon and colleagues managed to produce 
sexually mature frogs from embryonic and somatic cell nuclei in Xenopus 
laevis12-15. After decades of effort, the first mammalian clone was successfully 
derived from adult differentiated cells of mammary glands and was named as 
Dolly the sheep in 199716. In 2018, the first non-human primate was cloned 
from fatal fibroblasts through modifying contents in donor eggs17,18. 
 
Notably, forming a totipotent zygote through fertilization is usually highly 
efficient except for the failure of fertilization caused by the deterioration or 
defects of gametes. However, forming a totipotent cell through somatic cell 
nuclear transfer is of low efficiency due to the resistance of donor cell nuclei to 
reprogramming triggered by maternal factors of eggs. Since both routes allow 
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a nucleus to become totipotent, the different efficiency between fertilization 
and somatic cell nuclear transfer into eggs suggests the resistance of somatic 
cell nuclei to the maternal reprogramming factors in eggs. 
 
To study the maternal effect on SCNR, extracts of oocytes/eggs are useful to 
investigate the immediate response. Somatic nuclei are exposed to maternal 
factors of oocyte/egg extracts. Also maternal factors from oocyte/egg extracts 
are shown to epigenetically change the somatic cell nuclei and change the 
nuclear structure to improve the SCNR19,20. Intriguingly, cytoplasm of GV-
oocytes (Prophase I) and MII-oocytes (Metaphase II) affects the somatic cell 
nuclei in different ways. For example, the activity of Pol I and Pol II 
polymerases is maintained when incubating the somatic cell nuclei in the 
cytoplasm of GV-oocytes but the activity is abolished in the cytoplasm of MII-
oocytes19. 
 
In addition, the cytoplasm of GV-oocytes may be more potent to induce 
pluripotency than MII-oocytes since the cytoplasm of GV-oocytes can activate 
and maintain the expression of NANOG in fibroblasts after 7 days of extract 
treatment while cytoplasm of MII-oocytes can only activate but not maintain 
the NANOG expression21. Furthermore, it has been shown that the exposure 
of fibroblasts to a GV-oocyte cytoplasmic extract can epigenetically improve 
somatic cell nuclear reprogramming because it can increase the efficiency of 




1.1.2 SCNR to pluripotency  
After fertilization or nuclear transfer to eggs, the totipotent zygotes/cells divide 
and, after rounds of cell division, some of these cells become pluripotent23. 
Pluripotent cells are able to derive cells that form three germ layers and, in 
embryos, pluripotent cells can be found at characterized anatomical 
positions23,24. During the transition from totipotency to pluripotency, it has 
been found that the mobility of core histones decreases as development 
proceeds and pluripotent cells retain higher mobility of histones than the 
differentiated trophectoderm25.  
 
There are several types of cultured pluripotent stem cells, including embryonic 
stem cells (ESCs), epiblast-derived stem cells (EpiSCs), embryonic germ cells 
and embryonal carcinoma cells26. Several findings point out that these 
pluripotent stem cells are interconvertible by modulating cell-intrinsic and 
exogenous factors26. One in vivo way to examine if a cell is pluripotent is to 
transplant it to the blastocyst and confirm its pluripotency by the formation of a 
chimera24. The other in vivo way is to implant the cell subcutaneously into 
kidney a capsule and see if it can form a teratoma24. 
 
ESCs are one type of pluripotent stem cells and are derived from the inner 
cell mass of blastocysts24. In mouse, pluripotent states of ESCs can be 
divided to naïve and primed pluripotency in pre-implantation blastocysts and 
post-implantation embryos respectively27. Interestingly, human ESCs have 
only primed pluripotency and naïve pluripotency of human ESCs can be 
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derived experimentally by resetting transcription factor control circuitry or 
modified culture conditions28-30.  
 
Although ESCs can be a good resource for making all the functional cells and 
can be applied in medicine, they can only be used in research due to ethical 
issues. Therefore, induced pluripotent stem cells were derived by forced 
expression of combinatorial sets of transcription factors, mainly Yamanaka 
factors, in various differentiated cells31. Likewise, iPSCs were proven to 
generate the cells of all three germ layers via in vivo assays and have the 
benefit of producing personalized iPSCs for regenerative medicine and drug 
discovery3. 
 
In 2006, Yamanaka and Takahashi found as few as four transcription factors, 
Oct3/4, Sox2, c-Myc and Klf4, can reprogram embryonic and adult fibroblasts 
to pluripotent state32. Later, it has been shown that Nanog-expressed iPSCs 
are germline-competent and iPSCs can be derived from terminally 
differentiated B lymphocytes accompanied by the interruption of 
transcriptional state maintaining B lymphocyte identity33,34. For the 
equivalence between ESCs and iPSCs, although it remains controversial, 
ESCs and iPSCs were reported to be transcriptionally and epigenetically 
identical when they have the same genetic origin26,35.  
 
In addition to induced pluripotency, cell fusion can also be utilized to study 
pluripotency23. By fusing somatic cells with pluripotent stem cells, the 
pluripotency genes in somatic cells are activated and the reprogrammed 
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fusion hybrid cells can differentiate to three germ layers in vitro and in vivo36. 
In the absence of cell division, Do and Schöler fused either karyoplasts of 
ESCs or cytoplasts of ESCs with neurosphere cells and found the Oct4 gene 
was only activated by karyoplasts37. Additionally, Nanog was shown to 
promote transfer of pluripotency after fusion of ESCs and differentiated cell 
nuclei while elevated Nanog improves the yield of hybrid cell colonies with 
ESC characteristics38. 
 
The other pluripotent stem cells, cell extracts of embryonal carcinoma cells, 
were shown to up-regulate the expression of OCT4 and NANOG genes and 
caused the demethylation of OCT4 promoter and enhancer39. Also, the 
acetylation of H3K9 and demethylation of H3K9 and H3K27 occur during this 
transcriptional activation39. 
 
For the activation of silenced genes by cell fusion, a biphasic remodeling was 
proposed40. The early phase of the activation of silenced genes is triggered by 
transcription activators and repressors independent of cell division and this 
happens when fusing somatic cells with either another type of somatic cell or 
ESCs40. The late phase of activation of silenced genes involves a DNA 
methylation changes and chromatin remodeling of silenced genes which relies 




1.1.3 SCNR to other differentiated cell types  
The third type of SCNR reprograms somatic cells to cell-types of the same or 
related cell lineages, providing a resource for regenerative medicine4. Two 
routes can be involved in this type of SCNR4. One is dedifferentiation and the 
other is transdifferentiation4. Dedifferentiation and transdifferentiation happen 
naturally in many animals, such as in heart regeneration in zebrafish, limb 
regeneration in urodele amphibians and Schwann cell proliferation in 
mammals4. Resulting cells could be the progenitors of the reprogrammed 
somatic cells or other types of differentiated functional cells4. Additionally, 
upon tissue injury, adult cells can dedifferentiate and gain plasticity to 
differentiate into other cell types41. 
 
Mechanistically, cell fusion can be used to study transdifferentiation. In 1983, 
Blau and colleagues fused human amniocytes with mouse muscle cells and 
made a stable heterokaryon that did not undergo cell division42. They also 
showed that muscle genes in human amniocytes could be activated by the 
cytoplasms of mouse muscle cells when the nuclei of these two cell types 
remained distinct in the heterokaryon42. Later, the same group proved that 
muscle gene activation in non-muscle cells by muscle cells is independent of 
DNA synthesis and the kinetics of gene activation are related to the plasticity 
of non-muscle cells and the germ layer difference43,44. 
 
Forced dedifferentiation and transdifferentiation can be achieved by the 
overexpression of transcription factors4. Ways to evaluate the successful 
dedifferentiation and transdifferentiation of reprogrammed somatic cells are to 
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examine the expression of cell/tissue specific genes, global expression 
profiles and to perform cell/tissue specific functional assays45,46. For example, 
fibroblasts can directly transdifferentiate into cardiomyocyes by the 
combinatorial overexpression of Gata4, Mef2 and Tbx545. Another way to 
transdifferentiate cells to other cell types is to dedifferentiate the original cell 
identity followed by differentiation condition. Take lens regeneration in newts 
as an example, Margariti and colleagues partially dedifferentiated fibroblasts 
via an induced pluripotency approach and then differentiated the partially 
dedifferentiated fibroblasts into endothelial cells by VEGF treatment46.  
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1.2 The resistance of cells to SCNR 
During development, cells become more specialized and ultimately 
differentiate to be functional as a variety of cell types. The genome-wide study 
showed that developmental specification is accompanied by chromatin 
restriction progressively47. Furthermore, exposure of collected human tissues 
and stem cells to serum triggers a distinct epigenome transition, involving de 
novo establishment of domains with features of constitutive heterochromatin47.  
 
From totipotent zygotes/cells, pluripotent stem cells, multipotent stem cells, 
unipotent progenitors to terminally differentiated cells, chromatin changes its 
conformation to be more restricted to certain cell-types along the 
developmental processes and influence the cell fate decision and 
reprogramming48. However, the maintenance and establishment of chromatin 
states for specialized cell identities become the barriers for SCNR2,49.  
 
Insufficient removal of epigenetic barriers for somatic cell nuclear 
reprogramming causes the low yield of cloned animals and abnormalities in 
developmental embryos and adults5. Mechanistically, chromatin dynamics 
during iPSC reprogramming were studied and it has been pointed out that 
complete epigenetic reprogramming is needed to prime for the transcriptional 





1.2.1 DNA methylation and SCNR resistance  
The DNA methylome of cells changes dynamically during the life cycle of 
animals and is responsible for genome stability and gene expression of 
specified cell-types53. Throughout development, global DNA demethylation 
occurs after fertilization and during the early phase of gametogenesis53. 
Afterwards, the DNA methylome builds up again for cell lineage specification 
and X-inactivation54.  
 
In terms of the relationship between DNA methylation and cell plasticity, it has 
been demonstrated that DNA demethylation is related to totipotency and 
pluripotency during early development and gametogenesis54. After fertilization, 
DNA demethylation occurs globally, including in the imprinted regions of 
genes, while the totipotent zygote is formed54. Then, the totipotent zygote 
divides into pluripotent cells of inner cell mass. The pluripotent cells keep on 
dividing and become pluripotent EpiSCs after X-inactivation (epiblast-derived 
stem cells) and pluripotent PGCs (primordial germ cells). During 
gametogenesis, PGCs then experience another DNA demethylation, genomic 
imprinting and become totipotency-competent germ cells again53-55. 
 
In addition, the stability of the DNA methylome has been shown to be 
indispensible for self-renewal of multipotent stem cells and the dynamics of 
DNA methylation is the determinant of tissue homeostasis and an abnormal 
change of DNA methylome may cause cancer56. However, despite the fact 
that X-inactivation is one of the crucial DNA methylation events during 
development, and occurs during the transition from naïve pluripotency to 
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primed pluripotency, its role remains unclear. To help explain this, Chen and 
colleagues showed that the X-inactivation was not tightly synchronized with 
differentiation although sex-related gene expression varies widely across 
these stages57. 
 
Since the DNA methylation restricts plasticity of cells and responsible for 
stability of the epigenome, it suggests that changes in DNA methylome are 
essential for SCNR58. A systematic cell-fusion study shows that DNA 
methylation functions as the memory of silenced genes in fibroblasts in the 
presence of transcriptional activators from other cell types59. 
 
 By fusion of non-muscle HeLa cells and muscle cells, muscle genes in HeLa 
nuclei were only activated under the treatment of the demethylation agent, 5-
azacytidine, and genes were activated sequentially and interdependently60. It 
has also been shown that 5-azacytidine can increase the efficiency of induced 
pluripotency61. Furthermore, DNA demethylase, AID, was shown to remove 
DNA methylation at promoters of pluripotency genes and is required for active 
DNA demethylation and initiation of nuclear reprogramming towards 
pluripotency in human somatic cells62. 
 
On the other hand, DNA methylation was shown to correlate with chromatin 
structure and to affect chromatin accessibility through methyl-CpG-binding 
domain (MBD) proteins58,63. It has been demonstrated that the MBD proteins 
Mbd3 can form a repressor complex with NuRD (nucleosome remodeling and 
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deacetylase) and enhance the efficiency of induced pluripotency to 100% 
within 7 days63. 
 
Interestingly, although DNA methylation increases during development, DNA 
methylation was also gained gradually along the process of SCNR in the 
induced pluripotency model64. After SCNR, a loss of DNA methylation is 
achieved instead when somatic cells become ESC-like cells and DNA 
methylation was shown to be a switch of pluripotency genes64. CpG-rich 
promoters of some pluripotency genes retain low methylation with strong 
engagement of histone marks and CpG-poor promoters of other pluripotency 




1.2.2 Histones and SCNR resistance  
It has long been known that histones wrap DNA and form nucleosomes as the 
basic unit of chromatin structure. To further compact DNA, nucleosomes 
interact with other regulatory proteins to form higher-order chromatin 
structures. There are two kinds of histones involved in the construction of 
chromatin structure - replication-dependent and replication-independent 
histones. These histones can change the chromatin structure by deposition 
and removal machineries and contribute to normal development, lineage 
commitment of stem cells and SCNR48,65.  
 
During development, the mobility of histones is correlated with the plasticity of 
cells. It has been shown that the mobility of core histones, H2A, H3.1, and 
H3.2, is unusually high in totipotent cells in two-cell embryos, and mobility 
decreases while totipotent cells develop into pluripotent cells25. During SCNR, 
histone variant macroH2A was shown to marks the differentiated cell states 
during mouse embryogenesis and removal of macroH2A increases the 
efficiency of induced pluripotency66. Interestingly, chromatin assembly by 
replication-dependent histones can repress basal transcription but can not 
repress the function of certain transactivators, such as Gal4-VP1667. 
 
In addition, variable histone modifications mark different chromatin regions 
and are crucial to transcriptional regulation and other functions68. For example, 
trimethylation of H3 lysine 4 (H3K4me3), H3K4me3 is a mark specifying the 
promoter of active genes. The breadth and location of it are linked to cell 
identities and broad H3K4me3 domains help to identify essential genes in 
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different cell-types69. The same study also pointed out that breadth of 
H3K4me3 correlates with the consistent expression of transcription factors, 
rather than with the expression level of transcription factors when comparing 
various cell-types69. 
 
For the repressive marks, trymethylation of H3 lysine 9 (H3K9me3), although 
it was traditionally associated with noncoding regions of the genome and 
studies have shown that it is also crucial to repress lineage-inappropriate 
genes and therefore impede SCNR70. It has been shown that ectopic 
expressed H3K9me3 demethylase, Kdm4d, could activate SCNR resistant 
genes and improves SCNR efficiency71. Additionally, SCNR efficiency can be 
improved by the depletion of H3K9 methyltransferases71.  
 
Furthermore, combining sonication-resistant heterochromatin with H3K9me3 
marked regions, these regions could more accurately predict the resistant 
genes to activation during direct cell type conversion than the genes marked 
by histone modification alone72. A recent breakthrough in SCNR shows that 
cloned non-human primate can be achieved by injection of H3K9me3 
demethylase Kdm4d mRNA and treatment with histone deacetylase inhibitor 




1.2.3 Chromatin modifiers/remodelers and SCNR resistance  
Global chromatin remodeling during differentiation leads to a progressive 
transition from a fairly open chromatin configuration to a more compact state 
and chromatin modifiers and remodelers play important roles in these 
developmental transitions73. Conversely, these chromatin states with varied 
plasticity are also critical to SCNR48. 
 
It has been reported that chromatin modifiers can be barriers or facilitators of 
SCNR74. When inducing pluripotency, inhibition of core components of 
polycomb repressive complex 1 and 2 results in both repression and 
enhancement of SCNR efficiency74. More specifically, inhibition of H3K27 
methyltransferase EZH2 reduced SCNR efficiency and suppression of 
SUV39H1, YY1 and DOT1L (H3K79 methyltransferase) enhanced 
reprogramming74. 
 
Moreover, histone chaperone CAF-1 was proven to safeguard somatic cell 
identity during induced pluripotency75. Optimal modulation of CAF-1 and 
transcription factor levels increased efficiency of induced pluripotency and 
facilitated iPSC formation in as little as 4 days75. Mechanistically, CAF-1 
suppression increases the accessibility of enhancers early during SCNR, 
followed by a decrease in somatic heterochromatin domains, an increase of 
Sox2 binding to pluripotent genes and activation of associated genes75. 
 
Interestingly, the pluripotent cells can be reprogrammed into a totipotent state 
by downregulating the replication-dependent chromatin assembly76. Ishiuchi 
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and colleagues showed that reprogramming from ESCs to totipotent 2C-like 
cells can be achieved by knockdown of the chromatin-assembly factor, CAF-1 




1.3 Strategies that lead to successful SCNR  
In previous section, it has discussed about the epigenetic barriers during 
SCNR. One genome-wide analysis for barriers in iPSC generation identified 
not only epigenetic barriers but also other putative barriers, such as genes 
involved in transcription, ubiqutination, dephosphorylation, vesicular transport 
and cell adhesion and inhibition of these barriers led to improved SCNR 
efficiency77,78. Another genome-wide study revealed factors needed at 
transition steps of induced pluripotency79. This study showed that some 
critical genes are associated with cell signaling pathways before cells acquire 
pluripotency and a specific gene set is important to mature iPSC formation79. 
 
For the establishment and maintenance of cell identities, the epigenetic states 
and transcriptional regulation are both crucial. During SCNR, transcription 
factors are mediators of reprogramming and the reestablishment of 
transcription regulator bindings on chromatin during cell division aids the 
transcriptional reprogramming80. Additionally, due to massive barriers during 
induced pluripotency, Yamanaka factors (OCT4, SOX2, KLF4 and c-MYC: 
OSKM) have been proposed as pioneer factors that can bind to target 
sequences reside in inaccessible chromatin81. In this section, the mechanisms 




1.3.1 The relationship among chromatin accessibility, TF binding and 
downstream gene regulation   
In Drosophila, a systematic study has shown that five principal chromatin 
types have been characterized by 53 selected chromatin components and 
DNA-binding factors bind to their cognate motifs differentially guided by these 
characterized chromatin types68. During Drosophila embryo development, it 
has been shown that the accessible regions of chromatin, DNase I 
hypersensitive sites, are associated with spatial-temporal expression pattern 
of linked genes82. Additionally, the level of occupancy of transcription factors 
in early Drosophila embryos on their target genes is more correlated with the 
degree of chromatin accessibility in vivo than the in vitro affinity 
measurements using purified protein and naked DNA83,84. Moreover, in highly 
accessible chromatin, transcription factors at a sufficiently high concentration 
can occupy their recognition sites without the physical cooperative aid from 
other proteins and so lead to widespread and overlapped binding patterns by 
transcription factors84. 
 
In early development of Xenopus, histone synthesis is not coordinated with 
DNA synthesis85. In Xenopus oocytes, replication-dependent histones are 
synthesized without DNA replication and the replication-dependent histones 
can repress basal gene expression and the ratio of histones to DNA 
represents the accessibility of DNA to transcription regulators67,85. After 
fertilization, histones are synthesized at a rate far more than immediate 
requirements for synthesized DNA and there is only a low amount of maternal 
gene expression and no zygotic gene expression due to the constraints of 
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chromatin accessibility to the transcription factors before mid-blastula 
transition67,85. It has been shown in Xenopus that the titration of H3/H4 
histones with an excessive amount of DNA can cause early activation of 
zygotic genes before mid-blastula transition86. Furthermore, the competition 
between unbound histones and transcription factors has been shown to cause 
early onset of zygotic gene expression before MBT in zebrafish87. 
 
In the same context, an increase or decrease in the amount of transcription 
factors can also affect the competition between histones and transcription 
factors and lead to the activation of silenced genes by transcription factors. 
During the self-renewal of pluripotent ESCs with a fixed landscape of 
chromatin structure, the amount of transcription factors controls the cell fate 
decision delicately88,89. A less than twofold increase of Oct-3/4 can cause the 
differentiation of mouse ESCs to primitive endoderm and mesoderm88; 
repression of Oct-3/4 can cause the loss of pluripotency and dedifferentiation 
of mouse ESCs to trophectoderm88. Additionally, a minor increase (less than 
twofold) of Sox2 in mouse ESCs leads to the differentiation to a wide range of 
cell-types, including neuroectoderm, mesoderm, and trophectoderm but not 
endoderm89.  
 
Interestingly, in the process of induced pluripotency, different levels of 
expression of KLF4 pause the partially reprogrammed iPSCs at successive 
stages and it may relate to the onset of different pluripotency genes following 
the increase of the expression of KLF490. In their study, Nishimura and 
colleagues analysed the effect of decreasing expression levels of OCT4, 
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SOX2, KLF4 and c-MYC and found that the expression level of KLF4 
reproducibly derives homogenous populations of partially reprogrammed 
iPSCs90. The different expression levels of KLF4 pause partially 
reprogrammed iPSCs at distinct intermediate stages and up-regulation of 
KLF4 leads cells to resume reprogramming and increases expression levels 




1.3.2 The effect of the combination of TFs on chromatin accessibility 
The binding of transcription factors to their recognition sites is correlated with 
chromatin accessibility during development and winning the competition with 
the unbound histones can lead to the reactivation of silenced genes82-84,87. In 
terms of the selection of a combination of transcription factors, this is 
unrelated to the cell-types and species since the combination of Oct4, Sox2, 
Klf4 and c-Myc (OSKM) gives rise to mouse iPSCs from several cell-types 
and the homologs of OSKM gives rise to the iPSCs in many species31.  
 
Furthermore, different combinations of transcription factors can also induce 
pluripotency although the majority of the combinations are still based on the 
combination of OSKM31. For example, the combination of OCT4, SOX2, 
NANOG and LIN28 can also be used to induce human iPSCs31,91. 
Interestingly, the OSKM based combination can be interchangeable with 
homologs of other species, such as the utilization of mouse OSKM to induce 
Xenopus iPSCs in vivo92. 
 
Since the binding of transcription factors largely relies on the landscape of 
chromatin accessibility, the increase of chromatin accessibility is essential for 
induction of pluripotency by OSKM at the beginning. With the aid of cell 
division, induced pluripotency is hypothesized to reverse this 
developmentally-imposed repression and it is believed to immensely change 
the chromatin structure of terminally differentiated somatic cells to a 
pluripotent state by combinations of few transcription factors80. It has been 
demonstrated that the inhibition of the p53/p21 pathway or overexpression of 
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Lin28 could increase the cell division rate and lead to accelerated kinetics of 
iPSC formation93. Interestingly, Nanog overexpression can also accelerate 
induced pluripotency reprogramming in a predominantly cell-division-rate-
independent manner93. 
 
Additionally, the combination of Oct4, Sox2 and Klf4 (OSK) without c-Myc has 
been proven to reset the epigenomes of somatic cells by upregulating the 
expression of several chromatin remodelers and chromatin modifiers94. 
Furthermore, the cooperative binding of OSK on enhancers of somatic genes 
early in the reprogramming process immediately initiates the redistribution of 
somatic TFs on enhancers of somatic genes and results in the repression of 
them by recruiting Hdac195. Some of the enhancers of pluripotency genes are 
bound by OSK in early reprogramming but most of them are selected later in 
reprogramming by OS and other pluripotency genes95. 
 
Altogether, the combination of OSKM to induce pluripotency from various 
somatic cells is versatile in many species31. The combination of OSKM can 
lead to the similar regulation of downstream genes via the cooperative 
interaction with other transcription regulators from the beginning to the 
completion of induced pluripotency and can reconstruct the chromatin 




1.3.3 Pioneer transcription factors and inaccessible regions of chromatin  
During development, chromatin accessibility defines the binding of TFs and 
the regulation of downstream genes by TFs. However, the combination of 
OSKM can reverse this process through mechanisms involving the change of 
landscape of chromatin structure93-95. It is understandable that the 
combination of OSKM may lead to the bindings to regulatory elements of their 
target genes. Conversely, it may be ideal that one or more of OSKM are 
pioneer transcription factors and can open closed chromatin, bind to target 
sequences and recruit other transcription factors to regulate necessary 
downstream genes for inducing pluripotency. 
 
In development, evidences have emerged for the roles of pioneer transcription 
factors in ESCs and early stages of development96. Take Foxa1 as an 
example, Foxa1 is a liver-specifying gene and expression initiates in the gut 
endoderm at E7/E8 of mouse embryos97. Foxa1 virtually regulates all the 
liver-specific genes and the binding of Foxa1 to inactive genes indicates its 
pioneer capability97. It has been shown that the early stages of liver 
development depend on Foxa1 and Foxa2 in vivo and the primary cells from 
Foxa1/Foxa2-deficient endoderm fail to initiate expression of liver-specific 
genes under the stimulation of exogenous FGF2 in vitro98. Therefore, Foxa1 
is competent to initiate expression of liver-specific genes.	
 
It has been reported that the high nucleosome-binding affinity of Foxa1/2 
contributes to the slower nuclear mobility of Foxa1/2 when compared with 
other transcription factors99. In addition to that, the slower nuclear mobility of 
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Foxa1/2 is caused by its non-specific binding due to the resemblance 
between DNA binding domain of Foxa proteins and linker histone99. However, 
it has been proven that Foxa1 may not always be the first transcription factor 
entering the closed chromatin and the bindings of steroid receptors are 
sometimes the first to enhance the binding of Foxa1100. 
 
Although it is controversial, pioneer factor activity may still be controlled by 
transcription factors, which can contribute to the SCNR. One example is the 
transdifferentiation of terminally differentiated fibroblasts or hepatocytes to 
induced neurons by the combination of Ascl1, Brn2 and Myt1l101,102. Ascl1 is 
shown to be a pioneer factor among these103. 
 
Furthermore, OSK, as potential pioneer factors, have been shown to promote 
induced pluripotency by binding to enhancers of silent pluripotency genes 
marked with H3K9me3, and these H3K9me3 marked regions prevent the 
initial binding of OSKM and impede the efficiency of reprogramming104. 
Moreover, the partial nucleosome-binding affinity of OSK has been reported to 
be evidence of OSK as pioneer factors105. By contrast, the change of 
epigenome during induced pluripotency is shown to be a downstream effect 
via the upregulation of several chromatin modifiers and remodellers94. 
Moreover, enhancers of silent pluripotency genes can only be bound by OSK 
cooperatively while there is no binding to enhancers by these pluripotency 
genes by overexpression of a single TF95. 
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1.4 The Yamanaka factors in ESCs and Xenopus eggs/oocytes 
contribute to maintain and induce pluripotency 
During induced pluripotency, it is evident that the overexpression of OSKM 
leads to ESC-like chromatin structures regardless of the original cell-types, 
although the mechanisms for the reconstruction of chromatin towards a 
pluripotency state by the combination of OSKM are elusive31,35. Therefore, it 
implies that diverse chromatin structures of various cell-types would be 
destined to uniform ESC-like chromatin structure by the combinatorial 
regulation of OSKM with the help of unknown mechanisms106. Then, the ESC-
like chromatin structures would be susceptible to certain extracellular stimuli 
and differentiate into all kinds of somatic cells. 
 
Interestingly, nuclear transfer into eggs (Egg-NT) follows the same conceptual 
transitions except that a totipotent chromatin structure is set as a result and 
the SCNR determinants for Egg-NT are more complicated than the 
combination of Yamanaka factors for induced pluripotency. For epigenetic 
reprogramming, the chromatin structural change by Egg-NT has been 
discussed in previous sections and in reviews5,26. In this section, I will 





1.4.1 Yamanaka factors in pluripotent cells maintain pluripotent chromatin 
conformation   
Pluripotency is a state that exists transiently in the early embryo and can be 
recapitulated in vitro by deriving embryonic stem cells or by induction of 
pluripotency in somatic cells107. The state of pluripotency is stabilized by a 
gene regulatory network of transcription factors and the epigenome of 
pluripotent cells is proposed to be under the control of TF network108. By 
integrating external signals and exerting control over the decision between 
self-renewal and differentiation, the imbalance of TF network would lead to 
the exit from pluripotency107.  
 
It has been reported that cell fusion with pluripotent cells would epigenetically 
reprogram the somatic cells, including DNA demethylation and reactivation of 
an X chromosome62,109. This means the factors within the pluripotent cells 
execute this epigenetic reprogramming process and maintain the self-renewal 
of pluripotent cells at the same time. For the maintenance of ESCs, it has 
been shown that Oct3/4 and Sox2 cooperatively activate Lefty1 by binding to 
its enhancers, mediated by the binding of Klf4 on its promoter110. Since Oct3/4 
and Sox2 are the core factors that supports the self-renewal of ESCs, the 
precise level of them is critical to govern the distinct fates of ESCs towards 
differentiation, dedifferentiation or self-renewal88,89,111. A small increase in the 
level of Sox2 would lead to the inhibition of its own expression and down-
regulate some Sox2:Oct-3/4 downstream genes possibly via feedback and 
feedforward gene regulation control89,111. 
 
	 35	
The binding of Yamanaka factors determines the continuity of the self-renewal 
circuit and the chromatin structure of pluripotent stem cells can be maintained 
by a core regulatory network in defined culture medium112. The TF network 
and signaling pathways defines the core regulation of a cell and explains the 
maintenance of pluripotent chromatin structure and pluripotent 
transcriptomes112. In mice, ESCs cultured in 2i/LIF are naïve-pluripotent and 
EpiSCs cultured in FGF/activinA medium are primed-pluripotent112. Under 
2i/LIF conditions, Oct4 primarily induces Klf2 expression, compared with Klf4 
expression, and LIF/Stat3 selectively enhances Klf4 expression113. The LIF 
dependence is reduced by overexpression of either Klf2 or Klf4 and the 
expression of either of these can reinstate naïve pluripotency from primed-
pluripotent EpiSCs113. Additionally, Klf2 sustains ground state pluripotency via 
the inhibition of Mek/Erk pathways while both prodifferentiation Mek/Erk and 
Gsk3/Tcf3 are inhibited under 2i/LIF condition114. Moreover, the Mek/Erk/Klf2 





1.4.2 The redundancy of Yamanaka factors in maintenance and induction of 
pluripotency  
Since the DNA binding domains of TFs belong to the same families and some 
members of a TF family have an identical or similar canonical binding motif, 
the functions of TFs would not totally depend on recognition of binding sites 
but also be context-dependent in maintenance and induction of pluripotency, 
early development and cancer115-117. The context-dependent functions of TFs 
in the same family are sometimes redundant while some members of the 
same TF family are interchangeable in the same context115-117. For Yamanaka 
factors, some family members can compensate them for sustaining self-
renewal of pluripotent stem cells and inducing pluripotency. 
 
Klf2, 4 and 5 have been shown to redundantly bind and regulate crucial 
pluripotency genes in mouse ESCs and to sustain self-renewal of ESCs118. 
Therefore, the spontaneous differentiation of mouse ESCs can only be 
achieved under triple siRNA knockdown of Klf2, 4 and 5 altogether while the 
triple siRNA knockdown leads to the loss of self-renewal of mouse ESCs118.  
 
Nevertheless, it has also been reported that Klf2, 4 and 5 regulate different 
sets of genes in mouse ESCs and therefore play different roles in self-renewal 
of mouse ESCs119,120. Moreover, inactivation of Klf5 by zinc finger nuclease 
has been shown to downregulate expression of pluripotency genes and to 
attenuate colony formation in mouse ESCs121. It has further been indicated 
that Klf4 and Klf5 differentially bind and repress endoderm and mesoderm 
markers in mouse ESCs, respectively, and knockdown of either of these 
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genes leads to the enhancement of differentiation towards endoderm or 
mesoderm in early embryo development122. 
 
During induced pluripotency and self-renewal of pluripotent stem cells, SOX1, 
SOX3 and re-engineered SOX7 and SOX17 have been reported to be 
functionally redundant with SOX2117. Interestingly, Sox7 and Sox17 can be 
converted to be reprogramming factors by a single amino-acid alteration 
within its DNA binding domain, HMG. Sox7EK and Sox17EK with a single 
amino-acid mutation from glutamate (E) to lysine (K) can replace Sox2 and 
interact with Oct4 to induce pluripotency while Sox4EK, Sox5EK, Sox6EK, 
Sox8EK, Sox9EK, Sox11EK, Sox12EK, Sox13EK and Sox18EK cannot123. 
Moreover, the C-termianl transactivation domain of Sox7 and Sox17 
enhances the potency of Sox2 to induce pluripotency and confers weak 




1.4.3 Yamanaka factor homologs in Xenopus and other species during early 
development    
Since we are using the Xenopus system to study SCNR in our lab, it is useful 
to understand the roles of Yamanaka factor homologs in early development of 
different species and evaluate the conservation of these factors in our system. 
 
The pluripotent gene, POU5F1 (OCT4), is a key regulator of stem cell fate 
and homologues of POU5F1 present throughout vertebrates116. In Xenopus, 
transcripts of members of Pou family are very abundant during early 
embryogenesis and absent from most somatic tissues124. During early embryo 
development, xpou60, xpou25 and xpou91 are highly related to mammalian 
Oct-3/4 and sequentially expressed124. Transcripts of xpou60 are maternally 
expressed in Xenopus oocytes and the xpou60 proteins are present in 
oocytes and in early embryos until gastrulation124,125. Transcripts of xpou25 
are present at a low level in oocytes and early embryos and are upregulated 
greatly in early gastrulation but xpou25 proteins are detected during 
gastrulation, not in oocytes and early embryos124. Transcripts of xpou91 are 
induced after midblastula transition and reach the highest level in late 
gastrulation124.  
 
Since xpou60 is expressed in oocytes but not expressed in somatic cells and 
the oocyte extract can activate xpou60 in somatic cells through the Oct-Sox 
binding motif, it suggests the expression of xpou60 in oocytes is possibly 
regulated by a positive feedback loop125. Furthermore, the expression of 
xpou25, xpou60 and xpou91 decrease during late gastrulation and early 
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neurulation due to the repression by sall4 for promoting posterior neural 
fates126. 
 
In the mouse, Oct4 is restricted to inner cell mass and plays a key role in 
lineage segregation of trophectoderm and inner cell mass127. However, in the 
pig, Oct4 is not restricted to inner cell mass cells and Sox2 becomes a 
pluripotency marker instead since Sox2 restricts to the inner cell mass127. 
Therefore, transcription factors related to lineage specification may be 
variable among species and the corresponding TF networks may differ as a 
result although the phenotypic outcomes are the same. 
 
During Xenopus embryogenesis, members of Klf families, such as xklf2, xklf4, 
xklf5, xklf6, xklf7, xklf8, xklf11, xklf15 and kxlf17, are involved in germ layer 
formation and body axis patterning128,129. It has been shown that these Klf 
family members are expressed in early Xenopus embryos with different 
spatial-temporal patterns128,129. Interestingly, each Klf member regulates 
distinct sets of genes that are essential for germ layer specification and body 
axis formation and sometimes there is an overlapping regulation of these 
downstream genes among different Klf members128,129. This explains the 
redundancy of some transcription factors of the same families while some of 
their downstream genes are overlapping but some other downstream genes 




1.4.4 The interspecies regulation and conservation of transcription factors in 
pluripotency from an evo-devo view  
Although conserved Yamanaka factors can be found not only in human and 
mouse but also in Xenopus and other species, the interspecies difference in 
transcriptional regulation of these factors is unclear. Interestingly, one study 
compared ChIP-seq among five vertebrates to determine the genome-wide 
occupancy of two TFs, C/EBP alpha and HNF4 alpha130. It showed that most 
binding is species-specific and aligned binding events present in all five 
species are rare although the DNA binding preferences are highly conserved 
for each TF130. Binding divergence between species can be explained by 
sequence changes to the bound motif and the interspecies transcriptional 
regulation is different evolutionarily130. 
 
For the homologues of pluripotent factor POU5F1, they are functionally 
conserved to regulate early embryonic potency and differentiation and exist 
throughout vertebrates. Mouse Pou5f1 (Oct3/4) was firstly identified among 
class V members of POU family and is a central regulator of ESC pluripotency 
and induced pluripotency116. Notably, some vertebrate lineages have both 
POU5F1 and POU5F3 orthologues whereas others have either only POU5F1 
or only POU5F3116. In Xenopus, three POU5F3 genes but no POU5F1 genes 
are present. These three POU5F3 genes are pou5f3.1 (xpou91), pou5f3.2 
(xpou25) and pou5f3.3 (xpou60), and only pou5f3.1 is expressed in primordial 




The Pou2 and Oct4 genes evolved from a POU class V gene ancestor. Some 
Pou2 and Oct4 homologues of different vertebrates, such as medaka and 
axolotl, were shown to induce pluripotency in mouse and human fibroblasts131. 
These results indicate that induction of pluripotency is not restricted to 
mammals but exists in the Oct4/Pou2 ancestral vertebrate131. 
 
It has been reported that PouV proteins of Xenopus and the axolotl, namely 
xpou25, xpou60, xpou91 and amOct4, can bind to an octamer-binding motif 
and support self-renewal of mouse Oct4-depleted ESCs132. Mouse Oct4 and 
axolotl Oct4 can rescue the xpouV-deleted phenotype of Xenopus embryos132. 
In addition, transcriptional activation of mouse Oct4 and Xenopus xpou91 by 
fusion with the activation domain, VP60, supports maintenance and induction 
of pluripotency and alleviates the dependence of LIF in ESC maintenance 
medium133. 
 
Interestingly, induced pluripotency can be achieved by direct delivery of 
mouse OSK into Xenopus muscle fibers92. Xenopus pluripotency genes can 
be activated by mouse OSK and xventx2, which functionally resembles Nanog, 
is induced consequently92. Furthermore, these pNanog-GFP positive cells can 
differentiate into derivatives of three embryonic lineages in vitro and into 
neurons and muscles in vivo 92. While Xenopus do not have a NANOG gene, 
axolotl Nanog activity was proven to support the ground state pluripotency of 
mouse ESCs and demonstrates that the mechanisms governing pluripotency 
are conserved from urodele amphibians to mammals134. 
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Chapter 2 Materials and Methods  
 
2.1 Introduction 
In our lab, we use nuclear transfer to oocytes (Oocyte-NT) to study the 
possible mechanisms involved in somatic cell nuclear reprogramming. 
 
In my thesis, I investigated the similarity and difference between nuclear 
transfer to oocytes and overexpression of transcription factors (TFs) through 
time course observations. By directly overexpressing single transcription 
factor in oocytes before Oocyte-NT, the transcriptional reprogramming 
induced by oocyte factors and the effect of TF overexpression on gene 
regulation during this process is compared.   
 
At first, I tested six Yamanaka homologs and one pioneer TF and selected 
xklf2-HA to perform the genome-wide evaluation via RNA-seq plus BrUTP 
pull-down. In addition, I used three cell types to perform Oocyte-NT and tried 
to find the nuclear reprogramming resistant genes in different cell types.  
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2.2 Overexpression of TF proteins in Xenopus oocytes 
Thanks to Jullien J, Garrett NJ and previous lab member, Pasque V, I 
received 6 plasmids of Yamanaka factors, including hOCT4-HA, mSox2-HA, 
hKLF4, xpou60-HA, xsox2-HA and xklf2-HA, in the laboratory repository. 
These plasmids can be used directly for in vitro transcription. For the pioneer 
transcription factor mFoxa1, the original plasmid pBabe-puro-FoxA1 was a gift 
from Prof Kenneth S. Zaret. The wild-type mFoxa1 on pBabe-puro-FoxA1 
contains a missense mutation possibly due to long-term cultivation so I 
mutated it back (Appendix I, page 318) referred to the published sequence 
(NM_008259.3) and added an HA tag to it through Gateway cloning system, 
as instructed by Jullien J and as referred to in manufacturers’ protocols. 
 
2.2.1 Plasmid construction 
The coding sequence of mFoxa1 in pBabe-puro-FoxA1 plasmid was first 
amplified by high-fidelity DNA polymerase (Phusion High-Fidelity DNA 
polymerase, 2U/µl, Cat No M0530, New England Biolabs). Since the mFoxa1 
coding sequence of pBabe-puro-FoxA1 plasmid was spotted with a missense 
mutation from Ser-12 to Asn-12, the mutation of plasmid was firstly mutated 
back to the original Ser-12. To add a T7 promoter and HA tags to the N-
terminus of mFoxa1, the mFoxa1 coding sequence on pTOPO-mFoxa1 
plsamid was recombined with pCS2-3HA-attR vector via LR clonase 




2.2.2 In vitro transcription 
Each constructed plasmid that contains the coding sequence of a transcription 
factor and a T7 promoter was used as starting materials for in vitro 
transcription. First, constructed plasmids were linearized by restriction 
enzymes and treated with proteinase K (800 units/ml, NEB). The linearized 
plasmids were then purified by phenol/chloroform extraction and ethanol 
precipitation. The resulting products were then used for producing TF mRNA 
with the RNA cap analog (m7G(5’)ppp(5’)G RNA cap structure analog, NEB) 
via in vitro transcription (MEGAscript T7 transcription kit, Thermo Fisher 
Scientific). The mRNA yield was then purified by spin-column chromatography 
(Illustra Microspin G-50 column, GE Healthcare), phenol/chloroform extraction 
and ethanol precipitation. The mRNA pellet then dissolved in DNase/RNase 
free H2O, aliquotted, snap-frozen on dry ice and stored in -70℃ freezer. 
 
2.2.3 Western blotting and oocyte dissection 
Having in vitro synthesized TF mRNA, the TF mRNA was injected into 
cytosols of Xenopus oocytes to produce TF proteins and TF protein 
production and localization can be evaluated via Western blotting. First, 
different doses of TF mRNA were injected into oocytes and collected at 
different time points after incubating the mRNA-injected oocytes at 18℃. Then, 
the oocytes were dissected in mineral oil and the fractions of cytosols and 
GVs were collected separately to confirm newly-made TF proteins are 
transported into GVs. Western blotting was then run to probe the newly-made 
TF proteins in different fractions and LI-COR Odyssey® CLx Imaging System 
was utilized to quantify the relative amount of newly-made TF proteins.  
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2.3 Nuclear transfer into Xenopus laevis oocytes 
Nuclear transfer into Xenopus laevis oocytes (Oocyte-NT) starts with 
preparing Xenopus oocytes, which were individualized and detached from 
layers of follicular cells by liberase treatment. Before Oocyte-NT, the oocytes 
of experimental groups were injected with TF mRNA and incubated at 18℃ 
for 24 hours. The donor cells used for Oocyte-NT were then permeabilized 
with streptolysin O (SLO) and the holes of permeablized cells allow oocyte 
factors and newly-made TF proteins to enter the cells immediately after 
Oocyte-NT. The experimental details refer to the paper of our previous lab 
member, Halley-Stott RP135. 
 
2.3.1 Xenopus oocyte preparation 
In all the experiments, the stage V/VI oocytes were used. Firstly, the ovaries 
were taken from the adult female Xenopus Laevis. The oocytes connected 
with stroma tissue were torn apart as strings by forceps and put into 50ml 
conical tubes.  The strings of oocytes were then treated with liberase (Roche, 
28U/ml in H2O) for 2 hours with gentle agitation (15 rpm). Then the liberase 
was washed away from the oocytes with 1X MBS and the stage V/VI oocytes 
with diameter range of 1 to 1.2 mm were selected for the following 
experiments. The selected oocytes were placed in petri dish in 1X MBS at 
16℃	and the follicular cell layer would detach in an overnight incubation. The 
oocytes were then stored in 1X MBS with 0.1% FBS at 16℃ and ready for 
manipulation.   
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2.3.2 Cell culture 
I have used four cell lines for nuclear transfer. B10 CHD4 is a mouse 
embryonic stem cell (mESC) line, TcR2 and sixiFM are mouse embryonic 
fibroblast (MEF) cell lines and C2C12 is mouse myoblast (mMyo) cell line.  
B10 CHD4, requires medium renewal everyday and medium contains GMEM, 
20% fetal bovine serum, leukemia inhibitory factor, non-essential amino acid, 
β-mercaptoethanol, sodium pyruvate, penicillin, streptomycin and fungizone. 
The flasks or dishes used for B10 CHD4 require gelatin coating before 
seeding. For MEF and mMyo cell lines, the medium needs to be renewed 
every two to three days and it contains DMEM, 10% fetal bovine serum, 
penicillin, streptomycin and fungizone. Cells were subcultured or frozen when 
they reached subconfluence and incubated at 37℃ with 5% CO2. 
 
2.3.3 Cell permeabilization 
Cells were cultured to semi- to sub-confluence. Cells were washed twice with 
PBS and detached with trypsin for 5 to 10 minutes at 37℃. Trypsin was 
neutralized with DMEM and cells were individualized by pipetting. Cells were 
centrifuged at 500 rpm for four minutes, the supernatant was discarded and 
the cells were resuspended with PBS. Cells were centrifuged at 2000 rpm for 
one minute and PBS was replaced with SuNaSp solution. Cells were 
centrifuged at 2000 rpm for one minute and the supernatant was discarded. 
20ul SLO (20,000 units/ml in PBS, containing 0.01% BSA and 5mM DTT, 
Sigma-Aldrich, S5265) was added plus 100ul SuNaSp solution for 3-6x106 
cells135. Cells were then resuspended by pipetting and permeablized at 37℃ 
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in a waterbath for one minute. Cells were incubated on ice and some cells 
were taken to check permeablization efficiency (95~99%) under a microscope 
by trypan blue staining. SLO reaction was stopped by adding SuNaSp BSA. 
Cells were centrifuged at 2000 rpm for one minute, the supernatant was 
discarded and then resuspended with SuNaSp BSA solution. Cells in SuNaSp 
BSA solution were then aliquotted, snap-frozen on dry ice and stored in a -70
℃ freezer. 
 
2.3.4 Nuclear transfer 
Pull the needles with suitable size for nuclear transfer. Mix cell suspension 
with plasmid encodes cytoplasmic membrane GFP. Inject 9.2nl cell 
suspension (300~500 cells) with 5pg plasmid of cytoplasmic membrane GFP 
into germinal vesicle of each oocyte. During Oocyte-NT, the permeabilized 
cells were sucked into micropipettes via Drummond Nanoinject injector and 
injected into GV of oocytes. Select GFP positive oocytes 24 hours after 
nuclear transfer. Collect samples at needed time points, snap-freeze samples 
on dry ice and store samples in -70℃ freezer. 
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2.4 Measurements of transcriptional reprogramming by 
oocytes and effects of overexpression of transcription factors 
Transcriptional changes after nuclear transfer are measured by two methods. 
One is quantitative PCR (QPCR) and the other is RNA-seq plus BrUTP pull-
down. Through time-point observations, QPCR shows the change of relative 
amount of transcripts in the donor cells and after nuclear transfer and RNA-
seq plus BrUTP shows the change of relative amount of newly-synthesized 
transcripts after nuclear transfer. The effect of overexpression of transcription 
factors can be evaluated by comparing the expression level of genes between 
nuclear transfer samples in the presence and absence of overexpressed 
transcription factors by both methods. The protocols are adapted and 
experimental details can refer to papers of our lab members and Nature 
protocols135-137. 
 
2.4.1 RNA extraction 
Collect Oocyte-NT samples as groups of ten for RNA extraction. Qiagen 
RNeasy Mini Kit is used for RNA extraction and procedures are modified for 
our purpose. Briefly, lyse Oocyte-NT samples with 900ul RLT buffer and votex 
for 4 minutes at 4℃. Add 900ul 70% ethanol and transfer mixture to RNeasy 
spin column. Centrifuge at 10,000 rpm for 30 seconds and discard flow-
through. Add 350ul RW1 buffer and centrifuge at 10,000 rpm for 30 seconds. 
Discard flow-through and add 80ul DNase I incubation mix. Incubate at room 
temperature for 15 minutes, add 350ul RW1 buffer and centrifuge at 10,000 
rpm for 30 seconds. Discard flow-through and add 500ul RPE buffer and 
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centrifuge at 10,000 rpm for 2 minutes. Place RNeasy spin column in new 2ml 
collection tubes and centrifuge at full speed for 1 minute. Place RNeasy spin 
column in new 1.5ml eppondorf and add 50ul RNase-free H2O. Centrifuge at 
10,000 rpm for 1 minute and measure RNA concentration by Nanodrop. 
Snap-freeze RNA extracts on dry ice and store RNA extract in -70℃ freezer. 
 
2.4.2 Reverse transcription 
SuperScript III Reverse Transcriptase Kit is used for reverse transcription. 
Briefly, mix 5ug RNA extract with 1ul gene-specific primer (100uM, Sigma-
Aldrich) and 1ul dNTP mix (10mM) and add RNase-free H2O to total 13ul. 
Heat mixture at 65℃ for 5 minutes and incubate on ice for at least 1 minute. 
Add 4ul 5X FS buffer, 1ul 0.1M DTT, 1ul RNase inhibitor and 1ul RNase-free 
H2O into mixture. Pipette mixture gently. Incubate mixture at 55℃ for 60 
minutes and increase to 70℃ for 15 minutes. Store cDNA in -20℃ freezer. 
 
2.4.3 QPCR 
SYBR Green Ready Mix (Sigma-Aldrich) is used for QPCR. Primers for 
neurogenic genes are listed in the Appendix II (page 324) and primers for 
pluripotency genes are listed in Halley-Stott’s paper135. For most experiments, 
50ng cDNA per well of a QPCR plate is used and cDNA is increased for 
genes of interest which are difficult to detect. mGapdh is used for 
normalization since the expression level of mGapdh is not changed before 
and after nuclear transfer and can be a indication of the number of 
transplanted donor cells.  
	 50	
2.4.4 RNA immunoprecipitation 
For labeling newly synthesized RNA and to exclude carry over in donor cells, 
BrUTP is injected into oocytes two hours after Oocyte-NT. Oocyte-NT 
samples are collected and RNA is extracted as previously mentioned. For 
immunoprecipitating BrUTP-labelled RNA, the first step is to prepare anti-
BrUTP conjugated agarose beads. Wash 100ul beads (for 5 samples) twice 
with 1ml Buffer I and block beads with 500ul Blocking buffer at 4℃ for 1.5 
hours. Centrifuge beads solution at 3000 rpm for 3.5 minutes at 4℃ and 
remove supernatant. Make RIP buffer by mixing 1170ul Binding buffer and 
30ul SUPERase•In RNase Inhibitor and distribute 200ul RIP buffer into 5 
eppondorf for immunoprecipitation. Use 25-50ug RNA extract per sample and 
add 2.5ul SUPERase In RNase Inhibitor into each sample. Heat RNA extract 
at 65℃ for 5 minutes, incubate on ice for at least 1 minute and spin down. 
Immunoprecipitate RNA with 200ul RIP buffer overnight at 4℃. Wash RNA 
bead mixture with Low salt buffer once, with High salt buffer twice and TET 
buffer once. Elute immunoprecipitated RNA with 100ul Elution buffer by 
incubating at room temperature for 1 minute. Centrifuge at 3000 rpm for 4 
minutes and collect supernatant. Repeat the elution steps 4 times. Extract 
eluted RNA by phenol/chloroform extraction and ethanol precipitation. Clean 
up RNA extract with Qiagen RNeasy Plus Micro Kit and measure 





Ovation Single Cell RNA-seq System is used to prepare RNA-seq libraries 
from newly-synthsized RNA. 10ng of newly-synthesized RNA is used for each 
sample preparation. Follow the steps provided by manufacturers. cDNA 
reverse transcribed from newly-synthesized RNA is then obatained and 
amplified as RNA-seq libraries. RNA-seq libraries were validated by Tape 
Station and sequenced on Illumina HiSeq 2000 and 4000 for SE 50. RNA-seq 
results were processed by our lab member, Simeone A (Appendix III, page 
325). Then I analysed results further by Excel, Matlab, Gene ontology, Venn 





Chapter 3 The effect of mammalian and Xenopus 
Yamanaka factors on somatic cell nuclear 




Somatic cell nuclear reprogramming (SCNR) is the process by which the 
terminally differentiated cell nuclei are reversed to totipotent or pluripotent 
states. This can be achieved by transferring a somatic cell nucleus into a 
mature and unfertilized egg (Egg-NT)12 or overexpressing a combination of 
three to four Yamanaka factors (YFs) or other transcription factors into 
somatic cells (induced pluripotency)32. Even now, the efficiency of SCNR via 
Egg-NT or induced pluripotency is low and the mechanistic details of how they 
work are unclear. To elucidate the mechanistic details of SCNR, especially 
the role of transcription factors, I combine both systems by overexpressing 
one of the Yamanaka factors before Oocyte-NT and evaluate how each of 
these affects SCNR by Xenopus oocytes. 
 
In this chapter, I selected six YFs, including three mammalian YFs and three 
Xenopus YFs. The reason for choosing two sets of YFs is that Oocyte-NT is 
usually an interspecies interaction when the transplanted nuclei do not belong 
to Xenopus laevis. A comparison of homologs between Xenopus and 
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mammals helps to elucidate how conserved the function of an YF is in the 
context of SCNR. 
 
3.1.2 Experimental design 
Before performing Oocyte-NT, the production and localization of each YF in 
Xenopus oocytes were checked by Western blotting (Figure 3.1.A). Different 
doses of YF mRNA were injected into the cytosol of Xenopus oocytes and the 
oocyte samples were collected at different time points from 6 hours to 6 days 
after mRNA injection. One day and three days after mRNA injection are the 
main time points to check since these time points coincide with the time points 
when Oocyte-NT is performed and the samples are collected. The protein 
counterpart of each YF mRNA was made in the cytosol and transported into 
germinal vesicle (GV) where it executed its function. The localization of 
synthesized YF proteins was checked by dissecting the GV directly from the 
oocytes and the relative amount of each YF in the GV fraction and cytosol 
was compared in Western blotting analysis. 
 
To evaluate the effect of each YF homolog on pluripotency genes during 
SCNR by oocytes, Oocyte-NT was performed and, 24 hours before Oocyte-
NT, 9.2 ng mRNA of one YF was injected into the cytosol of Xenopus oocytes 
(Figure 3.1.B). For Oocyte-NT, sixiFM MEFs were transplanted into GVs of 
Xenopus oocytes (~300-500 cells per oocyte). Two days later, Oocyte-NT 
samples were collected and RNA was extracted. The expression of 
pluripotency genes was then examined via QPCR.  
	 54	
 
Figure 3.1 Sample preparation of Western blotting for evaluating the protein 
production and localization of YF homologs (A) and sample preparation of QPCR for 
evaluating the effect of YF homologs on pluripotency genes (B) are shown.  
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3.2 Mammalian Yamanaka factors can be produced in 
Xenopus oocytes after mRNA injection and regulate 
pluripotency genes in MEFs at Day 2 after Oocyte-NT 
To evaluate the effect of mammalian YFs on pluripotency genes during SCNR 
by oocytes, three mammalian YFs were selected, namely hOCT4-HA, mSox2-
HA and hKLF4. Because the regulation of downstream genes by transcription 
factors usually follows in a dose-dependent manner, the production and 
localization of mammalian YFs after mRNA injection were examined via 
Western blotting before performing Oocyte-NT (Subsection 3.2.1). After 
confirming that the YF proteins can be produced in the cytosol and 
transported into GVs, Oocyte-NT was performed (Subsection 3.2.2). 
 
3.2.1 The production and localization of mammalian YFs after mRNA injection 
in Xenopus oocytes 
To confirm if the mammalian YFs can be produced in the Xenopus oocytes, 
Western blotting was performed. Different doses of YF mRNA were injected 
into the cytosol of Xenopus oocytes at Day 0 and samples were collected at 
different time points after mRNA injection. The localization of newly 
synthesized YF proteins was evaluated by comparing the amount of YF 
protein in the GV fractions to the amount in the cytosol fractions or whole 
oocytes. The YF proteins on the Western blots were recognized by anti-HA 
antibody (hOCT4-HA, mSox2-HA) or by the antibody against the epitopes of 
the proteins (hKLF4) and anti-actin antibody was used to recognize the 
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internal control, actin. The amount of YF protein was quantified by LI-COR 
Odyssey® CLx Imaging System. 
 
3.2.1.1 Human OCT4-HA 
3.2.1.1.1 The amount of hOCT4-HA protein increases dose-dependently and 
decreases at Day 2 or Day 3 after mRNA injection 
 
On the Western blot (Figure 3.2.1.A), three doses were chosen (4.6, 9.2 and 
13.8 ng) for examining hOCT4-HA protein production and the samples 
collected at different days (Day 1, 2, 3 and 5) after mRNA injection. Each lane 
was loaded with a sample of 0.5 equivalent of whole oocyte. The black arrow 
indicates the position of hOCT4-HA protein bands and the signal intensity of 
hOCT4-HA protein bands is quantified and shown as numbers above the 
rectangles containing the quantification areas.  
 
Comparing the samples collected at different days after injecting the oocytes 
with different doses of hOCT4-HA mRNA, the production of hOCT4-HA 
proteins is dose-dependent from 4.6 ng to 13.8 ng (Figure 3.2.1.A and B). For 
example, the signal intensity of Day 1 samples increases from 18700 for 4.6 
ng, 38100 for 9.2 ng to 41400 for 13.8 ng. Besides, the increase of hOCT4-
HA proteins in Day 1 samples reaches a plateau after the dose of hOCT4-HA 
mRNA at 9.2 ng since the change of signal intensity of hOCT4-HA proteins 
from 9.2 ng to 13.8 ng tends to level off (Figure 3.2.1.B). 
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However, the amount of hOCT4-HA protein decreases at Day 2 or Day 3 after 
mRNA injection because the signal intensity of all the doses of Day 2/Day 3 
are lower than the signal intensity of corresponding doses of Day 1 samples. 
It is hard to judge when the amount of hOCT4-HA protein starts to decrease 
since the signal intensity of hOCT4-HA protein bands of Day 2 samples for 
each mRNA dose is less than the signal intensity of samples for 
corresponding doses of any other days. Therefore, it is likely that the protein 
transfer of Day 2 samples to the blot was not complete or the sample integrity 
is compromised for improper sample preparation.  
 
The decrease of hOCT4-HA proteins at Day 2 may reduce the effectiveness 
of hOCT4-HA on regulating the downstream genes after Oocyte-NT 
performed at Day 1 after mRNA injection since the samples for Oocyte-NT are 
collected at Day 3 after mRNA injection. It is also possible that the decrease 
of hOCT4-HA proteins happens at Day 3 after mRNA injection and therefore 
the decrease of hOCT4-HA protein will not be a concern for Oocyte-NT. 
 
3.2.1.1.2 hOCT4-HA proteins accumulate in the GVs dose-dependently after 
mRNA injection 
 
To check the localization of hOCT4-HA proteins after they are made in the 
cytosol from injected mRNA, Xenopus oocytes were injected with three 
different doses of mRNA, namely 4.6, 9.2, 13.8 ng per oocyte, and the 
samples were collected two days after hOCT4-HA mRNA injection (Figure 
3.2.1.C). Oocyte dissection is utilized to separate the GV fractions and cytosol 
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fractions and each lane is loaded with one GV fraction or one cytosol fraction 
for the Western blot. Black arrows indicate the positions of hOCT4-HA protein 
bands and actin protein bands. The signal intensity of hOCT4-HA protein 
bands is shown above the rectangles containing the quantification areas. 
 
Comparing the signal intensity of hOCT4-HA proteins for 1 GV fraction to the 
signal intensity of hOCT4-HA proteins for 1 cytosol fraction, the signal 
intensity for 1 cytosol fraction is more than the signal intensity for 1 GV 
fraction in all three test doses (Figure 3.2.1.C-D). Taking the dose of 13.8 ng 
mRNA for example, the signal intensity for 1 cytosol fraction is 44700 and is 
more than 39400 for the signal intensity in 1 GV fraction (Figure 3.2.1.C). For 
the line graph demonstrating the correlation of the signal intensity of hOCT4-
HA proteins versus hOCT4-HA mRNA (Figure 3.2.1.D), the nearly identical 
slopes of the lines between 1 cytosol fraction (y=3x+4) and 1 GV fraction 
(y=2.9x-0.5) show that the more hOCT4-HA mRNA injected into the cytosol of 
Xenopus oocytes, the more proteins made in the cytosol and the more 
proteins are transported into GV. 
 
Considering the volume of cytosol is about 30 times more than the volume of 
GV in the Xenopus oocytes and the signal intensity of hOCT4-HA proteins in 
the cytosol fraction is almost equal to the signal intensity in the GV fraction 
(Figure 3.2.1.C), the hOCT4-HA proteins accumulate in the GV and the 
OCT4-HA proteins are actively transported into GV after being made in the 
cytosol from the injected hOCT4-HA mRNA.  
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Therefore, the amount of hOCT4-HA protein accumulating in the GVs 
increases when injecting the Xenopus oocytes with more hOCT4-HA mRNA. 
The more hOCT4-HA proteins accumulate in the GV, the greater is the 
chance hOCT4-HA proteins will bind to target sites to regulate downstream 
genes during the period after Oocyte-NT. 
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Figure 3.2.1 hOCT4-HA proteins are produced dose-dependently and the amount of 
hOCT4-HA protein decreases at Day 2 or Day 3 after mRNA injection in the Xenopus 
oocytes. Additionally, hOCT4-HA proteins accumulate in the GV dose-dependently 
after hOCT4-HA proteins are made in the cytosol from the mRNA injected into the 
Xenopus oocytes 
(A) The hOCT4-HA proteins of samples collected at different days after injecting the oocytes 
with different doses of mRNA are detected by anti-HA antibody and analysed on the Western 
blot. The position of hOCT4-HA protein bands is indicated (black arrow) and the signal 
intensity of hOCT4-HA protein bands is shown next to the rectangles containing the 
quantification areas. 
(B) The line graph displays the dose-dependency of hOCT4-HA protein production after 
injecting the oocytes with different doses of hOCT4-HA mRNA at all sample collection days. 
The amount of hOCT4-HA protein decreases at Day 2 or Day 3 after mRNA injection. Since 
the signal intensity of each dose of Day 2 samples is less than the Day 3 and Day 5 samples 
with corresponding doses, the fall-off of hOCT4-HA signal of Day 2 samples is likely to be 
caused by incomplete protein transfer or improper sample preparation 
(C) A Western blot of hOCT4-HA proteins from the samples collected at Day 2 after injecting 
the Xenopus oocytes with three doses of mRNA. Each lane is loaded with 1 cytosol fraction 
or 1 GV fraction. Black arrows indicate the position of hOCT4-HA proteins and actin and the 
signal intensity of hOCT4-HA proteins and actin are noted above the rectangles for 
quantification. For the signal intensity of 4.6 ng groups, the ratio of cytosol to GV is 1.4; for 
the signal intensity of 9.2 ng groups, the ratio of cytosol to GV is 1.2; for the signal intensity of 
18.4 ng groups, the ratio of cytosol to GV is 1.1. Considering the ratio of the volume of cytosol 
to GV is about 30, hOCT4-HA proteins accumulate strongly in the GV after being made in the 
cytosol from injected mRNA. 
(D) The line graphs are made by comparing the signal intensity of hOCT4-HA to the doses of 
hOCT4-HA mRNA. The equation of the line for the 1 cytosol groups is y=3x+4 and the slope 
is 3. The equation of the line for the 1 GV groups is y=2.9x-0.4 and the slope is 2.9. The 
nearly identical slope demonstrates that the more hOCT4-HA mRNAs are injected into the 
Xenopus oocytes, the more proteins are made in the cytosol and the more proteins are 




3.2.1.2 Mouse Sox2-HA 
3.2.1.2.1 The amount of mSox2-HA protein increases dose- and time-
dependently after mRNA injection 
 
To evaluate the production of mSox2-HA proteins, three doses of mSox2-HA 
mRNA are chosen, namely 4.6, 9.2 and 18.4 ng (Figure 3.2.2.A). The 
samples are collected at Day 1, 2 and 3 after mSox2-HA mRNA injection into 
Xenopus oocytes. Each lane of the Western blot is loaded with 0.7 whole 
oocytes. Black arrows indicate the positions of mSox2-HA protein bands and 
actin protein bands. The signal intensity of mSox2-HA proteins is shown next 
to the rectangles containing the quantification areas. 
 
Comparing the samples collected at different days, the signal intensity of 
mSox2-HA per 0.7 whole oocytes increases over time from Day 1 to Day 3 
after injecting each Xenopus oocyte with 9.2 ng of mSox2-HA mRNA (Figure 
3.2.2.A-B). Comparing the samples at different doses of mSox2-HA mRNA, 
the signal intensity of mSox2-HA proteins per 0.7 oocytes increases from 4.6 
ng to 18.4 ng of mSox2-HA mRNA in samples collected at Day 2 after mRNA 
injection (Figure 3.2.2.A and C). Since the increase of mSox2-HA proteins 
from 9.2 ng to 18.4 ng is less than the increase of mSox2-HA proteins from 
4.6 ng to 9.2 ng, the production of mSox2-HA proteins is close to the plateau 
at 18.4 ng. 
 
The production of mSox2-HA increases continuously from Day 1 to Day 3 
after injecting the Xenopus oocytes with 9.2 ng of mSox2-HA mRNA and 
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therefore it would be fine to utilize this time period and mRNA dose for 
Oocyte-NT. 
 
3.2.1.2.2 mSox2-HA proteins accumulate in the GV dose-dependently after 
mRNA injection 
 
To evaluate the localization of mSox2-HA proteins after being produced in the 
cytosol from injected mSox2-HA mRNA, the samples are collected at Day 2 
after mRNA injection and three doses of mRNA are used, namely 4.6 ng, 9.2 
ng and 13.8 ng (Figure 3.2.2.D). The GV and cytosol fractions are separated 
by oocyte dissection and each lane of Western blot is loaded with 1 GV 
fraction or 1 cytosol fraction. The black arrows indicate the positions of 
mSox2-HA protein bands and actin protein bands. The signal intensity of 
mSox2-HA proteins are shown next to the black rectangles containing the 
areas for quantification. 
 
Comparing the signal intensity of mSox2-HA proteins in GV samples at 
different doses (Figure 3.2.2.D-E), the signal intensity increases from 14100 
for 4.6 ng mRNA group to 27000 for 9.2 ng mRNA group but decreases to 
15400 for 13.8 ng mRNA group. The decrease of mSox2-HA protein from 9.2 
ng mRNA group to 13.8 ng mRNA group may be caused by an inhibitory 
mechanism on the transportation of mSox2-HA protein to the GVs or caused 
by improper handling during oocyte dissection. 
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Although the amount of mSox2-HA protein falls at 13.8 ng (Figrue 3.2.2.D-E), 
the signal intensity of mSox2-HA proteins at 4.6 ng and 9.2 ng still shows the 
accumulation of mSox2-HA proteins in the GVs after injecting the oocytes with 
mRNA when comparing the signal intensity of 1 cytosol fraction to the signal 
intensity of 1 GV fraction. Because the ratio of volume of cytosol to GV is 30:1 
and the mSox2-HA protein signals of 1 GV fraction is more than the signal of 
1 cytosol fraction for 4.6 ng groups and 9.2 ng groups, the mSox2-HA proteins 
obviously accumulate in the GV and the amount of mSox2-HA protein is more 
than the amount of mSox2-HA protein in the cytosol. 
 
The dose-dependent accumulation of mSox2-HA proteins in the GV shows 
that the more mSox2-HA mRNAs are injected into oocytes, the more mSox2-
HA proteins are synthesized in the cytosol and the more mSox2-HA proteins 
are transported into GV where the permeabilized MEFs will be transplanted 
into during Oocyte-NT. Interestingly, the difference in transportation between 
hOCT4-HA proteins (Figure 3.2.1) and mSox2-HA proteins (Figure 3.2.2) 
demonstrate the different mobility of different transcription factors and it 
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Figure 3.2.2 The amount of mSox2-HA protein increases time- and dose-dependently 
and mSox2-HA proteins accumulate in the GV at Day 2 dose-dependently from 4.6 ng 
to 9.2 ng after mRNA injection. 
(A) On the Western blot, the samples are collected at different days after injecting the 
Xenopus oocytes with different doses of mSox2-HA mRNA. The positions of mSox2-HA 
protein bands and actin protein bands are indicated (black arrows). The signal intensity of 
mSox2-HA proteins are shown next to the quantification areas (black rectangles). 
(B) The signal intensity of mSox2-HA increases from Day 1 to Day 3 after injecting the 
oocytes with 9.2 ng of mSox2-HA mRNA. 
(C) The signal intensity of mSox2-HA in the Day 2 samples increases from 4.6 ng to 18.4 ng 
of mSox2-HA mRNA. For the signal intensity of mSox2-HA, the ratio of 9.2 ng to 4.6 ng is 2.3; 
the ratio of 18.4 ng to 9.4 is 1.4. Since the doses double from 4.6 ng to 9.2 ng and from 9.2 
ng to 18.4 ng, the increase of mSox2-HA proteins from 9.2 ng to 18.4 ng is close to the 
plateau due to the ratio of 18.4 ng to 9.4 ng is close to 1. 
(D) On the Western blot, the signal intensity of mSox2-HA proteins and actin proteins are 
shown as numbers next to the quantification areas (black rectangles). The oocytes were 
injected with three different doses of mSox2-HA mRNA and samples were collected at Day 2 
after mRNA injection. Each lane is loaded with the samples of 1 GV fraction or 1 cytosol 
fraction. The positions of mSox2-HA protein bands and actin protein bands are indicated 
(black arrows). 
(E) The line graph shows the signal intensity of mSox2-HA proteins comparing the samples of 
1 GV fraction and 1 cytosol fraction at three test doses of mRNA. The signal intensity of 1 GV 
fraction is more than 1 cytosol fraction at 4.6 ng and 9.2 ng but is less than 1 cytosol fraction 
at 13.8 ng. The fall of the mSox2-HA protein signals at 13.8 ng may be due to inhibitory 




3.2.1.3 Human KLF4 
3.2.1.3.1 hKLF4 proteins of GV fractions are detected by anti-KLF4 antibody 
and indicate the production and transportation of hKLF4 proteins after mRNA 
injection 
 
Since there is no HA tag in the hKLF4 expression construct, an antibody 
(Abcam, ab194750) against human KLF2 was used for detecting the hKLF4 
proteins for the 100% homology of the immunogenic sequence between 
hKLF2 and hKLF4. Additionally, the antibody is suggested to be able to 
recognize Xenopus klf2 (xklf2) and klf4 (xklf4) for the homology of the 
immunogenic sequence among different species. The exact immunogenic 
sequence is proprietary and it is a gift from Abcam (Data sheet is in 
appendices). 
 
To evaluate the production and localization of hKLF4 proteins after injecting 
the oocytes with hKLF4 mRNA, Western blotting is performed (Figure 3.2.3.A). 
The samples are collected at Day 1 and Day 2 after injecting the oocytes with 
or without 9.2 ng of hKLF4 mRNA. The oocytes without mRNA injection are 
also collected because the antibody is suggested to recognize xklf2 and xklf4 
and the endogenous xklf2 and xklf4 can be distinguished by comparing the no 
mRNA injection groups and hKLF4 mRNA groups. Each lane of the Western 
blot is loaded with 1.5 whole oocytes, 1.5 cytosol fractions, 18 GV fractions or 
36 GV fractions. The predicted positions of hKLF4 proteins and the position of 
actin proteins are indicated by black arrows. The signal intensity of hKLF4 
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protein bands and actin protein bands is shown next to the black rectangles 
containing the quantification areas. 
 
Comparing the GV fractions of no mRNA injection group to the GV fractions of 
hKLF4 mRNA group (Figure 3.2.3.A), hKLF4 proteins are recognized by 
antibody in the mRNA injection group because the signal intensity of band d 
for 18 GV fractions (signal intensity=2510) is 14 times more than the signal 
intensity of band a for 36 GV fractions (signal intensity=179) at the predicted 
hKLF4 position 1. Since the antibody can recognize xklf2 and xklf4, the four 
visible bands, b, c, e and f, are most likely to be endogenous xklf2/4 protein or 
unspecific bands (Figure 3.2.5.A and B). The reason is that the signal 
intensity for 18 GV fractions of hKLF4 mRNA group (Band e at Positon 2 and 
Band f at Position 3) is less than the signal intensity for 36 GV fractions of no 
mRNA injection group (Band b at Position 2 and Band c at Position 3) while 
the number of GV fractions in the no mRNA injection group is twice as many 
as the number of GV fractions in the hKLF4 mRNA group (Figure 3.2.3).  
 
When I tried to locate the predicted hKLF4 positions, I have found that the 
relatively more mineral oil in the GV fractions than the mineral oil in the 
cytosol fractions makes the actin protein bands of GV fractions shift upwards 
on the blots, compared to the actin protein bands of the cytosol fractions 
(white arrowhead, Fig 3.2.3.A). Therefore, the positions of bands representing 
the same proteins may differ if the samples contain different levels of mineral 
oil and it needs extra care when performing oocyte dissection and analyzing 
the samples through Western blotting.  
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Although hKLF4 proteins can be detected in the GV fractions, no visible 
protein bands of the cytosol fractions and of whole oocytes are seen on the 
blot at the predicted hKLF4 positions or proximity at Day 1 and Day 2 after 
mRNA injection (Figure 3.2.3.A and 3.2.4.A). When quantifying the hKLF4 
protein signals of whole oocytes and the cytosol fractions at predicted hKLF4 
positions (Figure 3.2.4), the signal intensity is below zero since the signals in 
the quantification areas (middle rectangles) reduce the signals in the 
background areas (top and bottom black rectangles surround the middle black 
rectangles) for normalization. Comparing the hKLF4 signals of 1 whole oocyte, 
1 cytosol fraction and 1 GV fraction (Figure 3.2.4.B), the hKLF4 signals are 
131 for 1 GV fraction of hKLF4 mRNA group and 5 for 1 GV fraction of no 
mRNA injection group whereas the signals for 1 whole oocyte and 1 cytosol 
fraction are below zero of both groups (Figure 3.2.4.B). 
 
Although the specificity of hKLF4 antibody is not enough to recognize the 
hKLF4 proteins in whole oocytes and the cytosol fractions, the signals of 
hKLF4 proteins in the GV fractions indicate that hKLF4 proteins can be 
synthesized from hKLF4 mRNA and transported into GV. This is an important 
check before performing Oocyte-NT. In addition to this point, it will 
demonstrate that the overexpression of hKLF4 proteins has effects on the 
transplanted MEFs and regulates certain pluripotency genes in 3.2.2.3.   
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Figure 3.2.3 hKLF4 protein band at position 1 and unknown protein bands at position 2 
and 3 are detected in the GV fractions, but not detected in whole oocytes and the 
cytosol fractions. 
(A) The samples of hKLF4 mRNA groups are collected at Day 1 and Day 2 after mRNA 
injection. In the GV fractions, three positions are predicted for hKLF4 protein bands (black 
arrows, ~58kD) and visible bands are detected by the anti-hKLF2/4 antibody in no mRNA 
injection groups (band a, b and c) and hKLF4 mRNA groups (band d, e and f). Actin protein 
bands (black arrow) are reprobed after hKLF4 detection because antibodies against actin and 
hKLF4 are raised from rabbit and hKLF4, xklf2/4 and actin have similar sizes. 
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The actin bands of GV fractions shift upwards (white arrows) since the mineral oil in the GV 
fractions is relatively higher than in the cytosol fractions. Signal intensity of hKLF4 proteins 
and actin proteins is shown next to the quantification area (black rectangles).  
(B) Because 36 GV fractions of no mRNA injection group is more than 18 GV fractions of 
hKLF4 mRNA group, the endogenous xklf2/4 protein signals or unspecific protein signals of 
hKLF4 mRNA groups are expected to be lower than the signals of no mRNA injection groups. 
On the contrary, if the protein signals of the hKLF4 mRNA group are higher than the signals 
of no mRNA injection group, the bands represent where hKLF4 proteins locate. Therefore, 
Position 1 indicates the position of hKLF4 protein bands and Position 2 and 3 indicate 
endogenous xklf2/4 or unspecific protein bands. 
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Figure 3.2.4 No hKLF4 signals are detected in whole oocytes and the cytosol fractions 
at the position of hKLF4 proteins. 
(A) The magnified image of Fig 3.2.5.A. No visible bands are seen in the samples of whole 
oocyte or the cytosol fractions of hKLF4 mRNA injection groups. The black arrow indicates 
Position 1 of predicted hKLF4 positions. The signal intensity quantified at hKLF4 Position 1 is 
shown next to the quantification areas (black rectangles) for the samples of whole oocytes, 
the cytosol fractions and GV fractions.  
(B) The signals at hKLF4 Position 1 for 1 whole oocyte, 1 cytosol fraction and 1 GV fraction 
are compared. It shows no signals of 1 whole oocyte or 1 cytosol fraction are detected in no 
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3.2.2 The overexpression of mammalian YFs regulates pluripotency genes in 
MEFs at Day 2 after Oocyte-NT 
In 3.2.1, I have confirmed that the proteins of mammalian Yamanaka factors 
(YFs) can be made in the Xenopus oocytes from the corresponding mRNA 
and the proteins made in the cytosol of oocytes can be transported into the 
GV. In 3.2.2, I have performed Oocyte-NT after overexpressing each YF for 
one day and evaluated how the overexpression of each YF affects the 
expression of selected pluripotency genes of MEFs under the process of 
somatic cell nuclear reprogramming (SCNR) by Xenopus oocytes. 
 
The experimental settings are the same for each YF. Twenty-four hours 
before Oocyte-NT, 9.2 ng mRNAs of each YF are injected into the cytosol of 
Xenopus oocytes. The immortalized mouse embryonic fibroblast (MEFs) 
strain, sixiFM, is used in Oocyte-NT. At Day 0, Oocyte-NT is performed and 
SLO-permeabilized MEFs are transplanted into the GVs of oocytes (~500 
MEFs per oocyte). The oocyte samples are collected two days after Oocyte-
NT. The RNA of oocytes will be processed and analyzed by QPCR. 
 
Two groups are compared for each YF factor. In the control groups, SLO-
permeabilized MEFs are transplanted into GVs at Day 0 without mRNA 
injection. In YF overexpression groups, the mRNA injection of each YF is 
performed 24 hours before Oocyte-NT and then SLO-permeabilized MEFs are 
transplanted into GVs at Day 0. To quantify the expression of pluripotency 
genes of MEFs by QPCR, the relative amount of transcript of mGAPDH is 
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used as an internal control for normalizing the relative amount of transcript of 
pluripotency genes and also for estimating the number of transplanted MEFs.  
 
The effect of YF on pluripotency genes is defined by the fold change between 
the YF overexpression groups and control groups. If the average fold change 
is more than 2 or less than 0.5, pluripotency gene is judged to be up-regulated 
or down-regulated by the overexpression of one of the YFs. The biological 
replicates are produced from different batches of Xenopus oocytes and each 
batch of oocytes is taken from the ovary of different female frog. The variable 
fold change is caused by the individual difference between Xenopus oocytes 
and the resistance of MEF genes to the maternal factors and the 
overexpressed transcription factors and this point will be discussed further in 
the following chapters. 
 
3.2.2.1 The overexpression of hOCT4-HA up-regulates the expression of 
mSox2 in MEFs at Day 2 after Oocyte-NT 
To evaluate the effect of hOCT4-HA proteins on pluripotency genes during 
SCNR by oocytes, Oocyte-NT is performed with SLO-permeabilized MEFs 
after overexpressing the hOCT4-HA proteins for one day. The result shows 
that the overexpression of hOCT4-HA up-regulates the expression of mSox2 
by 3.6-fold and does not regulate 8 other pluripotency genes with average fold 
changes less than 2 and more than 0.5 (Figure 3.2.5.A). 
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3.2.2.2 The overexpression of mSox2-HA up-regulaties the expression of 
mOct4, mSox2 and mKlf4 in MEFs at Day 2 after Oocyte-NT 
To evaluate the effect of mSox2-HA proteins on pluripotency genes during 
SCNR by oocytes, Oocyte-NT is performed with SLO-permeabilized MEFs 
after overexpressing the mSox2-HA proteins for one day. The result shows 
that the overexpression of mSox2-HA up-regulates the expression of mOct4 
by 2.6-fold, mSox2 by 14.4-fold and mKlf4 by 2.3-fold (Figure 3.2.5.B). 
 
3.2.2.3 The overexpression of hKLF4 up-regulates the expression of 
mOct4, mSox2, mKlf2, mSall4 and mUtf1 in MEFs at Day 2 after Oocyte-
NT 
To evaluate the effect of hKLF4 proteins on pluripotency genes during SCNR 
by oocytes, Oocyte-NT is performed with SLO-permeabilized MEFs after 
overexpressing the hKLF4 proteins for one day. The result shows that the 
overexpression of hKLF4 up-regulates the expression of mOct4 by 3.3-fold 
(p<0.05), mSox2 by 4.3-fold, mKlf2 by 1.3-fold (p<0.01), mSall4 by 4-fold 




Figure 3.2.5 The overexpression of mammalian Yamanaka homologs up-regulates 
different sets of selected pluripotency genes in MEFs at Day 2 after Oocyte-NT  
The relative expression of transcripts in control group (No mRNA injection) is 1 for each 
pluripotency gene and shown as a bar in red.  (Figure legend continues on the next page) 
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(A) The relative expression of transcripts in hOCT4-HA overexpression group (9.2 ng hOCT4-
HA mRNA) for each pluripotency gene represents the effect of the overexpression of hOCT4-
HA proteins and shown as bars in blue (n=3, t-test). 
 (B) The relative expression of transcripts in mSox2-HA overexpression group (9.2 ng mSox2-
HA mRNA) for each pluripotency gene represents the effect of the overexpression of mSox2-
HA proteins and shown as bars in green (*p<0.05, n=3, t-test). 
(C) The relative expression of transcripts in hKLF4 overexpression group (9.2 ng hKLF4 
mRNA) for each pluripotency gene represents the effect of the overexpression of hKLF4 




To sum, proteins of mammalian YF homomologs, hOCT4-HA and mSox2-HA, 
can be synthesized in cytosol of Xenopus oocytes from injected mRNA dose-
dependently and time-dependently. After YF proteins are made, these 
proteins are transported into GVs and accumulate in the GVs dependent on 
the dose of mRNA injected. Therefore, dose- and time- dependent synthesis 
of mammalian proteins with HA tag can be measured in Xenopus oocytes via 
our Western blotting system.  
 
Additionally, the regulation of pluripotency genes in transplanted nuclei by 
mammalian YF homologs can be detected in the Xenopus oocyte system 
after nuclear transfer although the protein degradation of hOCT4-HA is 
observed at Day 2 after mRNA injection and hKLF4 can not be detected due 
to the lack of HA tag and useful antibody. 
 
It shows that different mammalian YFs regulate different sets of tested 
pluripotency genes in sixiFM MEFs. hOCT4-HA up-regulates the expression 
of mSox2 by 3.6-fold at Day 2 after Oocyte-NT. mSox2-HA up-regulates the 
expression of mOct4 by 2.6-fold, mSox2 by 14-fold and mKlf4 by 2.3-fold. 
hKLF4 up-regulates the expression of mOct4 by 3.3-fold (p<0.05), mSox2 by 
4.3-fold, mSall4 by 4-fold (p<0.05) and mUtf1 by 2.9-fold (p<0.05). 
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3.3 Xenopus Yamanaka factors can be produced in the 
Xenopus oocytes after mRNA injection and regulate 
pluripotency genes in MEFs at Day 2 after Oocyte-NT 
In 3.2, it has been proven that the proteins of mammalian Yamanaka factors 
(YFs) can be produced in the cytosol of the Xenopus oocytes from injected 
mRNA and transported into GV where the YFs bind to their target genes. It 
has also been shown that the overexpression of each mammalian YF can 
regulate different sets of pluripotency genes in MEFs during the somatic cell 
nuclear reprogramming (SCNR) by oocytes. 
 
The next question is whether Xenopus YFs can regulate pluripotency genes in 
MEFs through a cross-species interaction? Therefore, I chose three Xenopus 
homologs of YFs, namely xklf2-HA, xpou60 and xsox2, and examine their 
ability to regulate pluripotency genes in MEFs.  
 
To evaluate the effect of Xenopus YFs on pluripotency genes in MEFs during 
SCNR by oocytes, Oocyte-NT is performed after overexpressing each 
Xenopus YF for one day. Because the binding of transcription factors to their 
target genes relates to the amount of transcription factor, the production and 
localization of Xenopus YFs after mRNA injection were examined via Western 
blotting before performing Oocyte-NT (Section 3.3.1). After confirming the 
Xenopus YF proteins can be produced in the cytosol and transported into GVs, 
Oocyte-NT is performed (Section 3.3.2). 
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3.3.1 The production and localization of Xenopus YFs after mRNA injection in 
Xenopus oocytes 
To evaluate the production and localization of Xenopus YFs in the Xenopus 
oocytes, Western blotting was performed. Different doses of YF mRNA were 
injected into the cytosol of Xenopus oocytes at Day 0 and samples were 
collected at different time points after mRNA injection. The localization of YF 
proteins made in the cytosol from injected mRNA is evaluated by comparing 
the amount of YF protein in the GV fractions to the amount in whole oocytes. 
The YF proteins on the Western blots are detected by the anti-HA antibody 
and actin detected by anti-actin antibody is used as internal control. The 
amount of YF protein and actin proteins is quantified by LI-COR Odyssey® 
CLx Imaging System. 
 
3.3.1.1 Xenopus sox2-HA 
3.3.1.1.1 The amount of xsox2-HA protein increases dose- and time-
dependently after mRNA injection 
 
Comparing the signal intensity of xsox2-HA proteins at different sample 
collection days after injecting the oocytes with 9.2 ng xsox2-HA mRNA (Figure 
3.3.1.A-B), the xsox2-HA proteins increase from Day 1 to Day 3 because the 
signal intensity of xsox2-HA per oocyte goes up from 32429 for Day 1 sample 
to 38143 for Day 3 sample. Comparing the signal intensity of Day 2 samples 
(Figure 3.3.1.A and C), the amount of xsox2-HA protein increase when 
injecting the oocytes with more xsox2-HA mRNA and the signal intensity of 
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xsox2-HA per oocyte increases from 22571 for 4.6 ng mRNA to 49857 for 
18.4 ng mRNA. 
 
In conclusion, the production of xsox2-HA proteins is dose-dependent from 
the dose of 4.6 ng to 18.4 ng xsox2-HA mRNA. In addition, the xsox2-HA 
proteins increase continuously from Day 1 to Day 3 after injecting the oocytes 
with 9.2 ng mRNA and this coincides with the time points when Oocyte-NT is 
performed and when the samples are collected. 
 
3.3.1.1.2 xsox2-HA proteins accumulate in the GVs after mRNA injection 
 
Comparing the signal intensity of 1 whole oocyte to the signal intensity of 1 
GV fraction (Figure 3.3.1.A and D), the signal intensity is 35286 for 1 whole 
oocyte and 22938 for 1 GV fraction. Since the ratio of the volume of 1 whole 
oocyte to 1 GV fraction is ~30 and the ratio of xsox2-HA signals of 1 whole 
oocyte to 1 GV fraction is ~1.5, the xsox2-HA proteins accumulate in the GVs 
after the xsox2-HA proteins are made in the cytosols and transported into 
GVs. It means that 40% of xsox2-HA proteins produced in the cytosol will 
enter the GVs and therefore the concentration of xsox2-HA proteins in the 
GVs is about 20 times more than the concentration in whole oocytes. 
 
The accumulation of xsox2-HA proteins in the GVs indicate the xsox2-HA 
proteins are transported into GVs where xsox2-HA proteins can bind to target 
genes as well as the genes in the MEFs via Oocyte-NT.   
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Figure 3.3.1 xsox2-HA proteins increase time- and dose-dependently and accumulate 
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(A) The xsox2-HA proteins and actin proteins of different samples are detected on the 
Western blot. The positions of xsox2-HA and actin protein bands are indicated (black arrows). 
Signal intensity of xsox2-HA is noted next to the quantification areas (black rectangles).  
(B) The production of xsox2-HA proteins is time-dependent. For the 9.2 ng xsox2-HA mRNA 
groups, the signal intensity of Day 1 sample is 32429 per oocyte; the signal intensity of Day 2 
sample is 35286 per oocyte; the signal intensity of Day 3 sample is 38143 per oocyte. 
(C) The production of xsox2-HA proteins is dose-dependent. For the Day 2 samples, the 
signal intensity of 4.6 ng group is 22571; the signal intensity of 9.2 ng group is 35286; the 
signal intensity of 18.4 ng group is 49857. 
(D) The xsox2-HA proteins accumulate in the GVs after the xsox2-HA proteins are made in 
the cytosol and transported into GVs. For the 9.2 ng xsox2-HA mRNA groups of Day 2 
samples, the ratio of signal intensity of 1 whole oocyte to 1 GV fraction is ~1.5 and it is 1/20 of 
the ratio of volume of 1 whole oocyte to 1 GV fraction, which is ~30. It means the 
concentration of xsox2-HA proteins in the GVs is 20 times as much as the concentration in 




3.3.1.2 Xenopus klf2-HA 
3.3.1.2.1 The amount of xklf2-HA increase dose- and time-dependently from 
Day 1 to Day 2 but decrease at Day 3 after mRNA injection 
 
Comparing the signal intensity of xklf2-HA proteins at different days after 
injecting the oocytes with 9.2 ng xklf2-HA mRNA per oocyte (Figure 3.3.2.A-
B), the signal intensity per oocyte increases as shown in Figure 3.3.2.B. 
 
The decrease of xklf2-HA proteins may affect the effectiveness of xklf2-HA on 
regulating downstream genes if the inhibitory mechanism of Xenopus oocytes 
is involved but it is not observed in 3.3.2.3 when the samples are collected at 
Day 3 after mRNA injection. 
 
3.3.1.2.2 The xklf2-HA proteins accumulate in the GVs dose-dependently 
after mRNA injection 
 
Comparing the signal intensity of xklf2-HA proteins of Day 2 samples between 
1 whole oocyte and 1GV fraction (Figure 3.3.2.A and C), it shows the xklf2-HA 
proteins accumulate in the GV because the ratio of the volume of 1 whole 
oocyte to 1 GV fraction is ~30 and the ratio of the signal intensity of 1 whole 
oocyte to 1 GV fraction is ~5 for both 9.2 ng and 18.4 ng mRNA groups. It 
means 1/6 of xklf2-HA proteins produced in the cytosol will enter the GVs and 
therefore the concentration of xklf2-HA proteins in the GVs is about 6 times as 
much as the concentration in whole oocytes. 
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Since the ratio of the xklf2-HA signals of 1 whole oocyte to 1 GV fraction is ~5 
for both 9.2 ng and 18.4 ng mRNA groups, the more xklf2-HA proteins 
produced from the injected mRNA in the cytosol, the more xklf2-HA proteins 
will be transported into GV. 
  
In sum, the accumulation of xklf2-HA proteins in the GV is dose-dependent. 
Therefore, the more xklf2-HA mRNAs are injected into Xenopus oocytes, the 
more xklf2-HA proteins will be made in the cytosol and the more xklf2-HA 




Figure 3.3.2 xklf2-HA proteins increase dose- and time-dependently from Day 1 to Day 
2 but decrease at Day 3 after mRNA injection. xklf2-HA proteins accumulate in GVs 
after xklf2-HA proteins are made in cytosols from xklf2-HA mRNA. 
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(A) The xklf2-HA and actin proteins are detected on the Western blot and indicated by black 
arrows. Signal intensity of xklf2-HA and actin proteins are shown above the quantification 
areas (black rectangles). Some degradation of xklf2-HA proteins are observed in the whole 
oocytes but not in the GV fractions (white arrowheads). 
(B) The time-dependent production of xklf2-HA proteins. For the 9.2 ng xklf2-HA mRNA 
groups, the signal intensity of Day 1 sample is 30857 per oocyte; the signal intensity of Day 2 
sample is 33000 per oocyte; the signal intensity of Day 3 sample is 32000 per oocyte. 
(C) The dose-dependent production of xklf2-HA proteins in 1 whole oocyte and the dose-
dependent accumulation of xklf2-HA proteins in 1 GV fraction. For the Day 2 samples, the 
signal intensity of 1 whole oocyte is 33000 for 9.2 ng mRNA group and 48714 for 18.4 ng 
mRNA group; the signal intensity of 1 GV fraction is 6659 for 9.2 ng mRNA group and 9454 
for 18.4 ng mRNA group. The ratio of signal intensity of 1 whole oocyte to 1 GV fraction is ~5 
for 4.6 ng and 9.2 ng mRNA groups and it is 1/6 of ratio of volume of 1 whole oocyte to 1 GV 
fraction, which is ~30. It means the concentration of xklf2-HA proteins in the GVs is 6 times as 




3.3.2 The overexpression of Xenopus YFs regulates pluripotency genes in 
MEFs at Day 2 after Oocyte-NT 
In subsection 3.3.1, it shows that the Xenopus YF proteins can be made from 
injected mRNA in the cytosol of Xenopus oocytes and then be transported 
into and accumulate in the GV. In subsection 3.3.2, I have performed Oocyte-
NT after overexpressing each YF for one day and evaluate how the 
overexpression of each YF affects the expression of selected pluripotency 
genes in MEFs during the somatic cell nuclear reprogramming by Xenopus 
oocytes. 
 
The experimental settings are the same as Oocyte-NT performed for 
mammalian YFs and described in subsection 3.2.2. Briefly, 9.2 ng of each 
Xenopus YF mRNA is injected into Xenopus oocytes a day before Oocyte-NT. 
The MEF cell line, sixiFM, is used for Oocyte-NT. The oocyte samples are 
collected two days after Oocyte-NT. The RNA of oocytes will be processed 
and analyzed by QPCR. 
 
The normalization of transcripts and the definition of fold change have been 
described in subsection 3.2.2. In short, the relative amount of pluripotency 
gene is normalized by the relative amount of internal control, mGAPDH. The 
fold change between control group (MEF) and YF overexpression group 
(MEF+YF mRNA) defines if pluripotency genes are regulated by the 
overexpression of one of the Xenopus YFs. If the fold change of pluripotency 
gene is more than two or less than 0.5, this gene is up-regulated or down-
regulated by the overexpression of YFs. 
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3.3.2.1 The overexpression of xpou60-HA upregulates the expression of 
mSox2, mKlf2 and mSall4 in MEFs at Day 2 after Oocyte-NT 
To evaluate the effect of xpou60-HA proteins on pluripotency genes during 
SCNR by oocytes, Oocyte-NT is performed with SLO-permeabilized MEFs 
after overexpressing the xpou60-HA proteins for one day. The result shows 
that the overexpression of xpou60-HA up-regulates the expression of mSox2, 
mKlf2, and mSall4 as shown in Figure 3.3.3.A. 
 
3.3.2.2 The overexpression of xsox2-HA does not regulate the selected 
pluripotency genes in MEFs at Day 2 after Oocyte-NT 
To evaluate the effect of xsox2-HA proteins on pluripotency genes during 
SCNR by oocytes, Oocyte-NT is performed with SLO-permeabilized MEFs 
after overexpressing the xsox2-HA proteins for one day. The result shows that 
the overexpression of xsox2-HA does not regulate any of the selected 
pluripotency genes (Figure 3.3.3.B). 
 
3.3.2.3 The overexpression of xklf2-HA upregulates the expression of 
mOct4, mSox2, and mSall4 in MEFs at Day 2 after Oocyte-NT 
To evaluate the effect of xklf2-HA proteins on pluripotency genes during 
SCNR by oocytes, Oocyte-NT is performed with SLO-permeabilized MEFs 
after overexpressing the xklf2-HA proteins for one day. The result shows that 
the overexpression of xklf2-HA up-regulates the expression of mOct4, mSox2 
and mSall4 as shown in Figure 3.3.3.C.  
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Figure 3.3.3 The overexpression of Xenopus Yamanaka homologs up-regulates 
different sets of selected pluripotency genes in MEFs at Day 2 after Oocyte-NT. 
The relative expression of transcripts in control group (No mRNA injection) is 1 for each 
pluripotency gene and shown as a bar in red. (Figure legend continues on the next page) 
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(A) The relative expression of transcripts in xpou60-HA overexpression group (9.2 ng xpou60-
HA mRNA) for each pluripotency gene represents the effect of the overexpression of xpou60-
HA proteins and shown as bars in blue (*p<0.05, **p<0.01, n=3, t-test). 
(B) The relative expression of transcripts in xsox2-HA overexpression group (9.2 ng xsox2-
HA) for each pluripotency gene represents the effect of the overexpression of xsox2-HA 
proteins and shown as bars in green (n=3, t-test). 
(C) The relative expression of transcripts in xklf2-HA overexpression group (9.2 ng xklf2-HA 
mRNA) for each pluripotency gene represents the effect of the overexpression of xklf2-HA 





Overall, protein synthesis and gene regulation of Xenopus YF homologs are 
evaluated in this section. It shows that proteins of Xenopus YF homologs are 
synthesized from injected mRNA dose- and time-dependently in Xenopus 
oocytes. Furthermore, the accumulation of Xenopus YF homologs in GVs of 
Xenopus oocytes is dependent to the dose of injected mRNA. 
 
Importantly, in this section, it shows that the regulation of pluripotency genes 
by YF homologs is conserved across species since Xenopus YF homologs 
regulate similar sets of tested pluripotency genes in mammalian nuclei as 
their mammalian counterparts. While hOCT4-HA up-regulates the expression 
of mSox2 by 3.6-fold in sixiFM MEFs, xpou60 up-regulates the expression of 
mSox2 by 5.2-fold and mSall4 by 3.2-fold in the sixiFM MEF nuclei. While 
hKLF4 up-regulates the expression of mOct4 by 3.3-fold, mSox2 by 4.3-fold, 
mSall4 by 4-fold and mUtf1 by 2.9-fold in sixiFM MEFs, xklf2-HA up-regulates 
the expression of mOct4 by 5.8-fold, mSox2 by 2.1-fold and mSall4 by 5.5-
fold. Therefore, the Xenopus oocyte system can demonstrate the inter-
species regulation of genes since mammalian and Xenopus YF homologs can 
regulate similar sets of genes. 
 
However, xsox2-HA, unlike mSox2-HA, cannot up-regulate any of tested 
pluripotency genes while mSox2-HA can up-regulate mOct4 by 2.6-fold, 
mSox2 by 14-fold and mKlf4 by 2.3-fold in sixiFM MEFs. This indicates that 
the different regulation of genes by YF homologs can happen possibly due to 
the presence of specific cofactors and the amount of these cofactors. 
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3.4 Conclusions 
In Section 3.2.1 and 3.3.1, the production and localization of mammalian and 
Xenopus YF proteins are examined to confirm that these YFs can be 
translated from injected YF mRNA in the cytosol and transported to the GV 
where they bind to their target genes. In Section 3.2.2 and 3.3.2, it has proven 
that the overexpression of each YF can regulate different sets of selected 
pluripotency genes in the MEFs via Oocyte-NT. 
 
However, since the experimental settings for Oocyte-NT is based on 
interspecies interaction, it would be rational to understand how the extent of 
interspecies interaction would affect the regulation of downstream genes by 
transcription factors. In this chapter, test YFs belong to four species: Homo 
sapien (human, hOCT4-HA and hKLF4), Mus musculus (house mouse, 
mSox2-HA), Xenopus laevis (Africa clawed frog, xpou60-HA and xklf2-HA) 
and Xenopus tropicalis (Western clawed frog, xsox2-HA). Additionally, human 
and house mouse are within the same class, mammal; Africa clawed frog and 
Western clawed frog are within the same genus, Xenopus.  
 
During Oocyte-NT, the recipient cells are oocytes of Africa clawed frog and 
the donor cells are embryonic fibroblasts of house mouse. As a result, they 
will share the contents in the cells and there will be crosstalk between their 
molecules. Based on this point, to evaluate if transcription factors from one 
species can regulate downstream genes of another species during Oocyte-NT, 




For this matter, I took the data from 3.2.2 and 3.3.2 and made two tables for 
easy comparison among test YFs and evaluate how conserved it is for 
mammalian and Xenopus YFs to regulate pluripotency genes in mouse 
genome (Table 3.4). Since the regulation of downstream genes by members 
of the same TF families is context-dependent115-117, it is sensible that 
homologs of the same YF families regulate different sets of pluripotency 
genes. 
 
Among these three YF families, KLF family members, hKLF4 and xklf2-HA, 
upregulated the most of selected pluripotency genes in MEF and it suggests 
KLF members are able to activate pluripotency genes in the Oocyte-NT 
system. Therefore, I chose xklf2-HA as the major transcription factor for the 
following experiments to evaluate the role of transcription factors during 







mOct4 mSox2 mKlf4 mKlf2 mNanog mSall4 mUtf1 mEsrrb mFbxo15
Mammalian YFs
hOCT4-HA (n=3) 1.4 3.6 0.9 1.2 1.2 1.3 1 0.9 1.2
mSox2-HA (n=3) 2.6 14.4 2.3 1 1.1 0.7* 1.2 1.8 1.1
hKLF4 (n=2) 3.3* 4.3 1.1 1.3** 1.3 4* 2.9* 1.1 1.2
Xenopus YFs
xpou60-HA (n=3) 1 5.2** 0.9 1.3* 0.9 3.2 1.5 1.2 1.2
xsox2-HA (n=3) 0.6 1.4 1.3 1.4 0.9 0.7 0.9 1.7 1.2
xklf2-HA (n=3) 5.8*** 2.1* 1.4 1.5 0.7 5.5 1.2 0.9 0.8
mOct4 mSox2 mKlf4 mKlf2 mNanog mSall4 mUtf1 mEsrrb mFbxo15
Mammalian YFs
hOCT4-HA (n=3) +
mSox2-HA (n=3) + + +
hKLF4 (n=2) +* + +* +*
Xenopus YFs
xpou60-HA (n=3) +** +
xsox2-HA (n=3)
xklf2-HA (n=3) +*** +* +
Table 3.4
Table 3.4.B Up-regulation of pluripotency genes in sixiFM MEFs by the overexpression of
mammalian and Xenopus YFs at Day 2 after Oocyte-NT is shown.
+ means the up-regulation of pluripotency genes by the overexpression of YFs
*p<0.05, **p<0.01, ***p<0.001, t-test
Table 3.4.A Fold change of pluripotency genes in sixiFM MEFs between Control groups
(No mRNA injection) and YF overexpression groups (9.2 ng YF mRNA) at Day 2 after
Oocyte-NT is shown.
*p<0.05, **p<0.01, ***p<0.001, t-test
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Chapter 4 Time-point observation demonstrates gene 
regulation in mammalian nuclei by oocyte factors and 




In chapter 3, it has been shown that interspecies regulation of downstream 
genes is achievable through Oocyte-NT, and that paired Yamanaka factor (YF) 
homologs can regulate similar sets of pluripotency genes during SCNR by 
Xenopus oocytes. However, the increased relative expression is variable and 
this may relate to the time points of gene activation. Therefore, I have used 
time-point observations after Oocyte-NT to examine gene activation by oocyte 
factors and xklf2-HA overexpression. 
 
Among tested Yamanaka homologs, KLF family members, hKLF4 and xklf2-
HA, exert the strongest effect on the selected pluripotency genes in MEFs. 
Additionally, xklf2 is predicted to be an oocyte factor in Xenopus oocytes and 
eggs based on its mRNA expression profile140. It has been shown that xklf2 
mRNA is expressed before MBT and to decline afterwards and its dynamic 
mRNA expression profile correlates with the protein expression profile from 
fertilization to hatching of Xenopus embryos140-142. 
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Hence, in this chapter, I have chosen xklf2-HA to mimic the maternal 
transcription factors in Xenopus oocytes and ask how xklf2-HA 
overexpression affects the regulation of pluripotency genes in MEFs and 
mMyoblasts (mMyo) during SCNR by oocytes. 
 
4.1.2 Experimental design 
To distinguish the effects of Xenopus oocyte factors from ectopic xklf2-HA, 
Oocyte-NT is performed with or without xklf2-HA overexpression and samples 
are collected at multiple time points after Oocyte-NT. Comparing the samples 
at multiple time points from time 0 when performing Oocyte-NT to later time 
points demonstrates the progressive increase or decrease of transcripts 
regulated by oocyte factors during SCNR. Comparing the samples collected 
at the same time point reveals how xklf2-HA overexpression affects gene 
expression during SCNR by oocytes. 
 
In the experimental settings (Figure 4.1), 9.2 ng of xklf2-HA mRNA was 
injected into each Xenopus oocyte 24 hours before Oocyte-NT. Three types of 
cell lines were used for Oocyte-NT. sixiFM and TcR2 are cell lines of mouse 
embryonic fibroblasts (MEFs) and C2C12 is a cell line of mouse myoblasts 
(mMyos). Samples were collected directly after performing Oocyte-NT at Day 
0 or collected at days between Day 0 and Day 3. The RNA of samples was 
then extracted and analyzed by QPCR. 
 
The expression of pluripotency genes is normalized to the expression of 
mGapdh and mGapdh level is also an indication of the number of cells 
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transplanted into GVs of oocytes. Six of the selected pluripotency genes, 
namely mOct4, mSox2, mSall4, mEsrrb, mNanog and mFbxo15, are shown to 
be bound by mKlf2/4/5 on their promoters, enhancers or gene bodies via ChIP 
analysis118 and all of them have one or two mKlf2 binding motif on their 
promoters according to TRANSFAC database143.   
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Figure 4.1 Sample preparation for comparing the effects of oocyte factors at multiple 
time points and xklf2-HA overexpression at fixed time points on the regulation of 
selected pluripotency genes is shown. 
  
24 hours before Oocyte-NT Day 0 Day 3








RNA processing and QPCR
Sample collection at Oocyte-NT and different days after Oocyte-NT
Control group: No mRNA injection
Figure 4.1
Figure 4.  ple preparation for comparing the eff cts be ween maternal factors of
Xenopus oocytes and the overexpression f xklf2-HA on the regulation of pluripotency genes
at multiple time points
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4.2 The overexpression of xklf2-HA regulates some tested 
pluripotency genes in sixiFM MEFs and may be an oocyte 
factor during SCNR by Xenopus oocytes 
To compare the effect of oocyte factors with xklf2-HA overexpression on 
regulating selected pluripotency genes during SCNR by Xenopus oocytes, the 
samples are collected at Day 0, 1, 2 and 3 after Oocyte-NT with or without 
xklf2-HA mRNA injection. SLO-permeabilized sixiFM MEFs were used for 
Oocyte-NT in this section.  
 
4.2.1 Oocyte factors up-regulate mOct4, mSox2, mKlf4, mSall4, mUtf1 and 
mEsrrb in sixiFM MEFs from Day 0 to Day 3 after Oocyte-NT 
Comparing the relative expression of transcripts in the no mRNA injection 
groups at different time points (red lines, Figure 4.2.1, 4.2.2 and 4.2.3), the 
trend of the lines for the pluripotency genes shows how oocyte factors affect 
their expression.  
 
For mOct4 (red line, Figure 4.2.1.A), the relative expression at Day 0 is 
undetermined by QPCR due to nil or low expression of mOct4 in the sixiFM 
MEFs. Then oocyte factors up-regulate the expression of mOct4 to a 
detectable level from Day 0 to Day 1 and by 2.9-fold from Day 1 to Day 3. The 
up-regulation of mSox2 by oocyte factors is strong from Day 0 to Day 3 by 
243-fold (red line, Figure 4.2.1.B) and, comparably, mKlf4, mSall4 and mUtf1 
have relatively mild increases in their expression from Day 0 to Day 3 by 12-
fold, 33-fold and 19-fold (red lines, Figure 4.2.1.C-D and 4.2.2.A), respectively. 
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The expression of mEsrrb is up-regulated by oocyte factors gently and 
steadily with a 4.6-fold increase from Day 0 to Day 3 (red line, Figure 4.2.2.B). 
 
For mKlf2, mNanog and mFbxo15 (Figure 4.2.3), it seems the expression of 
these genes is negatively regulated by oocyte factors by 0.4-fold, 0.3-fold and 
0.4-fold from Day 0 to Day 3. However, they could be unaffected by oocyte 
factors and degraded due to the post-transcriptional mechanisms in the donor 
cells or Xenopus oocytes. 
 
4.2.2 xklf2-HA overexpression augments the up-regulation of mOct4, mSox2, 
mKlf4 and mSall4 by oocyte factors by oocyte factors at Day 1, 2 and 3 after 
Oocyte-NT 
Overall, the trend of xklf2-HA mRNA groups shows that xklf2-HA 
overexpression augments the up-regulation of mOct4, mSox2, mKlf4 and 
mSall4 by oocyte factors at Day 1, 2 and 3 after Oocyte-NT (Figure 4.2.1). 
 
mUtf1 and mEsrrb have been shown to be up-regulated by oocyte factors but 
they are not affected by xklf2-HA overexpression (Figure 4.2.2). Furthermore, 
it is the same for oocyte factors that mKlf2, mNanog and mFbxo15 are not 




4.2.3 The fluctuating augmentation caused by xklf2-HA overexpression 
explains the stochastic nature of oocyte 
When comparing the relative expression of xklf2-HA mRNA groups to the 
relative expression of no mRNA injection groups at the same time points, the 
effect of xklf2-HA on the up-regulation of pluripotency genes by oocyte factors 
can be observed at all time points for mOct4, mSox2, mKlf4 and mSall4 (red 
and orange dots, Figure 4.2.1). Take mOct4 as an example (Figure 4.2.1.A), 
xklf2-HA overexpression augments the up-regulation of mOct4 by oocyte 
factors by 5.5 times at Day 1, by 23 times at Day 2 and by 11 times at Day 3. 
 
However, each pluripotency gene responds to xklf2-HA overexpression at 
different time points and to a different extent. Among these four genes (Figure 
4.2.1), only the up-regulation of mSox2 by oocyte factors is augmented by 
xklf2-HA overexpression with steadily increasing values by 1.5-fold at Day 0, 
1.9-fold at Day 1, 2.8-fold at Day 2 to 3.2-fold at Day 3 (Figure 4.2.1.B). For 
mOct4 and mSall4 (Figure 4.2.1.A and D), the augmentation by xklf2-HA 
overexpression is strong with a maximum 22-fold and 20-fold increase 
respectively, at Day 2 but this augmentation fluctuates throughout this period 
at each Day after Oocyte-NT. For mKlf4 (Figure 4.2.1.C), this augmentation 
also fluctuates. This phenomenon can explain why sometimes the effect of 
transcription factors is obvious but the statistical significance is hard to reach 
due to the stochastic nature of each oocyte even if all the oocytes are taken 
from the same ovary of one female frog. 
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4.2.4 The up-regulation of pluripotency genes by oocyte factors happens most 
strongly within one day after Oocyte-NT and the one-day regulation is 
sufficient to represent the long-term regulation from Day 0 to Day 3 
Comparing the relative expression of each pluripotency gene between Day 0 
and Day 1 after Oocyte-NT, the scale of up-regulation for each gene by 
oocyte factors is stronger than at other time points within 1-day period (red 
dots, Figure 4.2.1). For example, the relative expression of mSox2 form Day 0 
to Day 3 increases by 243-fold and it is more than the fold change of 33 for 
mSall4 from Day 0 to Day 3 (red dots, Figure 4.2.1.B and D). Likewise, this 
scale of up-regulation can be decided by the increase of relative expression 
from Day 0 to Day 1. For example, the increased fold change for mSox2 is 
107 and it is more than 12 for mSall4 (red dots, Figure 4.2.1.B and D). 
 
Additionally, the relative expression increases most obviously from Day 0 to 
Day 1, compared to other relative expression difference within one day. Take 
mSox2 as an example (red dots, Figure 4.2.1.B), the increased fold change 
from Day 0 to Day 1 is 107 (107/1=107) and it is 59 times more than the 
increased fold change from Day 1 to Day 2, which is 1.8 (=193/107). Also, it is 
82 times more than the increased fold change form Day 2 to Day 3, which is 
1.3 (=243/193). 
 
These two points suggest that SCNR by oocyte happens most vigorously 
within one day after Oocyte-NT. This allows further manipulation to be applied 
after Oocyte-NT while Oocyte-NT experiments usually end within two days 
and Xenopus oocytes tend to deteriorate over time after Oocyte-NT. 
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4.2.5 Up-regulation of mOct4, mSox2, mKlf4, mSall4 and mUtf1 by xklf2-HA 
overexpression starts at different time points after Oocyte-NT 
It has been shown that mOct4, mSox2, mKlf4 and mSall4 are up-regulated 
and mUtf1 is unaffected by xklf2-HA overexpression at Day 2 after Oocyte-NT 
(Figure 4.2.1 and 4.2.2.A). Notably, xklf2-HA overexpression starts to up-
regulate the expression of these pluripotency genes at different time points 
after Oocyte-NT, including mUtf1, which is judged to be unaffected by xKlf2-
HA. For mOct4 and mSall4, the expression is up-regulated by xklf2-HA 
overexpression by 5.5-fold and 3.7-fold at Day 1 after Oocyte-NT (red and 
orange dots at Day 1, Figure 4.2.1.A and D). In the case of mSox2 and mKlf4, 
xklf2-HA overexpression starts to up-regulate these two genes by 2.8-fold and 
2.3-fold at Day 2 after Oocyte-NT (red and orange dots at Day 2, Figure 
4.2.1.B-C). For mUtf1, it is unaffected at Day 1 and Day 3 after Oocyte-NT but 
it is up-regulated mildly at Day 0 by 2.3-fold and Day 2 by 2-fold after Oocyte-
NT by xklf2-HA overexpression (red and orange dots, Figure 4.2.2.A). 
 
Since pluripotency genes usually remained silent in MEFs, the different start 
points of up-regulation by xklf2-HA overexpression may suggest that 
pluripotency genes are released from closed chromatin and become 




4.2.6 xklf2-HA overexpression up-regulates some selected pluripotency genes 
as oocyte factors and it may be one of the effective oocyte factors 
Although all the selected pluripotency genes are direct binding targets of 
mKlf2 as previously mentioned and some of them indeed are regulated by 
xklf2-HA overexpression, xklf2-HA selectively regulates the genes, which are 
also regulated by oocyte factors (Figure 4.2.1 and 4.2.2). There is no doubt 
that some transcription factors already exist in the oocytes to up-regulate 
xklf2-HA target gene expression. Therefore, it suggests that xklf2 may be one 
of the oocyte factors to regulate some xklf2 target genes and that some other 
oocyte factors may function redundantly as xklf2. 
 
Although overexpressed xklf2-HA has a substantial effect on tested genes 
here, the overwhelmingly strong conclusion is that this factor overexpression 
is, in most cases, small by comparison with the effect of endogenous oocyte 




Figure 4.2.1 mOct4, mSox2, mKlf4 and mSall4 in sixiFM MEFs are up-regulated 
strongly by oocyte factors with fold changes of up to 243 after Oocyte-NT and this up-
regulation is augmented by xklf2-HA overexpression with fold change of up to 22. 
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Figrue 4.2.1 mOct4, mSox2, mSall4 and mKlf4 in sixiFM MEF are up-regulated by
maternal factors gradually after Oocyte-NT and this up-regulation is augmented by the 
overexpression of xklf2-HA
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Days after Oocyte-NT, sixiFM MEF 
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Figure 4.2.2 mUtf1 and mEsrrb in sixiFM MEFs are up-regulated by oocyte factors but 
un-affected by xklf2-HA overexpression after Oocyte-NT. 
0 1 2 3 
No mRNA 1 1.1 2.2 4.6 
xklf2-HA mRNA 1.3 0.6 1.5 1.8 



















Figrue 4.2.2 mUtf1 and mEsrrb in sixiFM MEFs is up-regulated by maternal factors slightly but
un-affected by the overexpression of xklf2-HA after Oocyte-NT
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Days after Oocyte-NT, sixiFM MEF 
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Figure 4.2.3 mKlf2, mNanog and mFbxo15 in sixiFM MEFs are un-affected by oocyte 
factors and xklf2-HA overexpression after Oocyte-NT. 
  
0 1 2 3 
No mRNA 1 0.8 0.6 0.3 
xklf2-HA mRNA 0.7 0.6 0.4 0.3 
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xklf2-HA mRNA 1.4 0.8 1.3 0.8 
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No mRNA 1 0.7 0.6 0.4 
xklf2-HA mRNA 1.7 0.7 0.8 0.4 




















Figrue 4.2.3 mNanog, mKlf2 and mFbxo15 in sixiFM MEFs are un-affected by maternal
factors and the overexpression of xklf2-HA after Oocyte-NT
Days after Oocyte-NT, sixiFM MEF 
Days after Oocyte-NT, sixiFM MEF 




















To sum up, the effect of overexpressed xklf2-HA on expression of 9 mouse 
pluripotency genes in transplanted sixiFM MEFs has been tested in Xenopus 
oocytes. Through a time-point observation, 6 of the tested pluripotency genes 
were up-regulated strongly by oocyte factors by up to 243-fold from Day 0 to 
Day 3 after Oocyte-NT and 4 of tested pluripotency genes were up-regulated 
mildly by xklf2-HA overexpression by up to 22-fold at Day 2 after Oocyte-NT. 
 
The up-regulation of pluripotency genes by oocyte factors is most strongly 
seen within one day after Oocyte-NT and these genes are continuously up-
regulated mildly by oocyte factors afterwards. Overexpressed xklf2-HA 
redundantly up-regulates the genes that are also up-regulated by oocyte 




4.3 The overexpression of xklf2-HA facilitates the expression 
of pluripotency genes in MEFs at the beginning of SCNR by 
Xenopus oocytes 
To investigate the timing of enhanced gene expression by xklf2-HA 
overexpression, the expression of pluripotency genes is compared in different 
ways and another MEF cell line, TcR2, is used for Oocyte-NT in this section. 
The effect of oocyte factors on regulation of pluripotency genes is evaluated 
by comparing gene expression in no mRNA injection groups at Day 0 with 
gene expression at Day 2 after Oocyte-NT (Figure 4.3.A). The effect of xklf2-
HA overexpression is evaluated at Day 0 and Day 2 after Oocyte-NT in order 
to demonstrate the immediate and long-term influence of xklf2-HA on 
regulation of pluripotency genes during SCNR by Xenopus oocytes (Figure 
4.3.B and C). 
 
4.3.1 Up-regulation of pluripotency genes in TcR2 MEFs by oocyte factors 
and xklf2-HA overexpression is similar to the up-regulation of genes in sixiFM 
MEFs 
Similar to sixiFM MEFs, the expression of mOct4, mSox2 and mUtf1 in TcR2 
MEFs are up-regulated strongly by oocyte factors from Day 0 to Day 2 after 
Oocyte-NT by 92-fold, 39-fold and 13-fold, respectively (Figure 4.3.A). 
Additionally, the expression of mJun in TcR2 MEFs is also up-regulated by 
oocyte factors by 7.3-fold (Figure 4.3.A).  
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Likewise, the expression of mOct4 and mSox2 in TcR2 MEFs is up-regulated 
mildly by xklf2-HA overexpression at Day 2 after Oocyte-NT (Figure 4.3.C). At 
Day 2 after Oocyte-NT, mOct4 and mSox2 are up-regulated by xklf2-HA 
overexpression by 3.4-fold and 6.4-fold, respectively (Figure 4.3.C). 
Interestingly, mOct4 and mUtf1 are up-regulated by xklf2-HA overexpression 
at Day 0 after Oocyte-NT with fold changes of 41-fold and 3.7-fold (Figure 
4.3.B), which are much bigger than the fold changes of the same genes up-
regulated by xklf2-HA overexpression at Day 2 after Oocyte-NT (Figure 4.3.C). 
 
4.3.2 Early and late response of pluripotency genes to xklf2-HA 
overexpression at Day 0 and Day 2 after Oocyte-NT 
It has been shown that pluripotency genes in sixiFM MEFs are regulated by 
xklf2-HA overexpression at different time points after Oocyte-NT (Figure 4.2.1, 
page 110). Here, it also has been shown that mOct4 and mUtf1 in TcR2 
MEFs are up-regulated by xklf2-HA overexpression at Day 0 after Oocyte-NT 
(Figure 4.3.B) and mOct4 and mSox2 are up-regulated at Day 2 after Oocyte-
NT (Figure 4.3.C). 
 
It seems the effects of xklf2-HA overexpression on different genes starts at 
different time points and genes affected by xklf2-HA overexpression can be 
categorized into two responses. mOct4 and mUtf1 are categorized as the 
early response genes and mSox2 is categorized as late response genes. 
Take mOct4 as an example, the fold change between xklf2-HA mRNA groups 
and no mRNA injection groups at Day 0 is 41-fold and it is more than the fold 
change of 3.7 at Day 2 after Oocyte-NT (Figure 4.3.B-C). On the contrary, the 
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up-regulation of mSox2 by xklf2-HA overexpression at Day 0 is smaller than 
the up-regulation of mSox2 by xklf2-HA overexpression at Day 2 while the fold 
changes are 1.6 at Day 0 and 6.4 for Day 2 after Oocyte-NT (Figure 4.3.B-C). 
 
The difference in the starting time points of xklf2-HA effects suggests that the 
regulation process by xklf2-HA overexpression may be affected by other 
mechanisms. A possible one is the original chromatin structures of genes in 
donor cells and the accessibility of chromatin structures may hinder or delay 
the binding of transcription factors, and hence, the gene activation. 
 
4.3.3 mOct4 is a SCNR resistant gene in MEFs and is up-regulated by xklf2-
HA overexpression immediately at Day 0 after Oocyte-NT with the highest fold 
change among all test pluripotency genes 
In section 4.2, the expression of mOct4 is not determined in the sixiFM MEFs 
(Figure 4.2.1.A, page 110) while the expression of mOct4 is detectable in the 
TcR2 MEFs due to the increase of reversed transcribed cDNA for QPCR 
analysis (Figure 4.3). From a nil or low expression state in MEFs, mOct4 was 
activated to a detectable level by oocyte factors one day after Oocyte-NT 
(Figure 4.2.1.A, page 110) and it might suggest mOct4 is an resistant gene to 
SCNR by oocytes. Interestingly, the expression of mOct4 in TcR2 MEFs is up-
regulated by the oocyte factors from Day 0 to Day 2 after Oocyte-NT by 92-
fold (Figure 4.3.A) and by xklf2-HA overexpression at Day 0 by 41-fold (Figure 
4.3.B) with the highest fold change among all test pluripotency genes. 
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This shows that the nil or lowly expressed genes in MEFs, such as mOct4, 
would be up-regulated by oocyte factors more strongly than other middle or 
highly expressed genes, such as mSox2, mUtf1 and mJun (Figure 4.3.A). 
Additionally, the early response of mOct4 to xklf2-HA overexpression at Day 0 
after Oocyte-NT also suggests the ability of xklf2-HA overexpressoin to 
access the closed chromatin and activate downstream genes (Figure 4.3.B). 
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Figure 4.3 The immediate and long-term effect of xklf2-HA overexpression on 
regulation of pluripotency genes in TcR2 MEFs. 
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Effect of xklf2-HA overexpresion
Day 0 after Oocyte-NT, TcR2 MEF
No mRNA injection 9.2 ng xklf2-HA mRNA 
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Effect of oocyte factors 
Day 0 to Day 2 after Oocyte-NT, TcR2 MEF 
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** **
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Effect of xklf2-HA overexpression 
Day 2 after Oocyte-NT, TcR2 MEF 




mOct4, mSox2, mNanog, mUtf1 and mJun are up-regulated by both maternal factors from 
Day 0 to Day 2 and the overexpression of xklf2-HA at either Day 0 or Day 2 after Oocyte-NT. 
mOct4, mSox2, mNanog (n=3, t-test); mUtf1, mJun, mLefty1, mMyc (n=2, t-test). *p<0.05, 
**p<0.01, ***p<0.001 
(A) The effect of oocyte factors on pluripotency genes from Day 0 to Day 2 after Oocyte-NT 
(B) The immediate effect of xklf2-HA on pluripotency genes at Day 0 of Oocyte-NT. In all 
these figures, ng means the amount of xklf2-HA mRNA. Effect at Day 0 is an early response 
of genes to xklf2-HA overexpression and samples may incubate in oocytes for maximal 10 
mins because it takes about 10 mins to finish nuclear transfer for 10 oocytes. 





All in all, oocyte factors and xklf2-HA overexpression up-regulate the same 
sets of pluripotency genes in TcR2 and sixiFM MEFs. Therefore, chromatin 
structures may be similar between TcR2 and sixiFM MEFs. In addition, the 
SCNR resistant gene, mOct4, is up-regulated most strongly by oocyte factors 
among tested pluripotency genes. 
 
Furthermore, the immediate response of mOct4 to xklf2-HA overexpression at 
Day 0 after Oocyte-NT suggest the ability of xklf2-HA overexpression to 
activate downstream genes when these genes are still resistant to be 
activated by oocyte factors. As with the genes in sixiFM MEFs, the 
endogenous factors in oocytes are much more effective than overexpressed 




4.4 The similar and different response of pluripotency genes 
in MEFs and mMyoblasts to oocyte factors and to xklf2-HA 
overexpression 
In section 4.2 and 4.3, the regulation of tested pluripotency genes in sixiFM 
and TcR2 MEFs by oocyte factors and xklf2-HA overexpression is discussed. 
For both cell lines of MEFs, sixiFM and TcR2, the sets of pluripotency genes 
regulated by the oocyte factors and xklf2-HA overexpression are probably 
similar due to their similar cellular characteristics, namely chromatin state and 
expression of genes. In order to examine the regulation of the same genes in 
different cell types by oocyte factors and xklf2-HA overexpression, MEFs 
(TcR2) and mMyos (C2C12) are compared in this section. 
 
4.4.1 Similar response of tested pluripotency genes in MEFs and mMyos to 
oocyte factors and xklf2-HA overexpression except for the response of mUtf1 
in mMyos to oocyte factors 
Comparing the Day 2 samples to the Day 0 samples for each gene in MEFs 
without mRNA injection, oocyte factors strongly up-regulate the expression of 
mOct4 by 27-fold, mSox2 by 41-fold, mUtf1 by 5.6-fold and mJun by 6.3-fold 
(solid red lines, Figure 4.4.1 and 4.4.2). Similar to the effect of oocyte factors 
on MEFs, mOct4, mSox2 and mJun in mMyos are also up-regulated by 
oocyte factors by 437-fold, 577-fold and 4-fold from Day 0 to Day 2 after 
Oocyte-NT (dotted red lines, Figure 4.4.1 and 4.4.2.B) except that mUtf1 is 
un-affected (dotted red lines, Figure 4.4.2.A). For mNanog, mMyc and 
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mLefty1, these genes in both MEFs and mMyos are unaffected by oocyte 
factors or xklf2-HA overexpression (Figure 4.4.3). 
 
The similar sets of up-regulated genes in MEFs and mMyos by oocyte factors 
except for mUtf1 in mMyos suggest the difference of intrinsic nature between 
MEFs and mMyos.  It may also suggest the mUtf1 in mMyo is resistant to 
oocyte factors while mUtf1 in MEF can be up-regulated by these factors. 
 
On top of the effect of oocyte factors, xklf2-HA overexpression enhances the 
up-regulation of mOct4 and mSox2 in MEFs by oocyte factors at Day 0 and 
Day 2 after Oocyte-NT (solid red and orange dots, Figure 4.4.1). At Day 0, 
mOct4 in MEFs is up-regulated by 13-fold and mSox2 in MEFs is unaffected 
by xklf2-HA overexpression (Figure 4.4.1). At Day 2 after Oocyte-NT, both 
mOct4 and mSox2 in MEFs are up-regulated by xklf2-HA overexpression by 
5.3-fold and 2.8-fold, respectively (Figure 4.4.1). In mMyos, mOct4 is up-
regulated by xklf2-HA overexpression at Day 0 after Oocyte-NT but is 
unaffected at Day 2 after Oocyte-NT (Figure 4.4.1.A). Additionally, mSox2 in 
mMyos is up-regulated by xklf2-HA overexpression at Day 2 but is unaffected 
at Day 0 after Oocyte-NT (Figure 4.4.1.B). 
 
Therefore, mOct4 in both MEFs and mMyos starts to be up-regulated strongly 
by xklf2-HA overexpression by 13-fold and 109-fold at Day 0 after Oocyte-NT 
while mSox2 in both cell types starts to be up-regulated mildly by xklf2-HA 
overexpression by 2.8-fold and 7.2-fold at Day 2 after Oocyte-NT (Figure 
4.4.1). It is consistent to the data shown in section 4.3 that mOct4 in MEFs is 
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strongly up-regulated by xklf2-HA overexpression by 41-fold at Day 0 and the 
up-regulation decrease to 3.7-fold at Day 2 after Oocyte-NT (Figure 4.3.B and 
4.3.C, page 118). Furthermore, mSox2 in MEFs is not up-regulated by xklf2-
HA overexpression at Day 0 but is up-regulated by xklf2-HA overexpression 
by 6.4-fold at Day 2 after Oocyte-NT (Figure 4.3.B and 4.3.C, page 118). 
Therefore, the time-dependent response of mOct4 and mSox2 in MEFs to 
xklf2-HA overexpression is the same as the response of mOct4 and mSox2 in 
mMyos. 
 
4.4.2 mOct4 and mSox2 in mMyos are up-regulated by oocyte factors and 
xklf2-HA overexpression more strongly than mOct4 and mSox2 in MEFs 
Among all tested pluripotency genes, mOct4 and mSox2 are the most strongly 
up-regulated by oocyte factors and by xklf2-HA overexpression in both cell 
types (Figure 4.4.1). Intriguingly, mOct4 and mSox2 respond to oocyte factors 
and xklf2-HA overexpression differently between MEFs and mMyoblasts. 
 
Comparing the expression of genes increased by oocyte factors, mOct4 in 
mMyos is up-regulated by oocyte factors by 437-fold, which is more than the 
fold change of 27 for mOct4 in MEFs up-regulated by oocyte factors from Day 
0 to Day 2 after Oocyte-NT (solid and dotted red lines, Figure 4.4.1.A). 
Likewise, mSox2 in mMyos is up-regulated by oocyte factors by 577-fold and 
it is more than the fold change of 41 for mSox2 in MEFs up-regulated by 
oocyte factors from Day 0 to Day 2 after Oocyte-NT (solid and dotted red lines, 
Figure 4.4.1.B). Hence, the different chromatin states of mSox2 and mOct4 in 
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MEFs and mMyos probably lead to the different up-regulation of these genes 
by oocyte factors. 
 
For MEFs, xklf2-HA overexpression augments the up-regulation of mOct4 by 
oocyte factors by 13-fold at Day 0 and by 5.3-fold at Day 2 after Oocyte-NT 
(red and orange dots on the solid line, Figure 4.4.1.A). As for mMyos, xklf2-
HA overexpression augments the up-regulation of mOct4 by oocyte factors by 
109-fold at Day 0 and by 1.5-fold at Day 2 after Oocyte-NT (red and orange 
dots on the dotted line, Figure 4.4.1.A). Therefore, mOct4 in mMyos responds 
to xklf2-HA overexpression more strongly than mOct4 in MEFs at Day 0 after 
Oocyte-NT (red and orange dots on the dotted line, Figure 4.4.1.A). 
Additionally, mSox2 in mMyo is up-regulated at Day 2 after Oocyte-NT more 
strongly by xklf2-HA overexpression by 7.2-fold, compared to mSox2 in MEF 
up-regulated by xklf2-HA overexpression by 2.8-fold. 
 
Overall, the response of the same genes in different cell types to oocyte 
factors is the same as the response of these genes to xklf2-HA 
overexpression. That is, the more fold change of gene expression increased 
by oocyte factors in certain cell types, the more fold change of gene 
expression increased by xklf2-HA overexpression. Therefore, the chromatin 
structures of genes in different cell types probably affect the response of 
genes to oocyte factors and xklf2-HA overexpression in a similar way. 
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4.4.3 The nil or low expressed genes in donor cells are more susceptible to 
the up-regulation induced by oocyte factors and xklf2-HA overexpression 
In section 4.3, it suggests that the nil or low expressed genes, such as mOct4 
in MEFs, are more sensitive to oocyte factors and xklf2-HA overexpression 
and up-regulated by oocyte factors by more fold change than other genes 
(Figure 4.3.A-B, page 118). Based on this point, because mOct4 in mMyos 
are up-regulated more strongly by oocyte factors (437-fold) and by xklf2-HA 
overexpression (109-fold) with more fold change than mOct4 in MEFs, which 
is up-regulated by oocyte factors by 27-fold and by xklf2-HA overexpression 
by 13-fold, the chromatin structure of mOct4 in mMyos may be more 
compacted than mOct4 in MEFs (Figure 4.4.1.A). 
 
From the same point, the chromatin structure of mSox2 in mMyos is more 
compacted than the chromatin structure of mSox2 in MEF because mSox2 in 
mMyo is more strongly up-regulated by oocyte factors and xklf2-HA 
overexpression than mSox2 in MEFs (Figure 4.4.1.B). 
 
Therefore, I conclude that the more fold change for genes in certain cell types 
induced by oocyte factors or xklf2-HA overexpression, the more compacted 
the chromatin structures of those genes are. That is, the more those genes 




Figure 4.4.1 mOct4 and mSox2 in mMyos are up-regulated more strongly by oocyte 
factors and xklf2-HA overexpression than mOct4 and mSox2 in MEFs. 
In all these figures, ng means the amount of xklf2-HA mRNA. Effect at Day 0 is an early 
response of genes to xklf2-HA overexpression and samples may incubate in oocytes for 
maximal 10 mins because it takes about 10 mins to finish nuclear transfer for 10 oocytes. 
0 2 
0 ng, MEF 1 41 
9.2 ng, MEF 1.6 115 
0 ng, mMyo 1 577 
9.2 ng, mMyo 1.6 4183 
9.2 ng/0 ng, MEF 1.6 2.8 



































0 ng, MEF 1 27 
9.2 ng, MEF 13 141 
0 ng, mMyo 1 437 
9.2 ng, mMyo 109 658 
9.2 ng/0 ng, MEF 13 5.3 





































Figrue 4.4.1 mOct4 and mSox2 in C2C12 mMyoblasts are more suseptible to the





Figure 4.4.2 mJun in both MEFs and mMyos is up-regulated mildly by oocyte factors 
while mUtf1 in MEFs is up-regulated mildly by oocyte factors but mUtf1 in mMyos is 
unaffected by oocyte factors. 
In all these figures, ng means the amount of xklf2-HA mRNA. 
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9.2 ng, MEF 1.3 11 
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Figrue 4.4.2 After Oocyte-NT, mUtf1 and Jun in TcR2 MEFs are up-regulated by maternal
factors and the overexpression of xklf2-HA while mUtf1 in C2C12 mMyoblasts is un-affected
by both and mJun in C2C12 mMyoblasts is up-regulated by maternal factors and this





Figure 4.4.3 mNanog, mMyc and mLefty are unaffected by neither oocyte factors nor 
xklf2-HA overexpression. 
In all these figures, ng means the amount of xklf2-HA mRNA.  
1 2 
0 ng, MEF 1 1.7 
9.2 ng, MEF 1.2 2.2 
0 ng, mMyo 1 0.8 
9.2 ng, mMyo 0.6 0.7 
9.2 ng/0 ng, MEF 1.2 1.3 
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Figrue 4.4.3 mNanog, mMyc and mLefty in TcR2 MEFs are slightly up-regulated by maternal
factors and the overexpression of xklf2-HA while mNanog and mMyc in C2C12 mMyoblasts
are slightly up-regulated by maternal factors but un-affected by the overexpression of 























To sum, similar sets of tested pluripotency genes in MEFs and mMyos are up-
regulated by oocyte factors and xklf2-HA overexpression except for the mUtf1 
in mMyos. In addition to effects of oocyte factors on gene regulation, xklf2-HA 
overexpression regulates downstream pluripotency genes synergistically with 
oocyte factors and this regulation is cell-type dependent. When genes are 
strongly up-regulated by oocyte factors in certain cell types, theses genes 
also respond to xklf2-HA overexpression strongly in those cell types. 
Additionally, this synergistic regulation by xklf2-HA overexpression is time-
dependent. For example, mOct4 in both MEFs and mMyos is up-regulated 
immediately at Day 0 after Oocyte-NT and mSox2 in MEFs and mMyos is up-
regulated at Day 2 after Oocyte-NT. Therefore, the up-regulation by oocyte 
factors and xklf2-HA overexpression is cell-type dependent in terms of the 
sets of up-regulated genes and the fold change in gene expression and it is 





In this chapter, I have compared the effects of oocyte factors and xklf2-HA 
overexpression on regulating selected pluripotency genes at different time 
points after Oocyte-NT. All the tested genes have one or two mKlf2 binding 
motifs on their promoters143. Three cell lines have been used for evaluating 
the different responses of the same gene in different cell lines to oocyte 
factors and to xklf2-HA overexpression. These cell lines include sixiFM and 
TcR2 for MEFs and C2C12 for mMyoblasts. 
 
To summarize the effect of oocyte factors on the pluripotency genes in each 
cell line, the effects are divided into groups according to the fold change (FC) 
of transcripts between Day 0 and Day 2 samples without xklf2-HA mRNA 
injection (Table 4.5.1). For the down-regulated/unaffected/weakly up-
regulated genes (FC<2), oocyte factors do not change much of the 
expression of mLefty1, mMyc and mNanog in MEFs and mMyoblasts. mJun is 
mildly up-regulated by oocyte factors in MEFs and mMyoblasts (2≤FC<16), 
and mOct4 and mSox2 are strongly up-regulated in both cell types (FC≥16).  
 
Notably, mUtf1 in mMyoblasts is down-regulated/unaffected/weakly up-
regulated (FC<2) but mUtf1 in MEFs is mildly up-regulated (2≤FC<16). 
Additionally, all the tested pluripotency genes were up-regulated by oocyte 
factors to the same range of relative expression in both MEF cell lines except 
for mOct4 while the expression of mOct4 at Day 0 is undetermined in sixiFM 
MEF so the relative expression is unknown. This indicates the chromatin 
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structures of tested pluripotency genes in sixiFM and TcR2 MEFs are fairly 
similar and therefore they respond to oocyte factors in a similar way. 
 
Regarding the effect of xklf2-HA overexpression, xklf2-HA effect is determined 
by dividing the relative expression of xklf2-HA mRNA injection groups by no 
mRNA injection groups. There are two different phases for the response of 
genes to xklf2-HA overexpression. The early phase is measured immediately 
at Day 0 and the late phase is measured at Day 2 after Oocyte-NT. 
 
For the early phase of xklf2-HA effect at Day 0 after Oocyte-NT, mLefty1, 
mMyc, mNanog, mJun and mSox2 are down-regulated/unaffected/weakly up-
regulated by xklf2-HA overexpression in both MEFs and mMyoblasts 
(9.2ng/0ng<2, Table 4.5.2.A). mUtf1 is down-regulated/unaffected/weakly up-
regulated in mMyoblasts (9.2ng/0ng<2) but is mildly up-regulated in MEFs 
(2≤9.2ng/0ng<16). mOct4 is strongly up-regulated in mMEFs and Myoblasts 
(9.2ng/0ng≥16). 
 
For the late phase of xklf2-HA effect at Day 2 after Oocyte-NT (Table 4.5.2.B), 
mLefty1, mMyc and mNanog, mUtf1 and mJun are down-
regulated/unaffected/weakly up-regulated by xklf2-HA overexpression in 
MEFs and mMyoblasts (9.2ng/0ng<2). mOct4 is down-
regulated/unaffected/weakly up-regulated in mMyoblasts (9.2ng/0ng<2) while 
it is mildly up-regulated in MEFs (2≤9.2ng/0ng<16). mSox2 is mildly up-
regulated in both MEFs and mMyoblasts (2≤9.2ng/0ng<16) and no tested 
gene is strongly up-regulated in both cell types (9.2ng/0ng≥16).  
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Overall, mLefty1, mMyc and mNanog are down-regulated/unaffected/weakly 
up-regulated by oocyte factors and by xklf2-HA overexpression in both MEFs 
and mMyoblasts. mUtf1 is down-regulated/unaffected/weakly up-regulated by 
oocyte factors and xklf2-HA overexpression in mMyoblasts but it is mildly up-
regulated by oocyte factors and xklf2-HA overexpression in MEFs. mOct4 and 
mSox2 are strongly up-regulated by oocyte factors in both MEFs and 
mMyoblasts. mOct4 is strongly up-regulated at Day 0 and mSox2 is mildly up-
regulated at Day 2 after Oocyte-NT by xklf2-HA overexpression in both MEFs 
and mMyoblasts. 
 
The similar and different response of tested pluripotency genes in MEFs and 
mMyos to oocyte factors and xklf2-HA overexpression indicates the way by 
which oocyte factors and xklf2-HA overexpression regulated gene expression 
in different cell types due the different chromatin structures of these genes 
from different donor cell types. 
 
There are only two ways can be utilized to rejuvenate the totipotent or 
pluripotent state in the cells from adults: one is nuclear transfer and the other 
one is induced pluripotency. From this point, I will interpret the data acquired 




Table 4.5.1 Effect of endogenous oocyte factors on the regulation of pluripotency 
genes from Day 0 to Day 2 after Oocyte-NT is shown. 
V means the specified genes belong to the groups of down-regulated/unaffected/weakly up-
regulated genes (FC<2), mildly up-regulated genes (2≤FC<16) or strongly up-regulated 
genes (FC≥16). 
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Table 4.5.1 Effect of oocyte factors on the regulaton of pluripotency genes
FC = fold change of transcripts between Day 0 and Day 2
v = the specified gene belongs to the group with 0 < FC < 2, 2 ≤ FC < 16 or 16 ≤ FC
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Table 4.5.2.A The early phase of xklf2-HA effect on the regulation of pluripotency 
genes at Day 0 after Oocyte-NT 
9.2ng/0ng=(relative expression of xklf2-HA mRNA samples at Day 0)/(relative expression of 
no mRNA injection samples at Day 0) 
 
Table 4.5.2.B The late phase of xklf2-HA effect on the regulation of pluripotency genes 
at Day 2 after Oocyte-NT 
9.2ng/0ng=(relative expression of xklf2-HA mRNA samples at Day 0)/(relative expression of 
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Table 4.5.2.A The early phase of the xklf2-HA effect on the regulaton of pluripotency genes at
Day 0 after Oocyte-NT
9.2ng/0ng = (FC of 9.2ng xklf2 HA mRNA samples at Day 0) ÷ (FC of 0ng samples at Day 0)
v =  the specified gene belongs to the groups with 0 < 9.2ng/0ng < 2, 2 ≤ 9.2ng/0ng < 16 or 16 ≤ FC
v v v v v
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mLefty1 mMyc mNanog mUtf1 mJun mOct4 mSox2
Table 4.5.2.B The late phase of the xklf2-HA effect on the regulaton of pluripotency genes at
Day 2 after Oocyte-NT
9.2ng/0ng = (FC of 9.2ng xklf2-HA mRNA samples at Day 2) ÷ (FC of 0ng samples at Day 2)
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Table 4.5.2.A The arly phase of the xklf2-HA effect on the regulaton of pluripotency genes at
Day 0 after Oocyt -NT
9.2ng/0ng = (FC of 9.2ng xklf2-HA mRNA samples at Day 0) ÷ (FC of 0ng samples at Day 0)
v =  the specified gene belongs to the groups with 0 < 9.2ng/0ng < 2, 2 ≤ 9.2ng/0ng < 16 or 16 ≤ FC
v v v v v
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Table 4.5.2.B The late phase of the xklf2-HA effect on the regulaton of pluripotency genes at
Day 2 after Oocyte-NT
9.2ng/0ng = (FC of 9.2ng xklf2-HA mRNA samples at Day 2) ÷ (FC of 0ng samples at Day 2)
v =  the specified gene belongs to the groups with 0 < 9.2ng/0ng < 2, 2 ≤ 9.2ng/0ng < 16 or 16 ≤ FC
	 131	
Chapter 5 Oocytes reprogram gene expression of 
transcriptomes of mESCs, MEFs and mMyos to an 




Mature eggs are able to reprogram somatic cell nuclei into a totipotent state 
and the resulting totipotent cell can develop into an adult9. It has been shown 
that various somatic cell types can be reprogrammed into a totipotent state in 
many species but the success rate is usually low due to the resistance of 
somatic nuclei to SCNR2. Therefore, my question is why can oocytes 
reprogram various cell types? What is the difference or similarity among 
various cell types against SCNR by oocytes? Are there certain functions of 
oocytes to reprogram cell nuclei regardless of cell types? 
 
In Chapter 4, it has been shown that the effect of oocyte factors on selected 
pluripotency genes can be examined by time-point observation via QPCR 
analysis and the increase of fold change for those genes regulated by oocyte 
factors is presumably related to the donor cell types due to the different 
chromatin states and transcriptional machinery of various donor cells. In this 
chapter, I used RNA-seq plus BrUTP pulldown to examine the transcriptional 
reprogramming in various cell types by oocyte factors genome wide. 
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In section 5.2, the time-dependent effect of oocyte factors on MEFs was first 
compared at Day 1 with Day 2 after Oocyte-NT. I expect to categorize the 
newly synthesized transcripts of reprogrammed transcriptomes of MEFs into 
those from up-regulated genes, down-regulated genes and constant genes. 
 
In section 5.3, reprogrammed transcriptomes of mESCs, MEFs and mMyos 
are compared to find the difference and similarity after various cell types are 
reprogrammed by oocytes. I expect to find some differentially expressed 
genes between cell types (Cell-type-DE genes). 
 
In section 5.4, the transcriptomes of each cell type before and after Oocyte-
NT will be compared. I expect to have lists of oocyte-off genes and oocyte-on 
genes. The oocyte-off genes can be either silenced by oocyte factors or not 
expressed after Oocyte-NT and the oocyte-on genes are activated by oocyte 
factors after Oocyte-NT. 
 
In section 5.5, the difference and similarity of reprogrammed transcriptomes 
among various cell types will be compared to understand the ways by which 
oocytes reprogram various cell types. I expect to have lists of cell-type 
specific genes and reprogrammable genes among cell types. These cell-type 
specific genes are either expressed in some cell types but not in other cell 
types or are resistant to activation by oocyte factors in some cell types but are 
able to be activated by oocyte factors in other cell types.  
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5.1.2 Experimental design 
To evaluate the effect of oocyte factors on various cell types, Oocyte-NT is 
followed by BrUTP injection and new synthesized transcripts are identified by 
BrUTP pull-down before RNA-seq (Figure 5.1.1). This procedure for analyzing 
induced expression of genes by oocyte factors is similar to experiments in 
Chapter 4. This is to say that the injection of BrUTP soon after Oocyte-NT 
marks only transcripts from genes that are newly transcribed at this point and 
afterwards, rather than paying attention to maternal transcripts already 
present in oocytes and transplanted cells.  
 
In contrast to SCNR by induced pluripotency, oocytes induce a particularly 
rapid response to injected nuclei and to overexpressed factors. New gene 
expression can be seen within one or two days at 18℃ and this is equivalent 
to 10 hours at 37℃ for mammalian cultured cells. An added advantage of 
oocytes is that DNA replication is not involved in any gene response observed. 
 
There were three cell lines used for Oocyte-NT and they represent different 
cell types, namely B10 CHD4 for mESCs (mouse embryonic stem cells), 
sixiFM for MEFs (mouse embryonic fibroblasts) and C2C12 for mMyos 
(mouse adult myoblasts) (Figure 5.1.1). These cells were SLO-permeabilized 
and were injected into GV of Xenopus oocytes at Day 0. Two hours later, 
BrUTP was injected into oocytes, which was incorporated into newly 
synthesized transcripts after RNA Polymerase II on chromatin of donor cells 
was replaced by RNA Polymerase II of Xenopus oocytes136. The oocyte 
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samples were then collected at Day 1 or Day 2 after Oocyte-NT and 
processed for RNA-seq. 
 
In order to evaluate the genome-wide effect of oocyte factors, Oocyte-NT was 
performed, followed by BrUTP injection. Reprogrammed transcriptomes of 
mESCs, MEFs and mMyos (mESC-NT, MEF-NT and mMyo-NT) were 
analyzed by RNA-seq (Figure 5.1.1). The time-dependent effect of oocyte 
factors on MEFs was examined by comparing samples collected at Day 1 and 
Day 2 after Oocyte-NT (Figure 5.1.1.A). Moreover, the difference among 
mESC-NT, MEF-NT and mMyo-NT were evaluated by comparing Oocyte-NT 
samples injected with different cell types and samples were collected at Day 2 
after Oocyte-NT (Figure 5.1.1.B). 
 
The RNA-seq data was first analyzed by Angela Simeone for alignment, 
hierarchical clustering, MDS (multidimensional scaling) analysis and DE 
(differential expression) analysis. Then, I further analysed these data for Venn 
diagram, Pearson correlation coefficient, Gene ontology and KEGG pathway. 
The description of preliminary data validation is in Appendix IV (page 327). 
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Figure 5.1.1 Sample preparation for evaluating the effect of oocyte factors on various 
cell types during SCNR by oocytes. 
(A) Time-dependent effect of oocyte factors on MEFs at Day 1 and Day 2 after Oocyte-NT 
(B) Effects of oocyte factors on mESCs, MEFs and mMyos at Day 2 after Oocyte-NT 
  
Figure 5.1.1






RNA processing and RNA-seq




Figure 5.1.1 Sample preparation for evaluating reprogrammed transcriptomes of mESCs,
MEF and mMyo by Xenopus oocytes
A. Comparison of reprogrammed transcriptomes of MEFs at Day 1 and 2 after Oocyte-NT
B. Comparison of reprogrammed transcriptomes of mESCs, MEFs and mMyos at Day 2
     after Oocyte-NT. 
A.
B.
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5.2 Xenopus oocytes reprogram MEFs to a steady state within 
two days after Oocyte-NT 
In chapter 4, it has been shown that oocyte factors up-regulate some 
pluripotency genes time-dependently by either activating them from a silent 
state (mOct4, Figure 4.2.1.A, page 110) or by enhancing their expression 
when they are already expressed in the donor cells during SCNR by oocytes 
(Figure 4.2.1.B-E, page 110; Figure 4.2.2, page 111). The up-regulation of 
these oocyte-affected genes in MEFs has been shown to be strong for 
selected pluripotency genes with a fold change of more than 4 for mSall4, 
mKlf4, mUtf1 and more than 100 for mSox2 from Day 0 to Day 2 after Oocyte-
NT (Figure 4.2.1.B-E, page 110). 
 
Here, in Chapter 5, I compare MEF-NT between Day 1 and Day 2 after 
Oocyte-NT genome-wide in order to know how many genes are affected by 
oocyte factors and how strong and effective oocyte factors are in terms of 
regulating downstream genes. 
 
5.2.1 The Day 1 and Day 2 samples of MEF-NT are similar and the 
expression of only 0.5% of analyzed genes is changed by Xenopus oocytes 
from Day 1 to Day 2 after Oocyte-NT 
To examine the difference of libraries between Day 1 and Day 2 samples of 
MEF-NT, hierarchical clustering, MDS analysis and DE analysis were applied 
(paired biological duplicates, Frog 1 and 2, Figure 5.2.1). The hierarchical 
clustering shows that RNA-seq libraries of MEF-NT samples of Frog 1 and 2 
collected at Day 2 after Oocyte-NT are grouped together by the expression of 
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genes in MEF-NT and separated from libraries of MEF-NT samples collected 
at Day 1 (Figure 5.2.1.A). However, when the data were analyzed via MDS 
analysis, the RNA-seq libraries of Day 1 samples are not separated from 
libraries of Day 2 samples and it indicates the difference between Day 1 and 
Day 2 of MEF-NT is not significant (Figure 5.2.1.B). 
 
When comparing the expression of each gene between the MEF samples 
collected at Day 1 and Day 2 after Oocyte-NT via DE analysis, there are 97 
Oocyte-DE genes regulated by oocyte factors (FDR<0.1, Figure 5.2.1.C). 
Among these Oocyte-DE genes, 51 Oocyte-DE genes are up-regulated by a 
fold change of more than 4 and 46 Oocyte-DE genes are down-regulated by 
the fold change of less than -8 by oocyte factors from Day 1 to Day 2 after 
Oocyte-NT (Figure 5.2.1.C). Since 17812 newly synthesized transcripts are 
analyzed by DE analysis and there are 97 Oocyte-DE genes, only 0.5% of 
newly synthesized transcripts are significantly regulated by oocyte factors 
from Day 1 to Day 2 after Oocyte-NT. Therefore, the difference of MEF-NT 
between Day 1 and Day 2 samples is small and gene expression in MEF-NT 
is not greatly changed by oocyte factors from Day 1 to Day 2 after Oocyte-NT. 
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Figure 5.2.1 The difference between MEF-NT at Day 1 and Day 2 after Oocyte-NT is 
small and only 0.5% analyzed genes are Oocyte-DE genes (FDR<0.1, n=2, paired). 
(A-B) Hierarchical clustering (A) and MDS analysis (B) show the difference between MEF-NT 
at Day 1 (in green and intalic) and MEF-NT at Day 2 (in green) after Oocyte-NT. Height 
represents the dissimilarity across samples.  
(C) DE analysis shows 97 Oocyte-DE genes are significantly up- or down-regulated by oocyte 
factors by more than 4-fold and 8-fold from Day 1 to Day 2 after Oocyte-NT (orange dots).	  
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Day 1 vs Day 2
The expression of 51 Oocyte-DE genes in MEF-NT is up-regulated
from Day 1 to Day 2 after Oocyte-NT (FDR<0.1, 2<log2FC<12)
The expression of 46 Oocyte-DE genes in MEF-NT is down-regulated









































































5.2.2 The expression of 66% newly synthesized transcripts in MEF-NT 
remains constant from Day 1 to Day 2 after Oocyte-NT and some pluripotency 
genes are up-regulated by oocyte factors within one day after Oocyte-NT 
To further analyze the data of DE analysis without considering the statistical 
significance, the log2FC between Day 1 and Day 2 samples of MEF-NT 
against the number of genes is shown as a bar chart and the values for 
log2FC and the number of genes are shown (Figure 5.2.2 and Table 5.2). 
There are 11631 genes newly synthesized after Oocyte-NT in DE analysis are 
not changed from Day 1 to Day 2 after Oocyte-NT and it accounts for 66% of 
analyzed genes (-1<log2FC<1, Figure 5.2.2 and Table 5.2). Additionally, 19% 
of analyzed genes are weakly up- or down-regulated by oocyte factors 
(1<log2FC<2 and -2<log2FC<-1) and 15% of analyzed genes are strongly up- 
or down-regulated by oocyte factors (log2FC>2 and log2FC<-2) between Day 
1 and Day 2 after Oocyte-NT (Figure 5.2.2 and Table 5.2). 
 
In Chapter 4, some pluripotency genes in MEFs have been shown to be up-
regulated by oocyte factors between Day 0 and Day 2 after Oocyte-NT 
(Figure 4.2.1 and 4.2.2, Page 110 and 111). Now I took them as examples for 
the comparison between results obtained from QPCR and RNA-seq plus 
BrUTP. By comparison, some of the pluripotency genes up-regulated by 
oocyte factors from Day 0 and Day 2 in Chapter 4 (Figure 4.2.1 and 4.2.2, 
Page 110 and 111) are also up-regulated from Day 1 to Day 2 in this chapter 
but some are not (Table 5.2). Notably, none of them are judged as Oocyte-DE 
genes regulated by oocyte factors from Day 1 to Day 2 because all of them 
have FDR>0.1. 
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Among these pluripotency genes, the expression of mUtf1 and mEsrrb are 
enhanced by oocyte factors by 14-fold and 2.2-fold from Day 0 to Day 2 after 
Oocyte-NT, analyzed by QPCR in Chapter 4 (Figure 4.2.2, Page 111) and the 
expression of mUtf1 and mEsrrb increase by ~4-fold and ~128-fold from Day 
1 to Day 2 after Oocyte-NT, analyzed by RNA-seq plus BrUTP pulldown in 
this chapter (Table 5.2). 
 
For mSox2, mKlf4 and mSall4, they has been shown to be up-regulated by 
oocyte factors by 193-fold, 6.5-fold and 9.1-fold from Day 0 to Day 2 after 
Oocyte-NT in Chapter 4 (Figure 4.2.1.B-D, Page 110) but they are not up-
regulated by oocyte factors from Day 1 to Day 2 after Oocyte-NT in this 
chapter (-1<log2FC<1, Table 5.2). Therefore, the expression of mSox2, mKlf4 
and mSall4 remains constant from Day 1 to Day 2 after Oocyte-NT and the 
strong enhancement of expression by oocyte factors happens within one day 
after Oocyte-NT. 
 
Intriguingly, mOct4 in MEFs has been shown to be up-regulated by oocyte 
factor by 92-fold from a silent or low expressed state from Day 0 to Day 2 
after Oocyte-NT in Chapter 4 (Figure 4.2.1.A and 4.3.A, Page 110 and 118) 
but the expression of mOct4 seems to be down-regulated by oocyte factors 
from Day 1 to Day 2 after Oocyte-NT in this chapter (Table 5.2). It is possible 
that the resistance of mOct4 is so strong that the activation of mOct4 is 




Overall, the up-regulation of different pluripotency genes in MEFs at different 
time points may relate to when and how oocyte factors affect individual gene 




Figure 5.2.2 Without considering statistical significance, 2/3 analyzed genes are not 
changed by oocyte factors from Day 1 to Day 2 after Oocyte-NT. 
The exact number of genes is also shown in Table 5.2. 17812 genes are analyzed. The 
expression of 66% newly synthesized transcripts is not changed (11631 genes, -1<log2FC<1). 
10% newly synthesized transcripts are weakly up-regulated (1739 genes, 1<log2FC<2) and 
8% are strongly up-regulated (1360 genes, log2FC>2) by oocyte factors. 9% newly 
synthesized transcripts are weakly down-regulated (1673 genes, -2<log2FC<-1) and 8% are 
strongly down-regulated (1409 genes, log2FC<-2) by oocyte factors. 
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Table 5.2 mEsrrb and mUtf1 are up-regulated by oocyte factors from Day 1 to Day 2 
after Oocyte-NT while all the listed pluripotency genes except for mKlf2 are up-
regulated by oocyte factors from Day 0 to Day 2 after Oocyte-NT. 
* All the listed pluripotency genes in MEF-NT are not significantly regulated by oocyte factors 
from Day 1 to Day 2 after Oocyte-NT with FDR>0.1, judged by DE analysis. 
+ mEsrrb in MEFs is up-regulated by oocyte factors by 2.2-fold from Day 0 to Day 2 after 
Oocyte-NT, judged by QPCR (Figure 4.2.2.B, Page 111). 
++ mUtf1, mKlf4, mSox2, mSall4 and mOct4 in MEFs are up-regulated by oocyte factors by 
more than more than 6.5-fold and up to 193-fold from Day 0 to Day 2 after Oocyte-NT, judged 
by QPCR (Figure 4.2.1 and 4.2.2.A, Page 110 and 111). 
^ As a constant gene, the expression of mKlf2 in MEFs is not changed by oocyte factors from 
Day 0 to Day 2 after Oocyte-NT.	  
Table 5.2 Distribution of log2FC between Day 1 and Day 2 in MEF-NT
Table 5.2










2~3 662 4% mUtf1++
1~2 1739 10%
0~1 5816 33% mKlf4++, mSox2++
-1~0 5815 33% mKlf2^, mSall4++
-2~-1 1673 9%
-3~-2 700 4%









All the listed pluripotency genes of MEF-NT have FDR>0.1 f r DE analysis
from Day 1 to Day 2 after Oocyte-NT
mEsrrb of MEFs is up-regulated by maternal factors with 1<log2FC<2 from
Day 0 to Day 2 after Oocyte-NT
mUtf , mKlf4, mSox2, mSall4 and mOct4 of MEFs are up-regulated by
maternal factors with 2<log2FC from Day 0 to Day 2 after Oocyte-NT







5.2.3 The batch effects affect the speed of SCNR by Xenopus oocytes but 
different batches of oocytes still can reprogram transcriptomes of MEFs to a 
highly similar oocyte-steady state at Day 2 after Oocyte-NT 
To investigate the oocyte effects on SCNR at different time points, the 
expression level of newly synthesized transcripts (FPKM) of MEF-NT 
collected at different days after Oocyte-NT or from different frogs is analyzed 
by Pearson correlation coefficient (Figure 5.2.3 and 5.2.4). While the value of 
Pearson correlation coefficient (𝛒) approaches 1, genes of MEF-NT from 
different samples are linearly correlated with an upward trend. 
 
The result demonstrates that MEF-NT of Frog 1 between Day 1 and Day 2 
Oocyte-NT samples (𝛒=0.95, Figure 5.2.3.A) is more correlated linearly than 
MEF-NT of Frog 2 between Day 1 and Day 2 Oocyte-NT samples (𝛒=0.72, 
Figure 5.2.3.B). Hence, MEF-NT of Frog 1 does not change as much as MEF-
NT of Frog 2 and MEF-NT of Frog 1 almost reaches the same steady state as 
at Day 1 after Oocyte-NT when MEF-NT of Frog 2 still changes from Day 1 to 
Day 2 after Oocyte-NT. A similar result is also shown via MDS analysis when 
MEF-NT of Day 1 and Day 2 samples of Frog 1 are closer than MEF-NT of 
Day 1 and Day 2 samples of Frog 2 (Figure 5.2.1.B). 
 
Additionally, Day 1 samples of MEF-NT of Frog 1 and Frog 2 are compared 
and Day 2 samples of MEF-NT of Frog 1 and Frog 2 are also compared for 
evaluating the effects of oocyte factors from different batches of oocytes on 
SCNR at different sample collection days (Figure 5.2.4). For the correlation of 
Day 1 and Day 2 samples of MEF-NT between Frog 1 and Frog 2, MEF-NT of 
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Day 2 samples between Day 1 and Day 2 (𝛒=0.98, Figure 5.2.4.B) are more 
linearly correlated than Day 1 samples (𝛒=0.71, Figure 5.2.4.A). Therefore, 
the expression of genes of MEF-NT of Day 1 samples is slightly different with 
a lower value of Pearson correlation coefficient than Day 2 samples due to the 
batch effects of oocytes from different frogs. 
 
MEF-NT of Frog 1 does not change much from Day 1 to Day 2 (𝛒=0.95, 
Figure 5.2.3.A) and MEF-NT of Day 2 samples between Frog 1 and Frog 2 
are fairly similar (𝛒=0.98, Figure 5.2.4.B). Therefore, the change of MEF-NT of 
Frog 2 from Day 1 to Day 2 (𝛒=0.72, Figure 5.2.3.B) makes the final MEF-NT 
of Frog 2 reach the same steady state as MEF-NT of Frog 1, which does not 
change much from Day 1 to Day 2 (𝛒=0.95, Figure 5.2.3.A). It suggests that 
the batch effects of oocytes from different female frogs may result in the 
difference of MEF-NT at Day 1 because different batches of oocytes 
reprogram cell nuclei with different speeds but it is sufficient for oocyte to 





Figure 5.2.3 Pearson correlation coefficient shows different batches of oocytes (A and 
B) reprogram MEFs to the oocyte-steady state with different speed from Day 1 to Day 2 





Figure 5.2.4 Pearson correlation coefficient shows batch effects at Day 1 after Oocyte-
NT (A) between Frog 1 and Frog 2 is diminished at Day 2 after Oocyte-NT (B) while the 
expression of newly synthesized transcripts in MEF-NT between Frog 1 and Frog 2 at 





Since the change made by oocyte factors is time-dependent as has been 
shown in Chapter 4 (Figure 4.2.1 and 4.2.2, Page 110 and 111), the 
comparison of samples at different time points could provide clues regarding 
the way by which oocyte factors of oocytes can successfully reprogram 
somatic cell nuclei and how resistance of somatic cell nuclei hinders 
successful reprogramming by oocytes. Therefore, I evaluated the time-
dependent difference of MEF-NT by comparing the oocyte samples collected 
at Day 1 and Day 2 after Oocyte-NT and analyzed them by hierarchical 
clustering, MDS analysis, DE analysis and Pearson correlation coefficient. 
 
Hierarchical clustering shows that MEF-NT of Day 1 samples is separated 
from MEF-NT of Day 2 samples (Figure 5.2.1.A). However, MEF-NT of Day 1 
samples and Day 2 samples are not clearly separated from each other via 
MDS analysis (Figure 5.2.1.B). Furthermore, DE analysis shows that only 
0.5% of analyzed genes are significantly changed from Day 1 to Day 2 after 
Oocyte-NT (Figure 5.2.1.C). Hence, the difference between MEF-NT of Day 1 
and Day 2 samples is small. 
 
To look further into the data of DE analysis without considering the statistical 
significance, 66% of analyzed genes are not changed (11631 genes, -
1<log2FC<1), 19% of analyzed genes are weakly up- or down-regulated (1739 
genes, 1<log2FC<2; 1673 genes, -2<log2FC<-1) and 15% of analyzed genes 
are strongly up- or down-regulated (1360 genes, log2FC>2; 1409 genes, 
log2FC<-2) by oocyte factors from Day 1 to Day 2 after Oocyte-NT (Table 5.2). 
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Compared to pluripotency genes up-regulated by oocyte factors from Day 0 to 
Day 2 after Oocyte-NT in Chapter 4 (Figure 4.2.1 and 4.2.2, Page 110 and 
111), the expression of some pluripotency genes keeps increasing (mUtf1 and 
mEsrrb) but some pluripotency genes remains constant (mSox2, mKlf4 and 
mSall4) from Day 1 to Day 2 after Oocyte-NT in this chapter (Table 5.2). The 
time period difference indicates that some genes (mSox2, mKlf4 and mSall4) 
are up-regulated by oocyte factors to a steady state within one day after 
Oocyte-NT and some genes (mUtf1 and mEsrrb) are up-regulated by oocyte 
factors later. This is probably due to different epigenetic barriers for each 
gene and the stepwise molecular mechanisms to remove these barriers after 
nuclear transfer5. 
 
When comparing MEF-NT of Day 1 and Day 2 samples reprogrammed by two 
batches of Xenopus oocytes, Pearson correlation coefficient shows that one 
batch of oocytes can reprogram MEFs to a steady state less than a day 
without much change of transcriptomes from Day 1 to Day 2 (Figure 5.2.3.A). 
The other batch of oocytes needs more than a day to reprogram MEFs to a 
steady state (Figure 5.2.3.B and 5.2.4.B). The batch effects of oocytes 
decrease while increasing the time for oocyte reprogramming MEFs from one 
day to two days (Figure 5.2.4). Thus, the batch effects slightly affect the 
speed of transcriptional reprogramming by oocytes but the transcriptomes of 




All in all, the majority of the newly synthesized transcripts are reprogrammed 
successfully by oocyte factors to a certain level within a day and their 
expression remains constant from Day 1 to Day 2 after Oocyte-NT. Some 
genes are still changed from Day 1 to Day 2 after Oocyte-NT caused by the 
batch effects and the resistance of these genes. When increasing the 
reprogramming time from one day to two day, the batch effects can be 
diminished since batch effects affect the speed of SCNR by oocytes. For 
MEFs, two days are sufficient for Xenopus oocytes to reprogram the 
transcriptomes of MEFs to a steady state. 
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5.3 Xenopus oocytes reprogram the transcriptomes of mESCs, 
MEFs and mMyos to be almost identical at Day 2 after Oocyte-
NT 
During SCNR by eggs, the efficiency of successful reprogramming is usually 
low due to the barriers of transplanted cell nuclei2. In 5.2, it has been shown 
that transcriptomes of MEFs can be reprogrammed by oocyte factors to a 
steady state within two days regardless of batch effects of Xenopus oocytes. 
It seems MEFs can be reprogrammed successfully by oocyte factors within 
two days after Oocyte-NT but how about other cell types? Do the original 
transcriptional machineries of donor cell nuclei affect the SCNR by oocytes? 
Do the chromatin structures of donor cell nuclei affect SCNR by oocytes? 
 
Here, I used three cell types for Oocyte-NT and evaluated the difference 
between reprogrammed transcriptomes of mESCs (mESC-NT), MEFs (MEF-
NT) and mMyos (mMyo-NT) and the difference may relate to their potential 
functions. Since these experiments were designed to be paired for examining 
the effect of xklf2-HA on SCNR by oocytes in Chapter 6, two in three of the 
comparisons of reprogrammed transcriptomes via DE analysis are not paired 
in this section (mMyo-NT versus mESC-NT, paired, Figure 5.3.1; MEF-NT 
versus mMyo-NT, MEF-NT versus mESC-NT, unpaired, Figure 5.3.2 and 
5.3.3). However, the results of paired and unpaired analyses are similar and 
the batch effects for SCNR by oocytes at Day 2 after Oocyte-NT may not be 
significant, as has been shown in section 5.2. 
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5.3.1 mESC-NT, MEF-NT and mMyo-NT are not grouped by the difference of 
cell types or different origins of oocyte batches 
The difference between mESC-NT, MEF-NT and mMyo-NT at Day 2 after 
Oocyte-NT were first evaluated by hierarchical clustering and MDS analysis 
(Figure 5.3.1.A and B, Figure 5.3.2.A and B and Figure 5.3.3.A and B). The 
comparison of mMyo-NT to mESC-NT is paired (n=3). The comparisons 
between MEF-NT and mMyo-NT and MEF-NT and mESC-NT are unpaired 
(n=3). 
 
For the comparison between mMyo-NT and mESC-NT (paired, n=3), three 
mMyo-NTs are not grouped together against three mESC-NTs and the 
batches of oocytes do not affect the grouping (Figure 5.3.1.A and B). For 
three libraries to the right of hierarchical clustering, mMyo-NT of Frog 3 was 
first grouped with mESC-NT of Frog 2 and then grouped with mESC-NT of 
Frog 3 (Right, Figure 5.3.1.A). For the libraries of the left hand branches, 
mMyo-NTs of Frog 2 and Frog 4 are grouped together first and then grouped 
with mESC-NT of Frog 4 (Left, Figure 5.3.1.A). Additionally, this shows that 
mMyo-NTs of Frog 2, 3 and 4 are not separated from mESC-NTs of Frog 2, 3, 
and 4 via MDS analysis (Figure 5.3.1.B). 
 
Regarding the unpaired comparisons, namely MEF-NTs versus mMyo-NTs 
and MEF-NTs versus mESC-NTs, similar results were shown that 
reprogrammed transcriptomes of mESCs, MEFs and mMyos are not grouped 
or separated by the cell types via hierarchical clustering and MDS analysis 
(Figure 5.3.2.B and 5.3.3.B).	  
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5.3.2 There are less than 40 Cell-type DE genes differentially expressed 
between reprogrammed transcriptomes of mESCs, MEFs and mMyos at Day 
2 after Oocyte-NT 
For the DE analysis of mMyo-NT versus mESC-NT, there are 20 Cell-type-DE 
genes expressed to different levels in mMyo-NT and mESC-NT at Day 2 after 
Oocyte-NT and this makes up only 0.1% of total analysed genes by DE 
analysis (FDR<0.1, paired, n=3, Figure 5.3.1.C). Six Cell-type-DE genes 
between mMyo-NT and mESC-NT are expressed more in mESC-NT than 
mMyo-NT by more than 16-fold and 14 Cell-type-DE genes are expressed 
more in mMyo-NT than mESC-NT by more than 8-fold (Figure 5.3.1.C). 
 
Furthermore, for the unpaired DE analyses between MEF-NT and mMyo-NT 
and MEF-NT and mESC-NT, these demonstrate that less than 40 Cell-type-
DE genes are differentially expressed between either MEF-NT and mMyo-NT 
or MEF-NT and mESC-NT at Day 2 after Oocyte-NT (Figure 5.3.2.C and 
5.3.3.C). While there are 34 Cell-type-DE genes that differ between MEF-NT 
and mMyo-NT, 11 Cell-type-DE genes are more expressed in mMyo-NT than 
in MEF-NT by more than 16-fold and 23 Cell-type-DE genes are more 
expressed in MEF-NT than in mMyo-NT by more than 8-fold (Figure 5.3.2.C). 
On the other hand, there are 24 Cell-type-DE genes differentially expressed 
between MEF-NT and mESC-NT and 11 Cell-type-DE genes are expressed 
more in mESC-NT by more than 16-fold and 13 Cell-type-DE genes are 
expressed more in MEF-NT than the other cell types by more than 8-fold 
(Figure 5.3.3.C). 
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Overall, DE analysis shows that less than 0.3% of analyzed genes are Cell-
type-DE genes when comparing reprogramming transcriptomes between cell 
types. In conclusion, DE analysis between cell types indicates that the 
reprogrammed transcriptomes at Day 2 after Oocyte-NT are almost identical 




Figure 5.3.1 The difference between mMyo-NT and mESC-NT is small and only 0.1% of 
analyzed genes are Cell-type-DE genes (FDR<0.1, n=3, paired). 
(A-B) Hierarchical clustering (A) and MDS analysis (B) show the difference between mMyo-
NT (in red) and mESC-NT (in blue) at Day 2 after Oocyte-NT. Height represents the 
dissimilarity across samples.  
(C) DE analysis shows 20 Cell-type-DE genes are differentially expressed between mMyo-NT 
and mESC-NT after Oocyte-NT (orange dots). 











































The expression of 6 Cell-type-DE genes is more in mESC-NT than in mMyo-NT
(FDR<0.1, 4<log2FC<11)
The expression of 14 Cell-type-DE genes is more in mMyo-NT than in mESC-NT
(FDR<0.1, -11<log2FC<-3)
mMyo-NT vs mESC-NT FDR
































































































Figure 5.3.2 The difference between MEF-NT and mMyo-NT is small and only 0.2% of 
analyzed genes are Cell-type-DE genes (FDR<0.1, n=3, unpaired). 
(A-B) Hierarchical clustering (A) and MDS analysis (B) show the difference between MEF-NT 
(in green) and mMyo-NT (in red) at Day 2 after Oocyte-NT. Height represents the dissimilarity 
across samples.  
(C) DE analysis shows 34 Cell-type-DE genes are differentially expressed between MEF-NT 
and mMyo-NT after Oocyte-NT (orange dots). 










































The expression of 11 Cell-type-DE genes is more in mMyo-NT than MEF-NT
(FDR<0.1, 4<log2FC<13)
The expression of 23 Cell-type-DE genes is more in MEF-NT than mMyo-NT
(FDR<0.1, -13<log2FC<-3)
MEF-NT vs mMyo-NT FDR































































































Figure 5.3.3 The difference between MEF-NT and mESC-NT is small and only 0.1% of 
analyzed genes are Cell-type-DE genes (FDR<0.1, n=3, unpaired). 
(A-B) Hierarchical clustering (A) and MDS analysis (B) show the difference between MEF-NT 
(in green) and mESC-NT (in blue) at Day 2 after Oocyte-NT. Height represents the 
dissimilarity across samples. 
(C) DE analysis shows 24 Cell-type-DE genes are differentially expressed between MEF-NT 
and mESC-NT after Oocyte-NT (orange dots).	  












































The expression of 11 Cell-type-DE genes is more in mESC-NT than in MEF-NT
(FDR<0.1, 4<log2FC<14)
The expression of 13 Cell-type-DE genes is more in MEF-NT than in mESC-NT
(FDR<0.1, -14<log2FC<-3)
MEF-NT vs mESC-NT


































































































5.3.3 At Day 2 after Oocyte-NT, more than 12000 genes in mESC-NT, MEF-
NT and mMyo-NT are reprogrammed by oocyte factors to the same level and, 
in addition to those genes, 1000-6000 genes are cell-type specific in the 
donor cells 
Less than 0.3% of analysed genes are Cell-type-DE genes when comparing 
mMyo-NT to mESC-NT, MEF-NT to mMyo-NT, and MEF-NT to mESC-NT. 
Since more than 99% of analysed genes are non-DE genes, judged by DE 
analysis, it seems the majority of newly synthesized transcripts of mESC-NT, 
MEF-NT and mMyo-NT are reprogrammed successfully to the same level by 
oocyte factors. 
 
However, are these Cell-type-DE genes the only cell-type specific genes? Are 
there other genes that are cell-type specific in the donor cells and is the 
expression of these genes after nuclear transfer maintained by transcriptional 
machineries of donor cells? Are there other genes that are donor cell-type 
specific and resistant to SCNR by oocytes due to the chromatin structure of 
these genes in the donor cells? 
 
To investigate these questions, I analysed the same RNA-seq data of mESC-
NT, MEF-NT and mMyo-NT by comparing the relative expression of newly 
synthesized transcripts (FPKM) via Venn diagrams and Pearson correlation 
coefficients (Figure 5.3.4 and 5.3.5). Reprogrammed transcriptomes for 
comparison are all transplanted into the same batch of oocytes (Frog 2) so 
the batch effect can be minimized and the difference between reprogrammed 
transcriptomes is caused by the cell-type specific traits of donor cells. 
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When comparing the genes, whose transcripts are newly synthesized after 
Oocyte-NT or maintained by the transcriptional machineries of donor cells, 
there are 12070 genes expressed in both mMyo-NT and mESC-NT (FPKM>0, 
Figure 5.3.4.A). In addition to these genes, 2902 cell-type specific genes are 
expressed only in mMyo-NT and 3683 cell-type specific genes are expressed 
only in mESC-NT (FPKM>0, Figure 5.3.4.A). Then, the expression level of 
those genes expressed in both mMyo-NT and mESC-NT is further analyzed 
by Pearson correlation coefficient and it shows that the expression level of 
those genes are linearly correlated (𝛒=0.80, Figure 5.3.5.A). Since the value 
of Pearson correlation coefficient (𝛒) is close to 1, 12070 genes in both 
mMyo-NT and mESC-NT are reprogrammed by oocyte factors to highly 
similar level at Day 2 after Oocyte-NT. 
 
For the comparison of newly synthesized transcripts of MEF-NT to mMyo-NT, 
13303 genes are expressed in both MEF-NT and mMyo-NT (Figure 5.3.4.B). 
Furthermore, 5107 cell-type specific genes are only expressed in MEF-NT 
and 1669 cell-type specific genes are expressed only in mMyo-NT (Figure 
5.3.4.B). For the comparison of MEF-NT to mESC-NT, 13537 genes are 
expressed in both reprogrammed transcriptomes. 4873 cell-type specific 
genes are expressed only in MEF-NT and 2216 cell-type specific genes are 
only expressed in mESC-NT (Figure 5.3.4.C). When comparing the 
expression level of shared genes between two reprogrammed transcriptomes, 
the expression level of shared genes between MEF-NT and mMyo-NT is 
linearly correlated with 𝛒=0.81 and the expression level of shared genes 
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between MEF-NT and mESC-NT is linearly correlated with 𝛒=0.94 (Figure 
5.3.5.B and 5.3.5.C). Therefore, more than 13000 genes are reprogrammed 
by oocyte factors to highly similar level at Day 2 after Oocyte-NT when 
comparing MEF-NT with either mMyo-NT or mESC-NT. 
 
Notably, because the value of Pearson correlation coefficient for MEF-NT 
versus mESC-NT (𝛒=0.94) is higher than the value for mMyo-NT versus 
mESC-NT (𝛒=0.80) and MEF-NT versus mMyo-NT (𝛒=0.81), the gene 
expression level of MEF-NT and mESC-NT are reprogrammed by oocyte 
factors to a more identical level than other two comparisons (Figure 5.3.5). 
This suggests that embryonic cell types, namely mESCs and MEFs, at early 
developmental stages may be more susceptible to the effect of oocyte factors 
than differentiated adult cells (mMyos) and are reprogrammed to the steady 





Figure 5.3.4 More than 12000 genes have transcripts synthesized after Oocyte-NT in 
reprogrammed transcriptomes of all three cell types and 1000-6000 cell-type specific 
genes have transcripts synthesized after Oocyte-NT in at least one of the three cell 
types. 
Genes with FPKM>0 are those genes have transcripts synthesized after Oocyte-NT. 




Figure 5.3.5 More than 12000 genes are reprogrammed to a fairly similar level in 
reprogrammed transcriptomes of all three cell types while expression of genes is 






During SCNR by eggs, the resistance of genes in somatic cell nuclei is the 
major factor causing the low efficiency of successful reprogramming. In 5.3, it 
has been shown that Xenopus oocytes can reprogram the majority of genes 
(99%) in MEFs to a steady state within 2 days after Oocyte-NT but it is 
unknown if the resistant genes are also reprogrammed successfully. In this 
section, I tried to identify cell-type specific genes by comparing mESC-NT, 
MEF-NT and mMyo-NT at Day 2 after Oocyte-NT. 
 
RNA-seq libraries of mESC-NT, MEF-NT and mMyo-NT were first analyzed 
by hierarchical clustering and MDS analysis. These analyses show that 
libraries of mESC-NT, MEF-NT and mMyo-NT are not grouped by cell types 
or the batches of oocytes (Figure 5.3.1.A-B, 5.3.2.A-B and 5.3.3.A-B). When 
comparing mESC-NT, MEF-NT and mMyo-NT via DE analysis, there are less 
than 0.3% of analyzed genes differentially expressed between different cell 
types and more than 99% of analyzed genes not differentially expressed 
(Figure 5.3.1.C, 5.3.2.C, 5.3.3.C). 
 
To look into the difference among mESC-NT, MEF-NT and mMyo-NT, newly 
synthesized transcripts of reprogrammed transcriptomes of different cell types 
are evaluated by Venn diagrams and Pearson correlation coefficients. This 
shows that 1000 to 6000 cell-type specific genes are expressed in mESC-NT, 
MEF-NT and mMyo-NT and more than 12000 genes in mESC-NT, MEF-NT 
and mMyo-NT are reprogrammed to the same level by oocyte factors (Figure 
5.3.4 and 5.3.5). 
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The different outcomes for Cell-type-DE genes via DE analysis and cell-type 
specific genes via Venn diagrams suggests that the definition for those genes 
in donor cells, which affect SCNR by oocytes, needs to be more delicately 




5.4 Transcriptional reprogramming of mESCs, MEFs and 
mMyos by Xenopus oocytes 
In 5.3, it has been shown that Xenopus oocytes can reprogram 
transcriptomes of mESCs, MEFs and mMyos to be very similar in terms of the 
expression level of newly synthesized transcripts and the majority of these 
genes are regulated to a steady state by oocyte factors at Day 2 after Oocyte-
NT. However, the way by which the original transcriptomes of mESCs, MEFs 
and mMyos are reprogrammed by oocytes is not known. In this section, I ask 
how the transcriptomes of mESCs, MEFs and mMyos change before and 
after Oocyte-NT and what kinds of genes are silenced after Oocyte-NT.  
 
5.4.1 Large-scale change of transcriptomes of mESCs, MEFs and mMyos 
before and after Oocyte-NT 
To examine the change of transcriptomes of mESCs, MEFs and mMyos and 
understand how oocyte factors regulate genes during SCNR by oocytes, the 
genes of transcriptomes of mESCs, MEFs and mMyos before and after 
Oocyte-NT are compared via Venn diagrams and Pearson correlation 
coefficients (Figure 5.4.1, 5.4.2 and 5.4.3). 
 
The transcriptomes of original mESCs and MEFs refer to database, 
Expression Atlas (EMBL-EBI). The transcriptome of mMyos refers to 
database, ENCODE project. Additionally, housekeeping genes are included in 
these comparisons since they are typically required for maintaining the basic 
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functions of all cells144. Including housekeeping genes in the comparisons 
helps to define the shared and unshared genes before and after Oocyte-NT.  
 
The genes in transcriptomes of mESCs, MEFs and mMyos with FPKM≥1 
before and after Oocyte-NT are first compared via Venn diagrams (Figure 
5.4.1). It shows that 4070 genes in mESCs are silenced and 4718 genes are 
activated in mESC-NT by oocyte factors (Figure 5.4.1.A). In MEFs, 2591 
genes are silenced and 6524 genes are activated by oocyte factors after 
Oocyte-NT (Figure 5.4.1.B). In mMyos, 4584 genes are silenced and 4508 
genes are activated by oocyte factors after Oocyte-NT (Figure 5.4.1.C). For 
the housekeeping genes, more genes are silenced by oocyte factors than the 
genes that are activated after Oocyte-NT in all three cell types (Figure 5.4.1). 
 
For the shared genes in transcriptomes with FPKM≥1 before and after 
Oocyte-NT, 8658 genes are shared in mESCs, 8660 genes are shared in 
MEFs and 7892 genes are shared in mMyos before and after Oocyte-NT 
(Figure 5.4.1). Among these shared genes, approximate 3000 genes are 
housekeeping genes (Figure 5.4.1). When examining the expression level of 
these shared genes, excluding house keeping genes, via Pearson correlation 
coefficient, the expression level of these genes are lowly linearly correlated 
with 𝛒=0.38 for mESCs, 𝛒=0.07 for MEFs and 𝛒=0.15 for mMyos between 
shared genes before and after Oocyte-NT (Figure 5.4.2). Therefore, 
regardless of housekeeping genes, 5000-6000 shared genes are expressed 
before and after Oocyte-NT and the expression of these genes is subjected to 
change to the level determined by oocyte factors. 
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Furthermore, since highly expressed genes are usually considered to be 
important to the functions of specified cell types, the top 1000 genes highly 
expressed in mESCs, MEFs and mMyos before and after Oocyte-NT are 
compared (Figure 5.4.3). It shows that 771 genes in mESCs are down-
regulated by oocyte factors to be less expressed than the level of the top 
1000 genes in mESC-NT. Through the same comparison, 831 genes in MEFs 
and 796 genes in mMyos are down-regulated to be less than top 1000 genes 
in MEF-NT and mMyo-NT by oocyte factors, respectively (Figure 5.4.3.B and 
5.4.3.C). Among these top 1000 genes, 35%~50% are housekeeping genes 
in transcriptomes of mESCs, MEFs and mMyos both before and after Oocyte-
NT (Figure 5.4.3). 
 
Altogether, the large-scale change of transcriptomes contributed by oocyte 
factors contains both up-regulation and down-regulation of genes. For up-
regulation of genes, oocyte factors can either enhance the expression of 
genes, which are already transcribed in donor cells, or activate genes, which 
are silent in donor cells. 4718 genes in mESCs, 6524 genes in MEFs and 
4508 genes in mMyos are activated by oocyte factors. On the other hand, 
oocyte factors can also down-regulate genes in donor cells either by 
repressing the expression of genes to a certain level or by silencing genes if 
these genes are not needed for reprogrammed transcriptomes. 4070 genes in 





Figure 5.4.1 Large-scale transcriptional change of mESCs, MEFs and mMyos before 
and after Oocyte-NT. 
(Figure legend continues on the next page) 
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Approximate 1/3 of genes expressed before and after Oocyte-NT are housekeeping genes.  
(A.) In mESCs, 8658 genes are expressed both before and after Oocyte-NT and 32% of them 
are housekeeping genes. Additionally, there are 4070 genes (=3533+537) silenced and 4718 
genes (=4664+54) activated after Oocyte-NT. 13% of silenced genes are housekeeping 
genes and 1% of activated genes are housekeeping genes. 
(B.) In MEFs, 8660 genes are expressed both before and after Oocyte-NT and 35% of them 
are housekeeping genes. Additionally, there are 2591 genes (=2251+340) silenced and 6524 
genes (=6449+75) activated after Oocyte-NT. 13% of silenced genes are housekeeping 
genes and 1% of activated genes are housekeeping genes. 
(C) In mMyos, 7892 genes are expressed both before and after Oocyte-NT and 36% of them 
are housekeeping genes. Additionally, there are 4584 genes (=4098+486) silenced and 4508 
genes (=4457+51) activated after Oocyte-NT. 11% of silenced genes are housekeeping 




Figure 5.4.2 Genes, expressed in both donor cells and repromgrammed transcriptomes, 






Figure 5.4.3 More than 2/3 of top 1000 genes expressed highly in donor cells are down-
regulated by oocyte factors to be less than the top 1000 genes of reprogrammed 
transcriptomes of mESCs (A), MEFs (B) and mMyos (C). 
1/3 to 1/2 of top 1000 genes for both before and after Oocyte-NT are housekeeping genes. 
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5.4.2 Some genes of mESCs, MEFs and mMyos are silent during SCNR by 
Xenopus oocytes 
For genes silent after Oocyte-NT, the functions of these genes are usually 
cell-type specific and not needed for reprogrammed transcriptomes. The 
functions of silenced genes in mESCs, MEFs and mMyos are analyzed via 
Gene ontology and KEGG pathway and detailed descriptions are in Appendix 
(Appendix V, page 331). In addition to that, the functions of reprogrammed 
transcriptomes will be discussed further in 5.5. 
 
5.4.3 Summary 
In 5.3, it has been shown that oocytes can reprogram the transcriptomes of 
mESCs, MEFs and mMyos to a steady state within 2 days after Oocyte-NT 
and the majority of genes are regulated to a steady level by oocyte factors.  
  
Through Venn diagrams, I see that 2500-5000 genes of mESCs, MEFs and 
mMyos are silenced and 4500-7000 genes in reprogrammed transcriptomes 
are activated from a silent state by oocyte factors (Figure 5.4.1). For the 
shared genes of transcriptomes before and after Oocyte-NT, these are 
regulated by oocyte factors to the level for the oocyte-determined cell identity 
(Figure 5.4.2). More than 2/3 of top 1000 genes expressed highly in donor 
cells are down-regulated by oocyte factors to be less than the top 1000 genes 
of reprogrammed transcriptomes. These genes are probably either repressed 
actively by oocyte factors or remain active but less active than genes that are 
more actively promoted by oocyte factors (Figure 5.4.3).   
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The genes silenced (32% in mESCs, 23% in MEFs and 37% in mMyos) by 
oocyte factors are cell-type specific to the functions of donor cells and these 
functional genes of donor cells are probably no longer needed for the oocyte-
determined cell identity (Appendix V, page 331). 
 
All in all, oocyte factors drive a large-scale change of transcriptomes of 
mESCs, MEFs and mMyos after Oocyte-NT and lead the transcriptomes of 
donor cells to an oocyte-determined cell identity within 48 hours.  
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5.5 Distinguish between reprogrammable genes and cell-type 
specific genes among mESC-NT, MEF-NT and mMyo-NT and 
the extent to which oocytes activate silent genes  
Since the transcriptomes represent the identities of different cell types, the 
similarity and difference of transcriptomes shows the common part and the 
cell specific part of different cell types. It has been shown in previous sections 
(Section 5.2, 5.3 and 5.4) that oocytes can reprogram transcriptomes of 
mESCs, MEFs and mMyos to a highly similar and steady state at Day 2 after 
Oocyte-NT.  
 
During SCNR by oocytes, thousands of genes in donor cells can be silenced 
or activated by oocyte factors and the expression of transcribed genes are 
regulated by oocyte factors to an oocyte-determined level. Therefore, it seems 
that oocytes are so competent that they can reprogram all cell types 
successfully but the efficiency of successful SCNR is actually low due to the 
existence of SCNR resistant genes. In this section, the aim is to find the cell-
type specific genes that contain SCNR resistant genes and investigate the 
extent to which oocytes activate silent genes in the donor cells to the oocyte-
steady state. 
 
5.5.1 Reprogrammed transciptomes of mESCs, MEFs and mMyos contain 
reprogrammable genes and cell-type specific genes 
To look deeper into the difference between reprogrammed transcriptomes 
among mESCs, MEFs and mMyos, a Venn diagram is used to separate the 
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newly synthesized transcripts of mESC-NT, MEF-NT and mMyo-NT into two 
types (Figure 5.5.1). 
 
The first type contains 11488 newly synthesized transcripts, which are 
expressed in all three reprogrammed transcriptomes of mESCs, MEFs and 
mMyos, and these genes are called reprogrammable genes (intersection of 
mESC-NT, MEF-NT and mMyo-NT, Figure 5.5.1). 
 
The second type contains 10225 newly synthesized transcripts, which are 
expressed (FPKM>0) only in one or two reprogrammed transcriptomes and 
are not expressed (FPKM=0) in at least one reprogrammed transcriptomes, 
and they are called cell-type specific genes (Figure 5.5.1). Therefore, 2049 
genes are expressed in mESC-NT and MEF-NT but not in mMyo-NT; 1815 
genes are expressed in MEF-NT and mMyo-NT; 582 genes are expressed in 
mMyo-NT and mESC-NT (Figure 5.5.1). Moreover, 1634 genes are only 
expressed in mESC-NT; 3058 genes are only expressed in MEF-NT; 1087 
genes are only expressed in mMyo-NT (Figure 5.5.1). 
 
When analyzing the correlation of these newly synthesized transcripts of 
reprogrammed transcriptomes via Pearson correlation coefficient, the 
expression level of reprogrammable genes are linearly correlated between 
MEF-NT and mESC-NT (𝛒=0.96), mMyo-NT and mESC-NT (𝛒=0.82) and 
MEF-NT and mMyo-NT (𝛒=0.81) (Figure 5.5.2). Notably, while comparing the 
expression level of cell-type specific genes, the values (𝛒) of Pearson 
correlation coefficient between reprogrammed transcriptomes are lower than 
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the values for the reprogrammable genes between reprogrammed 
transcriptomes (Figure 5.5.2 and 5.5.3). Therefore, the expression level of 
cell-type specific genes between reprogrammed transcriptomes are less 
linearly correlated than the expression level of reprogrammable genes while 
the values are 0.48, 0.35 and 0.47 for the expression level of cell-type specific 
genes between MEF-NT and mESC-NT, mMyo-NT and mESC-NT and MEF-
NT and mMyo-NT, respectively (Figure 5.5.3). 
 
Intriguingly, if examining the histogram for the expression level of newly 
synthesized transcripts, the expression level of reprogrammable genes peaks 
higher at FPKM=4 approximately (Figure 5.5.2) than the expression level of 
cell-type specific genes peaks at FPKM=2 approximately (Figure 5.5.3 and 
5.5.4). It suggests that the expression level of cell-type specific genes is lower 
because these genes are less needed for oocyte-determined cell identity or 
they are activated from a silent state by oocyte factors.  
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Figure 5.5.1 11488 reprogrammable genes have transcripts synthesized (FPKM>0) in 
reprogrammable transcriptomes of all three cell types. 10225 cell-type specific genes 
have newly synthesized transcripts synthesized in either one type of cells or two types 
of cells. 
Cell-type specific genes contain genes whose expression is maintained by the transcriptional 






Figure 5.5.2 The expression level of reprogrammable genes, which are expressed in 
mESC-NT, MEF-NT and mMyo-NT, is strongly linearly-correlated between MEF-NT and 
mESC-NT (𝛒=0.96), mMyo-NT and mESC-NT (𝛒=0.82), and MEF-NT and mMyo-NT 






Figure 5.5.3 The cell-type specific genes expressed in two cell types are weakly 
linearly-correlated between MEF-NT and mESC-NT (𝛒=0.48), mMyo-NT and mESC-NT 
(𝛒=0.35), and MEF-NT and mMyo-NT (𝛒=0.47). The expression level of cell-type specific 






Figure 5.5.4 The cell-type specific genes, which are only expressed in one of cell types, 
peaks at approximate FPKM=2. 
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5.5.2 Reprogrammable genes possess the ability to change chromatin 
structures and regulate genes as the new functions of oocyte-determined cell 
identity 
Since oocytes reprogrammed transcriptomes of donor cells to an oocyte-
determined state regardless of original cell types, the functions of the oocyte-
determined cell identity may be crucial to the establishment of totipotency. 
Therefore, reprogrammed genes are analyzed via Gene ontology and KEGG 
pathway for predicting the future functions of reprogrammed transcriptomes 
and details are noted in Appendix (Appendix VI, page 341). 
 
Importantly, the reprogrammable transcriptomes are enriched for Signaling 
pathways regulating pluripotency of stem cells and this suggests that the 
reprogrammed transcriptomes may be primed for the establishment of 
pluripotency (Appendix VI, Figure 10.6.2.A, page 346). 
 
5.5.3 Summary 
In Section 5.2 and 5.3, it has been shown that oocyte factors reprogrammed 
transcriptiomes of various cell types to an oocyte-steady state within 2 days 
after Oocyte-NT. Additionally, more than 2500 functional genes in 
transplanted mESCs, MEFs and mMyos are silenced by oocyte factors and 
more than 4500 genes are activated by oocyte factors (Section 5.4). 
Therefore, genes have new transcripts synthesized after Oocyte-NT are either 
activated by oocyte factors or expressed already in the donor cells. 
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In this section, I used Venn diagrams to categorize genes expressed in 
reprogrammed transcriptomes of mESCs, MEFs and mMyos as 
reprogrammable genes and cell-type specific genes. This shows that 11488 
reprogrammable genes are expressed in reprogrammed transcriptomes of all 
three cell types and 10225 cell-type specific genes are expressed in 
reprogrammed transcriptomes of one or two cell types. Furthermore, Pearson 
correlation coefficients show that reprogrammable genes are reprogrammed 
to oocyte-steady state in all three cell types and cell-type specific genes are 
not. 
 
Moreover, functions of reprogrammable genes are enriched by Gene ontology 
analysis and KEGG pathway. This shows that functions related to chromatin 
structural changes and signaling pathways regulating pluripotency of stem 
cells are enriched from 11488 reprogrammable genes. 
 
All in all, reprogrammable genes are reprogrammed to oocyte-steady state by 
oocyte factors and have functions to make chromatin structural changes. For 
the cell-type specific genes, these genes are expressed in reprogrammed 
transcriptomes of one or two cell types with different expression level and 
contain one group genes whose expression is maintained by transcriptional 
machinery of donor cells and another group of genes that are resistant to be 




It has been shown that, by comparing the range of genes regulated by oocyte 
factors of oocytes, transcriptomes of mESCs, MEFs and mMyos are 
reprogrammed to highly similar states. It suggests the expression of genes 
and chromatin structures are subjected to change towards the oocyte-driven 
state. It has also been shown that multiple genes in reprogrammed 
transcriptomes are involved in early embryo development, change of histone 
modification, chromatin remodeling and DNA conformation change. Therefore, 
oocyte factors have the ability to modify chromatin structure, transform the 







Chapter 6 Xenopus klf2-HA overexpression facilitates 
regulation of target genes in mESCs, MEFs and 




In Chapter 5, maternal factors of oocytes have been shown to reprogram 
mESCs, MEFs and mMyos to highly similar transcriptomes within 1 day after 
Oocyte-NT. It suggests the original chromatin structures of these three cell 
types are changed forcibly by maternal factors to a fairly similar landscape 
and allow maternal transcription factors to regulate target genes with modified 
hindrance, which resembles the change of chromatin structures and permit 
upcoming gene regulation to happen during early embryo development82.  
 
In development, the chromatin structure of cells is subjected to change in a 
spatial and timely way, and to prime regulatory elements for the linked genes 
need to be regulated by transcription factors82. It has been shown that 
different levels of chromatin accessibility can quantitatively restrict the 
occupancy of transcription factors on their recognition sites84. Additionally, 
genome-wide patterns of transcription factor binding shows that transcription 
factors can occupy their recognition sites in highly accessible chromatin 
regions without physical cooperative interactions83. Although extracts of 
oocytes have been reported to epigenetically reprogram somatic cell 
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nuclei21,22, the roles of maternal transcription factors in SCNR by oocytes are 
elusive145. I now, in this chapter, examine the effects of TF overexpression on 
a wide range of genes during SCNR by oocytes. It is of particular interest to 
analyze oocyte components versus TF overexpression at once in the same 
system. 
 
This chapter concerns a wide range of genes (15,000 to 20,000 mouse genes 
for differential expression analysis out of 48663 genes in the mouse reference 
genome) in transplanted somatic cells that maybe up- or down-regulated by 
oocytes with or without supplementation of xklf2-HA overexpression. In the 
previous Chapters 3 and 4, I have examined the effect of YF overexpression 
on expression of a limited number of known pluripotency gene markers during 
Oocyte-NT. Of the so-called Yamanaka factors, xklf2-HA has shown the 
greatest effect on transplanted MEF nuclei among three Xenopus Yamanaka 
factor homologs. Since the xklf2 transcripts are expressed maternally before 
MBT129,140,146 although the level of xklf2 protein counterparts are 
unclear141,142,147,148, xklf2 may be crucial in early development and in building 
totipotency during SCNR by eggs. 
 
Therefore, I investigate the effect of xklf2-HA overexpression on gene 
regulation during SCNR by oocytes (Section 6.2). Is the regulation of 
downstream genes by xklf2-HA overexpression different in various cell types 
during SCNR by oocytes (Section 6.3)? If xklf2 proteins maternally exist in 
Xenopus oocytes, what are the functions of xklf2 downstream genes (Section 
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6.4)? What are the different effects of oocyte factors and xklf2-HA 
overexpression on gene regulation during SCNR by oocytes (Section 6.5)? 
	
6.1.2 Experimental design 
For investigating the change after Oocyte-NT and disregarding the carried 
over transcripts in donor cells and Xenopus oocytes, BrUTP injection was 
performed after Oocyte-NT and the newly synthesized transcripts were 
incorporated with BrUTP. Before RNA-seq library preparation, the amount of 
BrUTP-incorporated transcripts was enriched by anti-BrUTP antibody pull-
down. 
 
The time-dependent effect of xklf2-HA overexpression on MEF-NT was 
evaluated by comparing oocyte samples of control and xklf2-HA groups at 
Day 1 and Day 2 after Oocyte-NT (Figure 6.1.1.A). The cell-type specific 
effects of xklf2-HA overexpression on reprogrammed transcriptomes of 
mESCs, MEFs and mMyos (mESC-NT, MEF-NT and mMyo-NT) were 
evaluated by comparing oocyte samples of control and xklf2-HA groups at 
Day 2 after Oocyte-NT (Figure 6.1.1.B) 
 
At the beginning, xklf2-HA proteins were overexpressed in xklf2-HA groups by 
injecting xklf2-HA mRNA (9.2 ng, 1ug/ul) into oocytes 1 day before Oocyte-NT 
(Figure 6.1.1). For the control groups, no xklf2-HA mRNA was injected at this 
point. During Oocyte-NT, SLO-permeablized cells (300-500 per oocyte) were 
injected into GVs of oocytes in the presence or absence of xklf2-HA proteins 
(Figure 6.1.1). In this chapter, MEFs (mouse embryonic fibroblast cell line, 
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sixiFM) were used for the time-dependent effect of xklf2-HA overexpression 
(Figure 6.1.1.A). For the cell-type specific effects of xklf2-HA overexpression, 
mESCs (mouse embryonic stem cell line, B10 CHD4), sixiFM MEFs and 
mMyo (mouse myoblast cell line, C2C12) were tested for Oocyte-NT (Figure 
6.1.1.B). 
 
Two hours after Oocyte-NT, BrUTP (4.6 nl, 100 mM) was injected into the 
cytoplasm of oocytes and Oocyte-NT samples were incubated at 18℃ (Figure 
6.1.1). After one or two days of incubation in injected cultured oocytes, RNA 
was extracted, BrUTP RNA was selected, and samples were prepared for 
RNA-seq following cDNA systhesis from newly synthesized transcripts. 
 
The RNA-seq data was first analyzed by Angela Simeone for alignment, 
hierarchical clustering, MDS (multidimensional scaling) analysis and DE 
(differential expression) analysis. Then, I further analysed these data for Venn 
diagram, Pearson correlation coefficient, Gene ontology, KEGG pathway and 
TRANSFAC. The preliminary data validation of RNA-seq libraries is in 
Appendix VII (page 348). 
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Figure 6.1.1 Sample preparations for evaluating the effect of xklf2-HA overexpression 
on various cell types during SCNR by oocytes 
A. Time-dependent effect of xklf2-HA overexpression on MEF-NT at Day 1 and Day 2 after 
Oocyte-NT 











RNA processing and RNA-seq
Sample collection
2 hours after Oocyte-NT
BrUTP
BrUTP injection
1 day before Oocyte-NT
xklf2-HA mRNA injection
xklf2-HA mRNA









2 hours after Oocyte-NT
BrUTP
BrUTP injection
1 day before Oocyte-NT
xklf2-HA mRNA injection
xklf2-HA mRNA
Control: No injection of mRNA
Exp: xklf2-HA mRNA
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6.2 Overexpression of xklf2-HA reprograms MEF 
transcriptome within 1 day after Oocyte-NT  
In Chapter 4, xklf2-HA overexpression has been shown to activate silent 
genes in MEFs, namely mOct4, mUtf1 and mEsrrb, at the beginning of 
Oocyte-NT and the difference of expression level of these genes between 
Control and xklf2-HA groups is diminished at later time points. In Chapter 5, it 
has been shown that maternal factors reprogram MEFs to an oocyte-steady 
state within 1 day after Oocyte-NT. In this section, I ask if xklf2-HA 
overexpression can also reprogram MEF nuclei within 1 day after Oocyte-NT. 
 
In this section, I ask if xklf2-HA overexpression could also trigger a genome 
wide reprogrammiing of MEF within 1 day after Oocyte-NT. For that purpose, I 
compare control and xklf2-HA groups at Day 1 after Oocyte-NT. I also 
evaluate the time-dependent effect of xklf2-HA overexpression by comparing 
transcriptome at one and two days after Oocyte-NT. 
 
6.2.1 xklf2-HA acts mostly as a transcriptional activator and xklf2-HA 
overexpression reprogram MEF transcriptome within 1 day after Oocyte-NT 
To evaluate the short-term effect of xklf2-HA overexpression within 1 day after 
Oocyte-NT, MEF-NT of Control groups and xklf2-HA groups at Day 1 after 
Oocyte-NT are compared (Figure 6.2.1 and Table 6.2.1). 
 
It shows that libraries of MEF-NT are different between Control groups and 
xklf2-HA groups genome wide and libraries are clustered by expression level 
of newly transcribed genes according to xklf2-HA treatment (Hierarchical 
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clustering, Figure 6.2.1.A; MDS analysis, Figure 6.2.1.B). This effect of xklf2-
HA overexpression on transplanted MEF transcriptome is further evaluated 
using differential expression analysis. Out of the 19241 genes expressed after 
Oocyte-NT, 852 genes are differentially expressed (DE) in the presence of 
xklf2-HA one day after transplantation (xklf2-DE genes; n=2, FDR<0.1, Figure 
6.2.1.C). Among these xklf2-DE genes in MEF-NT, 779 xklf2-DE genes are 
up-regulated (log2FC>0, FDR<0.1) and 73 xklf2-DE genes are down-
regulated (log2FC<0, FDR<0.1) by xklf2-HA overexpression at Day 1 after 
Oocyte-NT (Figure 6.2.1.C). Therefore, the transcriptome analysis suggests 
that xklf2-HA overexpression acts mostly as a transcriptional activator during 
the first day after transplantation of MEF to Xenopus oocytes. 
 
The distribution of 19241 analysed genes in DE analysis among different 
ranges of log2FC is further examined regardless of FDR values (Table 6.2.1) 
and focusing instead on the range of log2FC values observed. 5817 genes are 
up-regulated with log2FC more than 1 and 2659 genes are down-regulated 
with log2FC less than -1 by xklf2-HA overexpression (Table 6.2.1). mKlf2, 
mSox2, mSall4 and mOct4 are up-regulated with 1<log2FC<2, mUtf1 is up-
regulated with 3<log2FC<4 and mEsrrb is up-regulated with 6<log2FC<7 by 
xklf2-HA overexpression at Day 1 after Oocyte-NT (BrUTP pull-down, RNA-
seq, Table 6.2.1) while mSall4 and mOct4 have been shown to be up-
regulated by xklf2-HA overexpression at Day 1 after Oocyte-NT (QPCR, 
Figure 4.2.1 in Chapter 4, page 110). Among these tested genes, only mOct4 
is shown to be up-regulated by xklf2-HA overexpression by both BrUTP pull-
down plus RNA-seq and QPCR. Since mOct4, mUtf1 and mEsrrb in MEFs are 
	 191	
silent in some of Oocyte-NT samples at Day 1 after Oocyte-NT (FPKM=0), the 
inconsistent up-regulation of genes, detected by QPCR and RNA-seq plus 
BrUTP pulldown, suggests the variable activation of silent gene by xklf2-HA 




Figure 6.2.1 xklf2-HA acts mostly as a transcriptional activator at Day 1 after Oocyte-NT. 
(A-B) Hierarchical clustering (A) and MDS analysis (B) show the difference between samples 
in the absence and presence of xklf2-HA overexpression. 
(C) 779 xklf2-DE genes (FDR<0.1) are up-regulated by 2-fold to 32768-fold and 73 xklf2-DE 
genes in MEF-NT are down-regulated by 2-fold to 16384-fold by xklf2-HA overexpression at 
Day 1 after Oocyte-NT. No cut-off is applied as the threshold of log2FC value.	  




































































779 xklf2-DE genes are up-regulated by xklf2-HA in MEF-NT
at Day 1 after Oocyte-NT (FDR<0.1, 1<log2FC<16)
73 xklf2-DE genes are down-regulated by xklf2-HA in MEF-NT







































































BrUTP BrUTP + xklf2-HA
	 193	
 
Table 6.2.1 Distribution of newly synthesized genes in MEF-NT among ranges of log2FC 
(Control/xklf2-HA), judged by DE analysis, under the treatment of xklf2-HA 
overexpression at Day 1 after Oocyte-NT was shown. The regulation of pluripotency 
genes by xklf2-HA overexpression at Day 1 after Oocyte-NT is compared between DE 
analysis and QPCR. 
* All the listed pluripotency genes are recognized as non-DE genes (FDR>0.1). 
+ mSall4 is up-regulated by xklf2-HA overexpression with 1<log2FC<2 at Day 1 after Oocyte-
NT, examined by QPCR (Figure 4.2.1 in Chapter 4). 
++ mOct4 is up-regulated by xklf2-HA overexpression with log2FC>2 at Day 1 after Oocyte-
NT, examined by QPCR (Figure 4.2.1 in Chapter 4). 
^ mSox2, mKlf4, mUtf1, mEsrrb and mKlf2 in MEF-NT is not regulated by xklf2-HA with 
log2FC<1 at Day 1 after Oocyte-NT, examined by QPCR (Figure 4.2.1, 4.2.2 and 4.2.3 in 
Chapter 4). 
  










6~7 257 1.34% mEsrrb^
5~6 215 1.12%
4~5 354 1.84%
3~4 782 4.06% mUtf1^
2~3 1311 6.81%
1~2 2377 12.35% mSall4+, mOct4++, mSox2^, mKlf2^






















6.2.2 Transcriptional reprogramming of transplanted cells by xklf2-HA 
overexpression happens mostly within 24 hours after Oocyte-NT 
To examine the time-dependent effect of xklf2-HA overexpression, MEF-NT of 
xklf2-HA groups at Day 1 and Day 2 are compared (Figure 6.2.2 and Table 
6.2.2). 
 
Libraries of MEF-NT under the treatment of xklf2-HA overexpression at Day 1 
after Oocyte-NT are grouped together and separated from libraries at Day 2 
after Oocyte-NT (Hierarchical clustering, Figure 6.2.2.A; MDS analysis, Figure 
6.2.2.B). From Day 1 to Day 2 after Oocyte-NT in the presence of xklf2-HA, 
133 DE genes are differentially expressed (DE genes; n=2, FDR<0.1, Figure 
6.2.2.C). 58 of these DE genes are up-regulated (log2FC>0, FDR<0.1) 
whereas 73 DE genes are down-regulated (log2FC<0, FDR<0.1) by xklf2-HA 
overexpression from Day 1 to Day 2 after Oocyte-NT (Figure 6.2.2.C). 
 
Therefore, there are much less genes regulated by xklf2-HA overexpression 
from Day 1 to Day 2 after Oocyte-NT (133 genes, Figure 6.2.2.C) than genes 
regulated by xklf2-HA at Day 1 after Oocyte-NT (852 genes, Figure 6.2.1.C). It 
suggests that the bulk of xklf2-HA overexpression effect on gene expression 
happens within 24 hours after Oocyte-NT and that few significant changes 
happen from Day 1 to Day 2 after Oocyte-NT. 
 
Interestingly, the major effect of xklf2-HA overexpression on gene expression 
from day 1 to day 2 after Oocyte-NT is toward down-regulation of genes (73 
out of 133 DE genes, Figure 6.2.2.C) whereas xklf2-HA overexpression 
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mostly up-regulates gene expression within the first day after Oocyte-NT (799 
out of 852 xklf2-DE genes, Figure 6.2.1.C). Since xklf2-HA majorly acts as a 
transcriptional activator at Day 1 after Oocyte-NT (Figure 6.2.1.C), the 
repression of genes from Day 1 to Day 2 after Oocyte-NT in the presence of 
xklf2-HA overexpression may suggest the secondary events triggered by 
downstream genes of xklf2-HA. 
 
Moreover, the distribution of analyzed genes located at different ranges of 
log2FC also shows that more genes are down-regulated than genes up-
regulated by xklf2-HA overexpression from Day 1 to Day 2 after Oocyte-NT 
when there are 3238 genes up-regulated by xklf2-HA overexpression with 
log2FC>1 and there are 4461 genes down-regulated by xklf2-HA 
overexpression with log2FC<-1 (Table 6.2.2). It suggests that xklf2-HA 
overexpression contribute more to up-regulate genes robustly within 1 day 
after Oocyte-NT but the up-regulation of some xklf2-HA downstream genes 
leads to the following down-regulation of other downstream genes from Day 1 
to Day 2 after Oocyte-NT. The involvement of xklf2-HA downstream genes in 
gene regulation during SCNR by oocytes were further discussed in Appendix 
VIII (page 353). 
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Figure 6.2.2 xklf2-HA overexpression reprogrammed MEFs within one day after 
Oocyte-NT. 
(A-B) Hierarchical clustering (A) and MDS analysis (B) show the difference between samples 
collected at Day 1 and Day 2 after Oocyte-NT in the presence of xklf2-HA overexpression. 
(C) 131 DE genes (FDR<0.1) are regulated by xklf2-HA overexpression form Day 1 to Day 2 
after Oocyte-NT. No cut-off is applied as the threshold of log2FC value.	  
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58 DE genes are up-regulated by xklf2-HA in MEF-NT
from Day 1 to Day 2 after Oocyte-NT (FDR<0.1, 2<log2FC<13).
73 DE genes are down-regulated by xklf2-HA in MEF-NT























































































Table 6.2.2 Distribution of newly synthesized genes in MEF-NT among ranges of log2FC 
(xklf2-HA at Day 2/xklf2-HA at Day 1), judged by DE analysis, under the treatment of 
xklf2-HA overexpression from Day 1 to Day 2 after Oocyte-NT. The regulation of 
pluripotency genes by xklf2-HA overexpression from Day 1 to Day 2 after Oocyte-NT is 
compared between DE analysis and QPCR. 
* All the listed pluripotency genes are recognized as non-DE genes (FDR>0.1). 
+ mUtf1, mSox2, mEsrrb, mKlf4 is up-regulated by xklf2-HA with 1<log2FC<2 from Day 1 to 
Day 2 after Oocyte-NT, examined by QPCR (Figure 4.2.1 and 4.2.2, page 110 and 111). 
++ mSall4 and mOct4 is up-regulated by xklf2-HA with log2FC>2 from Day 1 to Day 2 after 
Oocyte-NT, examined by QPCR (Figure 4.2.1, page 110). 
^ mKlf2 is not regulated by xklf2-HA overexpression with log2FC<1 from Day 1 to Day 2 after 
Oocyte-NT, examined by QPCR (Figure 4.2.3 , page 112). 
  











2~3 674 3.40% mUtf1+
1~2 1814 9.15% mSox2+
0~1 6030 30.43% mEsrrb+, mKlf4+, mSall4++, mOct4++





















In Chapter 5, it has been shown that maternal factors of oocytes reprogram 
MEFs to an oocyte-steady state within 1 day after Oocyte-NT and the speed 
of SCNR by oocytes can be varied due to the batch effects of oocytes. 
Likewise, xklf2-HA overexpression is shown to regulate genes in MEF-NT 
during SCNR by oocytes and reprogram MEFs to a xklf2-oocyte state within 1 
day after Oocyte-NT. 
 
When comparing genes regulated by xklf2-HA overexpression before and 
after Day 1 after Oocyte-NT, it shows that different sets of downstream genes 
are regulated by xklf2-HA overexpression at different time points. Additionally, 
more genes are up-regulated than down-regulated by xklf2-HA 
overexpression within Day 1 after Oocyte-NT while it is opposite after Day 1 
after oocyte-NT. It suggests not only maternal factors and xklf2-HA 
combinatorially regulates gene expression during SCNR by oocytes but 
downstream genes of xklf2-HA also participate in the gene regulation during 
SCNR by oocytes after they are up-regulated by xklf2-HA overexpression. 
This point can be further validated by cycloheximide treatment. 
 
To conclude, xklf2-HA overexpression reprograms MEF-NT to an xklf2-oocyte 
state within 1 day after Oocyte-NT. Moreover, xklf2-HA overexpression 
regulates different sets of genes at different time points because downstream 
genes of xklf2-HA also participate in gene regulation during SCNR by oocytes.  
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6.3 Overexpression of xklf2-HA facilitates the regulation of 
gene expression in mESCs, MEFs and mMyos during SCNR 
by oocytes 
In Chapter 5, maternal factors of Xenopus oocytes have been shown to 
reprogram transcriptomes of mESCs, MEFs and mMyos to an oocyte-steady 
state within 2 days after Oocyte-NT. Because compositions and amount of 
maternal factors are fixed in Xenoups oocytes and chromatin structures of 
various donor cell types are different, it suggests chromatin structures of 
mESCs, MEFs and mMyos are subjected to be changed by maternal factors 
and allow transcriptional machinery in oocytes to regulate expression of 
genes to an oocyte-steady level. 
 
In this section, I would like to ask the way by which xklf2-HA overexpression 
regulates gene expression in mESCs, MEFs and mMyos during SCNR by 
oocytes while chromatin structures of various cell types are dynamically 




6.3.1 Overexpression of xklf2-HA regulates more than 1000 genes in mESCs, 
MEFs and mMyos at Day 2 after Oocyte-NT 
To examine the effect of xklf2-HA overexpression on mESC-NT, MEF-NT and 
mMyo-NT, Control groups and xklf2-HA groups are compared at Day 2 after 
Oocyte-NT. 
 
Hierarchical clustering shows that reprogrammed transcriptomes of mESCs, 
MEFs and mMyos are clustered by expression level of newly synthesized 
transcripts genome wide and libraries are grouped together based on the 
xklf2-HA treatment (Figure 6.3.1.A, 6.3.2.A and 6.3.3.A). Similarly, Control 
groups and xklf2-HA groups of mESC-NT, MEF-NT and mMyo-NT are shown 
to fall separately on MDS plot (Figure 6.3.1.B, 6.3.2.B and 6.3.3.B). This 
indicates that xklf2-HA overexpression triggers a global shift in reprogrammed 
transcriptomes of mESCs, MEFs and mMyos irrespective of origin of donor 
cells and batch effects of Xenopus oocytes. 
 
In mESC-NT, 1110 xklf2-DE genes are significantly regulated by xklf2-HA 
overexpression at Day 2 after Oocyte-NT (n=3, FDR<0.1, Figure 6.3.1.C). 
Among these genes, 976 xklf2-DE genes in mESC-NT are up-regulated by 
more than 2-fold (2<FC<4096, FDR<0.1) and 134 xklf2-DE genes in mESC-
NT are down-regulated by more than 2-fold (-4096<Fold change<-2, FDR<0.1) 
by xklf2-HA at Day 2 after Oocyte-NT (Figure 6.3.1.C). Similarly, in MEF-NT, 
among 2871 xklf2-DE genes that are significantly regulated (n=4, FDR<0.1, 
Figure 6.3.2.C), 2044 xklf2-DE genes are up-regulated by more than 1-fold  
(1<FC<4096, FDR<0.1) and 827 xklf2-DE genes are down-regulated by more 
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than 1-fold (-512<FC<1, FDR<0.1) by xklf2-HA overexpresson (Figure 
6.3.2.C). Lastly, in mMyo-NT, there are 1077 xklf2-DE genes regulated by 
xklf2-HA overexpression (n=3, FDR<0.1, Figure 6.3.3): 936 xklf2-DE genes in 
mMyo-NT are up-regulated (2<FC<8192, FDR<0.1) and 141 xklf2-DE genes 
are down-regulated (-2048<FC<-2, FDR<0.1) by xklf2-HA overexpression 
(Figure 6.3.3.C). As it is observed that more than 2/3 of xklf2-DE genes are 
up-regulated by xklf2-HA overexpression in mESC-NT, MEF-NT and mMyo-
NT, it suggests that xklf2-HA mostly acts as a transcriptional activator during 
the time period analysed. 
 
Overall, xklf2-HA overexpression affects more than 1000 genes in mESC-NT, 
MEF-NT and mMyo-NT at Day 2 after Oocyte-NT (Figure 6.3.1.C, 6.3.2.C and 
6.3.3.C). Notably, there are more xklf2-DE genes identified in MEF-NT. This is 
because the number of biological replicates used for MEF-NT goes up to 4, 
rather than 3 for mESC-NT and mMyo-NT. Utilizing more biological replicates 
improves the identification of xklf2-DE genes while the number of xklf2-DE 
genes increases and more down-regulated xklf2-DE genes are found. 
 
In terms of fold change, xklf2-HA overexpression up-regulates xklf2-DE genes 
at lower expression level with higher log2FC (log2FC>0, FDR<0.1) and down-
regulates xklf2-DE genes at lower expression level with lower log2FC 
(log2FC<0, FDR<0.1) significantly in mESC-NT, MEF-NT and mMyo-NT 





Figure 6.3.1 xklf2-HA overexpression shift transcriptomes of mESCs genome wide at 
Day 2 after Oocyte-NT. Hierarchical clustering (A) and MDS analysis (B) show the difference 
between samples in the absence (in red) and presence (in orange) of xklf2-HA 
overexpression. (C) 1110 xklf2-DE genes (FDR<0.1, in orange) are found by DE analysis. No 
cut-off is applied as the threshold of log2FC value.  
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976 xklf2-DE genes are up-regulated by xklf2-HA in mESC-NT
at Day 2 after Oocyte-NT (FDR<0.1, 1<log2FC<12).
134 xklf2-DE genes are down-regulated by xklf2-HA in mESC-NT







Figure 6.3.2 xklf2-HA overexpression shift transcriptomes of MEFs genome wide at 
Day 2 after Oocyte-NT. Hierarchical clustering (A) and MDS analysis (B) show the difference 
between samples in the absence (in red) and presence (in orange) of xklf2-HA 
overexpression. (C) 2871 xklf2-DE genes (FDR<0.1, in orange) are found by DE analysis. No 
cut-off is applied as the threshold of log2FC value.  






































































2044 xklf2-DE genes are up-regulated by xklf2-HA in MEF-NT
at Day 2 after Oocyte-NT (FDR<0.1, 0<log2FC<12).
827 xklf2-DE genes are down-regulated by xklf2-HA in MEF-NT





























































































































Figure 6.3.3 xklf2-HA overexpression shift transcriptomes of mMyos genome wide at 
Day 2 after Oocyte-NT. Hierarchical clustering (A) and MDS analysis (B) show the difference 
between samples in the absence (in red) and presence (in orange) of xklf2-HA 
overexpression. (C) 2871 xklf2-DE genes (FDR<0.1, in orange) are found by DE analysis. No 
cut-off is applied as the threshold of log2FC value.	  





































































936 xklf2-DE genes are up-regulated by xklf2-HA in mMyo-NT
at Day 2 after Oocyte-NT (FDR<0.1, 1<log2FC<13).
141 xklf2-DE genes are down-regulated by xklf2-HA in mMyo-NT














































































































6.3.2 xklf2-HA overexpression facilitates regulation of downstream genes after 
Oocyte-NT in MEF-NT 
To evaluate regulation of newly synthesized genes by xklf2-HA 
overexpression regardless of FDR, Control groups and xklf2-HA groups are 
compared (Table 6.3.1). In MEF-NT, there are 5100 genes up-regulated by 
xklf2-HA overexpression (log2FC>1) and 3503 genes down-regulated by 
xklf2-HA overexpression (log2FC<-1) (Table 6.3.1). For up-regulation of genes 
by xklf2-HA overexpression, 30% of analyzed genes are up-regulated at Day 
1 after Oocyte-NT (Table 6.2.1, page 197) and 27% are up-regulated at Day 2 
after Oocyte-NT (Table 6.3.1). For down-regulation of genes by xklf2-HA 
overexpression, 14% of analyzed genes are down-regulated at Day 1 after 
Oocyte-NT (Table 6.2.1, page 197) and 19% are down-regulated at Day 2 
after Oocyte-NT (Table 6.3.1). 
 
Therefore, less genes are up-regulated by xklf2-HA overexpression at Day 2 
than at Day 1 after Oocyte-NT and more genes are down-regulated by xklf2-
HA overexpression at Day 2 than at Day 1 after Oocyte-NT (Table 6.2.1 and 
6.3.1) because more genes are down-regulated than up-regulated by xklf2-HA 
overexpression from Day 1 to Day 2 after Oocyte-NT (Table 6.2.2, page 201). 
At Day 2 after Oocyte-NT, two pluripotency genes in MEFs, namely mOct4 
and mSall4, are recognized as xklf2-DE genes (FDR<0.1, Figure 6.3.2; Table 
6.3.1). Since mOct4 is silent in MEFs (FPKM=0, ENCODE) and at nil/low 
expression level in MEF-NT by chance at Day 2 after Oocyte-NT while it is not 
successfully activated by maternal factors (FPKM=0), xklf2-HA 




Table 6.3.1 Distribution of newly synthesized genes in MEF-NT among ranges of log2FC 
(Control/xklf2-HA), judged by DE analysis, under the treatment of xklf2-HA 
overexpression at Day 2 after Oocyte-NT and the regulation of pluripotency genes by 
xklf2-HA at Day 2 after Oocyte-NT are compared between DE analysis and QPCR. 
* mOct4, mSall4 and mSox2 are recognized as xklf2-DE genes (FDR<0.1) 
+ mUtf1, mSox2, mKlf4 in MEF-NT is up-regulated by xklf2-HA overexpression with 
1<log2FC<2 at Day 2 after Oocyte-NT, examined by QPCR (Figure 4.2.1, page 110). 
++ mOct4 and mSall4 in MEF-NT is up-regulated by xklf2-HA overexpression with log2FC>2 
at Day 2 after Oocyte-NT, examined by QPCR (Figure 4.2.1 , page 110). 
^ mEsrrb and mKlf2 in MEF-NT is not regulated by xklf2-HA with log2FC<1 at Day 2 after 
Oocyte-NT, examined by QPCR (Figure 4.2.2 and 4.2.3, page 111 and 112). 
 
  









3~4 696 3.73% mOct4*++
2~3 1212 6.50% mSall4*++
1~2 2272 12.18% mUtf1+, mSox2*+, mEsrrb^, mKlf2*^


















In Chapter 5, it has been shown that maternal factors of Xenopus oocytes 
reprogram transcriptomes of mESCs, MEFs and mMyos to an oocyte-steady 
state at Day 2 after Oocyte-NT. The fixed composition and amount of 
maternal factors change the chromatin structure of mESCs, MEFs and 
mMyos and regulate expression of genes to an oocyte-steady level. 
 
During this dynamic SCNR process by oocytes, xklf2-HA overexpression 
regulated more than 1000 xklf2-DE genes in mESC-NT, MEF-NT and mMyo-
NT significantly at Day 2 after Oocyte-NT. More than half of xklf2-DE genes 
are at nil or low expression level. While expression level of genes correlates 
to chromatin accessibility, xklf2-HA overexpression tends to regulate genes 
with regulatory elements reside in closed chromatin. Since mOct4 has shown 
to be silent genes in MEFs and in some MEF-NT when mOct4 is not 
successfully activated by maternal factors, xklf2-HA overexpression promotes 
the activation of silent genes. 
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6.4 Overexpression of xklf2-HA regulates xklf2-DE genes to 
the xklf2-oocyte level in mESC-NT, MEF-NT and mMyo-NT at 
Day 2 after Oocyte-NT 
In Chapter 5, it has been shown that maternal factors reprogram 
transcriptomes of mESCs, MEFs and mMyos to a fairly similar state in 
Xenopus oocytes. In this section, the genome-wide regulation of downstream 
genes by xklf2-HA overexpression in mESCs, MEFs and mMyos is evaluated 
during this dynamic change of SCNR by oocytes and I would like to ask if 
xklf2-HA overexpression would affect different sets of downstream genes due 
to original chromatin structures of mESCs, MEFs and mMyos? 
 
6.4.1 xklf2-HA overexpression regulates different sets of xklf2-DE genes in 
mESC-NT, MFE-NT and mMyo-NT at Day 2 after Oocyte-NT while xklf2-DE 
genes are either up-regulated or down-regulated by xklf2-HA overexpression  
To distinguish cell-type specific effect of xklf2-HA overexpression on the 
regulation of downstream genes in mESC-NT, MEF-NT and mMyo-NT, up-
regulated and down-regulated xklf2-DE genes in mESC-NT, MEF-NT and 
mMyo-NT at Day 2 after Oocyte-NT are compared via Venn diagram (Figure 
6.4.1 and 6.4.2). 
 
Among all xklf2-DE genes in mESC-NT, MEF-NT and mMyo-NT, 347 xklf2-
DE genes are either up-regulated or down-regulated by xklf2-HA 
overexpression in all 3 cell types (Figure 6.4.1.A). 386 xklf2-DE genes are 
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only regulated in mESC-NT; 1876 xklf2-DE genes are only regulated in MEF-
NT; 371 xklf2-DE genes are only regulated in mMyo-NT (Figure 6.4.1.A). 
 
For up-regulated xklf2-DE genes, 333 xklf2-DE genes are up-regulated in all 3 
cell types (Figure 6.4.1.B). In mESC-NT, 65% of up-regulated xklf2-DE genes 
are also up-regulated in MEF-NT and mMyo-NT and 35% of up-regulated 
xklf2-DE genes are only up-regulated in mESC-NT (Figure 6.4.1.B). In MEF-
NT, 35% of up-regulated xklf2-DE genes are also up-regulated in mESC-NT 
and mMyo-NT and 65% of up-regulated xklf2-DE genes are only up-regulated 
in MEF-NT (Figure 6.4.1.B). In mMyo-NT, 66% of up-regulated xklf2-DE 
genes are also up-regulated in mESC-NT and MEF-NT and 34% of up-
regulated xklf2-DE genes are only up-regulated in mMyo-NT (Figure 6.4.1.B). 
Therefore, more than 30% of up-regulated xklf2-DE genes are only up-
regulated by xklf2-HA overexpression in one cell type. 
 
For down-regulated xklf2-DE genes, 12 xklf2-DE genes are down-regulated in 
all 3 cell types (Figure 6.4.1.C). In mESC-NT, 32% of down-regulated xklf2-
DE genes are also down-regulated in MEF-NT and mMyo-NT and 68% of 
down-regulated xklf2-DE genes are only down-regulated in mESC-NT (Figure 
6.4.1.C). In MEF-NT, 9% of down-regulated xklf2-DE genes are also down-
regulated in mESC-NT and mMyo-NT and 91% of down-regulated xklf2-DE 
genes are only down-regulated in MEF-NT (Figure 6.4.1.B). In mMyo-NT, 
40% of down-regulated xklf2-DE genes are also down-regulated in mESC-NT 
and MEF-NT and 60% of up-regulated xklf2-DE genes are only up-regulated 
in mMyo-NT (Figure 6.4.1.C). Hence, more than 60% of down-regulated xklf2-
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DE genes are only down-regulated by xklf2-HA overexpression in one cell 
type. 
 
When comparing all up-regulated and down-regulated xklf2-DE genes in 
mESC-NT, MEF-NT and mMyo-NT together, the majority of up-regulated 
xklf2-DE genes in any of these three cell types are not down-regulated in 
other cell types (Figure 6.4.2). Only few xkfl2-DE genes are up-regulated in 
one cell type and down-regulated in other cell types or reversely (number of 
xklf2-DE genes in red, Figure 6.4.2). It indicates the regulation of genes by 
xklf2-HA overexpression are mostly in one direction within 2 day after Oocyte-
NT and xklf2-DE genes are either up-regulated or down-regulated regardless 




Figure 6.4.1 The majority of shared xklf2-DE genes among mESC-NT, MEF-NT and 
mMyo-NT (A) are contributed by up-regulated xklf2-DE genes at Day 2 after Oocyte-NT 
(B and C). 31%, 56% and 31% of up-regulated (B) and 68%, 91% and 60% of down-
regulated (C) xklf2-DE genes are cell-type specific and only regulated in mESC-NT, 




Figure 6.4.2 Regulation of xklf2-DE genes by xklf2-HA overexpression is one direction 
during Oocyte-NT. xklf2-DE genes are either up-regulated by xklf2-HA overexpression 
in all 3 cell types or are down-regulated by xklf2-HA overexpression in all 3 cell types. 
14 xklf2-DE genes (in red) are up-regulated and down-regulated by xklf2-HA 




6.4.2 xklf2-HA overexpression up-regulates expression of xklf2-DE genes to 
xklf2-oocyte level 
To look further into up-regulation of xklf2-DE genes by xklf2-HA 
overexpression in different cell nuclei at Day 2 after Oocyte-NT, expression 
level of xklf2-DE genes in mESC-NT, MEF-NT and mMyo-NT are compared 
and log2FC of xklf2-DE genes between Control groups and xklf2-HA groups in 
mESC-NT, MEF-NT and mMyo-NT are compared (Figure 6.4.3, 6.4.4 and 
6.4.5). For the results of genes down-regulated by xklf2-HA overexpression, it 
is described in Appendix X (page 365). 
 
There are 333 xklf2-DE genes of mESC-NT, MEF-NT and mMyo-NT up-
regulated by xklf2-HA overexpression at Day 2 after oocyte-NT (Figure 
6.4.1.B). The means of expression level (FPKM) of these 333 xklf2-DE genes 
in mESC-NT, MEF-NT and mMyo-NT are 1.27, 1.63 and 0.12, respectively 
(Figure 6.4.3.A). The corresponding means of log2FC (xklf2-HA/Control) of 
these 333 xklf2-DE genes in mESC-NT, MEF-NT and mMyo-NT are 4.23, 
3.53 and 5.06, respectively (Figure 6.4.3.B). Therefore, xklf2-HA 
overexpression up-regulates genes at lower expression level (FPKM) with 
higher log2FC significantly (Mean of FPKM: 1.63 of MEF-NT>1.24 of mESC-
NT>0.12 of mMyo-NT; Mean of log2FC: 3.53 of MEF-NT<4.23 of mESC-
NT<5.06 of mMyo-NT, Figure 6.4.3).  
 
For xklf2-DE genes up-regulated in 2 cell types, it shows the same up-
regulation of genes by xklf2-HA overexpression (Figure 6.4.4) as xklf2-DE 
genes up-regulated in all 3 cell types (Figure 6.4.3). While the expression 
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level (FPKM) is lower in mESC-NT, MEF-NT or mMyo-NT of Control groups, 
xklf2-HA overexpression up-regulates expression of these genes to fixed 
xklf2-oocyte levels with higher log2FC. Take up-regulated xklf2-DE genes of 
mESC-NT and MEF-NT as an example, while mean of expression level 
(FPKM) of xklf2-DE genes is 0.35 in mESC-NT and 1.16 in MEF-NT (Figure 
6.4.4.A), mean of log2FC is 4.64 in mESC-NT and 3.17 in MEF-NT (Figure 
6.4.4.B). 
 
For xklf2-DE genes up-regulated in only 1 cell type (Figure 6.4.5), up-
regulation of genes by xklf2-HA overexpression is the same as genes up-
regulated in 2 and 3 cell types while the lower the expression level of genes in 
Control groups, the higher of log2FC is (Figure 6.4.3 and 6.4.4). It indicates 
each gene in transplanted cell nuclei is up-regulated by maternal factors and 
xklf2-HA overexpression to a fixed expression level, which is called xklf2-
oocyte level and decided by the effects of maternal factors and xklf2-HA 
overexpression. 
 
Notably, number of genes for log2FC comparison is sometimes different 
because some genes are resistant to be activated by xklf2-HA overexpression 
and are excluded from dataset. Therefore, although mean of expression level 
(FPKM) of up-regulated xklf2-DE genes of mESC-NT and MEF-NT is 1.16 in 
MEF-NT>0.68 in mMyo-NT>0.35 in mESC-NT (Figure 6.4.4.A), mean of 





Figure 6.4.3 Expression level (FPKM) in the absence of xklf2-HA and log2FC of shared 





















































Figure 6.4.4 Shared up-regulated xklf2-DE genes in 2 cell types have lower expression 
level (FPKM) in the absence of xklf2-HA and up-regulated by xklf2-HA overexpression 
with higher log2FC than the 3rd cell type at Day 2 after Oocyte-NT. 
(A, B) Up-regulated xklf2-DE genes shared between mESC-NT and MEF-NT 
(C, D) Up-regulated xklf2-DE genes shared between MEF-NT and mMyo-NT 
























































































































































Figure 6.4.5 Up-regulated xklf2-DE genes in only one cell type have lower expression 
level in the absence of xklf2-HA and up-regulated by xklf2-HA overexpression with 
higher log2FC than the other 2 cell types at Day 2 after Oocyte-NT. 
(A, B) Up-regulated xklf2-DE genes in only mESC-NT 
(C. D) Up-regulated xklf2-DE genes in only MEF-NT 






























































































































































In Xenopus oocytes, gene regulation by exogenous TFs in transplanted cell 
nuclei is comprehensive because maternal factors also participate in gene 
regulation in transplanted cell nuclei during SCNR by oocytes145. 
 
In this section, it shows that xklf2-HA overexpression regulates different sets 
of xklf2-DE genes in mESC-NT, MEF-NT and mMyo-NT and xklf2-DE genes 
that are either up-regulated or down-regulated by xklf2-HA overexpression at 
Day 2 after Oocyte-NT. Maternal factors and xklf2-HA overexpression 
combinatorially determine which genes are regulated in transplanted cell 
nuclei. While expression level of xklf2-DE genes of transplanted cell nuclei is 
distant from xklf2-oocyte level, log2FC is higher when genes are up-regulated 
by xklf2-HA overexpression or log2FC is lower when genes are down-
regulated by xklf2-HA overexpression. 
 
All in all, different sets of xklf2-DE genes in mESC-NT, MEF-NT and mMyo-
NT are decided by different expression levels of xklf2 down stream genes as 
well as resistance of downstream genes against SCNR by oocytes or xklf2-
HA overexpression. Therefore, all the xklf2-DE genes in mESC-NT, MEF-NT 
and mMyo-NT can be regulated by xklf2-HA overexpression by either up-






6.5 Up-regulated xklf2-DE genes by xklf2-HA overexpression 
during SCNR by oocytes are responsible for developmental 
processes and signaling pathways regulating pluripotency of 
stem cells 
During induced pluripotency, it has been shown that differentiated cells are 
reprogrammed to be epigenetically and transcriptionally identical to ESCs by 
overexpresssion of Yamanaka factors, OSKM35. In Chapter 5, it has been 
shown that transcriptomes of mESCs, MEFs and mMyos are reprogrammed 
to be almost identical at Day 2 after Oocyte-NT and chromatin structures of 
mESCs, MEFs and mMyos are forcibly changed by maternal factors of 
oocytes. Therefore, identical transcriptomes of reprogrammed cells are 
relevant to successful SCNR. 
 
In Section 6.3 and 6.4, xklf2-HA overexpression has been shown to regulate 
expression of genes to xklf2-oocyte level in mESC-NT, MEF-NT and mMyo-
NT during SCNR by oocytes. In this section, I would like to ask what 
functional interpretations are enriched for downstream genes of xklf2-HA 
during SCNR by oocytes and provide evidence for the role of xklf2 if it is one 
of maternal factors regulating genes during SCNR by oocytes/eggs? 
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6.5.1 The majority of xklf2-DE genes have mKlf2 binding motifs in their 
promoters and xklf2-DE genes are signaling pathways regulating pluripotency 
of stem cells are enriched for up-regulated xklf2-DE genes 
To evaluate the way that xklf2-DE genes are regulated by xklf2-HA 
overexpression at Day 2 after Oocyte-NT, xklf2-DE genes are enriched for 
prediction of transcription factor binding sites in promoters (TSS±3kb) via 
TRANSFAC database (Figure 6.5.1). 
 
2821 in 3672 xklf2-DE genes regulated by xklf2-HA overexpression at Day 2 
after Oocyte-NT are input into TRANSFAC database for enrichment (Figure 
6.5.1.A). It shows that 2184 in 2821 xklf2-DE genes are enriched for mKlf2-
binding motif: GGGGTGGKSN (p-value=5.47E-29, Figure 6.5.1.A). 1496 in 
2821 xklf2-DE genes are enriched for mKlf2-binding motif: NGGGCGG (p-
value=2.25E-24, Figure 6.5.1.A). 1693 in 2821 xklf2-DE genes are enriched 
for mKlf2-binding motif: CNCCACCCS (p-value=2.2E-34, Figure 6.5.1.A). 
 
Among 2821 xklf2-DE genes, 2024 xklf2-DE genes are up-regulated and 797 
xklf2-DE genes are down-regulated by xklf2-HA overexpression (Figure 
6.5.1.B). By overlapping with xklf2-DE genes with mKlf2 binding sites, 90% of 
up-regulated xklf2-DE genes and 77% of down-regulated xklf2-DE genes 
have mKlf2 binding motifs in their promoters (Figure 6.5.1.B). For the rest of 
up-regulated and down-regulated xklf2-DE genes, they are probably regulated 
either by xklf2-HA binding on enhancers by xklf2-HA or by downstream genes 
of xklf2-HA.  
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Notably, there is higher percentage of down-regulated xklf2-DE genes without 
mKlf2 binding sites in their promoters than percentage of up-regulated xklf2-
DE genes (Figure 6.5.1.B). It supports the hypothesis of section 6.2 that 
downstream genes of xklf2-HA are also involved in regulation of xklf2-DE 
genes because more genes are down-regulated in the presence of xklf2-HA 
overexpression from Day 1 to Day 2 after Oocyte-NT (Figure 6.2.2.C and 
Table 6.2.2, page 200 and 201) while xklf2-HA majorly plays as a 
transcriptional activator within one day after Oocyte-NT (Figure 6.2.1.C and 
Table 6.2.1, page 196 and 197). 
 
The functional enrichment of up-regulated and down-regulated xklf2-DE 
genes was analysed by Gene ontology and KEGG pathway analsysis in 
Appendix XI (page 369). Importantly, signaling pathways regulating 
pluripotency of stem cells (139 annotated genes in database) are enriched 
most significantly by up-regulated xklf2-DE genes and 37 up-regulated xklf2-
DE genes are annotated in these signaling pathways (p=6.23E-07, Figure 
10.11.4, page 380; these 37 genes are used later in Section 6.6). 
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Figure 6.5.1 mKlf2 binding motif in promoters is enriched for all xklf2-DE genes of all 3 
cell types regulated by xklf2-HA overexpression at Day 2 after Oocyte-NT. 90% of up-
regulated xklf2-DE genes and 77% of down-regulated xklf2-DE genes of all 3 cell types 
have mKlf2 binding sites in their promoters.	  
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6.5.2 Summary 
In section 6.4, it has been shown that gene regulation by xklf2-HA 
overexpression in Xenopus oocytes depends on the donor cell types and 
xklf2-HA overexpression selectively regulate genes especially at nil or low 
level in reprogrammed transcriptomes of mESCs, MEFs and mMyos at Day 2 
after Oocyte-NT. The selective regulation by xklf2-HA overexpression is 
caused by the fact that both maternal factors and xklf2-HA overexpression are 
involved in regulating expression of genes and xklf2-HA overexpression 
regulates those genes whose expression have not reached xklf2-oocyte level. 
Therefore, downstream genes of xklf2-HA during SCNR by oocytes should 
include all the xklf2-DE genes in mESCs, MEFs and mMyos. 
 
In order to predict the functions of maternal xklf2, all the xklf2-DE genes in 
mESCs, MEFs and mMyos are collectively annotated for functional 
interpretation via TRANSFAC database, GO enrichment analysis and KEGG 
pathway enrichment analysis.  
 
When analyzing xklf2-DE genes via TRANSFAC database, mKlf2 binding 
sites are significantly enriched in promoters (TSS±3kb) of xklf2-DE genes. 
90% of up-regulated xklf2-DE genes and 77% of down-regulated xklf2-DE 
genes have mKlf2 binding sites in their promoters. The rest 10% of up-
regulated xklf2-DE genes and 23% of down-regulated xklf2-DE genes can 
reasonably be judged to be regulated by downstream genes of xklf2-HA. 
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Additionally, functions enriched for up-regulated xklf2-DE genes and 
promoted by xklf2-HA overexpression include more than 100 developmental 
processes, transcriptional activator and repressor activity via core promoter 
proximal region binding, analyzed by GO enrichment analysis. Importantly, 
KEGG pathway enrichment analysis shows that 39 up-regulated xklf2-DE 
genes are annotated to be part of signaling pathways regulating pluripotency 
of stem cells. 
 
For down-regulated xklf2-DE genes, DNA, RNA and protein processing 
related functions are enriched via GO enrichment analysis. Furthermore, 
pathways for basic cellular functions are enriched for down-regulated xklf2-DE 
genes via KEGG pathway enrichment analysis, such as DNA replication, 
ribosome, nucleotide excision repair. 
 
All in all, more than 87% of xklf2-DE genes have mKlf2 binding sites in there 
promoters and can be regulated by direct binding of xklf2-HA while binding 
sites of transcription factor homologs are often identical or very similar. If xklf2 
is one of maternal factors in oocytes/eggs, it can activate genes, which are 
involved in developmental process, or activate genes, which are 





6.6 xklf2-HA overexpression activates SCNR resistant genes 
in mESCs, MEFs and mMyos  
In Chapter 5, the reprogrammable genes and cell-type specific genes during 
SCNR by oocytes are defined by expression level (FPKM) of genes in 
reprogrammed transcriptomes of mESCs, MEFs and mMyos. 
Reprogrammable genes are genes expressed at same level in all three 
reprogrammed transcriptomes of mESCs, MEFs and mMyos. Cell-type 
specific genes are genes, which are not expressed (FPKM=0) in one or two 
reprogrammed transcriptomes of mESCs, MEFs or mMyos. Among cell-type 
specific genes, while these genes are not expressed in all 3 cell types, 
expression of some cell-type specific genes are maintained by transcriptional 
machineries of transplanted cells and some cell-type specific genes are 
resistant to SCNR by oocytes due to inaccessible chromatin structure of 
transplanted cell types. 
 
In Section 6.4, it has been shown that xklf2-HA overexpression regulates 
different sets of xklf2-DE genes in reprogrammed transcriptomes of mESCs, 
MEFs and mMyos because both maternal factors and xklf2-HA regulate 
expression of genes to xklf2-oocyte level. Here, I would like to ask if xklf2-HA 




6.6.1 42~46% of xklf2-DE genes are reprogrammable genes and are 
regulated by both maternal factors and xklf2-HA overexpression 
Cell-type specific genes include some genes, whose expression is maintained 
by transcriptional machineries of transplanted cells, and SCNR resistant 
genes, which can be regulated in one or two reprogrammed transcriptomes by 
maternal factors but resist to be activated by maternal factors in other two or 
one reprogrammed transcriptomes at Day 2 after Oocyte-NT. To evaluate the 
way that xklf2-HA overexpression regulates genes during SCNR by oocytes, 
reprogrammed transcriptomes of mESCs, MEFs and mMyos (FPKM>0) are 
compared with xklf2-DE genes in reprogrammed transcriptomes of mESC, 
MEFs and mMyos (mESC-NT, MEF-NT and mMyo-NT, Figure 6.6.1, 6.6.2 
and 6.6.3). 
 
Among xklf2-DE genes, 63% of xkllf2-DE genes of mESC-NT are expressed 
in mESC-NT (FPKM>0) (703/1110, Figure 6.6.1.A), 77% of xklf2-DE genes of 
MEF-NT are expressed in MEF-NT (FPKM>0) (2202/2871, Figure 6.6.1.B) 
and 52% of xklf2-DE genes of mMyo-NT are expressed in mMyo-NT (FPKM) 
(562/1077, Figure 6.6.1.C). The rest 37%, 23% and 48% of xklf2-DE genes of 
mESC-NT, MEF-NT and mMyo-NT include 276, 359 and 362 cell-type 
specific genes, which are not expressed in mESC-NT, MEF-NT and mMyo-NT, 
and 131, 310 and 153 genes, which are not expressed in all 3 cell types, 
respectively (Figure 6.6.1). Therefore, more than 52% of xklf2-DE genes are 




For 11488 reprogrammable genes (FPKM>0, all 3 cell types), 505 xklf2-DE 
genes in mESC-NT, 1542 xklf2-DE genes in MEF-NT and 454 genes in 
mMyo-NT are reprogrammable genes and regulated by xklf2-HA 
overexpression at Day 2 after Oocyte-NT, which account for 46%, 54% 42% 
of xklf2-DE genes expressed in mESC-NT, MEF-NT and mMyo-NT (FPKM>0) 
(505/1100, Figure 6.6.1.A; 1542/2871, Figure 6.6.1.B; 454/1077, Figure 
6.6.1.C). Hence, more than 42% of xklf2-DE genes, which is expressed in 
mESC-NT, MEF-NT and mMyo-NT are regulated by both maternal factors 
and xklf2-HA overexpression. 
 
6.6.2 5~11% of cell-type specific genes resist to SCNR by oocytes but are 
activated by xklf2-HA overexpression within 2 days after Oocyte-NT 
For 5960 cell-type specific genes, which are not expressed in mESC-NT but 
expressed in MEF-NT, mMyo-NT or both, 276 xklf2-DE genes in mESC-NT 
are activated by xklf2-HA overexpression and accounts for 5% of cell-type 
specific genes (Figure 6.6.1.A). For 3303 cell-type specific genes, which are 
not expressed in MEF-NT, 359 xklf2-DE genes in MEF-NT are activated by 
xklf2-HA overexpression and accounts for 11% of cell-types specific genes, 
which are not expressed in MEF-NT (Figure 6.6.1.B). For 6741 cell-type 
specific genes, which are not expressed in mMyo-NT, 362 xklf2-DE genes in 
MEF-NT are activated by xklf2-HA overexpression and accounts for 5% of 
cell-types specific genes, which are not expressed in mMyo-NT (Figure 
6.6.1.C). Therefore, 5~11% of cell-type specific genes resist to be activated 
by maternal factors but are activated by xklf2-HA overexpression. 
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Interestingly, the third kind of genes is found when examining the effect of 
xklf2-HA overexpression. The third kind of genes is not expressed in all 3 cell 
types, resist to be activated by maternal factors and activated by xklf2-HA 
overexpression. For the third kind of genes, 131 genes are found in xklf2-DE 
genes of mESC-NT, 310 genes are found in xklf2-DE genes of MEF-NT and 
153 genes are found in xklf2-DE genes of mMyo-NT (Figure 6.6.1). 
 
6.6.3 Reprogrammed transcriptomes contain up-regulated and down-
regulated xklf2-DE genes but only up-regulated xklf2-DE genes contribute to 
activate resistant genes 
Within mESC-NT, MEF-NT and mMyo-NT (FPKM>0), 59%, 68% and 45% of 
up-regulated xklf2-DE genes are expressed in mESC-NT, MEF-NT and 
mMyo-NT and are up-regulated by xklf2-HA overexpression (571/976, mESC-
NT, Figure 6.6.2.A; 1382/2044, MEF-NT, Figrue 6.6.2.B; 422/936, Figure 
6.6.2.C). Additionally, almost all down-regulated xklf2-DE genes are 
expressed in mESC-NT, MEF-NT and mMyo-NT without the addition of xklf2-
HA (132/134, mESC-NT, Figure 6.6.3.A; 820/827, MEF-NT, Figure 6.6.3.B; 
140/141, mMyo-NT, Figure 6.6.3.C). Therefore, xklf2-DE genes expressed in 
mESC-NT, MEF-NT and mMyo-NT are either up-regulated or down-regulated 
by xklf2-HA overexpression. 
 
For genes that are not expressed in mESC-NT, MEF-NT and mMyo-NT, 405, 
662 and 514 xklf2-DE genes are up-regulated and 2, 7 and 1 genes are 
down-regulated by xklf2-HA overexpression at Day 2 after Oocyte-NT (Figure 
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6.6.2 and 6.6.3), respectively. Hence, genes resist to be activated by maternal 
factors are activated by xklf2-HA overexpression. 
 
Additionally, up-regulated xklf2-DE genes are activated by xklf2-HA 
overexpression to xklf2-oocyte level and the statistic analysis is in Appendix 




Figure 6.6.1 xklf2-HA overexpression regulates reprogrammable genes (expressed in 
all 3 cell types) and SCNR resistant genes, included cell-type specific genes 




Figure 6.6.2 46, 54 and 42% of up-regulated xklf2-DE genes of mESC-NT (A), MEF-NT (B) 
and mMyo-NT (C) are reprogrammable genes, respectively. 28%, 17% and 39% of xklf2-
DE genes of mESC-NT (A), MEF-NT (B) and mMyo-NT (C) are SCNR resistant genes of 
mESC-NT, MEF-NT and mMyo-NT, respectively. 13%, 15% and 16% of xklf2-DE genes 




Figure 6.6.3 Down-regulated xklf2-DE genes are genes expressed already in mESC-NT 
(A), MEF-NT (B) and mMyo-NT (C) in the absence of xklf2-HA at Day 2 after Oocyte-NT.  
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6.6.4 xklf2-HA overexpression activates and regulates genes responsible for 
signaling pathways regulating pluripotency of stem cells 
To evaluate the biological functions of up-regulation by xklf2-HA 
overexpression, the regulation of genes by xklf2-HA overexpression is applied 
in signaling pathways regulating pluripotency genes of stem cells. Previously, 
39 up-regulated xklf2-DE genes are annotated to participate in signaling 
pathways regulating pluripotency genes of stem cells via KEGG pathway 
enrichment analysis and the regulation of them by xklf2-HA overexpression is 
shown in Table 6.6.1 and 6.6.2. 
 
Since xklf2-HA overexpression can regulate both resistant genes and 
reprogrammable genes, the regulation of these two kinds of genes are 
separated in Table 6.6.1 and 6.6.2. In Table 6.6.1 and 6.6.2, resistant xklf2-
DE genes are divided into there levels. Resistant xklf2-DE genes with 
FPKM=0, 0<FPKM<0.1 and 0.1<FPKM<1 are shown in orange, green and 
blue, respectively. 
 
It has been shown that maternal factors, xklf2-HA and downstream genes of 
xklf2-HA are involved in gene regulation during SCNR by oocytes and the up-
regulation of genes by xklf2-HA overexpression is stronger when the genes 
are at nil or low expression level. It shows clearly that the relationship 
between expression level of reprogrammed transcriptomes and up-regulation 
of genes by xklf2-HA overexpression in different cell types while the lower the 
FPKM is, the higher the log2FC is (Table 6.6.1 and 6.6.2). 
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Take Pou5f1 (Oct4) as an example. When FPKM of Pou5f1 is 31.9, 0 and 0 in 
mESC-NT, MEF-NT and mMyo-NT, log2FC of Pou5f1 is 2, 3 and 6 in the 
presence of overexpressed xklf2-HA (Table 6.6.1). In some cases, log2FC of 
resistant xklf2-DE genes are not shown in some cell types but these resistant 
xklf2-DE genes can be activated/regulated by xklf2-HA overexpression in 
other cell types. Because genes would be excluded for DE analsys when they 
do not pass 50% fitering, it may indicate regulatory elements of them reside 
heterochromatin where it is R-form chromatin for being totally inaccessible by 
TFs149 (Table 6.6.1). 
 
Therefore, xklf2-HA overexpression can promote signaling pathways 
regulating pluripotency of stem cells by up-regulating 39 genes responsible for 




Table 6.6.1 SCNR resistant genes of xklf2-DE genes (all 3 cell types) responsible for 
“signaling pathways regulating pluripotency of stem cells (KEGG pathway)” are 
activated strongly by xklf2-HA overexpression with high log2FC. Expression level 
(FPKM) in the absence of xklf2-HA at Day 2 after Oocyte-NT is shown and FPKM=0 is in 
orange, 0<FPKM<0.1 is in green and 0.1<FPKM<1 is in blue. Log2FC and FDR are 
shown for genes regulated by xklf2-HA overexpression at Day 2 after Oocyte-NT. 
  
Table .6.4
Expression level of SCNR resistant genes of xklf2-DE genes in the absense of xklf2-HA
Regulation of SCNR resistant gene by xklf2-HA overexpression
Gene mESC-NT MEF-NT mMyo-NT
Fgf2 0.0 0.0 0.0
Neurog1 0.0 0.8 0.0
Inhbc 0.0 1.4 0.0
Inhba 0.0 1.9 0.6
Wnt7b 0.0 2.0 9.0
Onecut1 0.1 0.0 0.0
Lefty2 0.1 0.5 0.0
Hoxb1 0.2 0.0 0.0
Wnt16 0.4 0.0 0.0
Wnt8b 0.5 0.0 0.8
Lhx5 0.8 0.9 0.0
Inhbe 1.5 1.0 0.0
Isl1 3.7 0.0 0.0
Zic3 4.3 0.0 0.0
Dlx5 6.5 7.5 0.0
Pou5f1 31.9 0.0 0.0
FPKMA.
B. C.
Gene mESC-NT MEF-NT mMyo-NT Gene mESC-NT MEF-NT mMyo-NT
Fgf2 6 7 ND Fgf2 1.12E-01 7.57E-04 ND
Neurog1 7 4 ND Neurog1 7.52E-02 3.52E-02 ND
Inhbc 8 3 ND Inhbc 5.22E-02 6.01E-02 ND
Inhba 6 7 8 Inhba 4.24E-09 1.24E-30 1.68E-10
Wnt7b 5 1 0 Wnt7b 9.46E-02 7.79E-01 9.73E-01
Onecut1 4 6 6 Onecut1 5.29E-01 8.97E-03 3.35E-02
Lefty2 4 3 7 Lefty2 5.87E-02 1.25E-02 3.75E-03
Hoxb1 5 6 5 Hoxb1 2.46E-01 7.51E-07 1.76E-01
Wnt16 4 3 5 Wnt16 1.48E-01 1.26E-02 2.13E-01
Wnt8b 3 4 4 Wnt8b 4.28E-01 1.12E-02 5.85E-02
Lhx5 5 5 5 Lhx5 6.48E-03 1.15E-08 2.52E-02
Inhbe 3 3 7 Inhbe 2.36E-01 3.52E-03 4.63E-03
Isl1 1 5 7 Isl1 6.77E-01 3.54E-02 4.01E-02
Zic3 1 5 6 Zic3 8.35E-01 6.39E-03 1.18E-01
Dlx5 5 2 5 Dlx5 3.60E-06 1.28E-04 3.75E-03





Table 6.6.2 Reprogrammable genes of xklf2-DE genes (all 3 cell types) responsible for 
“signaling pathways regulating pluripotency of stem cells (KEGG pathway)” are 
activated mildly by xklf2-HA overexpression with high log2FC. Expression level (FPKM) 
in the absence of xklf2-HA at Day 2 after Oocyte-NT is shown and FPKM=0 is in orange, 
0<FPKM<0.1 is in green and 0.1<FPKM<1 is in blue. Log2FC and FDR are shown for 
genes regulated by xklf2-HA overexpression at Day 2 after Oocyte-NT. 
  
Table .6.5
Expression level of reprogrammable genes of xklf2-DE genes in the absense of xklf2-HA
Regulation of reprogrammable genes by xklf2-HA overexpression
Gene mESC-NT MEF-NT mMyo-NT
Wnt10a 0.1 3.7 2.4
Pik3cd 0.3 1.0 0.3
Pik3r1 0.6 3.6 4.2
Igf1r 0.6 0.4 0.0
Wnt2b 3.0 6.2 2.6
Stat3 4.0 3.2 1.9
Dvl3 7.8 6.0 8.1
Smad1 7.9 2.3 4.1
Kat6a 9.6 19.4 6.4
Otx1 12.1 13.2 2.7
Wnt6 13.3 7.7 3.8
Fzd10 13.4 0.1 5.0
Id3 15.4 60.7 31.6
Id2 15.8 20.3 39.3
Jak3 17.8 1.8 0.4
Id1 18.2 10.7 13.0
Bmp4 22.2 44.2 12.5
Hand1 22.9 2.4 0.1
Zfhx3 30.5 1.8 7.0
Pax6 80.5 30.5 10.2
Sox2 1297.4 69.2 4.2
FPKMA.
C.B.
Gene mESC-NT MEF-NT mMyo-NT Gene mESC-NT MEF-NT mMyo-NT
Wnt10a 7 4 4 Wnt10a 1.08E-09 5.02E-09 2.42E-01
Pik3cd 1 2 1 Pik3cd 7.40E-01 9.87E-02 6.77E-01
Pik3r1 4 2 2 Pik3r1 7.93E-04 8.90E-04 3.24E-02
Igf1r 1 2 5 Igf1r 7.83E-01 6.73E-02 1.49E-01
Wnt2b 1 1 3 Wnt2b 3.39E-01 6.12E-02 5.02E-02
Stat3 1 1 3 Stat3 7.63E-01 1.49E-01 7.00E-02
Dvl3 2 1 1 Dvl3 5.15E-02 3.62E-01 6.48E-01
Smad1 2 4 4 Smad1 2.82E-02 1.49E-07 4.55E-05
Kat6a 2 3 2 Kat6a 2.93E-02 7.80E-07 1.16E-02
Otx1 2 3 1 Otx1 3.94E-02 9.35E-07 6.94E-01
Wnt6 3 2 2 Wnt6 9.68E-03 2.25E-03 5.08E-01
Fzd10 1 3 -1 Fzd10 7.96E-01 2.92E-03 7.41E-01
Id3 2 1 2 Id3 2.66E-02 5.18E-02 3.15E-02
Id2 2 2 1 Id2 2.30E-01 3.61E-03 2.91E-01
Jak3 2 2 3 Jak3 1.41E-01 3.46E-02 6.23E-02
Id1 2 1 3 Id1 1.94E-01 4.73E-02 2.66E-02
Bmp4 3 2 2 Bmp4 3.49E-05 1.85E-02 1.36E-01
Hand1 4 3 5 Hand1 1.07E-02 5.11E-07 1.21E-02
Zfhx3 0 2 1 Zfhx3 8.97E-01 5.38E-02 6.43E-01
Pax6 1 1 2 Pax6 2.04E-01 3.98E-02 1.99E-02




In Chapter 5, it has been shown that there are two kinds of genes in 
reprogrammed transcriptomes of mESCs, MEFs and mMyos. One is 
reprogrammable genes, which are expressed in all 3 reprogrammed 
transcriptomes and regulated by matneral factors to the same level. The other 
kind of genes are cell-type specific genes and they are expressed in one or 
two cell types, rather than expressed in all 3 cell types. Cell-type specific 
genes contain genes, whose expression is maintained by transplanted cells, 
and SCNR resistant genes, which resist to be activated by maternal factors. In 
this section, it shows that xklf2-HA overexpression helps to recognize SCNR 
resistant genes by activating and regulating SCNR genes to xklf2-oocyte level. 
 
By comparing reprogrammable genes, SCNR resistant genes and xklf2-DE 
genes, it shows that 42~46% of xklf2-DE genes are reprogrammable genes. 
Additionally, 5~11% of cell-type specific genes are recognized as SCNR 
resistant genes and are activated by xklf2-HA overexpression. In addition to 
that, approximately 300 xklf2-DE genes are shown to be silent in all 3 cell 
types but activated by xklf2-HA overexpression. Importantly, xklf2-HA 
overexpression can regulates reprogrammable genes and activate SCNR 
resistant genes. 
 
Furthermore, activation of SCNR resistant genes is contributed by xklf2-HA 
up-regulation, rather than down-regulation. Maternal factors, xklf2-HA and 
downstream genes of xklf2-HA are involved in regulating expression of xklf2-
DE genes to xklf2-oocyte level. 
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When applying up-regulation of genes by xklf2-HA overexpression in signaling 
pathways regulating pluripotency of stem cells, it shows that xklf2-HA 
overexpression can promote these signaling pathways by up-regulating 39 
genes responsible for these pathways. Importantly, 16 genes of them resist to 
SCNR by oocytes and are activated by xklf2-HA overexpression. 
 
All in all, xklf2-HA overexpression is shown to activate SCNR resistant genes 
in reprogrammed transcriptomes and regulate expression of xklf2-DE genes 
to xklf2-oocyte level cooperatively with maternal factors and downstream 
genes. Moreover, xklf2-HA overexpression activates and up-regulates 37 
xklf2-DE genes, which participate in signaling pathways regulating 




In development, chromatin structures of cells are subjected to change to 
receive extracellular stimuli, which resulting new transcriptomes to be formed 
in the new cell types. During SCNR by oocytes, chromatin structures of 
transplanted cells are forcibly changed by maternal factors and nearly 
identical transcriptomes are formed at Day 2 after Oocyte-NT. However, 
SCNR resistant genes in transplanted cells are not always activated by 
maternal factors and it would lead to unsuccessful SCNR by oocytes. Since 
overexpression of transcription factors are also used to change cell identities, 
I would like to ask if overexpression of transcriptions can activate SCNR 
resistant genes and how transcription factors regulate genes during SCNR by 
oocytes? 
 
Time-dependent effect of xklf2-HA overexpression has shown that most of 
xklf2-HA downstream genes are regulated by xklf2-HA overexpression within 
one day after Oocyte-NT. While more xklf2-HA downstream genes up-
regulated by xklf2-HA overexpression than down-regulated by xklf2-HA 
overexpression within 1 day after Oocyte-NT but more xklf2-HA downstream 
genes are down-regulated than up-regulated by xklf2-HA overexpression from 
Day 1 to Day 2 after Oocyte-NT, it indicates downstream genes of xklf2-HA, 
especially repressors, are also involved in gene regulation by xklf2-HA 
overexpression. 
 
When comparing effects of xklf2-HA overexpression on different cell types, 
xklf2-HA overexpression up-regulates expression of xklf2-DE genes, mostly at 
	 240	
nil or low expression level in reprogrammed transciptomes of tested cell types, 
to xklf2-oocyte level at Day 2 after Oocyte-NT. When comparing up-regulated 
and down-regulated in all 3 cell types, it shows that the regulation of genes by 
xklf2-HA overexpression is one direction and xklf2-DE genes are either up-
regulated or down-regulated by xklf2-HA overexpression. Additionally, mKlf2 
binding motifs are enriched for xklf2-DE genes and shows regulation of xklf2-
DE genes is highly possible through direct binding in their promoters. 
 
Additionally, the functions of xklf2 downstream genes can be annotated to the 
functions promoted by xklf2-HA overexpression during SCNR by oocytes. 
Through Gene ontology enrichment analysis, up-regulated xklf2-DE genes are 
annotated to developmental processes, transcriptional activators and 
repressors. Additionally, signaling pathways regulating pluripotency of stem 
cells are enriched from up-regulated xklf2-DE genes via KEGG pathway 
enrichment analysis and it indicates these pathways are promoted by xklf2-
HA expression during SCNR by oocytes. 
 
Finally, xklf2-HA overexpression can significantly regulate both 
reprogrammable genes and cell-type specific genes in reprogrammed 
transcriptomes of mESCs, MEFs and mMyos. Importantly, xklf2-HA 
overexpression helps to recognize SCNR resistant genes among cell-type 
specific genes and is shown to activate/regulate SCNR resistant genes to 
xklf2-oocyte level, including 16 SCNR resistant genes responsible for 
signaling pathways regulating pluripotency of stem cells.  
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Chapter 7 The effect of the pioneer transcription 
factor, mFoxa1-HA, on somatic cell nuclear 




In Chapters 5 and 6, I have shown that oocyte factors can reprogram 
transcriptomes of transplanted cells to an oocyte-steady state and that 
overexpression of xklf2-HA can activate target genes that are resistant to 
oocyte factors genome-wide. In this chapter, I ask if the pioneer transcription 
factor, mouse Foxa1-HA (mFoxa1-HA), can activate pluripotency genes and 
neurogenic genes through its pioneer transcription factor activity. 
 
The difference between Yamanaka factors and mFoxa1 is that Yamanaka 
factors are important in early development since they are major factors to 
induce pluripotency whereas mFoxa1 is well known as a pioneer factor to 
access to and open the closed chromatin before the recruitment of other 
cofactors149. Furthermore, it has been shown that Xenopus foxa1 (xfoxa1) is 
activated after MBT in embryos140,141. Therefore, it would be possible that 
there is no redundant factor like the role of xfoxa1 or mFoxa1 in Xenopus 
oocytes and overexpression of mFoxa1-HA can induce expression of 
neurogenic genes, which are not induced by oocyte factors. However, it would 
be also possible that mFoxa1-HA, as a lineage-specific factor149-151, may not 
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work as well as Yamanaka factors do due to the lack of cofactors and proper 
post-translational modifications. 
 
7.1.2 Experimental design 
In this chapter, the experiment procedures are similar to Chapter 3 and 4, 
except that I overexpressed mFoxa1-HA 24 hours before Oocyte-NT (Figure 
7.1). In Section 7.2, I used a similar approach to overexpress mFoxa1-HA 
proteins and evaluate how it is produced in the Xenopus oocytes (Figure 
7.1.A). As mentioned in Chapter 3, I overexpressed mFoxa1-HA in Xenopus 
oocytes and examined if mFoxa1-HA overexpression affects expression of 
pluripotency genes and neurogenic genes150,151 (Figure 7.1.B, Section 7.3 and 
7.4). To compare the effect of oocyte factors and mFoxa1-HA overexpression 
on neurogenic genes, I did a time-course observation from 0 hour to 48 hours 




Figure 7.1 Sample preparations of Western blotting (A) and QPCR (B) for evaluating the 
production and effect of mFoxa1-HA overexpression are shown.  
24 hours before Oocyte-NT Day 2






RNA processing and QPCR
Sample collection at different days after Oocyte-NT
Control group: No mRNA injection
Figure 7.1






Sample collection at different time points











7.2 mFoxa1-HA accumulates in the GVs dose-dependently 
and SUMOylation of mFoxa1-HA is observed in the Xenopus 
oocytes 
To evaluate the production of mFoxa1-HA proteins, samples of different 
cellular compartments (whole oocytes, cytosol fractions and GV fractions) 
were collected at different days (Day 1, 2 and 3) after mFoxa1-HA mRNA 
injection (4.6 and 9.2 ng) and run on the same blot (Figure 7.2.1). The anti-HA 
antibody detects two obvious bands on the blot around the 55kD protein 
marker where the mFoxa1-HA should be (54kD = 49kD for mFoxa1 + 5kD for 
HA tag). 
 
Figure 7.2.1 Signal intensity of mFoxa1-HA and actin at different conditions is shown. 
The mFoxa1-HA proteins (upper black arrow and black arrowhead) are detected by anti-HA 
antibody and the actin proteins (lower black arrow) are detected by the anti-actin antibody. 
The signal intensity of mFoxa1-HA proteins and actin proteins are shown next to the 
quantification rectangles.	  
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5110 34400 12300 6620 49000 10300 13800 6890 14200
4680 4530 26500 9160 5610 33500 6820 9380 5140 9370
51900 46600 53600 44400 41500 56400 46500 44400 44700 46800
Figure 7.2.1
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7.2.1 mFoxa1-HA proteins accumulate in the GVs and increase time- and 
dose-dependently in different cellular compartments 
To ask whether the mFoxa1-HA proteins will accumulate in the GVs, I added 
up the signals of 54kD bands and 66kD bands to make the bar chart of Figure 
7.2.2.A. When injecting the oocytes with 4.6 ng and 9.2 ng of mFoxa1-HA 
mRNA and collecting the samples 1 day later, the mFoxa1-HA signals from 1 
whole oocyte is 3.85 times (=12500/3205, 4.6 ng mFoxa1-HA mRNA) and 
4.68 times (=21460/4583, 9.2 ng mFoxa1-HA mRNA) more than the signals 
from 1 GV fraction (Figure 7.2.2.A). Considering the volume ratio of 1 GV to 1 
oocyte is 1/30 and 1 GV contains 1/4~1/5 of mFoxa1-HA proteins in whole 
oocytes, the mFoxa1-HA proteins must accumulate in the GVs. In addition to 
that, the more mFoxa1-HA proteins are made in the cytosol, the more 
mFoxa1-HA proteins are transported in the GVs. 
 
Apart from these points, the actin signals in different fractions do not vary too 
much when the amount of mFoxa1-HA mRNA is doubled (Figure 7.2.1 and 
7.2.2.B). When statistically analyzing the signal intensity of actin in different 
oocyte fractions and whole oocytes regardless of the amount of mFoxa1-HA 
mRNA and the sample collection days (Figure 7.2.2.C), the average signals 
intensity is 46450 for 1 whole oocyte (±SD=2874, 4.6 and 9.2 ng mRNA, Day 
1, 2 and 3), 44050 for 1 cytosol fraction (±SD=3606, 4.6 and 9.2 ng mRNA, 
Day 1) and 3056 for 1 GV fraction (±SD=110, 4.6 and 9.2 ng mRNA, Day 1). 
The average signal intensity of 1 whole oocyte (46450) almost equals the 
average signal intensity of 1 cytosol fraction (44050) plus 1 GV fraction (3056). 
This means the detection of actin is very accurate within the signals from 
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3056 to 46450 and no dilution series of samples is needed for relative protein 
quantification here. 
 
For an easier description of the fractionation difference, a stacked bar chart 
can be made (Figure 7.2.3.A and B) and the signal intensity can be divided by 
the whole oocyte sample and shown as percentages of relative signal 
intensity. It can help to examine what percent of protein signals in 1 whole 
oocyte is distributed to 1 cytosol fraction and 1 GV fraction. For example, in 
4.6 ng mFoxa1-HA mRNA groups (left part, Figure 7.2.3.A), the mFoxa1-HA 
signals from 1 whole oocyte (100%) almost equals to the signals from 1 
cytosol fraction (77%) plus the signals from 1 GV fraction (26%). 26% of the 
mFoxa1-HA signals in 1 whole oocyte is distributed to 1 GV fraction. When 
doubling the mFoxa1-HA mRNA to 9.2 ng per oocyte (right part, Figure 
7.2.3.A), the signal percentages of 1 whole oocyte increase from 100% (4.6 
ng group) to 172% (9.2 ng group) and the signal distribution to 1 GV is around 
27% [= 37%/(37%+98%)], which is almost the same as the distribution of 4.6 
ng group (26%). Therefore, the distribution of mFoxa1-HA proteins to the GVs 
is not affected by the total amount of mFoxa1-HA proteins in the whole 
oocytes. Notably, in the 9.2 ng mFoxa1-HA mRNA groups, the signal 
percentages of 1 whole oocyte (172%) is ~1.3 times more than the signal 
percentages of 1 cytosol fraction (37%) plus 1 GV fraction (98%) and the 
uneven values would be acceptable due to the variable sizes of Xenopus 




If checking the actin signals (Figure 7.2.3.B), the signals from 1 whole oocyte 
also roughly equal the signals from 1 cytosol fraction plus the signals from 1 
GV fraction in both 4.6 ng mRNA groups and 9.2 ng mRNA groups. 
Additionally, because the actin signals from 1 GV fraction is ~1/15 of the 1 
whole oocyte values (Figure 7.2.2.C and 7.2.3.B) and because the actin 
signals are not distributed to 1 GV fraction and 1 cytosol fraction with regard 
to the ratio of volume (GV:cytosol = ~1/30), it is not suitable to normalize the 
signals of proteins with signals of actin when comparing proteins in different 
fractions. 
 
Then, I evaluated the dose- and time-dependency of mFoxa1-HA protein 
production and compared the mFoxa1-HA signals in whole oocyte samples at 
Day 1, 2 and 3 after mRNA injection (4.6 and 9.2 ng) (Figure 7.2.1 and 7.2.4). 
Firstly, the signals of two mFoxa1-HA bands are added up and normalized to 
the value of 4.6 ng group at Day 1 to make the line chart (Figure 7.2.4.A). At 
Day 1, the mFoxa1-HA signals of 9.2 ng mRNA group is 1.7 times more than 
the signals of 4.6 ng mRNA group, which is also validated previously (Figure 
7.2.2.A and 7.2.3.A). At Day 2 and Day 3, the mFoxa1-HA signals of 9.2 ng 
group is 1.4 and 2 times more than the signals of 4.6 ng group, respectively 
(Figure 7.2.4.C). Since the amount of mFoxa1-HA proteins does not change 
greatly from Day 1 to Day 3 after mRNA injection without sign of protein 




Figure 7.2.2 mFoxa1-HA proteins increase dose-dependently in GV and cytosol at Day 
1 after mRNA injection. 
(A) mFoxa1-HA protein signals in different cellular compartments increase dose-dependently. 
(B) Different doses of mFoxa1-HA mRNA do not affect actin signals in different cellular 
compartments. 
(C) Average actin signals of 1 whole oocyte equal to average actin signals of 1 cytosol 
fraction plus 1 GV fraction.  
Fig 7.2.2.C. Average value of actin signal intensity in 1 whole oocyte, 1 cytosol fraction and
                    1 GV fraction
Fig 7.2.2.A. mFoxA1-HA proteins accumulate in the GV dose-dependently at Day 1 after
                    mRNA injection
Fig 7.2.2.B. Actin signals do not change in different cell compartments when doubling the
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Figure 7.2.3 mFoxa1-HA proteins accumulate in GV dose-dependently at Day 1 after 
mRNA injection. 
(A) About 1/4 of mFoxa1-HA proteins in 1 whole oocyte is distributed to 1 GV fraction 
regardless of the doses of mFoxa1-HA mRNA. 
(B) About 1/15 of actin proteins in 1 whole oocyte is in 1 GV fraction.  
Fig 7.2.3.A. One fourth of mFoxA1-HA proteins in 1 whole oocyte is distributed to 1 GV
                    fracti n regardless of doubling tha amount of mFoxA1-HA mRNA
Fig 7.2.3.B. 1/14-1/16 of mFoxA1-HA proteins in 1 whole oocyte is distributed to 1 GV
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Figure 7.2.4 mFoxa1-HA proteins increase until Day 2 after mRNA injection and 
decrease slightly afterwards. 
(A) Relative signal intensity of mFoxa1-HA per oocyte at Day 1, 2 and 3 after mRNA injection 
(B) Relative signal intensity of actin per oocyte at Day 1, 2 and 3 after mRNA injection 
(C) Relative signal intensity of mFoxa1-HA per oocyte is normalized by relative signal 
intensity of actin and is shown as relative protein expression.  
Fig 7.3.4.B. Relative signal intensity of actin at Day 1, 2 and 3 after mRNA injection
Fig 7.3.4.C. Relative protein expression shows mFoxA1-HA decreases at Day 3 after mRNA
                    injection
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7.2.2 SUMOylation is observed in mFoxa1-HA protein detection 
For the double bands detected by anti-HA antibody (Figure 7.2.1), it might be 
similar to xklf2-HA that the anti-HA antibody sometimes detects small-sized 
bands of proteins when the protease inhibitors are insufficient to inhibit the 
protein degradation during sample handling or when the protein degradation 
is part of the post-translation modification for maintaining the half-life of 
protein of interest (Chapter 3). However, it is different between mFoxa1-HA 
and xklf2-HA since that the small-sized bands of xklf2-HA only exist in the 
cytosol fractions but two detected bands of mFoxa1-HA exist both in the GV 
and cytosol fractions. The absence of small-sized band of xklf2-HA in the GV 
fractions indicates the small-sized bands result from protein degradation in the 
cytosols, rather than in the GVs. 
 
A possible explanation for the unexpected size of the presumed mFoxa1-HA 
bands in Figure 7.2.1 is the SUMOylation of mFoxa1-HA, which results in a 
bigger size band, and the SUMOylation is quite often seen in the Fox 
family139,152. It has been shown that the SUMOylation of mFoxa1 is related to 
nuclear mobility, transcriptional activity and chromatin occupancy139. If the 
double bands are caused by SUMOylation, the large-sized bands would 
represent SUMOylated mFoxa1-HA proteins (black arrowhead, ~66kD = 54kD 
for mFoxa1-HA + 12kD for SUMO protein) and the small-sized bands would 
be the native mFoxa1-HA (black arrow, 54kD) (Figure 7.2.1). It is interesting 
that the amount of 66kD SUMOylated mFoxa1-HA is more than the amount of 
55kD native mFoxa1-HA in all samples regardless of the fractions, time points 
or doses (Figure 7.2.5). 
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For the whole oocyte samples (Figure 7.2.5.A), the relative expression of 
SUMOylated mFoxa1-HA (66kD) to native mFoxa1-HA (54kD) is different 
according to the doses of mFoxa1-HA mRNA and sample collection days. At 
Day 1, the SUMOylated mFoxa1-HA is 1.67 times more than the native 
mFoxa1-HA at Day 1 after mRNA injection. Since it has been proved that the 
distribution of the mFoxa1-HA proteins to the GVs is the same in both 4.6 and 
9.2 ng mRNA groups (Figure 7.2.3.A), the different relative expression of 
SUMOylated mFoxa1-HA to native mFoxa1-HA is not related to the mFoxa1-
HA distribution. Additionally, the difference of relative expression is also not 
related the dose of mFoxa1-HA mRNA because the relative expression of the 
4.6 ng mRNA groups (1.67X) is more than the relative expression of the 9.2 
ng mRNA groups (1.34X) at Day 1 (Figure 7.2.5.A). Instead, the relative 
expressions show that the SUMOylated mFoxa1-HA proteins increase in a 
time-dependent way and more mFoxa1-HA proteins are SUMOylated when 
incubation time increases (Figure 7.2.5.A). 
 
On the other hand, when analyzing the GV and cytosol samples (Figure 
7.2.5.B and 7.2.5.C), the relative expressions of SUMOylated mFoxa1-HA to 
native mFoxa1-HA only increase slightly in GV and in cytosol samples. For 
the GV samples, the relative expressions increase from 1.30X in 4.6 ng 
mRNA groups to 1.46X in 9.2 ng mRNA groups at Day 1 after mRNA injection. 
For the cytosol samples, the relative expression increase from 1.13X in 4.6 ng 
mRNA groups to 1.18X in 9.2 ng mRNA groups at Day 1 after mRNA injection. 
However, if comparing the difference of mFoxa1-HA SUMOylation between 
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GV samples and cytosol samples, the relative expressions of mFoxa1-HA 
SUMOylation is 1.38X in GV samples, which is more than the 1.16X in cytosol 
samples, and it might imply some functions involved SUMOylation and may 







Figure 7.2.5 More mFoxa1-HA are SUMOylated dependent on the increase of 
incubation time. 
(A) The relative expressions of SUMOylated mFoxa1-HA to native mFoxa1-HA for oocyte 
samples at different time points and doses are shown. 
(B and C) The relative expressions of SUMOylated mFoxa1-HA to native mFoxa1-HA for GV 
samples (B) and cytosol samples (C) at Day 1 after mRNA injection.  
Fig 7.2.5.A. The fold change of SUMOylation of mFoxA1-HA per whole oocyte at Day 1, 2 and
                    3 after mRNA injection
Fig 7.2.5.B. The fold change of SUMOylation of mFoxA1-HA per GV at Day 1 after mRNA
                    injection
Fig 7.2.5.C. The fold change of SUMOylation of mFoxA1-HA per cytosol at Day 1 after mRNA
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In all, this section proved that mFoxa1-HA proteins accumulate in the GVs 
dose-dependently after being translated from mRNA in the cytosol and the 
distribution of mFoxa1-HA proteins in the GVs does not change when 
introducing more mRNA into the cytosol. Additionally, the amount of mFoxa1-
HA proteins increases in a dose- and time-dependent manner in the whole 
oocyte samples and decreases slightly at Day 2 after mRNA injection. 
Interestingly, slightly increased SUMOylation is observed on the newly-made 
mFoxa1-HA proteins and it might relate to the functions of mFoxa1-HA139,152.  
 
In conclusion, the fractionation of Xenoups oocytes provides a way to interpret 
the functions of proteins of interest further via a quantitative image system. 
Moreover, the translational machinery of Xenopus oocytes is able to translate 
a lineage-specification transcription factor, mFoxa1-HA, and process it 
constantly with SUMOylation, which can be further validated by anti-SUMO 
antibodies. This oocyte mRNA injection procedure therefore seems to provide 
a satisfactory assay to access the effect of mFoxa1-HA on transplanted 
somatic cell nuclei. 
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7.3 The overexpression of mFoxa1-HA up-regulates mSox2 
only in MEFs during SCNR by Xenopus oocytes 
In Chapter 3, it has been shown that each Yamanaka factor can selectively 
up-regulate tested pluripotency genes. In Chapter 4, it has also been shown 
that oocyte factors can up-regulate tested pluripotency genes up to ~600-fold 
while overexpression of xklf2-HA has smaller effect on tested pluripotency 
genes. Here, I used mFoxa1-HA, a lineage-specification factor and pioneer 
transcription factor, to examine if overexpression of mFoxa1-HA affects the 
expression of pluripotency genes during SCNR by Xenopus oocytes. 
 
7.3.1 The overexpression of mFoxa1-HA up-regulates mSox2 among tested 
pluripotency genes 
To evaluate the effect of mFoxa1-HA overexpression on tested pluripotency 
genes, Oocyte-NT (MEF cell line, sixiFM) is performed one day after mRNA 
injection and samples are collected 48 hours after Oocyte-NT (Figure 7.1.B). 
In Figure 7.3.1, I statistically analyzed the relative expression of tested 
pluripotency genes in MEFs, namely the genes, mSox2, mKlf4, mSall4, 
mOct4, mUtf1, mFbxo15, mNanog, mMyc, mEsrrb and mKlf2 (n=3, t-test). 
 
Among the tested pluripotency genes, mSox2 is up-regulated by mFoxa1-HA 
overexpression with relative expression of 4.1, compared to oocyte factors 
(No mRNA injection groups, Figure 7.3.1). Other tested pluripotency genes 
are unaffected by mFoxa1-HA overexpression with relative expression less 
than 2 although mKlf4, mUtf1 and mFbxo15 are shown to be mildly up-
regulated by mFoxa1-HA overexpression significantly (relative expression 
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less than 2, p<0.05, Figure 7.3.1). It is hard to judge if a transcription factor 
regulates the downstream genes with relative expressions close to one 
although the relative expressions are statically meaningful. 
 
Figure 7.3.1 Among ten tested pluripotency genes, the overexpression of mFoxa1-HA 
up-regulates expression of only mSox2 in sixiFM MEF at Day 2 after Oocyte-NT. 
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7.3.2 The overexpression of mFoxa1-HA up-regulates tested pluripotency 
genes with variable relative expression in each biological replicate 
In Figure 7.3.1, standard deviation of some genes is huge in the case of 
mSox2 (4.1-fold, p<0.08), mOct4 (1.6-fold, p<0.45) and mSall4 (1.6-fold, 
p<0.35) and this may eliminate their biological meaning. Therefore, I 
compared the relative expressions of each gene from different frogs and 
examined how the individual difference affects the data readout (Figure 7.3.2). 
The frogs listed in Figure 7.3.2 are the same as those used in Figure 7.3.1 for 
statistical analysis. 
 
For mSox2, the relative expressions of mSox2 are more than two in Frog 1, 2 
and 3 without statistical significance (Relative expression=3, 2.6 and 6.6, 
Figure 7.3.2.A). For mSall4, the highest relative expressions are in the Frog 1 
(2.6-fold), which are 2.5 times more than the lowest relative expressions in the 
Frog 3 (0.9-fold, Figure 7.3.2.C). For mOct4, the highest relative expressions 
are in the Frog 2 (2.8-fold), which are 3 times more than the lowest relative 
expressions in the Frog 1 (0.9-fold, Figure 7.3.2.D). Therefore, the statistical 






Figure 7.3.2 The overexpression of mFoxa1-HA up-regulates tested pluripotency genes 
with variable relative expression in each biological replicates. 
  















































































































































































































To sum, the overexpression of mFoxa1-HA in the Xenopus oocytes mildly up-
regulates only mSox2 among ten tested pluripotency genes. Combining both 
statistic analysis at Day 2 after Oocyte-NT and the change of transcripts at 
different time points after Oocyte-NT, mFoxa1-HA overexpression can up-
regulate mSox2 during SCNR by oocytes even though mFoxa1, as a lineage-
specification factor, may not exist or be important in early developmental 
stages before MBT. 
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7.4 The regulation of neurogenic genes by mFoxa1 is different 
between Oocyte-NT and neurogenesis of mDA 
neurons/progenitors 
mFoxa1 is well characterized as a pioneer transcription factor, and can 
access low signal chromatin (the intermediate chromatin state between the 
active and repressed chromatin ) and promote the recruitment of other 
transcription factors to regulate downstream genes149. In addition, the early 
expression of mFoxa1 during normal neurogenesis as well as the effect of 
mFoxa1/2 on the neurogenic genes bound by mFoxa1 are recognized as in 
vivo evidence for mFoxa1 utilizing pioneer factor activities to affect the 
specification and differentiation of midbrain dopaminergic (mDA) 
neurons/progenitors in vivo150,151. With these pioneer factor capabilities during 
neurogenesis, I wonder how mFoxa1 regulates the neurogenic genes in the 
context of somatic cell nuclear reprogramming by Xenopus oocytes and how 
effective it is to regulate neurogenic genes when compared with the oocyte 
factors in Xenopus oocytes? 
 
In this section, Oocyte-NT (MEF, sixiFM) is performed one day after the 
injection of mFoxa1-HA mRNA and samples are collected on either Day 0 or 
Day 2 after Oocyte-NT (Figure 7.1.B). The neurogenic genes are selected 
from the paper described previously and are bound by mFoxa1 and mFoxa2 
during the differentiation of mDA neurons/progenitors on mouse embryonic 
day (E) 12.5150. In the referenced paper, mFoxa1 and mFoxa2 function 
redundantly during the specification and differentiation of mDA 
neurons/progenitors and a mFoxa1/2 double cKO mutant is made for 
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observing how the mFoxa1/2 binds and regulates the neurogenic genes (cko, 
conditional knockout, Cre-Lox system)150. 
 
Table 7.4 shows how the mFoxa1/2-bound neurogenic genes are regulated in 
the mFoxa1/2 cko embryos150. In the first category, Arx, Dmrtb1, Ferd3l, 
Kcnip3, Lmcd1, Lmx1b, Rora and Smarca1 are down-regulated in the 
mFoxa1/2 cko embryos and it suggests they may be up-regulated by 
mFoxa1/2 in normal mDA neurons/progenitors on E12.5. The second 
category includes Gli1, Meis2, Otx1 and Otx2, which are up-regulated in the 
Foxa1/2 cko embryos and therefore may possibly be down-regulated in the 
normal mDA neurons/progenitors on E12.5. The third category shows Elk3 
and Foxb1 are not affected in the mFoxa1/2 cKO mDA neurons/progenitors 
on E12.5 although they are bound by mFoxa1/2. From the in vivo data of 
mFoxa1/2 bound genes during mDA neurons/progenitors differentiation 
(Table 7.4), I now ask how these genes are regulated in Xenopus oocytes 
where the oocyte factors might differ hugely from the endogenous factors of 
mDA neurons/progenitors.   
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Table 7.4 Regulation of mFoxa1 ChIP target genes in the mFoxa1/2 cKO embryos. 




Table 7.4 Regulation of mFoxa1 ChIP target genes in the mFoxa1/2 cKO embryos.
Genes are identified by ChIP-seq and RNA-seq.
Arx Dmrtb1 Ferd3l Kcnip3 Lmcd1
Lmx1b Rora Smarca1
Gli1 Meis2 Otx1 Otx2
Elk3 Foxb1
Down-regulated mFoxa1 ChIP target genes in the Foxa1/2 cKO embryos
Up-regulated mFoxa1 ChIP target genes in the mFoxa1/2 cKO embryos
Un-affected mFoxa1 ChIP target genes in mFoxa1/2 cKO embryos
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7.4.1 The overexpression of mFoxa1-HA up-regulates mDmrtb1, mFoxb1 and 
mOtx2 in sixiFM MEF up to 31-fold at Day 2 after Oocyte-NT 
In Figure 7.4.1, the mFoxa1-HA mRNA is injected into Xenopus oocytes one 
day before Oocyte-NT and the samples are collected at Day 2 after Oocyte-
NT (n=3, Figure 7.1.B, page 247). Fourteen neurogenic genes are evaluated 
here and analyzed by QPCR. Compared to the no mRNA injection groups, 
three neurogenic genes are up-regulated by the overexpression of mFoxa1-
HA (mDmrtb1, 2.3-fold; mFoxb1, 4.3-fold; mOtx2, 31-fold, Figure 7.4.1.A). 
While mDmrtb1 is down-regulated, mOtx2 is up-regulated and mFoxb1 is 
unaffected in the mFoxa1/2 cKO embryos (Table 7.4), the overexpression of 
mFoxa1-HA has a different effect on these genes during SCNR by oocytes. 
 
On the other hand, eleven neurogenic genes are unaffected by the 
overexpression of mFoxa1-HA with relative expressions less than two and 
without statistical significance (p>0.05, Figure 7.4.1.B). Within these 
unaffected genes, five genes have relative expression less than one (Figure 
7.4.1.B: mLmcd1, mFerd3l, mKcnip3 and mElk3) and the relative expressions 
of Lmcd1 and Ferd3l are not determined because the relative amount of 
transcripts is under the detection limit of QPCR machine (Figure 7.4.1.B). It is 
an indication for that these genes are silent in the sixiFM MEF. The other 
gene sets among these unaffected genes with relative expression more than 
one but less than two are mLmx1b, mOtx1, mSmarca1, mRora, mMeis2, 
mArx and mGli1 (Figure 7.4.1.B).  
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Figure 7.4.1 Effect of mFoxa1-HA overexpression on neurogenic genes at Day 2 after 
Oocyte-NT is shown (n=3, t-test). 
Neurogenic genes, which are ChIP targets of mFoxa1 in mDA neurons/progenitors, are up-
regulated (A) and unaffected (B) by mFoxa1-HA overexpression. None of these genes are 
shown to be significantly regulated by mFoxa1-HA overexpression. ND, not determined. 
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7.4.2 Oocyte factors up-regulate mOtx2, mFerd3l, mKcnip3, mOtx1, mGli1 in 
sixiFM MEF up to 313-fold from Day 0 to Day 2 after Oocyte-NT 
To compare the effect of oocyte factors and mFoxa1-HA on neurogenic genes, 
the samples are collected at Day 0 and Day 2 after Oocyte-NT (Figure 7.1.B, 
page 247). Samples for the time-point observation are the same as the 
samples of Frog 1 in Figures 7.4.4 and 7.4.5. 
 
For the up-regulated neurogenic genes, mDmrtb1, mFoxb1 and mOtx2 have 
been shown to be up-regulated by mFoxa1-HA overexpression at Day 2 after 
Oocyte-NT (Figure 7.4.1.A). Although these three genes are up-regulated by 
mFoxa1-HA overexpression, the oocyte factors affect them differently (Figure 
7.4.2). This shows that mOtx2 is up-regulated by oocyte factors from Day 0 to 
Day 2 after Oocyte-NT (1-fold to 17-fold, Figure 7.4.2.C) whereas mDmrtb1 
and mFoxb1 are unaffected by oocyte factors (mDmrtb1, 1-fold to 1.2 fold; 
mFoxb1, 1-fold to 0.9-fold, Figure 7.4.2.A and B). The unmatched gene 
regulation may be caused by the different contents between Xenopus oocytes 
at stage V/VI and mDA neuron/progenitors on E12.5 and different chromatin 
states between sixiFM MEF and mDA neurons/progenitors. 
 
For other neurogenic genes, mLmcd1, mFerd3l, mKcnip3, mElk3, mLmx1b, 
mOtx1, mSmarca1, mRora, mMeis2, mArx and mGli1 have been shown to be 
unaffected by mFoxa1-HA overexpression at Day 2 after Oocyte-NT (Figure 
7.4.1.B). Among these genes, mFerd3l, mKcnip3, mOtx1, mGli1 are up-
regulated by oocyte factors from Day 0 to Day 2 after Oocyte-NT with relative 
expression from 8.2 to 313 (Figure 7.4.3.B, C, F and K). Some data of 
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mFerd3l and mRora are undetermined due to the nil or low expression level of 
these two genes in sixiFM MEF (Figure 7.4.3.B and H).  
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Figure 7.4.2 In Frog 1, mOtx2 (C) is up-regulated by oocyte factors and mFoxa1-HA 
overexpression while mDmrtb1 (A) and mFoxb1 (B) are up-regulated by mFoxa1-HA 
overexpression but not affected by maternal factors due to the SCNR resistance. 
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Figure 7.4.3 While mFerd3l, mKcnip3, mOtx1 and mGli1 are strongly up-regulated by 
oocyte factors from Day 0 to Day 2 after Oocyte-NT, all these neurogenic genes are 
unaffected by mFoxa1-HA overexpression at Day 2 after Oocyte-NT. 
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7.4.3 mFoxa1-HA overexpression up-regulates mDmrtb1, mFoxb1 and mOtx2 
in sixiFM MEF with variable relative expression due to SCNR resistance 
In Figure 7.4.4, the relative expression of three up-regulated genes, mDmrtb1, 
mFoxb1 and mOtx2, are shown for three different frogs (Figure 7.4.4). For 
mDmrtb1, expression is up-regulated by 5.9-fold in Frog 1 but it seems to be 
down-regulated in Frog 2 and 3 with relative expression less than 1 (Figure 
7.4.4.A). The opposite regulation of mDmrtb1 might be caused by the nil or 
low expression of it in sixiFM MEF and mDmrtb1 in some samples is 
successfully activated by mFoxa1-HA overexpression but some are not. 
 
For mFoxb1 and mOtx2, they are clearly up-regulated by mFoxa1-HA 
overexpression in all three frogs although the relative expressions are variable 
(Figure 7.4.4.B and C). As mentioned previously for the effect of xklf2-HA 
overexpression, xklf2-HA overexpression up-regulates target genes with 
variable and high relative expression when target genes are resistant to 
oocyte factors. Similarly, mFoxa1-HA overexpression is shown to have the 
same effect on up-regulating target genes, which are resistant to SCNR by 
oocyte factors. 
 
As for the unaffected genes, mLmcd1 are up-regulated by mFoxa1-HA 
overexpression by 3.4-fold in Frog 1 and mFerd3l are up-regulated by 24-fold 
in Frog 2 (Figure 7.4.5.A and B). Although these two genes are not judged to 
be up-regulated by mFoxa1-HA overexpression, they are possible mFoxa1-
HA target genes and the random activation by mFoxa1-HA overexpression is 
caused by the resistance of mLmcd1 and mFerd3l to oocyte factors. 
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Figure 7.4.4 mDmrtb1, mFoxb1 and mOtx2 are up-regulated by mFox1-HA 
overexpression with variable relative expression in different frogs due to SCNR 
resistance of these genes in sixiFM MEF at Day 2 after Oocyte-NT.  
























































































Figure 7.4.5 Among mFoxa1-HA unaffected genes, mLmcd1 and mFerd3l are possible 
mFoxa1-HA target genes while they are up-regulated by mFoxa1-HA overexpression in 
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(Figure leg nd is on the next page)
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7.4.4 Summary 
The overexpression of mFoxa1-HA up-regulates three neurogenic genes, 
mDmrtb1, mFoxb1 and mOtx2 and does not affect other eleven neurogenic 
genes at Day 2 after Oocyte-NT. Although these neurogenic genes are bound 
by mFoxa1/2 in the mDA neurons/progenitors during neurogenesis, they are 
regulated by the expression of mFoxa1 in the mDA neurons/progenitors 
differently from being regulated during Oocyte-NT. All in all, mFoxa1-HA 
overexpression up-regulates some target genes with high and variable 





In the early developmental processes of Xenopus laevis, relative expression 
of xfoxa1 is activated after MBT and maintained at the same level until stage 
33140,141. Additionally, mFoxa1 has been shown to be crucial for the induction 
of neurogenic genes in mDA neurons/progenitors in neurogenesis150,151. It 
seems xfoxa1 or mFoxa1 is needed for later developmental processes, such 
as lineage specification, but not for the early developmental stages before 
MBT. To examine the role of mFoxa1 during SCNR by oocytes, I 
overexpressed mFoxa1-HA and examined how it affected pluripotency genes 
and neurogenic genes after Oocyte-NT. 
 
First, I have shown that mFoxa1-HA protein can be produced from mFoxa1-
HA mRNA injected into cytosols of Xenopus oocytes time- and dose-
dependently and mFoxa1-HA proteins accumulate in the GVs after being 
produced in the cytosols from mRNA dose-dependently. Furthermore, 
SUMOylation is observed on newly-made mFoxa1-HA proteins. 
 
In terms of gene regulation, mFoxa1-HA overexpression has been shown to 
up-regulate only mSox2 in sixiFM MEF among ten selected pluripotency 
genes at Day 2 after Oocyte-NT. Therefore, mFoxa1-HA overexpression 
seems not to be important to induce pluripotency genes. For neurogenic gene 
regulation, mFoxa1-HA overexpression has been shown to up-regulate 
mDmrtb1, mFoxb1 and mOtx2 in sixiFM MEF among 14 neurogenic genes at 
Day 2 after Oocyte-NT. Interestingly, gene regulation of the same sets of 
neurogenic genes by mFoxa1-HA overexpression is different between in mDA 
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neurons/progenitors during neurogenesis and in Xenopus oocytes during 
Oocyte-NT. 
 
In conclusion, the regulation of genes by overexpression of transcription 
factors is dependent on the factors in Xenopus oocytes and chromatin 
structure of donor nuclei during SCNR by oocytes. The cooperation between 
oocyte factors and transcription factors decides the regulation of transcription 
factor target genes. In addition to that, the overexpression of transcription 
factors can up-regulate target genes with small relative expression when the 
up-regulation is an enhancement of gene expression or with huge relative 
expression when the up-regulation is an activation of genes, more specifically, 
when these genes are resistant to activation by oocyte factors. 
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Chapter 8 Discussions 
 
8.1 Introduction 
The ultimate form of nuclear reprogramming is to derive a complete normal 
adult animal, and hence all cell-types, from the nucleus of a specialized cell. 
However, nuclear transfer to eggs and induced pluripotency are successful at 
a low frequency and this obstructs attempts to understand the mechanisms 
involved. In our lab we have made use of non-dividing oocytes (egg 
progenitors) to identify some steps in the nuclear reprogramming process. 
However, somatic nuclei injected into oocytes (amphibian) do not yield adult 
animals or even functional adult cells. Therefore, to what extent can somatic 
cell nuclear transfer to oocytes be used to analyse nuclear reprogramming? 
 
Complete nuclear reprogramming requires two steps. The first is to rejuvenate 
gene expression in adult cells back to that of an embryo. This requires the 
activation of embryo-expressing genes such as Oct4 and Sox2, which are 
usually dormant in adult cells. The second requires the suppression of cell-
type-specific genes that are active in adult cells. Nuclear transfer to oocytes 
achieves the first of these steps. It also achieves several of the clearly seen 
changes in chromatin configuration, including nuclear swelling and chromatin 
dispersion153. A special advantage of nuclear transfer to amphibian oocytes is 
that the chromatin changes observed applies to almost all transplanted nuclei 
from about 300-500 cells injected into an oocyte GV154. This cannot be said of 
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nuclear transfer to eggs or of induced pluripotency. We can therefore use 
nuclear transfer to oocytes to identify the first steps of reprogramming. 
 
All of the donor nuclei used in the work described here are nuclei from 
mammalian cells. We have done this because the genome of mice is fully 
sequenced making it possible to identify genes whose expression is changed 
in these experiments. Using mouse cells to test response avoids the possible 
problem of distinguishing mouse transcripts from homologous Xenopus 
transcripts contained in the recipient Xenopus oocyte. Although cross-species 
nuclear transfer to eggs do not develop normally155, much work with induced 
pluripotency has made use of cross-species combinations.  Therefore an 
understanding of reprogramming mechanisms observed by nuclear transfer to 
oocytes (Oocyte-NT) can benefit from the cross-species interactions. 
 
In this chapter I review the effects of endogenous factors and xklf2 
overexpression, and this is specifically on those genes that are believed to be 
important in pluripotency. Then I discuss the extent to which oocyte factors 
and overexpression of transcription factors activate reprogramming-resistant 
genes. Finally, I discuss possible mechanisms involved in nuclear 
reprogramming via nuclear transfer, induced pluripotency and cell fusion.	  
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8.2 Gene reprogramming by maternal factors of Xenopus 
oocytes and by TF overexpression 
In this thesis, I have used two different procedures, namely QPCR and RNA-
seq plus BrUTP pull-down, to evaluate the effects of maternal factors and 
xklf2-HA overexpression on gene regulation and hence to measure gene 
resistance against SCNR. 
 
The first method evaluates changes in the number of transcripts of individual 
genes over two days from the time of nuclear transfer (Day 0) to two days 
later (Day 2). For this, I have used QPCR (see Materials and methods, 
Chapter 2, Page 46). By this procedure I quantitate any change in the number 
of transcripts of a particular gene. The values obtained therefore reflect the 
balance between synthesis and turnover of transcripts for a gene. The values 
represent the steady state concentration in the oocyte nucleus for that 
transcript; they include any transcripts for that gene that have been carried 
over in the injected nuclei from the donor cell population. It does not therefore 
measure directly the transcriptional activity of a gene. It is this concentration 
of a gene product which is important in influencing other downstream genes 
whose activity is dependent on the gene in question. 
 
Using the same assay (QPCR), I have also assessed the effect of 
overexpressing the Yamanaka factor, xklf2-HA. This factor was chosen 
because it was found to affect more pluripotency genes than the others, and 
because its expression level is higher in early embryos than that at later 
stages after MBT, suggesting its role as a maternal factor in oocytes.  
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The fold changes in gene expression obtained by QPCR are shown in Figure 
8.2.1, 8.2.2, 8.2.3 and 8.2.4.  For each figure, I have chosen to present the 
results for mSox2 and mOct4 separately from those for other genes because 
the values of fold change for these two genes are much higher than for the 
others. These figures obtained are also summarized in Tables 8.2.1,8.2.2, 
8.2.3, and 8.2.4. An overall summary is shown in Table 8.2.5. 
 
I should first point out that the reference point for the values obtained are 
those for mGapdh, a well-expressed housekeeping gene, whose steady state 
concentration, measured by QPCR, does not change over the two-day period. 
Compared to this, the enhanced amount of mSox2 and mOct4 transcripts is 
enormous, ranging from over 10-fold to nearly 1500-fold for the two kinds of  
fibroblast cell lines tested. Changes for other genes are mild (4- to 23-fold) or 
not significant (0.5 to 1.9-fold) – see Table 8.2.1 and Summary Table 8.2.5.   
 
If we look now at assays for the values of fold change for nuclei of 
mMyoblasts (C2C12), the results are broadly in line with what I have found for 
MEF cells. This is to say that the major effects are seen for mSox2 and mOct4 
and a mild effect on mUtf1 and mJun; other genes show no effect (Figure 
8.2.3). All these effects described reflect the activity of the oocyte’s 
endogenous factors. 
 
We can now look at the effect of overexpressing the Yamanaka factor xklf2, 
using now the Xenopus homologue. The results are shown in the figures just 
referred to as well as in Table 8.2.1.  Table 8.2.5 lists the genes in decreasing 
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order of oocyte effect from strong (mSox2 and mOct4) to, mild, weak or nil (10 
other genes).  The striking result is that, in no case, does xklf2 significantly 
affect what I have found for the strong effect (mSox2 and mOct4) by 
endogenous oocyte factors.  It can be seen that in the column headed “xkfl2-
HA overexpression” in Table 8.2.5 there is never a significant effect of xklf2, 
whose effect is remarkably similar to the strong effect (mSox2 and mOct4) in 
the column “Oocyte factors”. This suggests that the endogenous oocyte factor, 
xklf2 or its equivalent, is unlikely to be limiting in causing activation of the 
tested pluripotency genes by nuclear transfer.  If it had been limiting, its 
overexpression should have had other effects. 
 
It is particularly interesting to now compare the effect of overexpressing the 
pioneer factor, mFoxa1, in the present system. Figure 8.2.4 (small purple bars) 
shows that mFoxa1 has very little effect on mSox2 and mOct4 and no obvious 
effect on other pluripotency genes. Recall the results of mFoxa1 effect on 
neurogenic genes in Chapter 7 (Figure 7.4.1, page 269). Overexpressed 
mFoxa1 also cannot up-regulate most of these neurogenic genes in MEFs 
even these genes were proven to be its binding targets during development. It 
suggests that genes activated by overexpressed pioneer factors in Oocyte-NT 
not only require corresponding binding sites but cofactors while oocytes may 
not contain neurogenic factors that can cooperate with mFoxa1 for effective 
gene activation. 
 
Overall, at least for the genes tested, and for the nuclei of the cell types tested, 
oocyte (endogenous) factors far outweigh the importance of the Yamanaka 
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factors and pioneer factors identified by an entirely different experimental 
system. 
 
In this work, I have included a completely different assay system, RNA-seq 
plus BrUTP pull-down. As explained in the Materials and methods (Chapter 2, 
Page 47 and 48), this uses the incorporation of 5-bromo-UTP into RNA that is 
synthesized from the time of nuclear transfer for the next two days. As 
validated by Jullien et al136, this quantitates the new synthesis of transcripts by 
each gene genome wide. This is a more accurate assessment of gene 
activation by oocytes compared to QPCR. In the first part of this section, I 
have looked at the steady state concentration of a transcript, and this includes 
any “carry over” RNA from the donor cells. In contrast, the BrUTP assay takes 
no account of carry over RNA. It represents the transcriptional activity of a 
gene from its time of introduction into an oocyte to the time of assay, two days 
later. 
 
It is therefore a true measure of gene transcriptional activation. This difference 
accounts for the fact that the Ct values for mNanog and mLefty1 are close to 
Ct value of mGapdh and much lower than Ct of mSox2 and this indicates 
these two genes are considered highly expressed in donor cell types, MEFs 
and mMyos (QPCR, Table 8.2.1 and 8.2.3). After 2 days of nuclear transfer, 
the expression of these two genes is still as high as the level in donor cells 
before nuclear transfer (QPCR, Table 8.2.1 and 8.2.3). However, this high 
expression level of mNanog and mLefty1 (QPCR, Summary Table 8.2.6) is in 
contrast to the nil/low expression level reprogrammed by oocyte factors at 
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oocyte steady state in Figure 8.2.6.B, 8.2.6.C and Summary Table 8.2.7. 
Therefore, the amount of mNanog and mLefty1 transcripts, measured at Day 
2 after Oocyte-NT by QPCR, are all from carry-over in donor cells and no new 
transcript synthesis induced by oocyte factors after nuclear transfer (RNA-seq 
plus BrUTP pull-down). 
 
Considering this difference, the similar oocyte effects between data obtained 
from these two assays can therefore be seen in mESCs, MEFs and mMyos 
(Table 8.2.6 and 8.2.7). While mSox2 and mOct4 are strongly up-regulated by 
oocyte factors from Day 0 to Day 2 after Oocyte-NT in MEFs and mMyos 
(QPCR, Figure 8.2.3), the expression level of them at oocyte steady state is 
different and this difference shows the resistance of genes corresponding to 
certain cell types (RNA-seq plus BrUTP pull-down, Figure 8.2.5.A). In the 
case of mSox2, mSox2 in MEFs is reprogrammed to be highly expressed 
(FPKM>4) by oocyte factors at an oocyte-steady state but mSox2 in mMyos is 
reprogrammed to be lowly/mildly expressed (FPKM≤4) at an oocyte-steady 
state (Figure 8.2.5.A and Table 8.2.7). This is consistent to the results 
obtained by QPCR, which shows that mSox2 in MEFs is reprogrammed to 
highly expressed at Day 2 after Oocyte-NT and mSox2 in mMyos is 
reprogrammed to be lowly expressed, judged by the Ct value between mSox2 
and mGapdh (QPCR, Table8.2.3 and 8.2.6). For mOct4 in MEFs and mMyos, 
the results are also consistent by using both assays and both results show 
that mOct4 in MEFs and mMyos are reprogrammed by oocyte factors (QPCR, 
Figure 8.2.3) to be lowly expressed at an oocyte-steady state (QPCR, Table 
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8.2.3 and 8.2.6; RNA-seq plus BrUTP pull-down, Figure 8.2.5.A and Table 
8.2.7). 
 
By taking all these into account, including effect of oocyte factors from Day 0 
to Day 2 (QPCR) and expression level of genes at an oocyte-steady state 
(QPCR and RNA-seq plus BrUTP pull-dwon), mSall4, mUtf1 and mEsrrb in 
MEFs are mildly reprogrammed (QPCR, Table 8.2.5) by oocyte factors to low 
expression level at oocyte steady state (RNA-seq, Figure 8.2.6.B) and this 
means the resistance of these three genes is counteracting reprogramming by 
oocyte factors. The same comparison can also apply on mMyos and this 
shows that mUtf1, mKlf2, mSall4 and mEsrrb in mMyos are resistant to be 
reprogrammed by oocytes (Figure 8.2.6.C, Table 8.2.3, 8.2.5, 8.2.6 and 8.2.7). 
 
If we now look at the results of overexpressing xklf2-HA, using the same 
RNA-seq plus BrUTP pull-down assay, these are shown in Figure 8.2.5.B and 
8.2.6.D-F. For mESCs and MEF, only the lowest effect is seen. I should 
explain that in these figures, the values for expression of genes at an oocyte-
steady state is set at 1.0 and the significant but very mild change from those 
values are for mSox2, mOct4, mKlf2 and mSall4 for both mESC and MEF 
donor cells (Figure 8.2.5.B, 8.2.6.D-E). Additionally, the mild change is also 
seen for mEsrrb in mESCs (Figure 8.2.6.D) and mUtf1 in MEFs (Figure 
8.2.6.E). For mMyo cells, xklf2 has a very large effect on mSox2, mOct4, 
mKlf2 and mSall4 and a medium effect on mEsrrb (Figure 8.2.5.B and 
8.2.6.F). Since xklf2-HA overexpression is most effective to activate 
reprogramming resistant genes from nil/low expression level by more fold 
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change, it means the resistance of mSox2, mOct4, mKlf2 and mSall4 in 
mMyos is stronger than resistance of these genes in mESCs and MEFs 
(Table 8.2.6.B). Therefore, overexpression of TFs in Oocyte-NT system can 
reveal the different levels of gene resistance between cell types. 
 
In summary, certain genes, including mSox and mOct4, show a huge up-
regulation by endogenous oocyte factors, with very little further up-regulation 
by overexpressed xklf2-HA when the genes are reprogrammed to an oocyte-
steady state successfully by oocyte factors. A mild response to endogenous 
factors is seen for five other genes, and a weak or nil response by a further 
five genes. Again, the strong xklf2-HA overexpression effect is seen when 
genes resistant to activation by oocyte factors. This conclusion applies to the 
steady state level of RNA transcripts.  When gene activation, as opposed to a 
steady state value is analysed, similar conclusions apply. Nuclei of mMyos 
show a similar response to those of MEF cells. It is also interesting that the 
pioneer factor mFox1a1 only enhances the expression of mSox2 and mOct4 
but not other genes. Therefore, pioneer factor mFoxa1 cannot change the 





Figure 8.2.1.A-B In sixiFM MEFs, oocyte factors strongly up-regulate expression of 
mSox2 and mOct4 by up to 545-fold and mildly up-regulate expression of mKlf4, mUtf1, 
mSall4, mEsrrb from Day 0 to Day 2 after Oocyte-NT. xklf2-HA overexpression mildly 
up-regulates expression of mOct4 by 13-fold and weakly up-regulates expression of 
mSox2, mKlf4 and mUtf1 by up to 3.3-fold (sixiFM, n=3, Table 8.2.1). 
Fold change more than 2 is shown in red. 
Expression of mGapdh is not changed after Oocyte-NT and not affected by oocyte factors or 
xklf2-HA overexpression.  
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Factor tested: Oocyte (maternal) and xklf2-HA overexpression
Gene response: A. mSox2 and mOct4
                            B. Other pluripotency genes
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Figure 8.2.1.C-D In TcR2 MEFs, oocyte factors strongly up-regulate expression of 
mSox2 and mOct4 by up to 85-fold and mildly up-regulate expression of mUtf1 and 
mJun by up to 14-fold. xklf2-HA overexpression mildly up-regulates expression of 
mSox2 by 6.2-fold and weakly up-regulates expression of mOct4 by 3.2-fold (TcR2, n=2 
or 3, Table 8.2.1). 
Fold change more than 2 is shown in red.  
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Figure 8.2.2 Pluripotency genes in different MEF cell lines, namely sixiFM and TcR2, 
respond to oocyte factors and xklf2-HA overexpression similarly (n=1, Table 8.2.2). 
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Figure 8.2.3 mSox2 and mOct4 in mMyoblast respond to oocyte factors stronger than 
MEF (n=1, Table 8.2.3). 
Fold change more than 2 is shown in red. mUtf1 in mMyoblasts is not up-regulated by oocyte 
factors and mOct4 in mMyoblasts is not up-regulated by xklf2-HA overexpression due to 
SCNR resistance. 
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Expression level at Day 0 (carry-over of mouse transcripts) 
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Figure 8.2.4 xklf2-HA overexpression can up-regulate more pluripotency genes than 
mFoxa1-HA overexpression (n=1, Table 8.2.4). 
mEsrrb is not up-regulated by oocyte factors due to SCNR resistance. mNanog is only up-
regulated by oocyte factors in this batch of oocytes but is not up-regulated in other oocyte 
batches. After normalization by mGapdh for cell number difference in each Oocyte-NT 







Factor tested: Oocyte (maternal) and overexpression of xklf2-HA and mFoxa1-HA
Gene response: A. mSox2 and mOct4
                            B. Other pluripotency genes
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Figure 8.2.5 mSox2 and mOct4 in mMyo-NT is resistant to be activated by oocyte 
factors and hence respond strongly to xklf2-HA overexpression at Day 2 after Oocyte-
NT. 
nd, not detectable by RNA-seq, FPKM=0; *FDR<0.1 
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Transcript assay: RNA-seq plus BrUTP pull-down
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                         B. xklf2-HA overexpression
Gene response: mSox2 and mOct4 at Day 2 after Oocyte-NT
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Transcript assay: RNA-seq plus BrUTP pull-down
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Gene response: Other pluripotency genes at Day 2 after Oocyte-NT
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Figure 8.2.6 The highest up-regulation of mKlf2 and mSall4 in mMyo-NT induced by 
xklf2-HA overexpression indicates mKlf2 and mSall4 in mMyo-NT have strongest SCNR 
resistance than the same genes in mESC-NT and MEF-NT. 
(A-C) Most pluripotency genes are expressed highly in mESC-NT while some pluripotency 
genes in mMyo-NT fail to be activated by oocyte factors. 
nd, not detectable by RNA-seq, FPKM=0 
(D-E) mKlf2 and mSall4 in mMyo-NT respond most strongly to xklf2-HA overexpression due 
to the strongest SCNR resistance of them than those in mESC-NT and MEF-NT. 
ND, not determined; *FDR<0.1   
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Table 8.2.1 QPCR analysis shows the effects of maternal factors from Day 0 to Day 2 
and xklf2-HA overexpression at Day 2 after Oocyte-NT on pluripotency genes in MEF 
(sixiFM, n=3) and MEF (TcR2, n=2 or 3). 
Fold change more than 2 is shown in red. Fold change more than 4 has background in pink. 
# For each sample, Ct value for mOct4 in MEF (sixiFM) at 0 hour (in bold with underline) is 
assigned as Ct value for mGapdh plus 15, referring to the Ct value for mOct4 in MEF (TcR2) 




Day 0 Day 2 Day 2
mGapdh 25 25 25 0.9 1.1
mSox2 34 27 25 165 3.0
mOct4 40# 34 29 91 24
mKlf4 30 28 26 5.5 2.5
mUtf1 34 30 29 12 2.1
mSall4 34 31 26 7.8 22
mKlf2 27 27 26 0.7 1.8
mEsrrb 32 31 31 1.9 0.8
mNanog 26 27 27 0.5 0.8
mFbxo15 31 32 32 0.5 1.6
mGapdh 27 28 27 0.7 2.0
mSox2 37 28 26 363 5.3
mOct4 43# 37 33 67 13
mKlf4 32 30 28 5.6 2.8
mUtf1 34 31 30 8.1 2.3
mSall4 37 33 30 14 10
mKlf2 30 30 29 1.0 1.5
mEsrrb 34 34 34 1.1 1.3
mNanog 33 32 32 2.4 1.0
mFbxo15 35 35 35 1.0 0.9
mGapdh 24 24 24 1.4 0.9
mSox2 33 24 24 296 1.8
mOct4 39# 29 28 1476 1.3
mKlf4 29 26 26 8.3 1.4
mUtf1 32 29 28 10 1.5
mSall4 34 29 25 23 14
mKlf2 27 26 26 1.7 1.0
mEsrrb 32 28 29 19 0.5
mNanog 26 26 26 1.7 0.9
mFbxo15 32 32 32 1.3 0.8
mGAPDH 21 21 21 1.1 1.0
mSox2 29 25 22 11 9.6
mOct4 36 30 29 86 1.8
mNanog 30 29 28 1.8 1.3
mUtf1 28 24 23 24 1.7
mJun 28 25 24 9.3 1.5
mLefty1 24 24 24 1.3 1.2
mMyc 17 17 17 1.0 1.1
mGAPDH 21 22 22 0.8 0.7
mSox2 29 24 23 32 2.02
mOct4 36 32 30 21 3.8
mNanog 27 27 27 1.2 1.0
mGAPDH 25 26 26 0.7 0.6
mUtf1 32 30 30 4.1 1.0
mJun 31 29 29 4.5 1.1
mLefty1 28 28 28 1.2 0.8
mMyc 22 21 22 1.3 0.7
mGAPDH 22 22 22 0.9 1.0
mSox2 30 24 22 59 7.1
mOct4 38 31 29 152 4.1

















Cell typeOocyte factors Oocyte factors 





Table 8.2.2 QPCR analysis shows the effects of oocyte factors from Day 0 to Day 3 
after Oocyte-NT and xklf2-HA overexpression at Day 3 after Oocyte-NT on pluripotency 
genes in MEF (sixiFM, n=1) and MEF (TcR2, n=1). 
Fold change more than 2 is shown in red. Fold change more than 4 has background in pink. 
# Ct value for mOct4 in MEF (sixiFM and TcR2) at 0 hour (in bold with underline) is assigned 
as Ct for mGapdh plus 15, referring to the average Ct difference between mOct4 and 







Day 0 Day 3 Day 3
mGapdh 21 20 20 2.1 0.7
mSox2 35 22 22 5503 1.1
mOct4 36# 34 32 3.6 3.4
mNanog 29 28 29 1.9 0.5
mUtf1 29 24 25 28 0.1
mJun 27 22 22 51 0.5
mLefty1 29 29 30 0.7 0.7
mMyc 17 17 17 1.3 0.8
mGapdh 20 20 19 1.6 1.1
mSox2 31 22 20 645 2.7
mOct4 35# 33 31 4.1 3.8
mNanog 28 29 29 0.9 0.7
mUtf1 29 25 24 19 1.2
mJun 26 22 22 22 0.6
mLefty1 28 29 29 0.8 0.9










Oocyte factors Oocyte factors 





Gene expression (Ct) and culture period
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Table 8.2.3 QPCR analysis shows the effects of oocyte factors from Day 0 to Day 2 
after Oocyte-NT and xklf2-HA overexpression at Day 2 after Oocyte-NT on pluripotency 
genes in MEF (TcR2, n=1) and mMyoblast (C2C12, n=1). 








Day 0 Day 2 Day 2
mGapdh 21 22 22 0.8 0.7
mSox2 29 24 23 32 2.0
mOct4 36 32 30 21 3.8
mNanog 27 27 27 1.2 1.0
mGapdh 21 21 21 0.8 1.1
mSox2 39 30 27 487 8.0
mOct4 39 30 29 368 1.7
mNanog 26 26 27 1.1 0.7
mGAPDH 25 26 26 0.7 0.6
mUtf1 32 30 30 4.1 1.0
mJun 31 29 29 4.5 1.1
mLefty1 28 28 28 1.2 0.8
mMyc 22 21 22 1.3 0.7
mGAPDH 25 25 25 0.8 1.1
mUtf1 32 32 32 0.8 1.0
mJun 31 29 30 3.4 0.5
mLefty1 28 29 29 0.7 1.0









Oocyte factors Oocyte factors 





TF Frog no. Gene




Table 8.2.4 QPCR analysis shows the effects of oocyte factors from Day 0 to 2 Day 2 
after Oocyte-NT and TF overexpression (xklf2-HA and mFoxa1-HA) at Day 2 after 
Oocyte-NT on pluripotency genes in MEF (sixiFM, n=1). 
Fold change more than 2 is shown in red. Fold change more than 4 has background in pink. 
# Ct value for mOct4 in MEF (sixiFM and TcR2) at 0 hour (in bold with underline) is assigned 
as Ct for mGapdh plus 15, referring to the average Ct difference between mOct4 and 





Day 0 Day 2 Day 2
mGapdh 27 28 27 0.7 1.98
mSox2 37 28 26 363 5.3
mOct4 43 37 33 67 13
mKlf4 32 30 28 5.6 2.8
mUtf1 34 31 30 8.1 2.3
mSall4 37 33 30 14 10
mKlf2 30 30 29 1.0 1.5
mEsrrb 34 34 34 1.1 1.3
mNanog 33 32 32 2.4 1.0
mFbxo15 35 35 35 1.0 0.9
mGapdh 27 27 26 1.4 1.4
mSox2 37 27 25 1011 3.7
mOct4 43 35 33 250 4.0
mKlf4 32 29 28 9.9 2.5
mUtf1 34 30 29 20 1.8
mSall4 37 32 31 36 1.7
mKlf2 30 29 29 1.6 0.9
mEsrrb 34 33 32 3.0 1.3
mNanog 33 32 32 2.4 1.0





TF Frog no. Gene
Gene expression (Ct) and culture period Fold change by
Cell typeOocyte factors Oocyte factors 





Table 8.2.5 Summary of QPCR analysis shows that, in MEF (sixiFM and TcR2), mSox2 
and mOct4 are strongly up-regulated by oocyte factors with average fold change from 
86 to 154 and 5 other tested pluripotency genes are mildly up-regulated. Comparably, 3 
tested pluripotency genes mildly respond to xklf2-HA overexpression with average fold 
change from 4.8 to 15 and mKlf4 weakly responds to xklf2-HA overexpression with 






Factor tested: Oocyte (maternal) and xklf2-HA overexpression
Gene response: level of reponse for all pluripotencyy genes
Cell type: MEF (sixiFM and TcR2)
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mNanog 1-6 1.5 1.1






mKlf2 1-3 1.1 1.4
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Table 8.2.6 QPCR analysis measures the expression level of pluripotency genes in 
MEFs and mMyos reprogrammed by oocytes factors at Day 2 after Oocyte-NT (A) and 





Factor tested: A. Oocyte (maternal)
                         B. xklf2-HA overexpression
Gene response: level of reponse for all pluripotencyy genes at Day 2 after Oocyte-NT
Cell type: MEF (sixiFM and TcR2), mMyo
Table 8.2.6
(CtmGapdh-CtGene)≤3 3<(CtmGapdh-CtGene)≤6 (CtmGapdh-CtGene)>6











(8.2.3) 2/8 3/8 3/8
MEF
(8.2.1) 6/13 5/13 2/13
Effect of oocte factors at Day 2 after Oocyte-NT
Reprogrammed expression level of pluripotency genes and mGapdh
High Medium Low/nil
Cell type (Tables)
No. of genes Gene No. of genes Gene No. of genes Gene No. of genes Gene
mSox2 mGapdh mSox2 mGapdh




















Effect of xklf2-HA overexpression at Day 2 after Oocyte-NT
Cell type 
(Figures)













Table 8.2.7 RNA-seq plus BrUTP pull-down measures the relative amount of newly 
synthesized transcripts (FPKM) at an oocyte steady state at Day 2 after Oocyte-NT. 
SCNR resistance of pluripotency genes can be judged by response of different cell 




Transcript assay: RNA-seq plus BrUTP pull-down
Factor tested: A. Oocyte (maternal)
                         B. xklf2-HA overexpression
Gene response: level of reponse for all pluripotency genes at Day 2 after Oocyte-NT
Cell type: mESC, MEF (sixiFM), mMyo






























High (FPKM>4) Medium (1 FPKM 4) Low/nil (FPKM<1)
Reprogrammed expression level of pluripotency genes and mGapdh
Cell type (Figures)







Effect of xklf2-HA overexpressioin at Day 2 after Oocyte-NT
Cell type (Figures)
Resistance of pluripotency genes













8.3 Cell-hybrid experiments 
Cell fusion or cell hybrids were first made by Okada, Y156-158 and gained wide 
interest after the results of Harris, H159,160 in the 1960s. There are several 
designs of experiments. In one, two whole single-cells are fused such that 
there are, initially, two nuclei enclosed in the mixed cytoplasm of two cells. 
These hybrids can be grown with much cell division and much selection. They 
are not particularly useful for analyzing early events that affect gene 
expression by these hybrids. 
 
Another design of experiment yields heterokaryons. These, again, are initially 
two nuclei in the fused cytoplasm of two cells, but these hybrid cells are not 
grown, but are cultured for a few days. These are the most useful experiments 
for comparison with nuclear transfer to amphibian oocytes. In some cases, a 
cell can be fused with the enucleated cytoplasm of another cell, called a 
cytoplast. Also, the ratio of number of nuclei to number of cytoplasms can be 
varied. Also, the amount of cytoplasm relative to nucleus can be varied by 
using the nuclei of red blood cells, which are very small, fused to cultured 
cells which are usually large. The two laboratories which have done the 
greatest amount of work with heterokaryons are those of Fisher (London) and 
Blau (Standford). Commonly, these experiments involved combining cells of 
two different species so that genes in one species can be seen to be activated 
by the cytoplasm of another. 
 
An early impressive experiment was that of Blau. This involved the fusion of a 
human hepatocyte with a mouse muscle cell42,44. It was found that, in this 
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heterokaryon, a human muscle antigen was expressed due to the inclusion of 
cytoplasm from a mouse muscle cell. In this case, the amount of mouse 
cytoplasm far exceeded that of the human hepatocyte cytoplasm because 
mouse cells are multinucleate. An advantage of this design of experiments is 
that the hybrid cells are not allowed to replicate DNA or divide (use of 
inhibitors) so that there is no loss of chromosomes during the incubation 
period. Also, mouse and human muscle genes can be distinguished by 
antibodies. 
 
Some of the points which emerge from this heterokaryon work are 
1. Gene activation is much influenced by an excess of cytoplasm from 
one cell partner to another. 
2. The two kinds of nuclei do not fuse and therefore can be readily 
distinguished, thereby giving attention to only those heterokaryons 
which contain one original cell of each type. 
3. Cell-type specific factors from one kind of cell operate functionally on 
another kind of cell, even if both are from unrelated animal species. 
4. The new gene activation takes place within a few days. 
 
There has been much discussion in the literature on the question of whether 
DNA synthesis and/or cell division are required for the transactivation of the 
gene of one species by the cytoplasm of another. In the experiments of Blau, 
it is clear that DNA synthesis and cell division are not required42,44. 
Conversely, in the experiments of Fisher, it is maintained that DNA synthesis 
and cell division are absolutely necessary161. For comparison, it is very clear 
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that, in nuclear injection to oocytes, no DNA synthesis or cell division is 
involved. 
 
In the experiments of Fisher, it is argued that the discontinuation of cell-type 
specific gene expression is involved in any reprogramming162,163. It is also 
argued that the gene Oct4 has to be expressed in the reprogramming process 
for other genes to be activated162. The extent and frequency of gene 




Chapter 9 References 
1 Buganim, Y., Faddah, D. A. & Jaenisch, R. Mechanisms and models of 
somatic cell reprogramming. Nature reviews. Genetics 14, 427-439, 
doi:10.1038/nrg3473 (2013). 
2 Vierbuchen, T. & Wernig, M. Molecular roadblocks for cellular 
reprogramming. Molecular cell 47, 827-838, 
doi:10.1016/j.molcel.2012.09.008 (2012). 
3 Shi, Y., Inoue, H., Wu, J. C. & Yamanaka, S. Induced pluripotent stem 
cell technology: a decade of progress. Nat Rev Drug Discov 16, 115-
130, doi:10.1038/nrd.2016.245 (2017). 
4 Jopling, C., Boue, S. & Izpisua Belmonte, J. C. Dedifferentiation, 
transdifferentiation and reprogramming: three routes to regeneration. 
Nature reviews. Molecular cell biology 12, 79-89, doi:10.1038/nrm3043 
(2011). 
5 Matoba, S. & Zhang, Y. Somatic Cell Nuclear Transfer Reprogramming: 
Mechanisms and Applications. Cell stem cell 23, 471-485, 
doi:10.1016/j.stem.2018.06.018 (2018). 
6 Lu, F. & Zhang, Y. Cell totipotency: molecular features, induction, and 
maintenance. Natl Sci Rev 2, 217-225, doi:10.1093/nsr/nwv009 (2015). 
7 Hochedlinger, K. & Jaenisch, R. Monoclonal mice generated by nuclear 
transfer from mature B and T donor cells. Nature 415, 1035-1038, 
doi:10.1038/nature718 (2002). 
8 Eggan, K. et al. Mice cloned from olfactory sensory neurons. Nature 
428, 44-49, doi:10.1038/nature02375 (2004). 
9 Gurdon, J. B. & Wilmut, I. Nuclear transfer to eggs and oocytes. Cold 
Spring Harb Perspect Biol 3, doi:10.1101/cshperspect.a002659 (2011). 
10 Briggs, R. & King, T. J. Transplantation of Living Nuclei from Blastula 
Cells into Enucleated Frogs Eggs. Proceedings of the National 
Academy of Sciences of the United States of America 38, 455-463, 
doi:DOI 10.1073/pnas.38.5.455 (1952). 
11 King, T. J. & Briggs, R. Changes in the Nuclei of Differentiating 
Gastrula Cells, as Demonstrated by Nuclear Transplantation. 
Proceedings of the National Academy of Sciences of the United States 
of America 41, 321-325 (1955). 
12 Gurdon, J. B., Elsdale, T. R. & Fischberg, M. Sexually mature 
individuals of Xenopus laevis from the transplantation of single somatic 
nuclei. Nature 182, 64-65 (1958). 
13 Gurdon, J. B. The developmental capacity of nuclei taken from 
intestinal epithelium cells of feeding tadpoles. J Embryol Exp Morphol 
10, 622-640 (1962). 
14 Gurdon, J. B. Adult frogs derived from the nuclei of single somatic cells. 
Developmental biology 4, 256-273 (1962). 
15 Gurdon, J. B. & Uehlinger, V. "Fertile" intestine nuclei. Nature 210, 
1240-1241 (1966). 
16 Wilmut, I., Schnieke, A. E., McWhir, J., Kind, A. J. & Campbell, K. H. S. 
Viable offspring derived from fetal and adult mammalian cells. Nature 
385, 810-813, doi:DOI 10.1038/385810a0 (1997). 
	 304	
17 Liu, Z. et al. Cloning of Macaque Monkeys by Somatic Cell Nuclear 
Transfer. Cell 174, 245, doi:10.1016/j.cell.2018.01.036 (2018). 
18 Cibelli, J. B. & Gurdon, J. B. Custom-Made Oocytes to Clone Non-
human Primates. Cell 172, 647-649, doi:10.1016/j.cell.2018.01.030 
(2018). 
19 Alberio, R., Johnson, A. D., Stick, R. & Campbell, K. H. Differential 
nuclear remodeling of mammalian somatic cells by Xenopus laevis 
oocyte and egg cytoplasm. Experimental cell research 307, 131-141, 
doi:10.1016/j.yexcr.2005.02.028 (2005). 
20 Bian, Y., Alberio, R., Allegrucci, C., Campbell, K. H. & Johnson, A. D. 
Epigenetic marks in somatic chromatin are remodelled to resemble 
pluripotent nuclei by amphibian oocyte extracts. Epigenetics 4, 194-202 
(2009). 
21 Miyamoto, K. et al. Cell-free extracts from mammalian oocytes partially 
induce nuclear reprogramming in somatic cells. Biology of reproduction 
80, 935-943, doi:10.1095/biolreprod.108.073676 (2009). 
22 Bui, H. T. et al. Epigenetic reprogramming in somatic cells induced by 
extract from germinal vesicle stage pig oocytes. Development 139, 
4330-4340, doi:10.1242/dev.086116 (2012). 
23 Yamanaka, S. & Blau, H. M. Nuclear reprogramming to a pluripotent 
state by three approaches. Nature 465, 704-712, 
doi:10.1038/nature09229 (2010). 
24 Martello, G. & Smith, A. The nature of embryonic stem cells. Annu Rev 
Cell Dev Biol 30, 647-675, doi:10.1146/annurev-cellbio-100913-013116 
(2014). 
25 Boskovic, A. et al. Higher chromatin mobility supports totipotency and 
precedes pluripotency in vivo. Genes & development 28, 1042-1047, 
doi:10.1101/gad.238881.114 (2014). 
26 Hanna, J. H., Saha, K. & Jaenisch, R. Pluripotency and cellular 
reprogramming: facts, hypotheses, unresolved issues. Cell 143, 508-
525, doi:10.1016/j.cell.2010.10.008 (2010). 
27 Nichols, J. & Smith, A. Naive and primed pluripotent states. Cell stem 
cell 4, 487-492, doi:10.1016/j.stem.2009.05.015 (2009). 
28 Gafni, O. et al. Derivation of novel human ground state naive 
pluripotent stem cells. Nature 504, 282-+, doi:10.1038/nature12745 
(2013). 
29 Takashima, Y. et al. Resetting transcription factor control circuitry 
toward ground-state pluripotency in human. Cell 158, 1254-1269, 
doi:10.1016/j.cell.2014.08.029 (2014). 
30 Warrier, S. et al. Direct comparison of distinct naive pluripotent states 
in human embryonic stem cells. Nature communications 8, 15055, 
doi:10.1038/ncomms15055 (2017). 
31 Stadtfeld, M. & Hochedlinger, K. Induced pluripotency: history, 
mechanisms, and applications. Genes & development 24, 2239-2263, 
doi:10.1101/gad.1963910 (2010). 
32 Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from 
mouse embryonic and adult fibroblast cultures by defined factors. Cell 
126, 663-676, doi:10.1016/j.cell.2006.07.024 (2006). 
	 305	
33 Okita, K., Ichisaka, T. & Yamanaka, S. Generation of germline-
competent induced pluripotent stem cells. Nature 448, 313-317, 
doi:10.1038/nature05934 (2007). 
34 Hanna, J. et al. Direct reprogramming of terminally differentiated 
mature B lymphocytes to pluripotency. Cell 133, 250-264, 
doi:10.1016/j.cell.2008.03.028 (2008). 
35 Choi, J. et al. A comparison of genetically matched cell lines reveals 
the equivalence of human iPSCs and ESCs. Nature biotechnology 33, 
1173-1181, doi:10.1038/nbt.3388 (2015). 
36 Do, J. T., Han, D. W. & Scholer, H. R. Reprogramming somatic gene 
activity by fusion with pluripotent cells. Stem Cell Rev 2, 257-264, 
doi:10.1007/BF02698052 (2006). 
37 Do, J. T. & Scholer, H. R. Nuclei of embryonic stem cells reprogram 
somatic cells. Stem cells 22, 941-949, doi:10.1634/stemcells.22-6-941 
(2004). 
38 Silva, J., Chambers, I., Pollard, S. & Smith, A. Nanog promotes transfer 
of pluripotency after cell fusion. Nature 441, 997-1001, 
doi:10.1038/nature04914 (2006). 
39 Freberg, C. T., Dahl, J. A., Timoskainen, S. & Collas, P. Epigenetic 
reprogramming of OCT4 and NANOG regulatory regions by embryonal 
carcinoma cell extract. Molecular biology of the cell 18, 1543-1553, 
doi:10.1091/mbc.E07-01-0029 (2007). 
40 Foshay, K. M. et al. Embryonic stem cells induce pluripotency in 
somatic cell fusion through biphasic reprogramming. Molecular cell 46, 
159-170, doi:10.1016/j.molcel.2012.02.013 (2012). 
41 Aloia, L., McKie, M. A. & Huch, M. Cellular plasticity in the adult liver 
and stomach. The Journal of physiology 594, 4815-4825, 
doi:10.1113/JP271769 (2016). 
42 Blau, H. M., Chiu, C. P. & Webster, C. Cytoplasmic activation of human 
nuclear genes in stable heterocaryons. Cell 32, 1171-1180 (1983). 
43 Chiu, C. P. & Blau, H. M. Reprogramming cell differentiation in the 
absence of DNA synthesis. Cell 37, 879-887 (1984). 
44 Blau, H. M. et al. Plasticity of the differentiated state. Science 230, 758-
766 (1985). 
45 Ieda, M. et al. Direct reprogramming of fibroblasts into functional 
cardiomyocytes by defined factors. Cell 142, 375-386, 
doi:10.1016/j.cell.2010.07.002 (2010). 
46 Margariti, A. et al. Direct reprogramming of fibroblasts into endothelial 
cells capable of angiogenesis and reendothelialization in tissue-
engineered vessels. Proceedings of the National Academy of Sciences 
of the United States of America 109, 13793-13798, 
doi:10.1073/pnas.1205526109 (2012). 
47 Zhu, J. et al. Genome-wide chromatin state transitions associated with 
developmental and environmental cues. Cell 152, 642-654, 
doi:10.1016/j.cell.2012.12.033 (2013). 
48 Yadav, T., Quivy, J. P. & Almouzni, G. Chromatin plasticity: A versatile 
landscape that underlies cell fate and identity. Science 361, 1332-+, 
doi:10.1126/science.aat8950 (2018). 
	 306	
49 Barrero, M. J., Boue, S. & Belmonte, J. C. I. Epigenetic Mechanisms 
that Regulate Cell Identity. Cell stem cell 7, 565-570, 
doi:10.1016/j.stem.2010.10.009 (2010). 
50 Theunissen, T. W. & Jaenisch, R. Molecular control of induced 
pluripotency. Cell stem cell 14, 720-734, 
doi:10.1016/j.stem.2014.05.002 (2014). 
51 Apostolou, E. & Hochedlinger, K. Chromatin dynamics during cellular 
reprogramming. Nature 502, 462-471, doi:10.1038/nature12749 (2013). 
52 Papp, B. & Plath, K. Epigenetics of reprogramming to induced 
pluripotency. Cell 152, 1324-1343, doi:10.1016/j.cell.2013.02.043 
(2013). 
53 Seisenberger, S. et al. Reprogramming DNA methylation in the 
mammalian life cycle: building and breaking epigenetic barriers. Philos 
Trans R Soc Lond B Biol Sci 368, 20110330, 
doi:10.1098/rstb.2011.0330 (2013). 
54 Messerschmidt, D. M., Knowles, B. B. & Solter, D. DNA methylation 
dynamics during epigenetic reprogramming in the germline and 
preimplantation embryos. Genes & development 28, 812-828, 
doi:10.1101/gad.234294.113 (2014). 
55 Seisenberger, S., Peat, J. R. & Reik, W. Conceptual links between 
DNA methylation reprogramming in the early embryo and primordial 
germ cells. Curr Opin Cell Biol 25, 281-288, 
doi:10.1016/j.ceb.2013.02.013 (2013). 
56 Broske, A. M. et al. DNA methylation protects hematopoietic stem cell 
multipotency from myeloerythroid restriction. Nat Genet 41, 1207-1215, 
doi:10.1038/ng.463 (2009). 
57 Chen, G. et al. Single-cell analyses of X Chromosome inactivation 
dynamics and pluripotency during differentiation. Genome Res 26, 
1342-1354, doi:10.1101/gr.201954.115 (2016). 
58 De Carvalho, D. D., You, J. S. & Jones, P. A. DNA methylation and 
cellular reprogramming. Trends Cell Biol 20, 609-617, 
doi:10.1016/j.tcb.2010.08.003 (2010). 
59 Looney, T. J. et al. Systematic mapping of occluded genes by cell 
fusion reveals prevalence and stability of cis-mediated silencing in 
somatic cells. Genome Res 24, 267-280, doi:10.1101/gr.143891.112 
(2014). 
60 Chiu, C. P. & Blau, H. M. 5-Azacytidine permits gene activation in a 
previously noninducible cell type. Cell 40, 417-424 (1985). 
61 Mikkelsen, T. S. et al. Dissecting direct reprogramming through 
integrative genomic analysis. Nature 454, 49-55, 
doi:10.1038/nature07056 (2008). 
62 Bhutani, N. et al. Reprogramming towards pluripotency requires AID-
dependent DNA demethylation. Nature 463, 1042-1047, 
doi:10.1038/nature08752 (2010). 
63 Rais, Y. et al. Deterministic direct reprogramming of somatic cells to 
pluripotency. Nature 502, 65-70, doi:10.1038/nature12587 (2013). 
64 Lee, D. S. et al. An epigenomic roadmap to induced pluripotency 
reveals DNA methylation as a reprogramming modulator. Nature 
communications 5, 5619, doi:10.1038/ncomms6619 (2014). 
	 307	
65 Buschbeck, M. & Hake, S. B. Variants of core histones and their roles 
in cell fate decisions, development and cancer. Nature reviews. 
Molecular cell biology 18, 299-314, doi:10.1038/nrm.2016.166 (2017). 
66 Pasque, V. et al. Histone variant macroH2A marks embryonic 
differentiation in vivo and acts as an epigenetic barrier to induced 
pluripotency. Journal of cell science 125, 6094-6104, 
doi:10.1242/jcs.113019 (2012). 
67 Almouzni, G. & Wolffe, A. P. Replication-coupled chromatin assembly 
is required for the repression of basal transcription in vivo. Genes & 
development 7, 15 (1993). 
68 Filion, G. J. et al. Systematic protein location mapping reveals five 
principal chromatin types in Drosophila cells. Cell 143, 212-224, 
doi:10.1016/j.cell.2010.09.009 (2010). 
69 Benayoun, B. A. et al. H3K4me3 breadth is linked to cell identity and 
transcriptional consistency. Cell 158, 673-688, 
doi:10.1016/j.cell.2014.06.027 (2014). 
70 Becker, J. S., Nicetto, D. & Zaret, K. S. H3K9me3-Dependent 
Heterochromatin: Barrier to Cell Fate Changes. Trends Genet 32, 29-
41, doi:10.1016/j.tig.2015.11.001 (2016). 
71 Matoba, S. et al. Embryonic development following somatic cell nuclear 
transfer impeded by persisting histone methylation. Cell 159, 884-895, 
doi:10.1016/j.cell.2014.09.055 (2014). 
72 Becker, J. S. et al. Genomic and Proteomic Resolution of 
Heterochromatin and Its Restriction of Alternate Fate Genes. Molecular 
cell 68, 1023-1037 e1015, doi:10.1016/j.molcel.2017.11.030 (2017). 
73 Chen, T. & Dent, S. Y. Chromatin modifiers and remodellers: regulators 
of cellular differentiation. Nature reviews. Genetics 15, 93-106, 
doi:10.1038/nrg3607 (2014). 
74 Onder, T. T. et al. Chromatin-modifying enzymes as modulators of 
reprogramming. Nature 483, 598-U119, doi:10.1038/nature10953 
(2012). 
75 Cheloufi, S. et al. The histone chaperone CAF-1 safeguards somatic 
cell identity. Nature 528, 218-224, doi:10.1038/nature15749 (2015). 
76 Ishiuchi, T. et al. Early embryonic-like cells are induced by 
downregulating replication-dependent chromatin assembly. Nat Struct 
Mol Biol 22, 662-671, doi:10.1038/nsmb.3066 (2015). 
77 Qin, H. et al. Systematic identification of barriers to human iPSC 
generation. Cell 158, 449-461, doi:10.1016/j.cell.2014.05.040 (2014). 
78 Winzi, M., Paszkowski-Rogacz, M. & Buchholz, F. Another Brick in the 
Wall: RNAi Screens Identify New Barriers in iPSC Reprogramming. 
Cell stem cell 15, 116-118, doi:10.1016/j.stem.2014.07.008 (2014). 
79 Yang, C. S., Chang, K. Y. & Rana, T. M. Genome-wide functional 
analysis reveals factors needed at the transition steps of induced 
reprogramming. Cell Rep 8, 327-337, doi:10.1016/j.celrep.2014.07.002 
(2014). 
80 Egli, D., Birkhoff, G. & Eggan, K. Mediators of reprogramming: 
transcription factors and transitions through mitosis. Nature reviews. 
Molecular cell biology 9, 505-516, doi:10.1038/nrm2439 (2008). 
81 Xu, Y. et al. Transcriptional Control of Somatic Cell Reprogramming. 
Trends Cell Biol 26, 272-288, doi:10.1016/j.tcb.2015.12.003 (2016). 
	 308	
82 Thomas, S. et al. Dynamic reprogramming of chromatin accessibility 
during Drosophila embryo development. Genome biology 12, R43, 
doi:10.1186/gb-2011-12-5-r43 (2011). 
83 Kaplan, T. et al. Quantitative models of the mechanisms that control 
genome-wide patterns of transcription factor binding during early 
Drosophila development. PLoS genetics 7, e1001290, 
doi:10.1371/journal.pgen.1001290 (2011). 
84 Li, X. Y. et al. The role of chromatin accessibility in directing the 
widespread, overlapping patterns of Drosophila transcription factor 
binding. Genome biology 12, R34, doi:10.1186/gb-2011-12-4-r34 
(2011). 
85 Adamson, E. D. & Woodland, H. R. Histone synthesis in early 
amphibian development: histone and DNA syntheses are not co-
ordinated. Journal of molecular biology 88, 263-285 (1974). 
86 Amodeo, A. A., Jukam, D., Straight, A. F. & Skotheim, J. M. Histone 
titration against the genome sets the DNA-to-cytoplasm threshold for 
the Xenopus midblastula transition. Proceedings of the National 
Academy of Sciences of the United States of America 112, E1086-
1095, doi:10.1073/pnas.1413990112 (2015). 
87 Joseph, S. R. et al. Competition between histone and transcription 
factor binding regulates the onset of transcription in zebrafish embryos. 
Elife 6, doi:10.7554/eLife.23326 (2017). 
88 Niwa, H., Miyazaki, J. & Smith, A. G. Quantitative expression of Oct-3/4 
defines differentiation, dedifferentiation or self-renewal of ES cells. Nat 
Genet 24, 372-376, doi:10.1038/74199 (2000). 
89 Kopp, J. L., Ormsbee, B. D., Desler, M. & Rizzino, A. Small increases 
in the level of Sox2 trigger the differentiation of mouse embryonic stem 
cells. Stem cells 26, 903-911, doi:10.1634/stemcells.2007-0951 (2008). 
90 Nishimura, K. et al. Manipulation of KLF4 expression generates iPSCs 
paused at successive stages of reprogramming. Stem Cell Reports 3, 
915-929, doi:10.1016/j.stemcr.2014.08.014 (2014). 
91 Yu, J. et al. Induced pluripotent stem cell lines derived from human 
somatic cells. Science 318, 1917-1920, doi:10.1126/science.1151526 
(2007). 
92 Vivien, C. et al. Non-viral expression of mouse Oct4, Sox2, and Klf4 
transcription factors efficiently reprograms tadpole muscle fibers in vivo. 
The Journal of biological chemistry 287, 7427-7435, 
doi:10.1074/jbc.M111.324368 (2012). 
93 Hanna, J. et al. Direct cell reprogramming is a stochastic process 
amenable to acceleration. Nature 462, 595-601, 
doi:10.1038/nature08592 (2009). 
94 Schmidt, R. & Plath, K. The roles of the reprogramming factors Oct4, 
Sox2 and Klf4 in resetting the somatic cell epigenome during induced 
pluripotent stem cell generation. Genome biology 13, 251, 
doi:10.1186/gb-2012-13-10-251 (2012). 
95 Chronis, C. et al. Cooperative Binding of Transcription Factors 
Orchestrates Reprogramming. Cell 168, 442-459 e420, 
doi:10.1016/j.cell.2016.12.016 (2017). 
	 309	
96 Smale, S. T. Pioneer factors in embryonic stem cells and differentiation. 
Current opinion in genetics & development 20, 519-526, 
doi:10.1016/j.gde.2010.06.010 (2010). 
97 Zaret, K. S. Regulatory phases of early liver development: paradigms 
of organogenesis. Nature reviews. Genetics 3, 499-512, 
doi:10.1038/nrg837 (2002). 
98 Lee, C. S., Friedman, J. R., Fulmer, J. T. & Kaestner, K. H. The 
initiation of liver development is dependent on Foxa transcription 
factors. Nature 435, 944-947, doi:10.1038/nature03649 (2005). 
99 Sekiya, T., Muthurajan, U. M., Luger, K., Tulin, A. V. & Zaret, K. S. 
Nucleosome-binding affinity as a primary determinant of the nuclear 
mobility of the pioneer transcription factor FoxA. Genes & development 
23, 804-809, doi:10.1101/gad.1775509 (2009). 
100 Swinstead, E. E. et al. Steroid Receptors Reprogram FoxA1 
Occupancy through Dynamic Chromatin Transitions. Cell 165, 593-605, 
doi:10.1016/j.cell.2016.02.067 (2016). 
101 Vierbuchen, T. et al. Direct conversion of fibroblasts to functional 
neurons by defined factors. Nature 463, 1035-1041, 
doi:10.1038/nature08797 (2010). 
102 Marro, S. et al. Direct lineage conversion of terminally differentiated 
hepatocytes to functional neurons. Cell stem cell 9, 374-382, 
doi:10.1016/j.stem.2011.09.002 (2011). 
103 Wapinski, O. L. et al. Hierarchical mechanisms for direct 
reprogramming of fibroblasts to neurons. Cell 155, 621-635, 
doi:10.1016/j.cell.2013.09.028 (2013). 
104 Soufi, A., Donahue, G. & Zaret, K. S. Facilitators and impediments of 
the pluripotency reprogramming factors' initial engagement with the 
genome. Cell 151, 994-1004, doi:10.1016/j.cell.2012.09.045 (2012). 
105 Soufi, A. et al. Pioneer transcription factors target partial DNA motifs on 
nucleosomes to initiate reprogramming. Cell 161, 555-568, 
doi:10.1016/j.cell.2015.03.017 (2015). 
106 Lowry, W. E. Does transcription factor induced pluripotency accurately 
mimic embryo derived pluripotency? Current opinion in genetics & 
development 22, 429-434, doi:10.1016/j.gde.2012.07.003 (2012). 
107 Li, M. & Belmonte, J. C. Ground rules of the pluripotency gene 
regulatory network. Nature reviews. Genetics 18, 180-191, 
doi:10.1038/nrg.2016.156 (2017). 
108 Niwa, H. How is pluripotency determined and maintained? 
Development 134, 635-646, doi:10.1242/dev.02787 (2007). 
109 Do, J. T. et al. Erasure of cellular memory by fusion with pluripotent 
cells. Stem cells 25, 1013-1020, doi:10.1634/stemcells.2006-0691 
(2007). 
110 Nakatake, Y. et al. Klf4 cooperates with Oct3/4 and Sox2 to activate 
the Lefty1 core promoter in embryonic stem cells. Molecular and 
cellular biology 26, 7772-7782, doi:10.1128/MCB.00468-06 (2006). 
111 Boer, B. et al. Elevating the levels of Sox2 in embryonal carcinoma 
cells and embryonic stem cells inhibits the expression of Sox2:Oct-3/4 
target genes. Nucleic acids research 35, 1773-1786, 
doi:10.1093/nar/gkm059 (2007). 
	 310	
112 Ng, H. H. & Surani, M. A. The transcriptional and signalling networks of 
pluripotency. Nature cell biology 13, 490-496, doi:10.1038/ncb0511-
490 (2011). 
113 Hall, J. et al. Oct4 and LIF/Stat3 additively induce Kruppel factors to 
sustain embryonic stem cell self-renewal. Cell stem cell 5, 597-609, 
doi:10.1016/j.stem.2009.11.003 (2009). 
114 Yeo, J. C. et al. Klf2 is an essential factor that sustains ground state 
pluripotency. Cell stem cell 14, 864-872, 
doi:10.1016/j.stem.2014.04.015 (2014). 
115 Tetreault, M. P., Yang, Y. & Katz, J. P. Kruppel-like factors in cancer. 
Nature reviews. Cancer 13, 701-713, doi:10.1038/nrc3582 (2013). 
116 Frankenberg, S. R. et al. The POU-er of gene nomenclature. 
Development 141, 2921-2923, doi:10.1242/dev.108407 (2014). 
117 Abdelalim, E. M., Emara, M. M. & Kolatkar, P. R. The SOX 
Transcription Factors as Key Players in Pluripotent Stem Cells. Stem 
Cells and Development 23, 2687-2699, doi:10.1089/scd.2014.0297 
(2014). 
118 Jiang, J. et al. A core Klf circuitry regulates self-renewal of embryonic 
stem cells. Nature cell biology 10, 353-360, doi:10.1038/ncb1698 
(2008). 
119 Bourillot, P. Y. & Savatier, P. Kruppel-like transcription factors and 
control of pluripotency. BMC Biol 8, 125, doi:10.1186/1741-7007-8-125 
(2010). 
120 Parisi, S. et al. Direct targets of Klf5 transcription factor contribute to 
the maintenance of mouse embryonic stem cell undifferentiated state. 
BMC Biol 8, 128, doi:10.1186/1741-7007-8-128 (2010). 
121 Long, X. & Singla, D. K. Inactivation of Klf5 by zinc finger nuclease 
downregulates expression of pluripotent genes and attenuates colony 
formation in embryonic stem cells. Mol Cell Biochem 382, 113-119, 
doi:10.1007/s11010-013-1724-5 (2013). 
122 Aksoy, I. et al. Klf4 and Klf5 differentially inhibit mesoderm and 
endoderm differentiation in embryonic stem cells. Nature 
communications 5, 3719, doi:10.1038/ncomms4719 (2014). 
123 Aksoy, I. et al. Sox transcription factors require selective interactions 
with Oct4 and specific transactivation functions to mediate 
reprogramming. Stem cells 31, 2632-2646, doi:10.1002/stem.1522 
(2013). 
124 Hinkley, C. S., Martin, J. F., Leibham, D. & Perry, M. Sequential 
expression of multiple POU proteins during amphibian early 
development. Molecular and cellular biology 12, 638-649 (1992). 
125 Morichika, K., Sugimoto, M., Yasuda, K. & Kinoshita, T. Possible 
regulation of Oct60 transcription by a positive feedback loop in 
Xenopus oocytes. Zygote 22, 266-274, 
doi:10.1017/S0967199412000536 (2014). 
126 Young, J. J., Kjolby, R. A., Kong, N. R., Monica, S. D. & Harland, R. M. 
Spalt-like 4 promotes posterior neural fates via repression of pou5f3 
family members in Xenopus. Development 141, 1683-1693, 
doi:10.1242/dev.099374 (2014). 
127 Liu, S. B., G; Sun, R.;Guo, S.; Xue, B.; Wei, R.; Cooney, A. J.; Liu, Z. 
Sox2 is the faithful marker for pluripotency in pig: evidence from 
	 311	
embryonic studies. Developmental dynamics : an official publication of 
the American Association of Anatomists 244, 9 (2015). 
128 Cao, Q. et al. Klf4 is required for germ-layer differentiation and body 
axis patterning during Xenopus embryogenesis. Development 139, 
3950-3961, doi:10.1242/dev.082024 (2012). 
129 Gao, Y. et al. Kruppel-like factor family genes are expressed during 
Xenopus embryogenesis and involved in germ layer formation and 
body axis patterning. Developmental dynamics : an official publication 
of the American Association of Anatomists 244, 1328-1346, 
doi:10.1002/dvdy.24310 (2015). 
130 Schmidt, D. et al. Five-vertebrate ChIP-seq reveals the evolutionary 
dynamics of transcription factor binding. Science 328, 1036-1040, 
doi:10.1126/science.1186176 (2010). 
131 Tapia, N. et al. Reprogramming to pluripotency is an ancient trait of 
vertebrate Oct4 and Pou2 proteins. Nature communications 3, 
doi:ARTN 1279 10.1038/ncomms2229 (2012). 
132 Morrison, G. M. & Brickman, J. M. Conserved roles for Oct4 
homologues in maintaining multipotency during early vertebrate 
development. Development 133, 2011-2022, doi:10.1242/dev.02362 
(2006). 
133 Hammachi, F. et al. Transcriptional activation by Oct4 is sufficient for 
the maintenance and induction of pluripotency. Cell Rep 1, 99-109, 
doi:10.1016/j.celrep.2011.12.002 (2012). 
134 Dixon, J. E. et al. Axolotl Nanog activity in mouse embryonic stem cells 
demonstrates that ground state pluripotency is conserved from urodele 
amphibians to mammals. Development 137, 2973-2980, 
doi:10.1242/dev.049262 (2010). 
135 Halley-Stott, R. P. et al. Mammalian nuclear transplantation to 
Germinal Vesicle stage Xenopus oocytes - a method for quantitative 
transcriptional reprogramming. Methods 51, 56-65, 
doi:10.1016/j.ymeth.2010.01.035 (2010). 
136 Jullien, J. et al. Hierarchical molecular events driven by oocyte-specific 
factors lead to rapid and extensive reprogramming. Molecular cell 55, 
524-536, doi:10.1016/j.molcel.2014.06.024 (2014). 
137 Roberts, T. C. et al. Quantification of nascent transcription by 
bromouridine immunocapture nuclear run-on RT-qPCR. Nature 
protocols 10, 1198-1211, doi:10.1038/nprot.2015.076 (2015). 
138 Oka, M., Moriyama, T., Asally, M., Kawakami, K. & Yoneda, Y. 
Differential Role for Transcription Factor Oct4 Nucleocytoplasmic 
Dynamics in Somatic Cell Reprogramming and Self-renewal of 
Embryonic Stem Cells. Journal of Biological Chemistry 288, 15085-
15097, doi:10.1074/jbc.M112.448837 (2013). 
139 Sutinen, P., Rahkama, V., Rytinki, M. & Palvimo, J. J. Nuclear mobility 
and activity of FOXA1 with androgen receptor are regulated by 
SUMOylation. Mol Endocrinol 28, 1719-1728, doi:10.1210/me.2014-
1035 (2014). 
140 Yanai, I., Peshkin, L., Jorgensen, P. & Kirschner, M. W. Mapping gene 
expression in two Xenopus species: evolutionary constraints and 
developmental flexibility. Developmental cell 20, 483-496, 
doi:10.1016/j.devcel.2011.03.015 (2011). 
	 312	
141 Peshkin, L. et al. On the Relationship of Protein and mRNA Dynamics 
in Vertebrate Embryonic Development. Developmental cell 35, 383-394, 
doi:10.1016/j.devcel.2015.10.010 (2015). 
142 Sun, L. et al. Quantitative proteomics of Xenopus laevis embryos: 
expression kinetics of nearly 4000 proteins during early development. 
Sci Rep 4, 4365, doi:10.1038/srep04365 (2014). 
143 Wingender, E. The TRANSFAC project as an example of framework 
technology that supports the analysis of genomic regulation. Brief 
Bioinform 9, 326-332, doi:10.1093/bib/bbn016 (2008). 
144 Eisenberg, E. & Levanon, E. Y. Human housekeeping genes, revisited. 
Trends Genet 29, 569-574, doi:10.1016/j.tig.2013.05.010 (2013). 
145 Biddle, A., Simeoni, I. & Gurdon, J. B. Xenopus oocytes reactivate 
muscle gene transcription in transplanted somatic nuclei independently 
of myogenic factors. Development 136, 2695-2703, 
doi:10.1242/dev.036327 (2009). 
146 Owens, N. D. et al. Measuring Absolute RNA Copy Numbers at High 
Temporal Resolution Reveals Transcriptome Kinetics in Development. 
Cell Rep 14, 632-647, doi:10.1016/j.celrep.2015.12.050 (2016). 
147 Smits, A. H. et al. Global absolute quantification reveals tight regulation 
of protein expression in single Xenopus eggs. Nucleic acids research 
42, 9880-9891, doi:10.1093/nar/gku661 (2014). 
148 Wuhr, M. et al. Deep proteomics of the Xenopus laevis egg using an 
mRNA-derived reference database. Current biology : CB 24, 1467-
1475, doi:10.1016/j.cub.2014.05.044 (2014). 
149 Iwafuchi-Doi, M. & Zaret, K. S. Cell fate control by pioneer transcription 
factors. Development 143, 1833-1837, doi:10.1242/dev.133900 (2016). 
150 Metzakopian, E. et al. Genome-wide characterisation of Foxa1 binding 
sites reveals several mechanisms for regulating neuronal differentiation 
in midbrain dopamine cells. Development 142, 1315-1324, 
doi:10.1242/dev.115808 (2015). 
151 Metzakopian, E. et al. Genome-wide characterization of Foxa2 targets 
reveals upregulation of floor plate genes and repression of ventrolateral 
genes in midbrain dopaminergic progenitors. Development 139, 2625-
2634, doi:10.1242/dev.081034 (2012). 
152 Belaguli, N. S., Zhang, M., Brunicardi, F. C. & Berger, D. H. Forkhead 
box protein A2 (FOXA2) protein stability and activity are regulated by 
sumoylation. PloS one 7, e48019, doi:10.1371/journal.pone.0048019 
(2012). 
153 Gurdon, J. B. Changes in somatic cell nuclei inserted into growing and 
maturing amphibian oocytes. J Embryol Exp Morphol 20, 401-414 
(1968). 
154 Jullien, J., Astrand, C., Halley-Stott, R. P., Garrett, N. & Gurdon, J. B. 
Characterization of somatic cell nuclear reprogramming by oocytes in 
which a linker histone is required for pluripotency gene reactivation. 
Proceedings of the National Academy of Sciences of the United States 
of America 107, 5483-5488, doi:10.1073/pnas.1000599107 (2010). 
155 Narbonne, P., Simpson, D. E. & Gurdon, J. B. Deficient induction 
response in a Xenopus nucleocytoplasmic hybrid. PLoS biology 9, 
e1001197, doi:10.1371/journal.pbio.1001197 (2011). 
	 313	
156 Okada, Y. Analysis of giant polynuclear cell formation caused by HVJ 
virus from Ehrlich's ascites tumor cells. I. Microscopic observation of 
giant polynuclear cell formation. Experimental cell research 26, 98-107 
(1962). 
157 Okada, Y. Analysis of giant polynuclear cell formation caused by HVJ 
virus from Ehrlich's ascites tumor cells. III. Relationship between cell 
condition and fusion reaction or cell degeneration reaction. 
Experimental cell research 26, 119-128 (1962). 
158 Okada, Y. & Tadokoro, J. Analysis of giant polynuclear cell formation 
caused by HVJ virus from Ehrlich's ascites tumor cells. II. Quantitative 
analysis of giant polynuclear cell formation. Experimental cell research 
26, 108-118 (1962). 
159 Harris, H. The reactivation of the red cell nucleus. Journal of cell 
science 2, 23-32 (1967). 
160 Harris, H., Miller, O. J., Klein, G., Worst, P. & Tachibana, T. 
Suppression of malignancy by cell fusion. Nature 223, 363-368 (1969). 
161 Tsubouchi, T. et al. DNA synthesis is required for reprogramming 
mediated by stem cell fusion. Cell 152, 873-883, 
doi:10.1016/j.cell.2013.01.012 (2013). 
162 Pereira, C. F. et al. Heterokaryon-based reprogramming of human B 
lymphocytes for pluripotency requires Oct4 but not Sox2. PLoS 
genetics 4, e1000170, doi:10.1371/journal.pgen.1000170 (2008). 
163 Terranova, R., Pereira, C. F., Du Roure, C., Merkenschlager, M. & 
Fisher, A. G. Acquisition and extinction of gene expression programs 
are separable events in heterokaryon reprogramming. Journal of cell 
science 119, 2065-2072, doi:10.1242/jcs.02945 (2006). 
164 Martin, M. Cutadapt removes adapter sequences from high-throughput 
sequencing reads. EMBnet.journal 17, 3 (2011). 
165 Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice 
junctions with RNA-Seq. Bioinformatics 25, 1105-1111, 
doi:10.1093/bioinformatics/btp120 (2009). 
166 Anders, S., Pyl, P. T. & Huber, W. HTSeq--a Python framework to work 
with high-throughput sequencing data. Bioinformatics 31, 166-169, 
doi:10.1093/bioinformatics/btu638 (2015). 
167 McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression 
analysis of multifactor RNA-Seq experiments with respect to biological 







Chapter 10 Appendices 
 
10.1 Appendix I: Plasmid construction 
To overexpress TF proteins in Xenopus oocytes, the TF mRNA was made via 
in vitro transcription. First, the coding sequence of TF on plasmids was 
amplified by PCR and inserted into pTOPO vector via Gateway cloning 
system. However, while I constructed the plasmids, there was a missense 
mutation found on the coding sequence of mFoxa1. Therefore, the 
mutagenesis PCR was performed to fix the mutation and the fixed mFoxa1 
was inserted into pCS2-HA vector to have T7 promoter on plasmid and add 
HA tags to mFoxa1. The TF mRNA was made from the TF containing 
plasmids via in vitro transcription. 
 
10.1.1 Construction of pTOPO-mFoxa1 plasmid from pBabe-puro-FoxA1 
plasmid and pTOPO vector via Gateway cloning system 
The coding sequence of mFoxa1 on pBabe-puro-FoxA1 plasmid was first 
amplified by high-fidelity DNA polymerase (Phusion High-Fidelity DNA 
polymerase, 2U/µl, Cat No M0530, New England Biolabs) with primers 
designed for Gateway cloning system (Figure 10.1.1). The amount of 
reagents and cycling parameter for PCR is as follows: 
1µl 100ng/µl plasmid (Miniprep eluent), 32.5µl H2O, 10µl 5X Phusion HF 
Buffer (NEB), 1µl dNTPs (10mM each, NEB), 2.5µl Forward primer (10µM, 
Sigma-Aldrich), 2.5µl Reverse primer (10µM, Sigma-Aldrich), 0.5µl Phusion 
DNA polymerase (NEB)  
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Number of cycles Temperature Duration 
1 98℃ 30 secs 
26 
98℃ 10 secs 
62℃ 30 secs 
72℃ 2 mins 
1 72℃ 10 mins 
1 4 ∞ 
 
The mFoxa1 amplicons were then inserted into pENTR/D-TOPO vector and 
introduced into competent E. coli via heat-shock transformation (pENTR/D-
TOPO cloning kit with One Shot TOP10 Chemically Competent E. coli, Cat No 
K240020, Thermo Fisher Scientific). The transformed E. coli was then 
selected by kanamycin and the propagated plasmids were extracted (QIAprep 
Spin Miniprep Kit, QIAGEN) and sequenced (Department of Biochemistry, 
University of Cambridge). However, the sequencing results showed there was 
a missense mutation on the coding sequence of mFoxa1 and it was also 











10.1.2 Fixation of the missense mutation of mFoxa1 coding sequence on 
pTOPO-mFoxa1 plasmid 
Since the mFoxa1 coding sequence of pBabe-puro-FoxA1 plasmid was 
spotted with a missense mutation from Ser-12 to Asn-12, the mutation of 
plasmid was firstly mutated back to the original Ser-12 by using designed 
primers (Figure 10.1.2). New plasmids containing the designed primers was 
synthesized by using high-fidelity DNA polymerase (PfuTurbo DNA 
polymerase, 2.5U/µl, Cat No 600252, Agilent Technologies) with the PCR 
cycling parameters: 
2µl pTOPO-mFoxa1 plasmid (Miniprep eluent), 5µl 10X Cloned Pfu buffer 
(Agilent), 1.25µl Forward primer (100µM, Sigma-Aldrich), 1.25µg 100µg/µl 
Reverse primer (100µM, Sigma-Aldrich), 1µl dNTPs (10mM each), 38.5µl H2O, 
1µl PfuTurbo DNA polymerase (Agilent) 
Number of cycles Temperature Duration 
1 95℃ 30 secs 
12 
95℃ 30 secs 
55℃ 1 min 
68℃ 8 mins 
1 4℃ ∞ 
 
The amplicons were introduced into competent E. coli via heat-shock 
transformation (One Shot TOP10 Chemically Competent E. coli, Thermo 
Fisher Scientific). The propagated plasmids were then extracted (QIAprep 
Spin Miniprep Kit, QIAGEN) and the fixed sequence was confirmed by Sanger 




Figure 10.1.2 Missense mutation of pBabe-puro-FoxA1 plasmid and primers used for 




10.1.3 Construction of pCS2-mFoxa1-3HA plasmid from pTOPO-mFoxa1 
plasmid and pCS2-3HA-attR vector 
To add HA tags to the N-terminus of mFoxa1, the mFoxa1 coding sequence 
on pTOPO-mFoxa1 plsamid was recombined with pCS2-3HA-attR vector via 
LR clonase (Gateway LR clonase II enzyme mix, Thermo Fisher Scientific). 
 
The reaction products were then introduced into competent E. coli via heat-
shock transformation (One Shot TOP10 Chemically Competent E. coli, 
Thermo Fisher Scientific) and the successful transformed E. coli was selected 
by Ampicillin. The resulting propagated plasmids were then extracted 
(QIAprep Spin Miniprep Kit, QIAGEN) and sequenced (Department of 




10.2 Appendix II: Primer list for neurogenic genes 
Gene Symbol Forward primer Reverse Primer 
Lmx1b GTGGAGATGACGGGAAAGAC CTTGAAAGCTCTTCGCTGCT 
Dmrtb1 GGCTACCTCTCTGCTCTCCA GCTTCTGCATCCTGGTCATT 
Lmcd1 TACCAGCGTGTGGAAGACCT TGACCCTTGGTGACGATGTA 
Smarca1 GGCTCAAATTGAACGTGGAG ATCTTGCAATTTTGGCATCC 
Arx TTTTCTAGGAGCAGCGGTGT GGGGCCATAGTGGAAAAGAG 
Kcnip3 GGCCATCATGAAGTCCATCT AACCTCTCCACATGCTCCAG 
Elk3 TGGAGCAGCCTTAGTCCTGT GTTGAGCAGTGTGGGGAACT 
Rora CGTGGCTTCAGGAAAAGGTA TTCCATCTTCTCGGTGGTTC 
Ferd3l CAGAAAGGTACCCACCTTCG GAGCTCGGTCATGAAGGAAA 
Gli1 TCAGCTGGACTTTGTGGCTA AGAGGGAGATGGGGTGTTTT 
Otx2 AGTCCCCAGCTTCTCTTTCC TTCCAAGAGGCAGTTTGGTC 
Foxb1 CCACCCTGCTCTCGAACTC CTGGTGAGTGTCTCGCTAGG 
Meis2 TGACCAGTCAAATCGAGCAG ATGTGTTGCTGACCATCCAA 
Otx1 CATCATCACCATCACCCTCA CAGAGCCTCCATAACCTTGG 
  
	 321	
10.3 Appendix III: Bioinformatics analysis 
10.3.1 Hybrid genome generation 
Fasta files from Mus musculus (mm10) and Xenopus laevis (xla9.1) have 
been concatenated one after the other in order to create a hybrid large 
mouse-Xenopus genome. To distinguish the X. laevis chromosomes in the 
fasta file, they have been renames as ”xla_chr” instead of just  “chr”. Similarly, 
the gtf files containing the annotation of all transcripts from Mouse (mm10) 
and of all primary transcript  from X. Laevis (xla 9.1) have been concatenated. 
 
10.3.2 Processing of fastq files 
FastQ files were processed with cutadatp (version 1.9.1, options -q 10 -O 
3)164 for adapter trimming. Filtered reads were then aligned to the hybrid 
mouse-Xenopus genome with tophat (version v2.1.1)165. Transcripts were 
assigned to gene and counted using htseq-count (HTSeq-0.5.4p3)166.  
 
10.3.3 Reproducibility analysis 
We performed hierarchical clustering of the libraries by using the hclust 
function of the stats package in R with default parameters. Clustering has 
been performed on both raw counts and then on normalized data. Data have 
been normalized with a double scaling procedure that uses the z-score 
transformation. The first scaling has been done on experiments belonging to 
the same batch (i.e. experiments produced at the same time) in order to 
reduce the batch variability. Then they have been scaled again. 
	 322	
Multidimensional scaling plots were obtained through the plotMDS function of 
the limma package in bioconductor using the normalized data.  
 
10.3.4 Differential expression (DE) analysis.  
Data were normalized and analyzed for differential expression using the 
package edgeR167 from Bioconductor. The functions glmFit and glmLRT were 
used to assess differential expression (logarithm on base 2 of fold change, 
logFC) and significance (false discovery rate, FDR) between each pair of 
conditions we explored. The DE analysis was performed considering how the 
experiments were paired by creating a design matrix with model.matrix from 
the stats package in order to keep into account the information of the frog, the 
treatment and the replicate. The set of genes used for the DE analysis was 
obtained by filtering those with at least 1 cpm (count per million) in half (50%) 
of the total number of the experiments under investigation. Genes 
differentially expressed significantly between samples was determined 
considering those with FDR less than 0.1. No cutoff is applied for the 




10.4 Appendix IV: Preliminary data validation for 
reprogrammed transcriptomes of mESCs, MEFs and mMyos 
by Xenopus oocytes 
As negative controls, Oocyte-NT samples without BrUTP injection were 
prepared in parallel with Oocyte-NT samples with BrUTP injection (n=2, Frog 
2 and 6, Table 10.4.1). In MEF libraries of Frog 2, the mapped reads/nM 
increased from 2 million to 13 million reads/nM for Mus musculus and 
decreased from 27 million to 8 million reads/nM for Xenopus laevis after 
BrUTP pull-down (Frog 2, #2, Table 10.4.1). Likewise, the mapped reads/nM 
increase from 1 to 6 million reads/nM for Mus musculus and decrease from 11 
to 4 million reads/nM for Xenopus laevis in Frog 6 after BrUTP pull-down 
(Frog 6, #6 and #7, Table 10.4.1). Therefore, the average ratio of mapped 
reads of Mus musculus to Xenopus laevis is 1:13 for no BrUTP samples (2:27 
for Frog 2 and 1:11 for Frog 6) and 1.6:1 for BrUTP samples (13:8 for Frog 2 
and 6:7 for Frog 6) after BrUTP pull-down. 
 
This indicates that genes of Mus musculus are actively transcribed after 
Oocyte-NT and BrUTP pull-down can efficiently isolate newly synthesized 
transcripts, mostly from Mus musculus. Furthermore, most non-specifically 
bound transcripts are from Xenopus laevis, as judged by the ratio of mapped 
reads in no BrUTP samples, and those non-specifically bound transcripts can 
be disregarded effectively after BrUTP pull-down.  
 
Interestingly, the mapped reads/nM for Mus musculus of MEF-NT plus BrUTP 
samples in Frog 1 and Frog 2 do not increase from Day 1 to Day 2 after 
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Oocyte-NT (Table 10.4.1). Additionally, the average ratio of mapped reads/nM 
of mESC-NT plus BrUTP to mMyo-NT plus BrUTP in Frog 2, 3 and 4 is 4 to 1 
(Table 10.4.1). It suggests that the amount of newly synthesized transcripts in 
MEF-NT keeps steady 24 hours after Oocyte-NT for the balance between 
synthesis and degradation of polyadenylated RNA. Furthermore, there are 
more newly synthesized transcripts from nuclei of mESCs than mMyos 
possibly because the chromatin of mESCs is generally more accessible to the 
effect of oocyte factors than the genes of mMyos48. 
 
For an overview of all the RNA-seq libraries used in this chapter, hierarchical 
clustering was applied and libraries are clustered by the expression level of 
newly synthesized transcripts genome-wide after Oocyte-NT (Figure 10.4.1). 
As expected, the RNA-seq libraries of MEF-NT without BrUTP treatment as 
negative controls are clearly separated from all other libraries with BrUTP 
treatment regardless of the donor cell types, the origins of oocyte batches and 
the collection days (Figure 10.4.1). In addition, the libraries of MEF-NT 
collected at Day 1 and Day 2 after Oocyte-NT are separated from other 
libraries of mESC-NT and mMyo-NT and are grouped together based on the 
origins of oocytes (Frog 1 and Frog 2, Figure 10.4.1). Unexpectedly, the RNA-
seq libraries of mESC-NT, MEF-NT and mMyo-NT collected at Day 2 after 
Oocyte-NT are not different from each other for either the difference of cell 
types or the origins of oocyte batches and it suggests that the reprogrammed 
nuclei mESC-NT, MEF-NT and mMyo-NT are similar after being 





Figure 10.4.1 Reprogrammed transcriptomes of newly synthesized transcripts in mESC, 
MEF and mMyo were similarly promoted by oocyte factors. 
Hierarchical clustering shows that RNA-seq libraries of mESC-NT (in blue), MEF-NT (in green) 
and mMyo-NT (in red) are grouped by expression of newly synthesized transcripts with or 
without BrUTP labeling (in black) regardless of cell types and frogs at Day 1 (in italics) and 



























Table 10.4.1 BrUTP pull-down efficiently enriches mapped reads of newly synthesized 
transcripts of mESC-NT (in blue), MEF-NT (in green) and mMyo-NT (in red) to mouse 
genome. 
Libraries of MEF-NT at Day 1 after Oocyte-NT are in italics and libraries of MEF-NT without 
the addition of BrUTP are in black. 
# Libraries were pooled together with specified concentrations (nM) and sequenced in the 
same lanes. 
* Libraries 1 and 2 of MEF-NT of Frog 6 are technical duplicates and mapped reads are 
added up together for bioinformatics analysis. 
  
Mus musculus (mm10) Xenopus laevis (xl9.1)
Frog 1_MEF_BrUTP_Day 1 17,273,206                 19,372,578                 
Frog 1_MEF_BrUTP_Day 2 19,103,794                 17,923,632                 
Frog 2_MEF_BrUTP_Day 1 32,492,438                 24,466,766                 
Frog 2_MEF_Day 2 331,171                     5,357,592                   
Frog 2_MEF_BrUTP_Day 2 31,605,380                 19,553,838                 
Frog 2_mMyo_BrUTP_Day 2 14,694,612                 21,543,039                 
Frog 2_mESC_BrUTP_Day 2 32,958,974                 23,907,495                 
Frog 3_mESC_BrUTP_Day 2 46,777,778                 18,751,556                 
Frog 3_mMyo_BrUTP_Day 2 10,153,737                 25,885,533                 
Frog 4_mMyo_BrUTP_Day 2 16,843,313                 18,907,652                 
Frog 4_mESC_BrUTP_Day 2 56,573,764                 19,038,998                 
Frog 5_MEF_BrUTP_Day 2 23,075,691                 9,662,453                   
Frog 6_MEF_Day 2_Library 1* 118,687                     1,372,291                   
Frog 6_MEF_Day 2_Library 2* 122,190
                     
1,398,516




Frog 6_MEF_BrUTP_Day 2_Library 2* 12,194,569                 7,239,653                   



























10.5 Appendix V: Gene ontology and KEGG pathway analysis 
of silenced genes in mESCs, MEFs and mMyos after Oocyte-
NT 
In mESCs, 3533 genes (Figure 5.4.1.A, page 172) of the original 
transcriptome are silent after Oocyte-NT, excluding housekeeping genes, are 
enriched for biological processes regarding development, morphogenesis, 
cell-cell interaction and signaling transduction pathways via Gene ontology 
(p<0.05, Figure 10.5.1). Additionally, silenced genes by oocyte factors in 
mESCs are enriched for pathways, including endocytosis, Rap1 signaling 
pathway and so on (p<0.05, Figure 10.5.2). Therefore, genes, involved in 
interaction between cells, accepting extracellular stimuli and signal 
transduction from extracellular stimuli to intracellular targets, are silenced by 
oocyte factors. 
 
In MEFs, 2251 silenced genes (Figure 5.4.1.B, page 172) by oocyte factors 
are enriched for 137 Gene ontology terms of Biological process (p<0.05, 
Figure 10.5.3). Among these terms, the biological processes selected for 
functions of MEFs are related to wound healing, extracelluar matrix 
organization, connective tissue development and response to growth factor 
stimulus (in red, Figure 10.5.3). The pathways come out from the KEGG 
pathway enrichment of silenced genes in MEFs by oocyte factors, including 




In mMyos, 4098 slienced genes (Figure 5.4.1.C, page 172) by oocyte factors 
are enriched for biological processes via Gene ontology and terms related to 
functions of mMyos include Striated muscle contraction, Cardiac muscle 
contraction, Muscle system process, Neuromuscular junction development, 
Muscle contraction and Heart contraction (in red, p<0.05, Figure 10.5.5). 
Pathways for mMyos from enrichment of silenced genes include Focal 
adhesion, Rap1 signaling pathway, Ras signaling pathway etc. (p<0.05, 
Figure 10.5.6). 
 
Interestingly, some common pathways are seen from enrichment of silenced 
genes of mESCs, MEFs and mMyos via KEGG pathway, including 
endocytosis, focal adhesion, axon guidance, adherens junction, Rap1 
signaling pathway and Ras signaling pathway (in red, Figure 10.5.2, 10.5.4, 
10.5.6). These pathways are not cell-type specific pathways and might be 
common pathways for cell lines, which have been through long-term cell 





 Figure 10.5.1 Silenced genes of mESCs after Oocyte-NT are enriched (p<0.05) for 
biological processes related to development, morphogenesis, cell-cell interaction and 




Figure 10.5.2 Silenced genes of mESCs after Oocyte-NT are enriched (p<0.05) for 
pathways, including endocytosis, Rap1 signaling pathway, glycerolipid metabolism 
and so on. 











Figure 10.5.3 Silenced genes in MEFs after Oocyte-NT are enriched (p<0.05) for 137 
Gene ontology terms of Biological processes and the terms related to the functions of 
MEFs include response to wounding, wound healing, inflammatory response and so 




 Figure 10.5.4 Silenced genes of MEFs after Oocyte-NT are enriched (p<0.05) for Rap1 
signaling pathway, axon guidance, adherens junction and so on. 






Figure 10.5.5 Silenced genes of mMyos after Oocyte-NT are enriched (p<0.05) for 
biological processes related to functions of mMyos, such as striated muscle 
contraction, cardiac muscle contraction, muscle system process, neuromuscular 






Figure 10.5.6 Silenced genes of mMyos after Oocyte-NT are enriched (p<0.05) for focal 
adhesion, Rap1 signaling pathway, Ras signaling pathway and so on. Pathways in red 





10.6 Appendix VI: Gene ontology and KEGG pathway analysis 
of reprogrammable genes in mESCs, MEFs and mMyos after 
Oocyte-NT 
This shows that reprogrammable genes among mESC-NT, MEF-NT and 
mMyo-NT (FPKM>0 in all three cell types) are involved in many DNA related 
biological processes, including DNA repair, Cellular response to DNA damage 
stimulus, DNA replication, DNA duplex unwinding, DNA packaging, DNA 
conformation change and so on (Figure 10.6.1.A). 
 
Additionally, reprogrammable genes are also involved in many biological 
processes regarding structural change, modification of chromatin and histone 
modification (Figure 10.6.1.B and C). For example, reprogrammable genes 
are involved in Covalent chromatin modification, Chromatin remodeling, 
Chromatin assembly and disassembly, Chromatin organization, Establishment 
of protein localization to chromosome and so on (Figure 10.6.1.B). 
Furthermore, reprogrammable genes are also involved in several histone 
modification related biological processes, including histone acetylation, 
deacetylation, methylation, ubiquitination and deupiquitination (Figure 
10.6.1.C). Since these chromatin and histone related biological processes 
could lead to the change of chromatin structure and chromatin accessibility, 
the oocyte-determined state of reprogrammed transcriptomes have the ability 
to change the chromatin accessibility and may aid the opening of regulatory 
elements of resistant genes, which are buried in condensed chromatin 
structures and silent before Oocyte-NT. 
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Moreover, the reprogrammable genes are also involved in transcription, 
translation and embryonic development (Figure 10.6.1.D-F). This means that 
the reprogrammed transcriptomes have these abilities for the establishment of 
totipotency, early development of embryos or the needs for SCNR by oocytes.  
 
For the pathways predicted for the functions of reprogrammable genes, some 
basic functions come out, such as Cell cycle, RNA transport, Spliceosome 
and so on (in red, Figure 10.6.2.A and B). Interestingly, Oocyte meiosis and 
Signaling pathways regulating pluripotency of stem cells are also predicted as 
results (Figure 10.6.2.A). For Oocyte meiosis, this suggests that the functions 
of Xenopus oocytes may also relate to the reprogrammed transcriptomes of 
donor cells since the oocyte factors perform functions not only for accepting 










Figure 10.6.1 Reprogrammable genes, which are expressed in mESC-NT, MEF-NT and 
mMyo-NT, are involved in DNA related biological processes (A), structural change and 
modification of chromatin (B), histone modification (C), transcription (D), translation (E) 









Figure 10.6.2 Reprogrammable genes, which are expressed in mESC-NT, MEF-NT and 
mMyo-NT, are enriched (p<0.05) for several pathways, including oocyte meiosis and 




10.7 Appendix VII: Preliminary data validation for 
reprogrammed transcriptomes of mESCs, MEFs and mMyos 
in the absence and presence of xklf2-HA overexpression in 
the Oocyte-NT system 
For RNA-seq analysis, there are 2-4 biological replicates for each group 
(Talbe 10.7.1). Each library was mapped to the mouse genome (Mus 
musculus, mm10) and Xenopus genome (Xenopus laevis, xla9.1). For mESC-
NT, there are an average of 50 million mapped reads to the mouse genome 
for each library (n=3, Talbe 10.7.1). For MEF-NT, there are an average of 25 
million mapped reads to mouse genome for each library (n=2 for Day 1 and 
n=4 for Day 2, Talbe 10.7.1). For mMyo-NT, there are an average of 15 
million reads to mouse genome for each library (n=3, Talbe 10.7.1). 
Interestingly, the amount of starting material in libraries of mESC-NT and 
mMyo-NT for sequencing is the same and libraries of mESC-NT and mMyo-
NT were pooled together for sequencing in the same sequencing lanes (#3, 
#4 and #5, Talbe 10.7.1). However, the resulting mapped reads to mouse 
genome of mESC-NT are 3 times more than mapped reads to mouse genome 
of mMyo-NT (n=3, Talbe 10.7.1). This suggests that the landscape of 
chromatin structures of transplanted mESCs may be more open and 
responsive to transcriptional machineries of oocytes. 
 
Regarding the efficiency of BrUTP pull-down, reads mapped to the mouse 
genome in MEF-NT with BrUTP addition has 6-9 times more reads than MEF-
NT without BrUTP addition (BrUTP/No BrUTP of mapped reads to the mouse 
genome, Frog 2 and 6, Talbe 10.7.1). Furthermore, reads mapped to the 
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mouse genome are approximately 1.4 times more than reads mapped to the 
Xenopus genome in MEF-NT with BrUTP addition (mapped reads to the 
mouse genome/Xenopus genome, BrUTP, Frog 2 and 6, Talbe 10.7.1). 
However, reads mapped to the the mouse genome are less than 1/10 of 
reads mapped to the Xenopus genome in MEF-NT without BrUTP addition 
(mapped reads to the mouse genome/Xenopus genome, No BrUTP, Frog 2 
and 6, Talbe 10.7.1). Therefore, the newly synthesized transcripts picked up 
specifically by anti-BrUTP antibodies come mostly from mouse nuclei than 
Xenopus nuclei. In addition, non-specifically bound transcripts in No BrUTP 
samples after BrUTP pull-down are more from Xenopus nuclei than mouse 
nuclei. 
 
For the time-dependent effect of xklf2-HA overexpression, Day 1 and Day 2 
samples of MEF-NT of Frog 2 are clustered by the expression level of genes 
genome wide in respect of xklf2-HA treatment, BrUTP addition, cell type 
difference and batch effect of oocytes (Day 1 and Day 2, Frog 2, Figure 
10.7.1). Yet, Day 1 and Day 2 samples of MEF-NT of Frog 1 are clustered by 
the expression level of genes genome wide based on xklf2-HA treatment but 
not cell type difference and batch effect of oocytes (Day 1 and Day 2, Frog 1, 
Figure 10.7.1). It suggests that the genome-wide difference may not be 
significant between Day 1 and Day 2 samples of MEF-NT and mMyo-NT 
under xklf2-HA overexpression. 
 
For the cell-type specific effects of xklf2-HA overexpression, Day 2 samples of 
mESC-NT, MEF-NT and mMyo-NT are clustered by the expression level of 
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genes genome wide only based on xklf2-HA treatment (Figure 10.7.1). 
Interestingly, cell type differences and batch effects of oocytes do not impact 
on the clustering of Day 2 samples of mESC-NT, MEF-NT and mMyo-NT 
(Figure 10.7.1). This resembles the clustering results in Chapter 5 that 
reprogrammed transcriptomes are very similar at Day 2 after Oocyte-NT 
regardless of cell type difference and batch effects of oocytes (Figure 10.4.1, 
page 329). It indicates that mESC-NT, MEF-NT and mMyo-NT under the 






Figure 10.7.1 Hierarchical clustering shows that RNA-seq libraries of mESC-NT (in 
blue), MEF-NT (in green) and mMyo-NT (in red) are grouped by expression of newly 
synthesized transcripts with or without BrUTP labeling (in black) in the presence or 
absence of xklf2-HA overexpression regardless of cell types and frogs at Day 1 (in 
italics) and Day 2 after Oocyte-NT. 












































Table 10.7.1 BrUTP pull-down efficiently enriches mapped reads of newly synthesized 
transcripts of mESC-NT (in blue), MEF-NT (in green) and mMyo-NT (in red) to mouse 
genome. 
Libraries of MEF-NT at Day 1 after Oocyte-NT are in italics and libraries of MEF-NT without 
BrUTP addition are in black.  
# Libraries were pooled together with specified concentrations and sequenced in the same 
lanes. 
* Libraries 1 and 2 of MEF-NT of Frog 6 are technical duplicates and mapped reads are 
added up together for bioinformatics analysis.   
Table 6.1 Mapped reads of each library to mouse and Xenopus reference





Day 1 samples of MEF-NT of Frog 1 and 2 are noted in Italic.
MEF-NT samples without addition of BrUTP are noted in Bold.
# RNA libraries were pooled together and sequenced in the same lanes
* Library 1 and 2 of MEF-NT samples of Frog 6 are technical duplicates and are added up













Mus musculus (mm10) Xenopus laevis (xl9.1)
Frog 1_MEF_BrUTP_Day 1 17,273,206                 19,372,578                 
Frog 1_MEF_BrUTP+xklf2-HA_Day 1 22,931,297                 19,110,888                 
Frog 1_MEF_BrUTP_Day 2 19,103,794                 17,923,632                 
Frog 1_MEF_BrUTP+xklf2-HA_Day 2 17,430,993                 20,019,654                 
Frog 2_MEF_BrUTP_Day 1 32,492,438                 24,466,766                 
Frog 2_MEF_BrUTP+xklf2-HA_Day 1 31,289,535                 31,719,250                 
Frog 2_MEF_Day 2 331,171                     5,357,592                   
Frog 2_MEF_BrUTP_Day 2 31,605,380                 19,553,838                 
Frog 2_MEF_xklf2-HA_Day 2 221,033                     4,965,468                   
Frog 2_MEF_BrUTP+xklf2-HA_Day 2 33,349,772                 17,195,567                 
Frog 2_mMyo_BrUTP_Day 2 14,694,612                 21,543,039                 
Frog 2_mMyo_BrUTP+xklf2-HA_Day 2 11,762,475                 20,986,915                 
Frog 2_mESC_BrUTP_Day 2 32,958,974                 23,907,495                 
Frog 2_mESC_BrUTP+xklf2-HA_Day 2 32,494,714                 23,422,173                 
Frog 3_mESC_BrUTP_Day 2 46,777,778                 18,751,556                 
Frog 3_mESC_BrUTP+xklf2-HA_Day 2 62,890,625                 17,062,270                 
Frog 3_mMyo_BrUTP_Day 2 10,153,737                 25,885,533                 
Frog 3_mMyo_BrUTP+xklf2-HA_Day 2 20,617,526                 17,200,578                 
Frog 4_mMyo_BrUTP_Day 2 16,843,313                 18,907,652                 
Frog 4_mMyo_BrUTP+xklf2-HA_Day 2 14,066,332                 15,045,898                 
Frog 4_mESC_BrUTP_Day 2 56,573,764                 19,038,998                 
Frog 4_mESC_BrUTP+xklf2-HA_Day 2 45,804,067                 17,651,509                 
Frog 5_MEF_BrUTP_Day 2 23,075,691                 9,662,453                   
Frog 5_MEF_BrUTP+xklf2-HA_Day 2 29,437,910                 11,161,692                 
Frog 6_MEF_Day 2_Library 1* 118,687                     1,372,291                   
Frog 6_MEF_BrUTP_Day 2_Library 1* 11,914,487                 7,102,116                   
Frog 6_MEF_BrUTP+xklf2-HA_Day 2_Library 1* 10,225,459                 7,959,804                   
Frog 6_MEF_Day 2_Library 2* 122,190                     1,398,516                   
Frog 6_MEF_BrUTP_Day 2_Library 2* 12,194,569                 7,239,653                   
Frog 6_MEF_BrUTP+xklf2-HA_Day 2_Library 2* 10,401,693                 8,089,930                   
















10.8 Appendix VIII: The involvement of xklf2-HA downstream 
genes in gene regulation during SCNR by oocytes 
To investigate the regulation of downstream genes by xklf2-HA 
overexpression, genes regulated by xklf2-HA overexpression at Day 1 after 
Oocyte-NT and genes regulated by xklf2-HA overexpression from Day 1 to 
Day 2 after Oocyte-NT are compared (Figure 10.8.1 and 10.8.2). 
 
For the DE genes regulated by xklf2-HA overexpression, xklf2-DE genes at 
Day 1 are regulated by xklf2-HA overexpression by comparing Control groups 
and xklf2-HA groups at Day 1 after Oocyte-NT (FDR<0.1, Figure 6.2.1, page 
196); DE genes from Day 1 to Day 2 after Oocyte-NT are regulated by xklf2-
HA overexpression by comparing xklf2-HA groups at Day 1 and xklf2-HA 
groups at Day 2 after Oocyte-NT (FDR<0.1, Figure 6.2.2, page 200). Since 
there are no common genes between xklf2-DE at Day 1 and DE genes from 
Day 1 to Day 2 after Oocyte-NT regulated by xklf2-HA overexpression, it 
shows that no genes are up-regulated (log2FC>0, FDR<0.1) or down-
regulated (log2FC<0, FDR<0.1) by xklf2-HA overexpression continuously and 
significantly from time points before Day 1 after Oocyte-NT to time points after 
Day 1 after Oocyte-NT (Figure 10.8.1). Furthermore, it shows that 
downstream genes of xklf2-HA regulate different sets of DE genes after Day 1 
after Oocyte-NT because DE genes up-regulated and down-regulated by 
xklf2-HA overexpression before and after Day 1 after Oocyte-NT are totally 
different (Figure 10.8.1). 
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While observing genes regulated by xklf2-HA overexpression regardless of 
FDR, 693 genes are up-regulated (log2FC>1) and 351 genes are down-
regulated (log2FC<1) by xklf2-HA overexpression continuously from time 
points before Day 1 after Oocyte-NT to time points after Day 1 after Oocyte-
NT (Figure 10.8.2). 
 
Nevertheless, the majority of genes regulated by xklf2-HA overexpression are 
different before and after Day 1 after Oocyte-NT. The difference of temporal 
gene regulation suggests that downstream genes of xklf2-HA may be involved 
in gene regulation by xklf2-HA overexpression or the epigenetic barriers of 
donor cell nuclei are removed temporally and xklf2-HA targets genes are 






Figure 10.8.1 xklf2-HA overexpression regulates different sets of genes between Day 1 
after Oocyte-NT and Day 1 to Day 2 after Oocyte-NT (FDR<0.1). 
Up-regulated (A) and down-regulated (B) xklf2-DE genes by xklf2-HA overexpression at Day 
1 after Oocyte-NT are compared with up-regulated and down-regulated DE genes by xklf2-




Figure 10.8.2 xklf2-HA overexpression regulates different sets of genes between Day 1 
after Oocyte-NT and Day 1 to Day 2 after Oocyte-NT with some shared genes 
regardless of FDR. 
Up-regulated (A) and down-regulated (B) genes by xklf2-HA overexpression at Day 1 after 
Oocyte-NT are compared with up-regulated and down-regulated genes form Day 1 to Day 2 
after Oocyte-NT, respectively.  
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10.9 Appendix IX: xklf2-HA overexpression activates genes at 
nil/low expression level and represses genes at high 
expression level during SCNR by Xenopus oocytes 
To look deeper into the effect of xklf2-HA overexpression on gene expression 
(log2FC (xklf2-HA/Control)) while expression of genes in mESCs, MEFs and 
mMyos is reprogrammed by oocyte factors to an oocyte-steady level from Day 
0 to Day 2 after Oocyte-NT, xklf2-DE genes are grouped by the expression 
level of newly synthesized transcripts in reprogrammed transcriptomes of 
mESCs, MEFs and mMyos in the absence of xklf2-HA (FPKM of Control 
groups) at Day 2 after Oocyte-NT (Figure 10.9.1, 10.9.2 and 10.9.3; p-value, 
Table 10.9.1, 10.9.2 and 10.9.3). 
 
Additionally, the number of xklf2-DE genes at different expression level in 
control groups shows that xklf2-HA overexpression tends to up-regulate 
genes at nil (FPKM=0) or low (FPKM<1) expression level in control groups 
and down-regulate genes at high expression level (FPKM>4) in control groups 
(Figure 10.9.1, 10.9.2 and 10.9.3; p-value, Table 10.9.1, 10.9.2 and 10.9.3). In 
mESC-NT, MEF-NT and mMyo-NT, more than half of up-regulated xklf2-DE 
genes are at nil/low expression level (0≤FPKM<1) and are up-regulated by 
xklf2-HA overexpression by 8-fold to 256-fold (3<mean of log2FC<8, Figure 
10.9.1.A, 10.9.2.A, 10.9.3.A). 
 
More than 80% down-regulated xklf2-DE genes are at high expression level in 
control groups (FPKM>4) and are down-regulated by xklf2-HA overexpression 
by more than 2-fold to 32-fold (1<mean of log2FC<5, Figure 10.9.1.B, 10.9.2.B 
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and 10.9.3.B). Therefore, xklf2-HA overexpression are more effective to 
activate genes at nil/low expression level in control groups and repress genes 
at high expression level in control groups when reprogrammed transcriptomes 
of donor cells in control groups are at oocyte-steady state. 
 
Since expression level of genes correlates with chromatin accessibility and 
the amount of factors that participate in transcription, the gene activation by 
xklf2-HA overexpression suggests that xklf2-HA overexpression can access 
regulatory elements reside in closed chromatin when the linked genes are 





Figure 10.9.1 xklf2-HA overexpression up-regulate xklf2-DE genes at lower expression 
level with higher log2FC and down-regulate xklf2-DE genes at higher expression with 
lower log2FC in mESC-NT at Day 2 after Oocyte-NT significantly (p-value is in Table 
10.9.1). Most up-regulated xkl2-DE genes are at nil or low expression level and most 































































































FPKM of Control at Day 2 after Oocyte-NT
Figure 6.3.2
Up-regulated xklf2-DE genes in mESC-NT






Figure 10.9.2 xklf2-HA overexpression up-regulate xklf2-DE genes at lower expression 
level with higher log2FC and down-regulate xklf2-DE genes at higher expression with 
lower log2FC in MEF-NT at Day 2 after Oocyte-NT significantly (p-value is in Table 
10.9.2). Most up-regulated xkl2-DE genes are at nil or low expression level and most 




























































































FPKM of Control at Day 2 after Oocyte-NT
Figure 6.3.4
Up-regulated xklf2-DE genes in MEF-NT






Figure 10.9.3 xklf2-HA overexpression up-regulate xklf2-DE genes at lower expression 
level with higher log2FC and down-regulate xklf2-DE genes at higher expression with 
lower log2FC in mMyo-NT at Day 2 after Oocyte-NT significantly (p-value is in Table 
10.9.3). Most up-regulated xkl2-DE genes are at nil or low expression level and most 



























































































FPKM of Control at Day 2 after Oocyte-NT
Up-regulated xklf2-DE genes in mMyo-NT
Figure 6.3.6






Table 10.9.1 p-value for Figure 10.9.1, p-value<0.05 is in red  
Up-regulated xklf2-DE genes in mESC-NT
Down-regulated xklf2-DE genes in mESC-NT
Table 6.3.1




4<FPKM<16 1.25E-70 2.17E-32 1.20E-09
16<FPKM<64 1.03E-32 7.02E-21 5.85E-10 0.012






















4<FPKM<16 0.5596 0.7959 0.9174
16<FPKM<64 0.1001 0.0661 0.0049 9.48E-04























Table 10.9.2 p-value for Figure 10.9.2, p-value<0.05 is in red  
Down-regulated xklf2-DE genes in MEF-NT
Up-regulated xklf2-DE genes in MEF-NT
Table 6.3.2




4<FPKM<16 6.66E-04 3.60E-03 4.76E-11
16<FPKM<64 3.62E-05 4.25E-07 5.71E-26 1.83E-21






















4<FPKM<16 8.33E-144 8.28E-76 1.84E-20
16<FPKM<64 2.93E-70 1.69E-54 4.56E-33 1.63E-11























Table 10.9.3 p-value for Figure 10.9.3, p-value<0.05 is in red 
 
  




4<FPKM<16 8.94E-45 7.60E-21 0.0027
16<FPKM<64 7.79E-17 1.67E-13 1.04E-09 1.04E-06























16<FPKM<64 0.1852 2.70E-03 1.42E-04


















Down-regulated xklf2-DE genes in mMyo-NT





10.10 Appendix X: xklf2-HA overexpression down-regulates 
xklf2-DE genes to xklf2-oocyte level at Day 2 after Oocyte-NT 
To look further into down-regulation of xklf2-DE genes by xklf2-HA 
overexpression in different cell nuclei at Day 2 after Oocyte-NT, expression 
level of xklf2-DE genes in mESC-NT, MEF-NT and mMyo-NT are compared 
and log2FC of xklf2-DE genes between Control groups and xklf2-HA groups in 
mESC-NT, MEF-NT and mMyo-NT are compared (Figure 10.10.1, 10.10.2 
and 10.10.3). 
 
For 12 xklf2-DE genes down-regulated in all 3 cell types at Day 2 after 
Oocyte-NT, when expression level (FPKM) is higher, the log2FC (xklf2-
HA/Control) is lower (Figure 10.10.1). It indicates there is a fixed xklf2-oocyte 
level for each gene being down-regulated by xklf2-HA overexpression. 
Likewise, this down-regulation of genes by xklf2-HA overexpression to xklf2-
oocyte level is also observed for xklf2-DE down-regulated in only 1 cell type 
by xklf2-HA overexpression (Figure 10.10.3). However, this down-regulation 
of genes by xklf2-HA overexpression is not obvious for down-regulated xklf2-
DE in 2 cell types possibly due to that the number of reference genes is not 





Figure 10.10.1 Expression level (FPKM) in the absence of xklf2-HA and log2FC of 





















































Figure 10.10.2 Shared down-regulated xklf2-DE genes in 2 cell types have higher 
expression level (FPKM) in the absence of xklf2-HA and down-regulated by xklf2-HA 
overexpression with lower log2FC than the 3rd cell type at Day 2 after Oocyte-NT. 
(A, B) Down-regulated xklf2-DE genes shared between mESC-NT and MEF-NT 
(C, D) Down-regulated xklf2-DE genes shared between MEF-NT and mMyo-NT 



































































































































































Figure 10.10.3 Down-regulated xklf2-DE genes in only one cell type have higher 
expression level in the absence of xklf2-HA and down-regulated by xklf2-HA 
overexpression with lower log2FC than the other 2 cell types at Day 2 after Oocyte-NT. 
(A, B) Down-regulated xklf2-DE genes in only mESC-NT 
(C. D) Down-regulated xklf2-DE genes in only MEF-NT 































































































































































10.11 Appendix XI: Gene ontology and KEGG pathway 
analysis for up-regulated and down-regulated xklf2-DE genes 
To predict biological functions promoted by xklf2 if xklf2 is one of maternal 
factors present in Xenopus oocytes, up-regulated xklf2-DE genes of mESC-
NT, MEF-NT and mMyo-NT are combined and applied for functional 
interpretation via Gene ontology enrichment analysis. 2024 in 2678 up-
regulated xklf2-DE genes are input into Gene ontology database for 
enrichment (Biological process, Figure 10.11.1; Cellular component, Figure 
10.11.2; Molecular function, Figure 10.11.3). 
 
For GO terms of biological process, up-regulated xklf2-DE genes of mESCs, 
MEFs and mMyos during SCNR by oocytes are annotated mostly for 
developmental processes, such as animal organ morphogenesis, cell fate 
commitment, enzyme linked receptor protein signaling pathway, cell projection 
morphogenesis, cell morphogenesis involved in differentiation (terms ranked 
top 5 with lowest p-value) and others (all terms with p-value<0.05, Figure 
10.11.1.A to E). 
 
For GO terms of cellular component enriched, which shows the locations 
xklf2-DE genes perform their functions, top 5 terms enriched are synapse, 
synapse part, plasma membrane region, somatodendritic compartment and 
proteinaceous extracellular matrix (terms are ranked from lowest p-value, all 
terms with p-value<0.05, Figure 10.11.2). Additionally, transcription factor 
complex is also enriched (in red, p=0.00355, Figure 10.11.2). 
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For GO terms of molecular function, top 16 terms plus one term ranked 21 
enriched are all about transcription, such as sequence-specific DNA binding, 
RNA polymerase II transcription factor activity, sequence-specific DNA 
binding (all terms with p<0.05, Figure 10.11.3). Among them, transcription 
activator activity, transcription repressor activity (in red) and core promoter 
proximal region binding (in blue) are enriched (Figure 10.11.3). It indicates 
many of up-regulated xklf2-DE genes are transcription factors and are able to 
activate or repress target genes via binding on recognition sites within core 
promoter proximal regions. 
 
To predict signaling pathways promoted by up-regulated xklf2-DE genes by 
xklf2-HA overexpression, KEGG pathway enrichment analysis is applied. 753 
in 2678 up-regulated xklf2-DE genes of mESCs, MEFs and mMyos during 
SCNR by oocytes are input into KEGG pathway database for enrichment 
(Figure 10.11.4). 
 
Overall, 15 pathways are enriched for up-regulated xklf2-DE genes (p<0.05, 
Figure 10.11.4). Importantly, signaling pathways regulating pluripotency of 
stem cells (139 annotated genes in database) are enriched most significantly 
by up-regulated xklf2-DE genes and 37 up-regulated xklf2-DE genes are 
annotated in these signaling pathways (p=6.23E-07, Figure 10.11.4; these 37 
genes are used later in Section 6.6). Therefore, xklf2-HA can solely promote 
signaling pathways regulating pluripotency of stem cells by up-regulating 
more than ¼ of annotated genes responsible for these pathways. 
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To predict functions of down-regulated xklf2-DE genes, GO enrichment 
analysis is applied. All the down-regulated xklf2-DE genes are combined and 
809 in 1008 down-regulated xklf2-DE genes are input in GO database for 
enrichment (Biological process, Figure 10.11.5; Cellular component, Figure 
10.11.6; Molecular function, Figure 10.11.7). 
 
For enriched biological processes, DNA, RNA and protein processing related 
terms are enriched and top 5 terms are RNA processing, mRNA processing, 
mRNA metabolic process, DNA metabolic process and RNA splicing (all 
terms with p-value<0.05, Figure 10.11.5). 
 
For enriched GO terms for cellular component, enriched terms are related to 
DNA, RNA and protein processing and top 5 terms enriched for down-
regulated xklf2-DE genes are intracellular ribonucleoprotein complex, 
ribonucleoprotein complex, nuclear body, chromosome and chromosomal part 
(all terms with p-value<0.05, Figure 10.11.6).  
 
For GO terms of molecular function, 6 terms are enriched for down-regulated 
xklf2-DE genes and all of them are related to DNA, RNA and protein 
processing, including mRNA binding, structural constituent of ribosome, 
helicase activity and so on (all terms with p<0.05, Figure 10.11.7). 
 
To predict signaling pathways affected by down-regulated xklf2-DE genes by 
xklf2-HA overexpression, KEGG pathway enrichment analysis is applied. 283 
in 1008 down-regulated xklf2-DE genes of mESCs, MEFs and mMyos during 
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SCNR by oocytes are input into KEGG pathway database for enrichment 
(Figure 10.11.8). 
 
Overall, six pathways are enriched for down-regulated pathways and are 
related to basic cellular functions, namely DNA replication, ribosome, 
nucleotide excision repair, fanconi anemia pathway, cell cycle and mRNA 
surveillance pathway (p<0.05, Figure 10.11.8). Fanconi anemia pathway is for 
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E. Gene ontology: Biological process
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10.12 Appendix XII: 6.6 xklf2-HA overexpression activates 
resistant genes and up-regulates the expression of genes to 
xklf2-oocyte level 
In Section 6.4, it has been shown that xklf2-HA overexpression can 
significantly regulate expression of genes at nil or low level to xklf2-oocyte 
level by comparing regulation of xklf2-DE genes in mESCs, MEFs and mMyos 
at Day 2 after Oocyte-NT. It has been also shown that xklf2-HA 
overexpression can activate SCNR resistant genes in mESC-NT, MEF-NT 
and mMyo-NT previously (Subsection 6.6.2, page 231). 
 
To evaluate regulation of xklf2-DE genes by xklf2-HA overexpression after 
xklf2-DE genes are activated, gene expression level in mESC-NT, MEF-NT 
and mMyo-NT without addition of xklf2-HA is compared with log2FC (xklf2-
HA/Control groups) after the addition of xklf2-HA (Figure 10.12.1 to 10.12.6). 
Up-regulated xklf2-DE genes are selected for comparison because down-
regulated xklf2-DE genes are usually regulated by downstream repressor of 
xklf2-HA (Subsection 6.2.2, page 198; 6.2.3, page 202; Appendix XI, page 
369) . 
 
For resistant genes that are silent in mESC-NT (FPKM=0) but up-regulated by 
xklf2-HA overexpression in mESC-NT (log2FC>0, FDR<0.1) (Figure 6.6.2.A, 
page 235), the regulation of them (log2FC, xklf2-HA/Control groups) by xklf2-
HA overexpression are compared among mESC-NT, MEF-NT and mMyo-NT 
(Figure 10.12.1). While xklf2-DE genes of mESC-NT are silent in mESC-NT 
and mMyo-NT but expressed in mMyo-NT (127 genes, Figure 6.6.2.A, page 
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235, and 10.12.1.A), they are up-regulated by xklf2-HA overexpression 
significantly with more log2FC in mESC-NT and mMyo-NT than the same 
genes up-regulated by xklf2-HA overexpression in MEF-NT (p<0.05, mean of 
log2FC=7.26, 2.72 and 5.03 in mESC-NT, MEF-NT and mMyo-NT, 
respectively, Figure 10.12.1.B).  
 
Likewise, when xklf2-DE genes of mESC-NT are silent in mESC-NT but 
expressed in MEF-NT and mMyo-NT (109 genes, Figure 6.6.2.A, page 235, 
and 10.12.1.C), the up-regulation by xklf2-HA overexpression in mESC-NT is 
significantly stronger than up-regulation by xklf2-HA overexpression in MEF-
NT and mMyo-NT (p<0.05, mean of log2FC=5.98, 2.16 and 2.75 in mESC-NT, 
MEF-NT and mMyo-NT, respectively, Figure 10.12.1.D). The different extent 
of up-regulation by xklf2-HA overexpression can also be seen when xklf2-DE 
genes of mESC-NT are silent in mESC-NT and MEF-NT but expressed in 
mMyo-NT (38 genes, Figure 6.6.2.A, page 235; p<0.05, 10.12.1.E and 
10.12.1.F). 
 
For resistant genes found in MEF-NT (Figure 10.12.2) and mMyo-NT (Figure 
10.12.3), it shows the different regulation of xklf2-DE genes by xklf2-HA 
overexpression. When the xklf2-DE genes resist activation by maternal 
factors, silent xklf2-DE genes (FPKM=) will be up-regulated with more log2FC 
than the same genes up-regulated by xklf2-HA overexpression in 
reprogrammed transcriptomes where they are expressed (FPKM>0). 
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For resistant genes of all 3 cell types, activation of resistant genes by xklf2-HA 
overexpression can also be seen (Figure 6.6.2, page 235, 10.12.4, 10.12.5 
and 10.12.6). In ESC-NT, MEF-NT and mMyo-NT, 131, 307 and 153 xklf2-DE 
genes are silent in all 3 cell types and up-regulated by xklf2-HA 
overexpression (Figure 6.6.2, page 235). When comparing these resistant 
genes with xklf2-DE genes, which are part of reprogrammable genes and are 
expressed in all 3 cell types, it shows the different regulation by xklf2-HA 
overexpression (xklf2-DE genes in mESC-NT, Figure 10.12.4; xklf2-DE genes 
in MEF-NT, Figure 10.12.5; xklf2-DE genes in mMyo-NT). While 
reprogrammable xklf2-DE genes are expressed in all 3 cell types (FPKM>0), 
the up-regulation of these genes by xklf2-HA overexpression is significantly 
lower than up-regulation of resistant xklf2-DE genes by xklf2-HA 
overexpression (Figure 10.12.4, 10.12.5 and 10.12.6; p<0.05, Table 10.12.1, 





Figure 10.12.1 Up-regulated xklf2-DE genes of mESC-NT resist to be activated by 
maternal factors but are activated by xklf2-HA overexpression (Figure 6.6.2.A, page 
235). Expression level (FPKM) and log2FC of SCNR resistant genes of mESC-NT 
expressed (A, B) in MEF-NT but not in mESC-NT and mMyo-NT, (C, D) in MEF-NT and 




































































































































































Figure 10.12.2 Up-regulated xklf2-DE genes of MEF-NT resist to be activated by 
maternal factors but are activated by xklf2-HA overexpression (Figure 6.6.2.B, page 
235). Expression level (FPKM) and log2FC of SCNR resistant genes of MEF-NT 
expressed (A, B) in mESC-NT but not in MEF-NT and mMyo-NT, (C, D) in mESC-NT and 






























































































































































Figure 10.12.3 Up-regulated xklf2-DE genes of mMyo-NT resist to be activated by 
maternal factors but are activated by xklf2-HA overexpression (Figure 6.6.2.C, page 
235). Expression level (FPKM) and log2FC of SCNR resistant genes of MEF-NT 
expressed (A, B) in mESC-NT but not in MEF-NT and mMyo-NT, (C, D) in mESC-NT and 







































































































































































Figure 10.12.4 For up-regulated xklf2-DE genes of mESC-NT that are reprogrammable 
genes or SCNR resistant genes of all 3 cell types (Figure 6.6.2.A, page 235), 
reprogrammable xklf2-DE genes have higher expression level and are up-regulated by 
xklf2-HA overexpression with lower log2FC than SCNR resistant xklf2-DE genes 



















3.76 6.10 4.03 0 0 0
Reprogrammable genes
Up-regulated xklf2-DE genes of mESC-NT
SCNR resistant genes



























Up-regulated xklf2-DE genes of mESC-NT
SCNT resistant genes
























Figure 10.12.5 For up-regulated xklf2-DE genes of MEF-NT that are reprogrammable 
genes or SCNR resistant genes of all 3 cell types (Figure 6.6.2.B, page 235), different 
regulation by xklf2-HA overexpression for these two types of genes are as mentioned 
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Figure 10.12.6 For up-regulated xklf2-DE genes of mMyo-NT that are reprogrammable 
genes or SCNR resistant genes of all 3 cell types (Figure 6.6.2.C, page 235), different 
regulation by xklf2-HA overexpression for these two types of genes are as mentioned 
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Table 10.12.1 p-value for Figure 10.12.4, p-value<0.05 is in red  
Table 6.6.1




mESC-NT 2.83E-67 2.83E-67 2.83E-67
MEF-NT 2.83E-67 2.83E-67 2.83E-67











































mESC-NT 2.62E-62 4.20E-65 8.25E-63
MEF-NT 3.63E-27 8.31E-38 5.46E-33 5.96E-08
mMyo-NT 3.67E-23 6.67E-32 2.64E-28 0.0094 0.174
log2FC (xklf2-HA/Control)

















































Table 10.12.2 p-value for Figure 10.12.5, p-value<0.05 is in red  
Table 6.6.2




mESC-NT 1.02E-151 1.02E-151 1.02E-151
MEF-NT 1.02E-151 1.02E-151 1.02E-151




































Reprogrammable genes of MEF Resistant genes of MEF




mESC-NT 1.22E-60 6.93E-62 3.69E-57
MEF-NT 1.19E-130 1.04E-137 1.29E-125 0.0185

















































Table 10.12.3 p-value for Figure 10.12.6, p-value<0.05 is in red 
Table 6.6.3




mESC-NT 2.26E-72 2.26E-72 2.26E-72
MEF-NT 2.26E-72 2.26E-72 2.26E-72









































mESC-NT 9.47E-30 2.43E-32 1.36E-16
MEF-NT 6.45E-31 1.17E-33 3.66E-17 0.3835
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